Comments
Description
Transcript
プログラム - 日本医用マススペクトル学会
ISSN 1881-5464 JSBMS Letters Vol.40 Supplement, 2015 第 40 回 日本医用マススペクトル学会年会 The 40th Annual Meeting of the Japanese Society for Biomedical Mass Spectrometry プログラム・抄録集 年会長 瀬藤 光利 浜松医科大学・解剖学講座 細胞生物学分野 教授 同・メディカルフォトニクス研究センター 教授 ( 会 期 2015 年 9 月 17 日（木）・18 日（金） 会 場 アクトシティ浜松 コングレスセンター Japanese Society for Biomedical Mass Spectrometry 日本医用マススペクトル学会 ) ┠ ḟ 㛤ദ࠶ࡓࡗ࡚ · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 2 ሙෆ · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 3 ᖺෆ · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 8 ᪥⛬⾲· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 13 ࣉࣟࢢ࣒ࣛ · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 14 ㅮ₇せ᪨ ᣍᚅㅮ₇ · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 26 ᯇᮏຬ㈹ཷ㈹ㅮ₇ · · · · · · · · · · · · · · · · · · · · · · · · · · 28 ≉ูㅮ₇ · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 30 ࢩ࣏ࣥࢪ࣒࢘ 1 · · · · · · · · · · · · · · · · · · · · · · · · · · · 33 ࢩ࣏ࣥࢪ࣒࢘ 2 · · · · · · · · · · · · · · · · · · · · · · · · · · · 37 ࢩ࣏ࣥࢪ࣒࢘ 3 · · · · · · · · · · · · · · · · · · · · · · · · · · · 41 ࢩ࣏ࣥࢪ࣒࢘ 4 · · · · · · · · · · · · · · · · · · · · · · · · · · · 45 ࣏ࢫࢱ࣮Ⓨ⾲ · · · · · · · · · · · · · · · · · · · · · · · · · · · · 49 ࣛࣥࢳ࣭࣮ࣙࣥࣔࢽࣥࢢࢭ࣑ࢼ࣮ · · · · · · · · · · · · · · · · · · 112 ࢸࢡࣀࣟࢪ࣮ࣇ࢛࣮࣒ࣛ · · · · · · · · · · · · · · · · · · · · · · 117 Ꮫ㈶ຓဨ୍ぴ · · · · · · · · · · · · · · · · · · · · · · · · · · · 126 ᖺ༠㈶ᴗ୍ぴ · · · · · · · · · · · · · · · · · · · · · · · · · · · 127 ᒎ♧ᴗ୍ぴ · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 128 ᖺ㐠Ⴀጤဨ୍ぴ · · · · · · · · · · · · · · · · · · · · · · · · · · · 129 ᴗᗈ࿌ · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 130 ḟᅇᖺண࿌ ➨ 40 ᅇ᪥ᮏ࣐ࢫࢫ࣌ࢡࢺࣝᏛᖺ㛤ദ࠶ࡓࡗ࡚ グᛕࡍࡁ➨ 40 ᅇࡢ᪥ᮏ་⏝࣐ࢫࢫ࣌ࢡࢺࣝᏛᖺࡣᯇࡀᢸᙜࡉࡏ࡚࠸ࡓࡔࡃ ࡇ࡞ࡾࡲࡋࡓࠋ᪥ᮏ་⏝࣐ࢫࢫ࣌ࢡࢺࣝᏛࡣࠊ㉁㔞ศᯒἲࡢ་Ꮫࡑࡢ㛵㐃㡿ᇦ ࡢᛂ⏝ࢆ┠ⓗࡋࠊ 51 ᖺࡽ᪥ࡲ࡛╔ᐇ࡞Ⓨᒎࢆ㐙ࡆ࡚ཧࡾࡲࡋࡓࠋ ➨ 40 ᅇᖺ࡛ࡣࠊᖜᗈ࠸ศ㔝࡛᭱᪂ࡢヰ㢟ࡘ࠸࡚㆟ㄽࡋࡓ࠸⪃࠼࡚࠾ࡾࡲࡍࠋ ࡑࡇ࡛ࠊᣍᚅㅮ₇ࡋ࡚ⱥᅜ Imperial College London ࡢ Dr. Jeremy K Nicholson Ặࠊ ≉ูㅮ₇ࡋ࡚ᕞᏛࡢ୰ᒣᩗ୍ᩍᤵࢆ࠾ᣍࡁࡋࡲࡋࡓࠋࡑࢀࡒࢀࡢඛ⏕ࡼࡾࠊ ࠕSystems Medicine in a Changing World: The Challenge of Measuring and Visualising Personal and Public Healthcare Data.ࠖࠊࠕḟୡ௦ࣉࣟࢸ࣑࢜ࢡࢫࢆ⏝࠸ࡓࡀࢇ≉ᛶ ࡢゎ᫂ࠖࡢ࠾ヰࢆ㡬ࡃணᐃ࡛ࡍࠋࡲࡓࠊࢩ࣏ࣥࢪ࣒࡛࢘ࡣࠊࢱࣥࢹ࣒࣐ࢫ࣭ࢫࢡ࣮ࣜࢽ ࣥࢢࠊ㉁㔞࣓࣮ࢪࣥࢢࠊࢺࣛࣥࢫ࣑࢜ࢡࢫࠊ༴㝤ࢻࣛࢵࢢࠊࡢ㸲ࡘࡢࢸ࣮࣐ࢆ⏬࠸ ࡓࡋࡲࡋࡓࠋࡉࡽ 4 ♫ࡼࡿࣛࣥࢳ࣭࣮ࣙࣥࣔࢽࣥࢢࢭ࣑ࢼ࣮ࠊ8 ♫ࡢ༠㈶ᴗࡼ ࡿࢸࢡࣀࣟࢪ࣮ࣇ࢛࣮࣒ࣛᴗㅮ₇ࠊࡉࡽᶵჾ࣭ၟရᒎ♧࣭ᴗᗈ࿌࠾࠸࡚ࡶከᩘ ࡢᴗࡈ༠ຊࢆ㡬ࡁࡲࡋࡓࠋ῝ࡃឤㅰࢆ⏦ࡋୖࡆࡿḟ➨࡛ࡍࠋ ୍⯡₇㢟ࡣࠊ࠾ࡆࡉࡲ࡛ྜィ 62 㢟㐣ཤ᭱ከࡢ⏦ࡋ㎸ࡳࢆ㡬ࡁࡲࡋࡓࠋ࣏ࢫࢱ࣮ ₇㢟ࡋ࡚ 2 ᪥㛫ࢃࡓࡾウㄽࢆ⾜࠺ணᐃ࡛ࡍࠋⱝᡭඃ⚽࣏ࢫࢱ࣮㈹ࢆ⏬ࡋ࡚࠾ࡾࡲ ࡍࡢ࡛ࠊホ㆟ဨࡢⓙᵝࡣ✚ᴟⓗ࡞ᢞ⚊ࢆ࠾㢪࠸⏦ࡋୖࡆࡲࡍࠋ᠓ぶሙ࡚⾲ᙲࢆ⾜ ࠸ࡲࡍࠋ᠓ぶࡣᖺึ᪥ࡢ 18 ༙ࡽཷ㛤ጞࠊ19 ࡼࡾሙ㏆ࡃࡢ࣐࣭ࣥࢩࣗ ࣟࢫ࡚㛤ᐗ࠸ࡓࡋࡲࡍࠋከᩘࡢࡈཧຍࢆ࠾ᚅࡕ⏦ࡋୖࡆࡲࡍࠋ ࡉࡽࡣࠊ᪥ᮏ་⏝࣐ࢫࢫ࣌ࢡࢺࣝᏛദࡢࠕ་⏝㉁㔞ศᯒㄆᐃኈไᗘࠖࡢ➨ 3 ᅇ ┠ㅮ⩦ࢆᖺ⩣᪥ணᐃࡋ࡚࠸ࡲࡍ㸦9 ᭶ 19 ᪥㸦ᅵ㸧ࢡࢺࢩࢸᯇࢥࣥࢢࣞࢫ ࢭࣥࢱ࣮㸲㝵㸧ࠋ⮫ᗋ᳨ᰝࡸデ⒪࠾ࡅࡿ㉁㔞ศᯒᢏ⾡ࡢᬑཬ࣭ᶆ‽ࡢࡼࡾ୍ᒙࡢ㐍 ᒎࢆᮇᚅࡋ࡚࠾ࡾࡲࡍࠋ ᮎ➹࡞ࡀࡽࠊᮏᖺࡢ㛤ദྥࡅ࡚ࡈᨭ࠸ࡓࡔࡁࡲࡋࡓᮏᏛࡢᙺဨ࣭ဨࡢⓙᵝࠊ ༠㈶࠸ࡓࡔࡁࡲࡋࡓᴗྛ♫ᚰࡼࡾ࠾♩⏦ࡋୖࡆࡲࡍࠋ ᮏᖺࡀࡈཧຍ࠸ࡓࡔ࠸ࡓⓙᵝࡢάⓎ࡞ウㄽࡼࡾᚋࡢⓎᒎࡘ࡞ࡀࡿࡇࢆ♳ ᛕ࠸ࡓࡋࡲࡍࠋ ➨ 40 ᅇ᪥ᮏ་⏝࣐ࢫࢫ࣌ࢡࢺࣝᏛ ᖺ㛗 ℩⸨ ග ᯇ་⛉Ꮫゎ๗Ꮫㅮᗙ⣽⬊⏕≀Ꮫศ㔝 ᩍᤵ ྠ࣭࣓ࢹ࢝ࣝࣇ࢛ࢺࢽࢡࢫ◊✲ࢭࣥࢱ࣮ ᩍᤵ ́́ ́́ ́́ ➨ 40 ᅇ᪥ᮏ་⏝࣐ࢫࢫ࣌ࢡࢺࣝᏛᖺሙぢྲྀࡾᅗ ە1㹄࢚ࣥࢺࣛࣥࢫࣟࣅ࣮࣭ᦙධཱྀ ە2㹄 ㆟ᐊ ە4㹄㆟ᐊ࣭ࣛࣥࢳ࣮ࣙࣥࣔࢽࣥࢢࢭ࣑ࢼ࣮࣭ㅮ⩦ሙ ́́ ᴗᒎ♧ࣈ࣮ࢫ㓄⨨ᅗ ձ ᪥ᮏ࢛࣮࢘ࢱ࣮ࢬᰴᘧ♫ ղ ࢪࣞࣥࢺ࣭ࢸࢡࣀࣟࢪ࣮ᰴᘧ♫ ճ ࣈ࣮࣭ࣝ࢝ࢲࣝࢺࢽࢡࢫᰴᘧ♫ մ ࢧ࣮ࣔࣇࢵࢩ࣮ࣕࢧ࢚ࣥࢸࣇࢵࢡᰴᘧ♫ յ ᰴᘧ♫࢚࣮ࣅ࣮ࢧ࢚ࢵࢡࢫ ն ࢪ࣮࢚ࣝࢧ࢚ࣥࢫᰴᘧ♫ շ ࢩࢫ࣓ࢵࢡࢫ࣭ࣅ࣓࣮࢜ࣜࣗᰴᘧ♫ ո ࢩࢢ࣐ࣝࢻࣜࢵࢳࢪࣕࣃࣥྜྠ♫ չ ᰴᘧ♫ᓥὠ〇సᡤ պ ሯ〇⸆ᰴᘧ♫ ջ 㹋㹑㹒 ୍⯡㈈ᅋἲே ᮦᩱ⛉Ꮫᢏ⾡⯆㈈ᅋ ́́ ᠓ぶሙࡢࡈෆ ࠙᪥࣭ሙᡤࠚ9 ᭶ 17 ᪥㸦ᮌ㸧19㸸00㹼㸦18㸸30㹼ཷ㛤ጞࠊ19㸸00 㛤ᐗ㸧 ࡣࡲࡲࡘᆅࣅ࣮ࣝᕤᡣ ࣐࣭ࣥࢩࣗࣟࢫ ఫᡤ㸸㟼ᒸ┴ᯇᕷ୰༊୰ኸ 3 ┠ 8-1 㟁ヰ㸸053-452-1146 ́́ ᖺ ෆ ࠙ᮇࠚ ᖹᡂ 27 ᖺ 9 ᭶ 17 ᪥㸦ᮌ㸧࣭18 ᪥㸦㔠㸧 㸦9 ᭶ 19 ᪥(ᅵ)་⏝㉁㔞ศᯒㄆᐃኈㅮ⩦㛤ദ㸧 ࠙ሙࠚ ᖺ ሙ 㸸ࢡࢺࢩࢸᯇ ࢥࣥࢢࣞࢫࢭࣥࢱ࣮ ࣓ࣥሙ㸸㸲㸯㆟ᐊ ᒎ ♧ ሙ 㸸㸲㸱㸩㸲㸲㆟ᐊ ࣛࣥࢳࣙࣥࢭ࣑ࢼ࣮ሙ㸸㸲㸯㆟ᐊࠊ㸰㸰㸩㸰㸱㆟ᐊ ࣮ࣔࢽࣥࢢࢭ࣑ࢼ࣮ሙ㸸㸲㸯㆟ᐊ ࠙ཧຍᡭ⥆ࡁࡘ࠸࡚ࠚ ཷ㸸㸲F ࣟࣅ࣮ 㛫㸸17 ᪥㸦ᮌ㸧9:00㹼ࠊ18 ᪥㸦㔠㸧8:30㹼 ࣭ཧຍⓏ㘓῭ࡳࡢ᪉ࡣࠊཷ࡛ྡᮐࢆ࠾Ώࡋࡋࡲࡍࠋ ࣭ᙜ᪥ཧຍࡢ᪉ࡣࠊཷ࡚ཧຍ㈝ࢆ࠾ᨭᡶ࠸ࡃࡔࡉ࠸ࠋ ṇဨ㸸7,000 ࠊ㠀ဨ㸸12,000 ࠊᏛ⏕ဨ㸸3,000 ࣭ᖺᮇ㛫୰ࡣᚲࡎࢿ࣮࣒ࣉ࣮ࣞࢺࢆࡈ╔⏝ࡃࡔࡉ࠸ࠋ ࠙ᗙ㛗ࡢ᪉ࠚ ࣭ᢸᙜ㛫ࡢ 10 ศ๓ࡣࠊሙෆࡢḟᗙ㛗ᖍ࠾㉺ࡋࡃࡔࡉ࠸ࠋ ࠙₇⪅ࡢ᪉ࠚ ࣭ㅮ₇㛫ࡣࠊࢩ࣏ࣥࢪ࣒࢘ࡢᗙ㛗ࡢᣦ♧㏻ࡾ࠾㢪࠸࠸ࡓࡋࡲࡍࠋ ࣭ᣍᚅㅮ₇ࠊ≉ูㅮ₇ࡣ 60 ศࠊཷ㈹ㅮ₇ࡣ 30 ศࠊࢩ࣏ࣥࢪ࣒࢘ࡣ࠾୍ே 20㹼30 ศࠊ ࢸࢡࣀࣟࢪ࣮ࣇ࢛࣮࣒ࣛࡣ୍♫ 15 ศࡢᣢࡕ㛫࡞ࡾࡲࡍ㸦ࡍ࡚㉁ᛂ⟅㎸㸧ࠋ ࣭Ⓨ⾲㛫ࡢཝᏲࢆ࠾㢪࠸࠸ࡓࡋࡲࡍࠋ ࣭Ⓨ⾲ࢫࣛࢻࠊ┈┦㸦COI㸧ࡢグ㍕ࢆ࠾㢪࠸࠸ࡓࡋࡲࡍࠋᏛࡢ࣮࣒࣮࣍࣌ࢪ 㸦http://www.jsbms.jp/㸧ࡲࡓࡣᖺࡢ࣮࣒࣮࣍࣌ࢪࡽ COI Ⓨ⾲⪅㛤♧࡞ࡋ㸦ᵝᘧ 1-A㸧ࠊࡲࡓࡣ COI Ⓨ⾲⪅㛤♧࠶ࡾ㸦ᵝᘧ 1-B㸧ࢆࢲ࣮࢘ࣥࣟࢻࡋ࡚ࡈ⏝ࡃࡔࡉ࠸ࠋ ۑⓎ⾲ࡢࡈὀព࠾㢪࠸ ࣭ࡍ࡚ PC (PowerPoint)ࡼࡿⓎ⾲࡞ࡾࡲࡍࠋ ࣭PC ཷ࡛ࡢⓎ⾲ࢹ࣮ࢱཷ⤊ᚋࠊⓎ⾲ 10 ศ๓ࡲ࡛ࡈㅮ₇ሙෆࡢḟ₇⪅ᖍ ࠾㉺ࡋࡃࡔࡉ࠸ࠋ ࣭₇ྎୖ࣮ࣞࢨ࣮࣏ࣥࢱ࣮ࢆ⏝ព࠸ࡓࡋࡲࡍࡢ࡛ࠊࡈ⏝ࡃࡔࡉ࠸ࠋ ۑⓎ⾲ࢹ࣮ࢱཷࡘ࠸࡚ ࣭ࡈⓎ⾲ࡢ 30 ศ๓ࡲ࡛ࠊPC ཷ࡚Ⓨ⾲ࢹ࣮ࢱࡢᥦฟࢆ࠾㢪࠸࠸ࡓࡋࡲࡍࠋ ࣭ࡈⓎ⾲๓ࠊPC ཷ࡚Ⓨ⾲ࢹ࣮ࢱࡢືస☜ㄆࢆ⾜ࡗ࡚࠸ࡓࡔࡁࡲࡍࠋUSB ࣇࣛࢵ ́́ ࢩ࣓࡚ࣗࣔࣜࠊⓎ⾲ࢹ࣮ࢱࢆࡈᣢཧࡃࡔࡉ࠸ࠋUSB ࣇࣛࢵࢩ࣓ࣗࣔࣜࡣヨ⤊ ᚋࠊ㏉༷࠸ࡓࡋࡲࡍࠋሙ࡛ࡢᥦฟࡣᚲせ࠶ࡾࡲࡏࢇࡀࠊᛕࡢࡓࡵሙࡣࡈᣢཧࡃ ࡔࡉ࠸ࠋ ࣭࠾㡸ࡾࡋࡓⓎ⾲ࢹ࣮ࢱࡣࠊⓎ⾲⏝ࣃࢯࢥࣥࢥࣆ࣮ࡉࡏ࡚࠸ࡓࡔࡁࡲࡍࡀࠊᮏᏛ ᖺࣉࣞࢮࣥࢸ࣮ࢩࣙࣥ௨እ⏝ࡍࡿࡇࡣ࠶ࡾࡲࡏࢇࠋᖺ⤊ᚋࠊᖺົᒁ ࡀ㈐௵ࢆᣢࡗ࡚ᾘཤ࠸ࡓࡋࡲࡍࠋ ۑⓎ⾲ࢹ࣮ࢱཷࡢࡈὀព ࣭ື⏬ࡸ㡢ኌࢆࡈ⏝࡞ࡿሙྜࡣࠊᚲࡎ࣮࢜࣌ࣞࢱ࣮⏦ࡋฟ࡚ࡃࡔࡉ࠸ࠋ ࣭ࢹ࣮ࢱࢆࣁ࣮ࢻࢹࢫࢡࢥࣆ࣮ࡋࠊヨ⏝ࣃࢯࢥ࡚ࣥືసࢆ☜ㄆࡋ࡚ࡃࡔࡉ࠸ࠋ ࣭PC ཷ࡛ࡢࢹ࣮ࢱࡢಟṇࠊኚ᭦ࡣ࡛ࡁࡲࡏࢇࠋ ࣭࢘ࣝࢫᐃ⩏ࢹ࣮ࢱࢆ᭱᪂ࡢࡶࡢ᭦᪂ࡋࡓ≧ែࡢࢭ࢟ࣗࣜࢸࢯࣇࢺ࡚ᚲࡎ ๓ࡈ⮬㌟࡛࢘ࣝࢫࢳ࢙ࢵࢡࢆ࠾㢪࠸ࡋࡲࡍࠋPC ཷ࡛ࠊᣢࡕ㎸ࡲࢀࡿ࣓ࢹ ࡚ࢆ࢘ࣝࢫࢳ࢙ࢵࢡࡉࡏ࡚࠸ࡓࡔࡁࡲࡍࠋ ࢱ࣮ࢹۑ㸦USB ࣇࣛࢵࢩ࣓ࣗࣔࣜ㸧ࢆᣢཧࡉࢀࡿ᪉ ࣭࠾ᣢࡕ㎸ࡳ࠸ࡓࡔࡅࡿࢹ࣮ࢱࡣࠊUSB ࣇࣛࢵࢩ࣓ࣗࣔࣜࡢࡳ࡛ࡍࠋ ࣭ࡲࡓࠊࡈ⮬㌟ࡢࣃࢯࢥࣥ௨እ࡛ᩥᏐࡅ➼ࡀ࡞ࡃࠊࢹ࣮ࢱࢆㄞࡳ㎸ࡵࡿᚲࡎࡈ☜ㄆ ࡃࡔࡉ࠸ࠋ ࣭Ⓨ⾲ࡢࢺࣛࣈࣝࢆ㜵ࡄࡓࡵࡶࠊᣢࡕ㎸ࡲࢀࡿ࣓ࢹࡣࠊⓎ⾲⏝ࡢࢹ࣮ࢱ㸦 ᡂ∧㸧௨እධࢀ࡞࠸ࡼ࠺ࡋ࡚ࡃࡔࡉ࠸ࠋࣇࣝྡࡣࠕ₇㢟␒ྕ࣭₇⪅ྡ.pptࠖࠊ ࡲࡓࡣࠕ₇㢟␒ྕ࣭₇⪅ྡ.pptxࠖࡋ࡚ࡃࡔࡉ࠸ࠋ ࣭ሙ࡛ࡈ⏝ពࡍࡿࣃࢯࢥࣥ OS㸸Windows 8 pro ࣉࣜࢣ࣮ࢩࣙࣥ㸸PowerPoint2013 ࣭Ⓨ⾲⏝࡛ࡁࡿࢹ࣮ࢱ Microsoft PowerPoint2003 ௨㝆࡛సᡂࡉࢀࡓࣇࣝ㸦Ⓨ⾲⪅ࢶ࣮ࣝᶵ⬟ࡣࡈ⏝ ࡞ࢀࡲࡏࢇ㸧 ࣭ᩥᏐࡢࣇ࢛ࣥࢺ ᪥ᮏㄒ㸸MS ࢦࢩࢵࢡ/MSP ࢦࢩࢵࢡ/MS ᫂ᮅ/MSP ᫂ᮅࡢ 4 ✀㢮ࡢࡳࠋ ⱥ ㄒ㸸Times New Roman/Arial/Arial Black/Arial Narrow/Century/Century Gothic/Courier/Courier New/Georgia/ Symbol ࡢྜィ 10 ✀㢮ࡢࡳࠋ ୖグ௨እࡢࣇ࢛ࣥࢺࢆ⏝ࡉࢀࡓሙྜࡣࠊ⾲♧ලྜࡀⓎ⏕ࡍࡿྍ⬟ᛶࡀ࠶ࡾࡲࡍࠋ ࣭⏬㠃ࡢゎീᗘࡣ XGA㸦1024x768㸧࡛ࡍࠋࡇࢀࡼࡾࡁ࠸ሙྜࠊࢫࣛࢻࡢ࿘ᅖࡀษ ࢀ࡚ࡋࡲ࠸ࡲࡍࠋࡲࡓࠊ⏬㠃ࡢࡂࡾࡂࡾࡲ࡛⏝ࡍࡿ⌧⎔ቃࡢ㐪࠸ࡼࡾᩥᏐࡸ ⏬ീࡢࡣࡳฟࡋ➼ࡢཎᅉ࡞ࡿࡇࡀ࠶ࡾࡲࡍࠋ ࣭ື⏬ࢆ⏝ࡍࡿሙྜࠊࢫࣛࢻࣇࣝື⏬ࢹ࣮ࢱࢆ୍⥴ಖ⟶ࡋ࡚ࡃࡔࡉ࠸ࠋ ࡞࠾ࠊື⏬ࣇࣝࡣ Windows Media Video㸦WMV ࣇࣝ㸧ᙧᘧࡋࠊᣑᙇᏊ 㸦.wmv㸧ࢆᚲࡎࡘࡅ࡚ࡃࡔࡉ࠸ࠋ ́́ ࡈࢆࣥࢥࢯࣃۑᣢཧࡉࢀࡿ᪉ ࣭ࢥࢿࢡࢱࡢᙧ≧ࡣࢼࣟࢢ VGA㸦D-Sub15 ࣆࣥ㸧㝈ࡾࡲࡍࠋኚࢣ࣮ࣈࣝࡀᚲせ ࡞ᶵ✀㸦Macintosh ➼㸧ࢆࡈ⏝ࡢሙྜࡣࠊኚࢣ࣮ࣈࣝࢆࡈᣢཧࡃࡔࡉ࠸ࠋ ࣭ࡈ⮬㌟ࡢࣃࢯࢥࣥࡽእ㒊ࣔࢽࢱ࣮ṇࡋࡃฟຊ࡛ࡁࡿࡇࢆ☜ㄆࡋ࡚ࡃࡔࡉ࠸ࠋ ಶࠎࡢࣃࢯࢥࣥࡸ OS ࡼࡾタᐃ᪉ἲࡀ␗࡞ࡾࡲࡍࡢ࡛ࠊ๓ࡈ☜ㄆࡃࡔࡉ࠸ࠋ ࣭⏬㠃ࡢゎീᗘࡣ XGA㸦1024x768㸧࡛ࡍࠋࡇࢀࡼࡾࡁ࠸ሙྜࠊࢫࣛࢻࡢ࿘ᅖࡀษ ࢀ࡚ࡋࡲ࠸ࡲࡍࠋ ࣭Ⓨ⾲୰ࢫࢡ࣮ࣜࣥࢭ࣮ࣂ࣮ࡸ┬㟁ຊ࣮ࣔࢻ࡞ࡽ࡞࠸ࡼ࠺๓タᐃࢆ࠾῭ࡲࡏ ࡃࡔࡉ࠸ࠋ ࣭㟁※ࢥࣥࢭࣥࢺࢆ⏝ពࡋ࡚࠾ࡾࡲࡍࡢ࡛ࠊᚲࡎ㟁※ࢣ࣮ࣈࣝࢆ࠾ᣢࡕ࠸ࡓࡔࡁࠊࣂࢵ ࢸ࣮࡛ࣜࡢࡈⓎ⾲ࡣࡈ㐲៖ࡃࡔࡉ࠸ࠋ ࣭ࡈ⮬㌟ࡢࣃࢯࢥࣥࡽヨ⏝ࣉࣟࢪ࢙ࢡࢱ࣮ࠊⓎ⾲ࢹ࣮ࢱࡀṇࡋࡃฟຊ࡛ࡁࡿࡇ ࢆ☜ㄆࡋ࡚ࡃࡔࡉ࠸ࠋ≉ື⏬ࠊ⏬ീࢹ࣮ࢱࡣࠊᮏయ⏬㠃ࡣ⾲♧ࡉࢀ࡚ࡶࠊእ㒊ฟ ຊ᥋⥆ࡋࡓ⏬㠃ࡣ⾲♧ࡉࢀ࡞࠸ሙྜࡀ࠶ࡾࡲࡍࠋ༑ศὀពࡋ࡚ࡈ☜ㄆࡃࡔࡉ࠸ࠋ ࣭ࡀ୍ࡢࢺࣛࣈࣝࡢሙྜഛ࠼ࠊணഛࡋ࡚ࡢࢹ࣮ࢱ㸦USB ࣇࣛࢵࢩ࣓ࣗࣔࣜ㸧ࢆ ᣢཧ㡬ࡁࡲࡍࡼ࠺࠾㢪࠸࠸ࡓࡋࡲࡍࠋ ࣏࠙ࢫࢱ࣮Ⓨ⾲ࡢ᪉ࠚ ࣭࣏ࢫࢱ࣮࣮࣎ࢻࡢࡁࡉࡣࠊᶓ 120 ⦪ 180 ࡛ࡍࠋᢲࡋࣆࣥࡣົᒁ࡛⏝ព࠸ ࡓࡋࡲࡍࠋᡤᐃࡢ࣮࣎ࢻᥖ♧ࡋ࡚ࡃࡔࡉ࠸ࠋⓎ⾲㛫୰ࡣࠊ࣏ࢫࢱ࣮๓࡛㉁ᛂ⟅ ࢆ࠾㢪࠸࠸ࡓࡋࡲࡍࠋ ࣭Ⓨ⾲࣏ࢫࢱ࣮┈┦㸦COI㸧ࡢグ㍕ࢆ࠾㢪࠸࠸ࡓࡋࡲࡍࠋᏛࡢ࣮࣒࣮࣍࣌ࢪ 㸦http://www.jsbms.jp/㸧ࡲࡓࡣᖺࡢ࣮࣒࣮࣍࣌ࢪࡽ COI Ⓨ⾲⪅㛤♧࡞ࡋ㸦ᵝᘧ 1-A㸧ࠊࡲࡓࡣ COI Ⓨ⾲⪅㛤♧࠶ࡾ㸦ᵝᘧ 1-B㸧ࢆࢲ࣮࢘ࣥࣟࢻࡋ࡚ࡈ⏝ࡃࡔࡉ࠸ࠋ ࣭࡞࠾ࠊ➨ 40 ᅇ᪥ᮏ་⏝࣐ࢫࢫ࣌ࢡࢺࣝᏛᖺ࡛ࡣࠊⱝᡭ◊✲⪅㸦35 ṓ௨ୗ㸧ࡢඃ ࢀࡓ࣏ࢫࢱ࣮ࠕⱝᡭඃ⚽࣏ࢫࢱ࣮㈹ࠖࢆ㉗ࡾࡲࡍࠋヲ⣽ࡣࠊู♧ࡍ㏻ࡾ࡛ࡍࠋ ࣭ᥖ♧㛫㸸9 ᭶ 17 ᪥㸦ᮌ㸧9:00㹼9 ᭶ 18 ᪥㸦㔠㸧15:00 㸦࣏ࢫࢱ࣮ᥖ♧ࡣ 9 ᭶ 17 ᪥㸦ᮌ㸧9:00㹼10:00 ࡲ࡛ࡢ㛫࠾㢪࠸࠸ࡓࡋࡲࡍࠋ㸧 9 ᭶ 17 ᪥㸦ᮌ㸧13:00㹼14:00 ࣭Ⓨ⾲㛫㸸 ወᩘ₇㢟 അᩘ₇㢟 9 ᭶ 18 ᪥㸦㔠㸧13:00㹼14:00 ࣭᧔ཤ㛫㸸9 ᭶ 18 ᪥㸦㔠㸧15:00㹼16:00 㸦㛫ࢆ㐣ࡂ࡚ࡶ᧔ཤࡉࢀ࡚࠸࡞࠸࣏ࢫࢱ࣮ࡣົᒁ࡚᩿ࡾ࡞ࡃฎศࡋࡲࡍࠋ㸧 ࣭⾲ᙲᘧሙ㸸9 ᭶ 17 ᪥㸦ᮌ㸧19:00 ᠓ぶሙ ࠙ᴗᒎ♧ࡢ᪉ࠚ ࣭㸯ᒎ♧ࢫ࣮࣌ࢫࡣࠊ㛫ཱྀ 200 cm ዟ⾜ 100 cm 㧗ࡉ 240 cm ࡢࣈ࣮ࢫ࡞ࡗ࡚࠾ࡾ ࡲࡍࠋࡲࡓࠊࣈ࣮ࢫࡢ୰ࡣᮘ㸦ᖜ 180 cm ዟ⾜ 60 cm 㧗ࡉ 70cm㸧ࢆ⏝ព࠸ࡓ ࡋࡲࡍࠋ㟁※ࡣ 1 ࣈ࣮ࢫ 500 W ࡲ࡛⏝࡛ࡁࡿࡼ࠺☜ಖࡋ࡚࠸ࡲࡍࠋ ́́ ࠙᠓ぶࠚ ࣭᠓ぶࡣࠊ17 ᪥(ᮌ)19:00 ࡼࡾ㸦18:30 ཷ㛤ጞࠊ19:00 㛤ᐗ㸧ࠊ࣐࣭ࣥࢩࣗࣟࢫ ࡚⾜࠸ࡲࡍࠋ࡞࠾ࠊ᠓ぶሙࡲ࡛ࡣࠊᚐṌ࡚ࡢ⛣ືࢆ࠾㢪࠸࠸ࡓࡋࡲࡍ㸦⣙ 5 ศ㸧ࠋ ಀࡢ⪅ࡀࡈෆ⏦ࡋୖࡆࡲࡍࠋᙜ᪥ཧຍ⪅ࡣࠊᖺཷࡲࡓࡣ᠓ぶሙ࡚᠓ぶ㈝ ࢆ࠾ᨭᡶ࠸ࡃࡔࡉ࠸㸦7,000 㸧ࠋ ࠙⌮ࠚ ࣭⌮ࡣ 16 ᪥㸦Ỉ㸧14:30 ࡼࡾࠊ㸰㸯㆟ᐊ࡚⾜࠸ࡲࡍࠋ ࣭᪂⌮ࡣ 16 ᪥㸦Ỉ㸧15:30 ࡼࡾࠊ㸰㸯㆟ᐊ࡚⾜࠸ࡲࡍࠋ ࠙♫ဨ⥲࣭ဨ㞟ࠚ ࣭♫ဨ⥲ࡣ 17 ᪥㸦ᮌ㸧12:00㹼12:30ࠊ2F 㸰㸰㸩㸰㸱㆟ᐊ࡚⾜࠸ࡲࡍࠋ ࣭ဨ㞟ࡣ 17 ᪥㸦ᮌ㸧15:00㹼15:30ࠊ㸲㸯㆟ᐊ࡚⾜࠸ࡲࡍࠋ ࠙ࡑࡢࠚ ࣭㆟ᐊ࠾ࡼࡧࣟࣅ࣮࡛ Wi-Fi ᥋⥆ࡀྍ⬟࡛ࡍࠋ ࣭㸲F ࢡ࣮ࣟࢡࡣタ⨨ࡋ࡚࠾ࡾࡲࡏࢇࠋ ࣭࣏ࢫࢱ࣮ࢭࢵࢩࣙࣥ୰༠㈶ᴗࡽࡢࢻࣜࣥࢡࢆᩘ㔞㝈ᐃ࡛ࡈ⏝ពࡋࡲࡍࠋ ࣭ࢡࢺࢩࢸᯇࢥࣥࢢࣞࢫࢭࣥࢱ࣮ࡢ㥔㌴ሙࢆࡈ⏝࡞ࢀࡲࡍ㸦᭷ᩱ㸧ࠋ ࠙ၥ࠸ྜࢃࡏඛࠚ ➨ 40 ᅇ᪥ᮏ་⏝࣐ࢫࢫ࣌ࢡࢺࣝᏛᖺົᒁ (TEL/FAX: 053-435-2092ࠊE-mail: jsbms40.hamamatsu㸾hama-med.ac.jp) ́́ ࣏ࢫࢱ࣮Ⓨ⾲⪅ྛ ᖺ࡛ⱝᡭ◊✲⪅㸦35 ṓ௨ୗ㸧ࡢඃࢀࡓ࣏ࢫࢱ࣮ࠕⱝᡭඃ⚽࣏ࢫࢱ࣮㈹ࠖࢆ㉗ࡾࡲࡍࠋ ࠐⱝᡭඃ⚽࣏ࢫࢱ࣮㈹ࡢᑂᰝ࠾ࡼࡧཷ㈹⪅ࡢⓎ⾲᪉ἲ ⱝᡭඃ⚽࣏ࢫࢱ࣮㈹ᛂເࡉࢀࡓ᪉ࡣࠊⓎ⾲⪅Ặྡୗ⥺ࢆグࡋ࡚ࡃࡔࡉ࠸ࠋ ᑂᰝࡣ 9 ᭶ 17 ᪥(ᮌ)ࡢⓎ⾲⤊ᚋࠊᢞ⚊ࡼࡗ࡚⾜࠸ࡲࡍࠋᢞ⚊⏝⣬ࡣ♫ဨ⥲࡛ 㓄ᕸࡋࠊᢞ⚊⟽ࡣ࣏ࢫࢱ࣮ሙධࡾཱྀタ⨨ࡋࡲࡍࡢ࡛ࠊホ㆟ဨ㸦♫ဨ㸧ࡢ᪉ࡣᚲࡎ ᢞ⚊ࢆ࠾㢪࠸ࡋࡲࡍࠋ9 ᭶ 17 ᪥㸦ᮌ㸧ࡢ᠓ぶ࡚⾲ᙲᘧࢆ⾜࠸ࡲࡍࠋ ྛ࣏ࢫࢱ࣮Ⓨ⾲⪅ࡣࠊୗグࡢ᮲௳ࡈ␃ពࡃࡔࡉ࠸ࠋ ࣮ࢱࢫ࣏ۑⓎ⾲㛫ࢆཝᏲࡋ࡚ࡃࡔࡉ࠸ࠋ ۑ₇㢟ࡣ᪥ᮏㄒⱥㄒࢆేグࡋ࡚ࡃࡔࡉ࠸ࠋ ۑᅗ୰ࡢᩥᏐᅗࡢ࢟ࣕࣉࢩࣙࣥࡣᚲࡎⱥㄒ࡛グ㍕ࡋ࡚ࡃࡔࡉ࠸ࠋ ۑ᪤ᐃࡢ㛫ࡲ࡛࣏ࢫࢱ࣮ࢆᥖ♧ࡋࠊࡲࡓつᐃࡢ㛫ࡼࡾ๓᧔ཤࡋ࡞࠸࡛ࡃࡔࡉ࠸ࠋ ᑂᰝᇶ‽ ௨ୗࡢᑂᰝᇶ‽ࢆࡶࠊ⥲ྜⓗุ᩿ࡋࡲࡍࠋ ࡢ✲◊ۑ㉁㛵ࡍࡿᇶ‽㡯┠ ࣭◊✲ࡢ᭷⏝ᛶ ࣭᪂つᛶࠊ⊂ᛶ ࣭ᐇ㦂ࡢ⤌ࡳ❧࡚ࡢጇᙜᛶࠋ ࣭⛉Ꮫⓗ࡞㘒ㄗࡀ࡞࠸ࠋ ࣥࣙࢩ࣮ࢸࣥࢮࣞࣉۑ㛵ࡍࡿᇶ‽㡯┠ ࣭࣏ࢫࢱ࣮ࢆぢΏࡋ࡚ࠊㄝ᫂ࢆ⪺࡞ࡃ࡚ࡶせⅬࢆࡍࡄ⌮ゎࡍࡿࡇࡀ࡛ࡁࡿ࠺ࠋ ࣭ᩥᏐࡸᅗࡢࡁࡉࡀ㐺ᙜࠋ࠶ࡿ⛬ᗘ㞳ࢀ࡚࠸࡚ࡶゎㄞ࡛ࡁࡿࠋ ࣭ᅗ⾲ࡢⱥㄒㄝ᫂ࡀ⌮ゎ࡛ࡁࡿࠋ ࣭ሗࡀ㐣ከ࡛ࡣ࡞࠸ࠋ ࣭⏝ㄒࡀṇࡋࡃ⏝ࡉࢀ࡚࠸ࡿࠋ ࣭Ⓨ⾲⪅ࡢㄝ᫂ࡀ⡆⣲ࡘࢃࡾࡸࡍࡃࠊㄝ᫂㛫ࡀ㐺ᙜࠋ ࣭㉁ၥᑐࡍࡿᅇ⟅ࡀ⡆⣲ࡘⓗ☜࡛࠶ࡿ࠺ࠋ ࣭ࡑࡢࠊయࡀつᐃࢆ㐓⬺ࡋ࡚࠸࡞࠸ࠋ ➨ 40 ᅇ᪥ᮏ་⏝࣐ࢫࢫ࣌ࢡࢺࣝᏛᖺົᒁ ́́ ᪥ ⛬ ⾲ ࠙㸯᪥┠ࠚ9 ᭶ 17 ᪥㸦ᮌ㸧 ሙ ᡤ 9㸸0 00㹼 ཷ㛤ጞ 㸲㹄ࣟࣅ࣮ 9㸸5 55㹼 10㸸 㸸00 㛤ࡢ㎡ 㸲㸯㆟ᐊ㸦㸲㹄㸧 10㸸0 00㹼 12㸸 㸸00 ࢩ࣏ࣥࢪ࣒࢘ 1 ࠌ 12㸸0 00㹼 12㸸 㸸30 ♫ဨ⥲ 㸰㸰㸩㸰㸱㆟ᐊ㸦㸰㹄㸧 12㸸0 00㹼 13㸸 㸸00 ࣛࣥࢳࣙࣥࢭ࣑ࢼ࣮1ࠊ2 㸲㸯㆟ᐊ㸦㸲㹄㸧 㸰㸰㸩㸰㸱㆟ᐊ㸦㸰㹄㸧 13㸸0 00㹼 14㸸 㸸00 ࣏ࢫࢱ࣮Ⓨ⾲㸦ወᩘ₇㢟㸧 㸲㸱㸩㸲㸲㆟ᐊ㸦㸲㹄㸧 14㸸0 00㹼 15㸸 㸸00 ᣍᚅㅮ₇ 㸲㸯㆟ᐊ㸦㸲㹄㸧 15㸸0 00㹼 15㸸 㸸30 ဨ㞟 ࠌ 15㸸3 30㹼 16㸸 㸸00 ᯇᮏຬ㈹ཷ㈹ㅮ₇ ࠌ 16㸸0 00㹼 17㸸 㸸30 ࢩ࣏ࣥࢪ࣒࢘㸰 ࠌ 17㸸3 30㹼 18㸸 㸸30 ≉ูㅮ₇ ࠌ 18㸸3 30㹼 ᠓ぶ㸦18㸸30㹼ཷ㛤ጞࠊ19㸸00 㛤ᐗ㸧 ᠓ぶሙ ࠙㸰᪥┠ࠚ9 ᭶ 18 ᪥㸦㔠㸧 ሙ ᡤ 8㸸3 30㹼 ཷ㛤ጞ 㸲㹄ࣟࣅ࣮ 9㸸0 00㹼 10㸸 㸸00 ࣮ࣔࢽࣥࢢࢭ࣑ࢼ࣮ 㸲㸯㆟ᐊ㸦㸲㹄㸧 10㸸0 00㹼 12㸸 㸸00 ࢩ࣏ࣥࢪ࣒࢘㸱 ࠌ 12㸸0 00㹼 13㸸 㸸00 ࣛࣥࢳࣙࣥࢭ࣑ࢼ࣮3 ࠌ 13㸸0 00㹼 14㸸 㸸00 ࣏ࢫࢱ࣮Ⓨ⾲㸦അᩘ₇㢟㸧 㸲㸱㸩㸲㸲㆟ᐊ㸦㸲㹄㸧 14㸸0 00㹼 15㸸 㸸30 ࢩ࣏ࣥࢪ࣒࢘㸲 㸲㸯㆟ᐊ㸦㸲㹄㸧 15㸸3 30㹼 17㸸 㸸30 ࢸࢡࣀࣟࢪ࣮ࣇ࢛࣮࣒ࣛ ࠌ 17㸸3 30㹼 17㸸 㸸35 㛢ࡢ㎡ ࠌ ۵࠙ㅮ⩦ࠚ9 ᭶ 19 ᪥㸦ᅵ㸧 ᪥ᮏ་⏝࣐ࢫࢫ࣌ࢡࢺࣝᏛദ ➨㸱ᅇ་⏝㉁㔞ศᯒㄆᐃኈㅮ⩦ࢆࢡࢺࢩࢸᯇ ࢥࣥࢢࣞࢫࢭࣥࢱ࣮㸲㝵࡚㛤ദ࠸ࡓࡋࡲࡍࠋ ཷㅮᩱ 5,000 ࠊ➨ 40 ᅇᖺཧຍ⪅ 3,000 㸦㈨ᩱ௦ྵࡴ㸧 ́́ ࣉࣟࢢ࣒ࣛ 9 ᭶ 17 ᪥㸦ᮌ㸧 9㸸00 ཷ㸦4㹄ࣟࣅ࣮㸧 9㸸55㹼10㸸00 㛤ࡢ㎡㸦41 ㆟ᐊ㸧 10㸸00㹼12㸸00 ࢩ࣏ࣥࢪ࣒࢘㸯㸸ࠕᅜ⮬య࡛ᴗࡉࢀࡓࢱࣥࢹ࣒࣐ࢫ࣭ࢫࢡ࣮ࣜࢽࣥࢢࡢᑐᛂࠖ 㸦41 ㆟ᐊ㸧 ࣮࢜࢞ࢼࢨ࣮㸸㔜ᯇ㝧㸦⚟Ꮫ㸧 ᗙ㛗㸸▼ẟಙஅ㸦⚟Ꮫ㸧 㹑1-1 ࠕࢥࣥࢧࣝࢱࣥࢺ་ᖌࡀ⾜࠺㝧ᛶࡢホ౯ᑐᛂࠖ ❑⏣ ‶㸦ᅜ❧ᡂ⫱་⒪◊✲ࢭࣥࢱ࣮⥲ྜデ⒪㒊㸧 㹑1-2 ࠗࠕᅜ⮬య࡛ᴗࡉࢀࡓࢱࣥࢹ࣒࣐ࢫ࣭ࢫࢡ࣮ࣜࢽࣥࢢࡢᑐᛂࠖ⢭ᐦ᳨ᰝࡢ ᑐᛂࡢ⌧ἣ࠘ 㛗㇂ᕝ᭷⣖㸦ᓥ᰿Ꮫ་Ꮫ㒊ᑠඣ⛉㸧 㹑1-3 ࠕṇᖖ᳨యᝈ⪅ࢹ࣮ࢱሗ㞟ࡼࡿࢱࣥࢹ࣒࣐ࢫࢫࢡ࣮ࣜࢽࣥࢢࡢ⢭ᗘ⟶⌮ࠖ ⰼ₶ᖌ 1, ⚟ኈ 2, ▼ẟಙஅ 3, ⏣ᓮ㝯 4㸦1 ᮐᖠᕷ⾨⏕◊✲ᡤ, 2 ᮐᖠ࣒ࣀࢲ ࢢࣀࢫࢸࢵࢡࣛ࣎ࣛࢺ࣮ࣜ, 3(බ㈈)ᮾி㒔ண㜵་Ꮫ༠, 4(୍㈈)Ꮫཬ⾑Ύ⒪ ἲ◊✲ᡤ㸧 㹑1-4 ࠕLC-MS/MS ࡼࡿḟ᳨ᰝἲࡢ㛤Ⓨࠖ 㔜ᯇ㝧 1, ⏿㑳Ụ 2, ୰ᓥⱥつ 3㸦1 ⚟Ꮫ་Ꮫ㒊ᗣ⛉Ꮫ, 2 ⚟Ꮫ་Ꮫ㒊ᑠඣ⛉Ꮫ, 3 ᅜ❧ᡂ⫱་⒪◊✲ࢭࣥࢱ࣮࣭࣐ࢫࢫࢡ࣮ࣜࢽࣥࢢ◊✲ᐊ㸧 12㸸00㹼12㸸30 ♫ဨ⥲㸦22㸩23 ㆟ᐊ㸧 12㸸00㹼13㸸00 ࣛࣥࢳࣙࣥࢭ࣑ࢼ࣮1㸦41 ㆟ᐊ㸧 ࣈ࣮࣭ࣝ࢝ࢲࣝࢺࢽࢡࢫᰴᘧ♫ 㹊㹑-1 ࠕ࣓࣮ࢪࣥࢢ㉁㔞ศᯒ࠾ࡅࡿ㧗ศゎ⬟࣭㧗⢭ᗘࣁࢫ࣮ࣝࣉࢵࢺࡢ࠸ศࡅࠖ 㡞⃝ ᓫ㸦ࣈ࣮࣭ࣝ࢝ࢲࣝࢺࢽࢡࢫᰴᘧ♫㸧 12㸸30㹼13㸸00 ࣛࣥࢳࣙࣥࢭ࣑ࢼ࣮2㸦22㸩23 ㆟ᐊ㸧 ᰴᘧ♫࢚࣮ࣅ࣮࣭ࢧ࢚ࢵࢡࢫ 㹊㹑-2 ࠕ࣐ࣝࢳ࣑࢜ࢵࢡࢫ࡞ࢹ࣮ࢱゎᯒࠊಖ⟶ࠊඹ᭷ࢆྍ⬟ࡍࡿ BaseSpace ࢡࣛ࢘ࢻࠖ 㛵 ᗈ㸦࣑ࣝࢼᰴᘧ♫ ࣉࣟࢲࢡࢺ࣐࣮ࢣࢸࣥࢢ㒊㸧 13㸸00㹼14㸸00 㹎-1 ࣏ࢫࢱ࣮Ⓨ⾲㸦ወᩘ₇㢟㸧 㸦43㸩44 ㆟ᐊ㸧 ࠕHILIC-MS/MS ἲࡼࡿࣄࢺయᾮ୰ tegafur ཬࡧ 5-fluorouracil ࡢ㧗ឤᗘศᯒἲࠖ ́́ ᑠῲᚊᏊ 1,2, ᮤ ᬡ㭉 1, ⇃⃝Ṋᚿ 1, ᘅ⃝ᵞᏊ 2, 㛗㇂ᕝᬛ⳹ 3, ධᡞ㔝 1, 㧗ᶫ ⏨ 2, బ⸨ၨ㐀 1㸦1 Ꮫ་Ꮫ㒊ἲ་Ꮫㅮᗙ, 2 Ꮫ་Ꮫ㒊║⛉Ꮫㅮᗙ, 3 ᮾ㑥 Ꮫ་Ꮫ㒊ἲ་Ꮫㅮᗙ㸧 㹎-3 ࠕḟளሷ⣲㓟ࡼࡾ㓟ࡉࢀࡓ࣍ࢫࣇࢳࢪࣝࢥࣜࣥࡢ LC/QTOF-MS ࢆ⏝࠸ࡓศᯒࠖ ᫍᒸభ⨾ 1, Ᏻ㒊ᐶᏊ 1, ▮ᓥ 1, ᒾ℩༤ኴ㑻 1,2 㸦1 ༓ⴥᏛᏛ㝔་Ꮫ◊✲㝔 ἲ ་Ꮫᩍᐊ, 2 ᮾிᏛᏛ㝔་Ꮫ⣔◊✲⛉ ἲ་Ꮫᩍᐊ㸧 㹎-5 ࠕHSD10 ࡢ⾑୰ࢩࣝ࢝ࣝࢽࢳࣥศᯒࡼࡿᏛデ᩿ࠖ 5 1 ⚟Ꮫ་Ꮫ㒊ᗣ⛉Ꮫ, 㔜ᯇ㝧 1, ⏿ 㑳Ụ 2, ୰ᓥⱥつ 3, ణ㤿 ๛ 4, ▼ẟಙஅ㸦 㹎-7 2 ⚟Ꮫ་Ꮫ㒊ᑠඣ⛉Ꮫ, 3 ᅜ❧ᡂ⫱་⒪◊✲ࢭࣥࢱ࣮࣭࣐ࢫࢫࢡ࣮ࣜࢽࣥࢢ◊✲ᐊ, 4 ᗈᓥᏛᏛ㝔ᑠඣ⛉Ꮫ◊✲ᐊ, 5 ᮾி㒔ண㜵་Ꮫ༠ᑠඣࢫࢡ࣮ࣜࢽࣥࢢ⛉㸧 ࠕGC/MS ศᯒࡼࡿࢩࢺࣝࣜࣥ⾑ᝈ⪅ᒀ୰࢜ࣝࢽࢳ᳨ࣥฟࡢ⮫ᗋព⩏ࠖ 㜲 㹎-9 ᐀ᾏ, ᮤ ወ, 㔠 ᫂ጲ, ᙇ ⰼ㸦࣑ࣝࢫࣥࢱ࣮ࢼࢩࣙࢼࣝ ◊✲㛤Ⓨ㒊㸧 ࠕLC-MS/MS ἲࡼࡿࣄࢺᒀ୰࠾ࡅࡿࣂࢽ࣐ࣜࣝࣥࢹࣝ㓟ࠊ࣍ࣔࣂࢽࣜࣥ㓟ࠊ࣓ࢱࢿ ࣇࣜࣥࠊࣀ࣓ࣝࢱࢿࣇࣜࣥ࠾ࡼࡧࢡࣞࢳࢽࣥࡢྠᐃ㔞ἲࡢ᳨ウࠖ ሷᕝுኴ 1, ⣽⏣㤶⧊ 1, ᰘᓮᾈ⨾ 2, ᶓᕝᙲ᭸ 2, ▼ኵ 1㸦1 ᮥᯘᏛಖᏛ㒊, 2 㹎-11 ᮾி⸆⛉Ꮫ⸆Ꮫ㒊㸧 ࠕDried Blood Spot(DBS)ᒀ୰ࡢከ⢾㢮ࢹ࢟ࢫࢺࣛࣥཬࡧࣄࢻࣟ࢟ࢩ࢚ࢳࣝࢫࢱ࣮ࢳ ࡢศᯒࠖ ᑠᓥ㯞ᐇ 1, ᒸ㔝㞞ே 1, ᅵ⫧⨾ᬛᏊ 2, 㝜ᒣಙ 1㸦1 ᰴᘧ♫ LSI ࣓ࢹ࢚ࣥࢫ ࣥࢳࢻ࣮ࣆࣥࢢࣛ࣎ࣛࢺ࣮ࣜ, 2 ᅜ❧ࢫ࣏࣮ࢶ⛉Ꮫࢭࣥࢱ࣮ ࣓ࢹ࢝ࣝࢭࣥࢱ࣮㸧 㹎-13 ࠕ⭠⒴ᝈ⪅∎୰ගᏛ␗ᛶయ௦ㅰ≀ࡢศᯒࠖ すᑿඃử, 㛬 ಇဴ, ㎘ᮌሀ୍㑻, Ỉ㔝 ึ, ㇏ᒸṇ㸦㟼ᒸ┴❧Ꮫ⸆Ꮫ㒊㸧 㹎-15 ࠕࣥࢻ࢟ࢩࣝ◲㓟ࡣṧᏑ⭈ᶵ⬟ࡢపୗࡶ⾑୰✚ࡋ࣑࢘ࣞࢵࢡࢧࣝࢥ࣌ࢽ 㛵ಀࡍࡿࠖ బ⸨ᜨ⨾Ꮚ 1,2, ᳃ ᘓᩥ 1, 㕥ᮌள㔛Ἃ 1, Ⳣཎ┿ᜨ 1, ⃝ዉ✑ 1, ୕ᯞ㍜ 3, ሙ 㑳Ꮚ 1, Ọ⤮⌮ 1, బ⸨ ༤ 1,2 , ⩚ 4, ఀ⸨㈆ 1㸦1 ᮾᏛᏛ㝔 ་Ꮫ⣔ ◊✲⛉, 2 ᮾᏛᏛ㝔 ⸆Ꮫ◊✲⛉, 3 ᮾ࣓ࢹ࣭࣓࢝ࣝ࢞ࣂࣥࢡᶵᵓ, 4 ಟᩥ Ꮫᗣᰤ㣴Ꮫ㒊㸧 㹎-17 ࠕ᥈㔪࢚ࣞࢡࢺࣟࢫࣉ࣮ࣞ/ࢱࣥࢹ࣒㉁㔞ศᯒ(PESI/MS/MS)ࡼࡿ࣐࢘ࢫ⫢⮚ෆࡢ࣓ࢱ ࣮࣒࣎ࣟ┤᥋ศᯒἲ㸦ࣥࢱࢡࢺ࣭࣓ࢱ࣮࣒࣎ࣟศᯒἲ㸧ࡢᵓ⠏ࠖ ᯘ ⏤⨾ 1,2, ㈈ὠ ᱇ 1,2, ᮧ⏣ 3, ཎ⨾ 1, ୰ษኴ 1, ⲡ㔝㯞⾰Ꮚ 1, 㑣㡲 ẸỤ 4, ୰ᓥᏹᶞ 3, ▼ᕝဴஓ 1, ᅵᶫ ᆒ 1, ▼ 1㸦1 ྡྂᒇᏛᏛ㝔་Ꮫ⣔ ◊✲⛉, 2 ྡྂᒇᏛ㧗➼◊✲㝔, 3 ᓥὠ〇సᡤ, 4 ୰㒊Ꮫ⏕ᗣ⛉Ꮫ㒊㸧 㹎-19 ࠕ⺯ග࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࡼࡿ࣐࢘ࢫ⫢⮚⅖㒊࠾ࡅࡿ GC-MS/MS ௦ㅰࣉࣟࣇ ࣜࣥࢢゎᯒࠖ ́́ ᕤ⸨ᜤᙪ, ୰す , ᕝྡಟ୍, ᆏᮁ, ᒣཱྀ ு, ➉ෆ ྖ, ᑿᓥ⾜ 㸦ᰴᘧ♫ ᓥὠ〇సᡤ㸧 㹎-21 ࠕᐇ ᇶ࡙ࡃ MS/MS ࢫ࣌ࢡࢺࣝࣛࣈ࣮ࣛࣜࢆ⏝࠸ࡓ㓟ࣜࣥ⬡㉁ࡢໟᣓⓗ࣓ࢱ࣎ࣟ ࣮࣒ゎᯒࢩࢫࢸ࣒ࡢ☜❧ࠖ 㟷ᰗⰋᖹ 1,2, ụ⏣㈗ 1,2, ᭷⏣ ㄔ 1,2㸦1 ⌮Ꮫ◊✲ᡤ⤫ྜ⏕་⛉Ꮫࢭࣥࢱ࣮࣓ࢱ࣎ ࣮࣒ࣟ◊✲ࢳ࣮࣒, 2 ᶓᕷ❧Ꮫ⏕་⛉Ꮫ◊✲⛉ศᏊ࢚ࣆࢤࣀ࣒⛉Ꮫ◊✲ᐊ㸧 㹎-23 ࠕ⬡⫫⣽⬊ࡢ⬡⫫࠾ࡅࡿ㐣㓟ࢺࣜࢢࣜࢭࣜࢻࡢศᯒࠖ ῄⴍ, ⦾ᐩ㸦ᰩᯘ㸧㤶⧊, ᑠᯘ ᝆ, ༓ⴥோᚿ㸦ᾏ㐨Ꮫ Ꮫ㝔ಖ⛉Ꮫ◊✲㝔㸧 㹎-25 ࠕ࣓ࢱ࣮࣒࣎ࣟゎᯒࡼࡿዷፎ㧗⾑ᅽ⭈⒪ᶆⓗศᏊࡢ᥈⣴ࠖ ὠᅧ⏤ెᏊ 1, బ⸨ᜨ⨾Ꮚ 1,2, అ㛫ᬛྐ 1, బ⸨ ༤ 1,2, 㧗ᶫಙ⾜ 1,2, ୕ᯞ㍜ 2,3 㸦1 ᮾᏛᏛ㝔⸆Ꮫ◊✲⛉, 2 ᮾᏛᏛ㝔་Ꮫ⣔◊✲⛉, 3 ᮾᏛᮾ࣓ࢹ ࣭࣓࢝ࣝ࢞ࣂࣥࢡᶵᵓ㸧 㹎-27 ࠕ࣐ࢡࣟࣇ࣮ࣟLC/MS/MS ࡼࡿᒀ୰పศᏊ࣌ࣉࢳࢻ୍ᩧศᯒἲࠖ ⏣ṇつ, బ⸨ᙪ, 㝜ᒣಙ, ᒸ㔝㞞ே㸦ᰴᘧ♫ LSI ࣓ࢹ࢚ࣥࢫ ࣥࢳࢻ࣮ ࣆࣥࢢࣛ࣎ࣛࢺ࣮ࣜ㸧 㹎-29 ࠕLC-MS/MS ἲࡼࡿ㇋ࢯࣇࣛ࣎ࣥ࠾ࡼࡧ࢚ࢡ࣮࢜ࣝࡑࡢᢪྜ௦ㅰ≀ࡢ୍ᩧศᯒἲ ࡢ᳨ウࠖ ᮌୗ⍞㈗ 1, ⣽⏣㤶⧊ 1, ᰘᓮᾈ⨾ 2, ᶓᕝᙲ᭸ 2, ▼ኵ 1㸦1 ᮥᯘᏛಖᏛ㒊, 2 㹎-31 ᮾி⸆⛉Ꮫ⸆Ꮫ㒊㸧 ࠕLC/ESI-MS/MS ࡼࡿ⾑₢୰ 25-hydroxyvitamin D3 ཬࡧࡑࡢ◲㓟ᢪྜయࡢྠᐃ㔞ἲ ࡢ㛤Ⓨࠖ ᚋ⸨ᙬె 1, ᶓ⏣㯞⾰ 1, ᑠᕝ⚈㑻 1, ᑠᯇ㈼ྖ 2, ᮡᾆᓫᾈ 2, ᮾ 㐩ஓ 1㸦1 ᮾி⌮ ⛉Ꮫ⸆Ꮫ㒊, 2 㟼ᒸ῭⏕⥲ྜ㝔㸧 㹎-33 ࠕ㔜Ỉ⣲ࣀࣅࣞࢳࣥࡢྜᡂ LC/MS/MS ࡼࡿࣀࣅࣞࢳࣥᐃ㔞ࡢᛂ⏝ࠖ 1 1 ୰㒊Ꮫᛂ⏝⏕≀Ꮫ㒊, ᖹ㔝ṇᝅ 1, ⡿⃝㈗அ 2, ㌴ Ⅸඔ 2, ⚷ ῭Ὀ 1,2,3, ሐෆ せ㸦 2 㹎-35 ୰㒊Ꮫ⏕≀ᶵ⬟㛤Ⓨ◊✲ᡤ, 3 ᰴᘧ♫ Ἀ⦖ࣜࢧ࣮ࢳࢭࣥࢱ࣮㸧 ࠕ㸰✀㢮ࡢᏳᐃྠయᶆ㆑ἲࢆ⏝࠸ࡓ⭤⬔⒴ࡢ⾑୰ࣂ࣐࣮࣮࢜࢝ࢱࣥࣃࢡ㉁ࡢ᥈⣴ࠖ ᖹ⏣ెஓ 1, 㐲⸨ඞஓ 1, ᩪ⸨㐩ஓ 1,2, ᕝᓥ♸ 2, ༡⏣ ㄽ 3, ᯇᮏᑗ 3, ᒾᮧṇႹ 3, ᑠᑎ⩏⏨ 1,2㸦1 㔛Ꮫ⌮Ꮫ㒊⏕≀≀⌮Ꮫ◊✲ᐊ, 2 㔛Ꮫ⌮Ꮫ㒊㝃ᒓᝈࣉࣟࢸ࣑࢜ ࢡࢫࢭࣥࢱ࣮, 3 㔛Ꮫ་Ꮫ㒊Ἢᒀჾ⛉㸧 㹎-37 ࠕᏳᐃྠయᶆ㆑ἲࢆ⏝࠸ࡓࢫࢺࣞࢫ㞀ᐖࣔࢹ࣐ࣝ࢘ࢫᾏ㤿ࡢࣉࣟࢸ࣮࣒࢜ኚືࡢゎᯒࠖ ᑠ㧗㡴Ꮚ 1, ᑠᯘ༓ 1, ຍ⸨ె 1,2, 㧗ᶫᯞ㔛 1, ᩧ⸨㐩ஓ 1,2, ᕝᓥ♸ 2, ᯈ ㄔ 3, ᒣ᳃᪩⧊ 3, Ọᒣ༤㏻ 3, 㣤⏣ㅍᐅ 4, ᐑᒸ ➼ 4, 㧗ᶫṇ㌟ 3, ᑠᑎ⩏⏨ 1,2㸦1 㔛Ꮫ⌮ Ꮫ㒊≀⌮Ꮫ⛉⏕≀≀⌮Ꮫ◊✲ᐊ, 2 㔛Ꮫ⌮Ꮫ㒊㝃ᒓᝈࣉࣟࢸ࣑࢜ࢡࢫࢭࣥࢱ࣮, 3 㔛Ꮫ་Ꮫ㒊⏕Ꮫ◊✲ᐊ, 4 㔛Ꮫ་Ꮫ㒊⢭⚄⛉㸧 ́́ 㹎-39 ࠕH-D ᛂࢆ⏝࠸ࡓࣁ࣑ࣝࣥࡢࢧࣟࢤ࣮ࢺ≀㉁ྜᡂࠖ ᶓᒣ⿱ኈ 1, ᖹ㔝ṇᝅ 1, ⡿⃝㈗அ 2, ㌴ Ⅸඔ 2, ⚷ Ꮫᛂ⏝⏕≀Ꮫ㒊, 㹎-41 㸰 ῭Ὀ 1,2,3, ሐෆ せ 1㸦1 ୰㒊 ୰㒊Ꮫ⏕≀ᶵ⬟㛤Ⓨ◊✲ᡤ, 3 ᰴᘧ♫Ἀ⦖ࣜࢧ࣮ࢳࢭࣥࢱ࣮㸧 ࠕMALDI-TOF MS ࡼࡿ⾑ᾮᇵ㣴㝧ᛶ࣎ࢺࣝᇵ㣴ᾮࢆ⏝࠸ࡓ┤᥋ྠᐃࡘ࠸࡚ࠖ ụࣨ㇂ెᑑᏊ, ᅵᒇ ᠇㸦㟼ᒸᕷ❧ΎỈ㝔 ᳨ᰝᢏ⾡⛉㸧 㹎-43 ࠕᚠ⎔ჾ㛵㐃⤌⧊࠾ࡅࡿ㹊㹇㹋ࢻ࣓ࣥࢱࣥࣃࢡ㉁」ྜయゎᯒࠖ ᒣ୰ᐶ᫂ 1, ᑎ⏣ ᜨ 1, ⳥ᆅἋ⪨Ꮚ 1, ᔱ⏣ᓫྐ 2, ᳜⏣ึỤ 3, 㣤ཎᘯ 4, ụᕝ㞞ဢ 1 㸦1 ྠᚿ♫Ꮫ⏕་⛉Ꮫ㒊་⏕ࢩࢫࢸ࣒Ꮫ⛉, 2 ᓥὠ〇సᡤᇶ┙ᢏ⾡◊✲ᡤ, 㸱 ᅜ❧ᚠ 4 ⎔ჾ◊✲ࢭࣥࢱ࣮⌮㒊, ᕞᏛᏛ㝔་Ꮫ◊✲㝔⬻⚄⤒እ⛉㸧 㹎-45 ࠕ⫵⥺⥔㛵㐃ࡋࡓ⬡㉁ࡢ⥙⨶ゎᯒࠖ ᒣྜྷᖾ 1,2, ṇᮌ⣖㝯 2, Ἑ㔝㞞ே 1, ᴮᮏ⣖அ 1, ୰ᮧ♸ኴ㑻 1, ⸨⃝᭸ᖾ 1, ┤ ㍤ 1, 㡲⏣㝯ᩥ 1, ℩⸨ග 2㸦1 ᯇ་⛉Ꮫ ෆ⛉Ꮫ➨ㅮᗙ, 2 ྠ ゎ๗Ꮫㅮᗙ⣽⬊⏕ ≀Ꮫศ㔝㸧 㹎-47 ࠕ⏕య࣑ࣥྜ≀ࢆᑐ㇟ࡋࡓ᪂つㄏᑟయἲࡼࡿ࣐࢘ࢫ⬻ࡢ㉁㔞ศᯒ࣓࣮ࢪࣥࢢࠖ ῝㔝 ⳹ 1, ⬥ ⣖ᙪ 1, Ṋྐ㑻 1,2 , ℩⸨ග 2, ▮ᑿ⫱Ꮚ 1㸦1 ᯇ་⛉Ꮫ࣓ࢹ ࢝ࣝࣇ࢛ࢺࢽࢡࢫ◊✲ࢭࣥࢱ࣮, 2 ᯇ་⛉Ꮫゎ๗Ꮫㅮᗙ⣽⬊⏕≀Ꮫศ㔝㸧 㹎-49 ࠕ㉁㔞ศᯒ࣓࣮ࢪࣥࢢࢹ࣮ࢱࢆ⏝࠸ࡓ⤌⧊ษ∦ࡢ࢚ࣥࢺࣟࣆ࣮࣓࣮ࢪࣥࢢゎᯒࠖ బ⸨㥴ᖹ, బ⸨ᬛோ, ṇᮌ⣖㝯, ℩⸨ග㸦ᯇ་⛉Ꮫ ゎ๗Ꮫㅮᗙ ⣽⬊⏕≀Ꮫศ㔝㸧 㹎-51 ࠕ◲㓟ࣥࣔࢽ࣒࢘ࡣ࣐ࢺࣜࢵࢡࢫῧຍࡋ࡚ MALDI-IMS ࠾ࡅࡿ⬻ෆ࢝ࣝࢽࢳࣥࠊ ࢭࢳࣝ࢝ࣝࢽࢳࣥࠊࢢࣜࢭࣟ࣍ࢫ࣍ࢥࣜࣥ⏤᮶ࡢࢩࢢࢼࣝࢆ 10 ಸ௨ୖቑᙉࡍࡿࠖ ᮡᒣᰤ, ṇᮌ⣖㝯, ᯇୗ⚈Ꮚ, ℩⸨ග㸦ᯇ་⛉Ꮫ་Ꮫ⣔◊✲⛉ゎ๗Ꮫㅮᗙ⣽ ⬊⏕≀Ꮫศ㔝㸧 㹎-53 ࠕ๓㢌ഃ㢌ⴥኚᛶᝈ⪅⬻ෆ࠾ࡅࡿࢱ࢘ࣜࣥࡢ⃰ᗘ࠾ࡼࡧศᕸゎᯒࠖ ᯇୗ⚈Ꮚ 1, ṇᮌ⣖㝯 1, ㏆⸨ 1, Ṋྐ㑻 1, ㉥ὠ⿱ᗣ 2,3, ⛅⏣ኳᖹ 4, ᮡᒣᰤ 1, ⚟⏣ᩔኵ 4, ▮ᑿ⫱Ꮚ 5, ℩⸨ග 1㸦1 ᯇ་⛉Ꮫゎ๗Ꮫㅮᗙ⣽⬊⏕≀Ꮫศ㔝, 2 ⚟♴ ᮧ㝔㛗ᑑ་Ꮫ◊✲ᡤ, 3 ྡྂᒇᕷ❧ᏛᏛ㝔་Ꮫ◊✲⛉ᆅᇦ་⒪ᩍ⫱Ꮫ, 4 ᯇ་ 5 ⛉Ꮫ⚄⤒⏕⌮Ꮫㅮᗙ, ᯇ་⛉Ꮫ࣓ࢹ࢝ࣝࣇ࢛ࢺࢽࢡࢫࢭࣥࢱ࣮ග࣓࣮ࢪࣥ ࢢ◊✲ᐊ㸧 㹎-55 ࠕ⫢ษ㝖㔞╔┠ࡋࡓ࣐࢘ࢫ⫢ษ㝖ᚋ⫢⏕ࡢ࣓࣮ࢪࣥࢢ㉁㔞ศᯒࠖ ཱྀබኴ 1, ㎷ 㞝 2, ୰ᕝ♸㍤ 2, ୰㑦ᬛஅ 3, Ἴከ㔝ᝋᮁ 1, ୖᮏఙ 1, ụᕝ㞞ဢ 2 㸦1 ி㒔Ꮫ་Ꮫ◊✲⛉⫢⫹⮅⛣᳜እ⛉, 2 ྠᚿ♫Ꮫ⏕་⛉Ꮫ㒊་⏕ࢩࢫࢸ࣒Ꮫ⛉, 3 㹎-57 㛵す་⛉Ꮫ⸆⌮Ꮫㅮᗙ㸧 ࠕ㹑㹂㹒ࣛࢵࢺࡢ⮅⮚ࢆᑐ㇟ࡋࡓࣉࣟࢸ࣑࢜ࢵࢡ㉁㔞࣓࣮ࢪࣥࢢࠖ ┈ᒣ 1, ᒾᓮᩍ 2, ⴱཎ⏤㈗ 3, ⱝᅬ ༤ 1, 㡞⃝ ᓫ 2, ⸨ࣨ㇂ᾈᩥ 1, ᮾᒣ┿ 1, ᪥ẚ 1, ᰗᾈ⏤⣖ 1, ᐟ㇂┿⏤ 3, ụᕝ㞞ဢ 3㸦1 ᑠ㔝⸆ရᕤᴗ, 2 ࣈ࣮ࣝ࢝ࢲࣝࢺࢽ ࢡࢫ, 3 ྠᚿ♫Ꮫ⏕་⛉Ꮫ㒊་⏕ࢩࢫࢸ࣒Ꮫ⛉㸧 ́́ 㹎-59 ࠕࡆࡗṑ㢮⢭ᕢ࠾ࡅࡿࢾࢡࣞ࢜ࢳࢻࡢ࣓࣮ࢪࣥࢢ㉁㔞ศᯒࠖ ୰すஅ 1, ㎷ 㞝 1, ୰ᕝ♸㍤ 1, ཱྀබኴ 1, ゅ⏣ఙே 1, ୰㑦ᬛஅ 2, ᯇ႐அ 3, ᕷᒸኴ㑻 4, ᑠᕝ ಟ 3, ụᕝ㞞ဢ 1㸦1 ྠᚿ♫Ꮫ⏕་⛉Ꮫ㒊་⏕ࢩࢫࢸ࣒Ꮫ⛉, 2 㹎-61 㛵す་⛉Ꮫ⸆⌮Ꮫㅮᗙ, 3 ி㒔ᏛᏛ㝔Ἢᒀჾ⛉Ꮫ, 4 ࠸ࡕ࠾Ἢᒀჾ⛉ࢡࣜࢽࢵࢡ㸧 ࠕ᪂㩭⤖ங⒴⤌⧊ษ∦ࢆ⏝࠸ࡓ MALDI-IMS ゎᯒࡼࡿங⒴≉␗ࢱࣥࣃࢡศᏊೃ⿵ࡢྠᐃࠖ బ⸨ኤᏊ 1,2, ୰す㇏ᩥ 2, ᒾᮏᙪ 1, ෆᒣஂ 1㸦㸯㜰་⛉Ꮫ㝃ᒓ㝔࣭ங⭢ෆ ศἪእ⛉, 2 㜰་⛉Ꮫ࣭⮫ᗋ᳨ᰝ་Ꮫᩍᐊ㸧 14㸸00㹼15㸸00 ᣍᚅㅮ₇㸦41 ㆟ᐊ㸧 ᗙ㛗㸸℩⸨ග㸦ᯇ་⛉Ꮫ㸧 㹊-1 ࠕSystems Medicine in a Changing World: The Challenge of Measuring and Visualising Personal and Public Healthcare Data.ࠖ Jeremy K. Nicholson㸦Department of Surgery and Cancer Imperial College London㸧 15㸸00㹼15㸸30 ဨ㞟㸦41 ㆟ᐊ㸧 15㸸30㹼16㸸00 ᯇᮏຬ㈹ཷ㈹ㅮ₇㸦41 ㆟ᐊ㸧 ᗙ㛗㸸⩚㸦ಟᩥᏛ㸧 㹊-2 ࠕ㉁㔞ศᯒᢏ⾡ࡢ⮫ᗋ᳨ᰝᛂ⏝㛵ࡍࡿ◊✲ࠖ 㔝ᮧᩥኵ㸦༓ⴥᏛ་Ꮫ㒊㝃ᒓ㝔࣐ࢫࢫ࣌ࢡࢺ࣓ࣟࢺ᳨࣮ࣜᰝデ᩿Ꮫ㸧 16㸸00㹼17㸸30 ࢩ࣏ࣥࢪ࣒࢘㸰㸸ࠕ㉁㔞࣓࣮ࢪࣥࢢゎᯒ̿ᇶ♏ࡽᛂ⏝ࡢ᪂ᒎ㛤ࠖ 㸦41 ㆟ᐊ㸧 ࣮࢜࢞ࢼࢨ࣮࣭ᗙ㛗㸸୰す㇏ᩥ㸦㜰་⛉Ꮫ㸧 㹑2-1 ࠕ࣓࣮ࢪࣥࢢ㉁㔞ศᯒ࠾ࡅࡿ㧗ឤᗘ ᐃࡢࡓࡵࡢẁ㝵࣐ࢺࣜࢵࢡࢫ౪⤥ἲᡭ ἲ᭱㐺ࠖ ᪂㛫⚽୍㸦㜰ᏛᏛ㝔ᕤᏛ◊✲⛉㸧 㹑2-2 ࠕ࣓࣮ࢪࣥࢢ㉁㔞ศᯒࡼࡿ᳜≀ྵ᭷ᡂศࡢゎᯒࠖ ᖹ ಟ 1, ➃ᓮ㔛ᕹ 1, ∦㔝 ⫕ 1, 㔠Ꮚస 2, ୰す㇏ᩥ 3㸦1 ⚟┴❧Ꮫ⏕≀㈨※Ꮫ 㒊, 2 ᕞᕤᴗᏛ, 3 㜰་⛉Ꮫ㸧 㹑2-3 ࠕ⤫ྜኻㄪ⒪⸆ࣁࣟ࣌ࣜࢻ࣮ࣝࡼࡿ⚄⤒ẘᛶⓎ⌧ᶵᵓࡢゎᯒ㸸㉁㔞࣓࣮ࢪࣥࢢ ᡭἲࡼࡿ⬻ෆࣆࣜࢪࢽ࣒࢘௦ㅰ≀ࡢྍどࠖ ྜྷ⏣ཎつ 1, ୰す㇏ᩥ 2, ᮡᮏ㤶ዉ 3, ༑ᔒ୍㞝 4㸦1 ㏆␥Ꮫ་Ꮫ㒊ἲ་Ꮫ, 2 㜰་⛉ Ꮫ⮫ᗋ᳨ᰝ་Ꮫ, 3 㜰ᏛᏛ㝔་Ꮫ⣔◊✲⛉ἲ་Ꮫ, 4 ୍⯡♫ᅋἲே་⸆ศᯒ༠㸧 㹑2-4 ࠕࣝࢶࣁ࣐࣮⬻◊✲ࡢࡓࡵࡢ㉁㔞࣓࣮ࢪࣥࢢゎᯒࠖ ụᕝ㞞ဢ 1, ᐑᆏ▱ᏹ 1, ゅ⏣ఙே 1, ᒾᓮᩍ 2, 㡞⃝ ᓫ 2, 㝮ⶶᖾ 3, ᮧᒣ⦾㞝 3, ཎᗣኵ 4㸦1 ྠᚿ♫Ꮫ⏕་⛉Ꮫ㒊, 2 ࣈ࣮࣭ࣝ࢝ࢲࣝࢺࢽࢡࢫओ, 3 ᮾி㒔ᗣ㛗ᑑ ་⒪ࢭࣥࢱ࣮◊✲ᡤ㧗㱋⪅ࣈࣞࣥࣂࣥࢡ, 4 ྠᚿ♫Ꮫ⬻⛉Ꮫ◊✲⛉㸧 ́́ 17㸸30㹼18㸸30 ≉ูㅮ₇㸦41 ㆟ᐊ㸧 ᗙ㛗㸸℩⸨ග㸦ᯇ་⛉Ꮫ㸧 㹊-3 ࠕḟୡ௦ࣉࣟࢸ࣑࢜ࢡࢫࢆ⏝࠸ࡓࡀࢇ≉ᛶࡢゎ᫂ࠖ ୰ᒣᩗ୍㸦ᕞᏛ ⏕య㜵ᚚ་Ꮫ◊✲ᡤ ศᏊ་⛉Ꮫศ㔝 ࣄࢺࣉࣟࢸ࣮࣒࢜◊✲ࢭࣥࢱ࣮㸧 19㸸00㹼 ᠓ぶ㸦ࡣࡲࡲࡘᆅࣅ࣮ࣝᕤᡣ ࣐࣭ࣥࢩࣗࣟࢫ 18㸸30 ཷࠊ19㸸00 㛤ጞ㸧 9 ᭶ 18 ᪥㸦㔠㸧 8㸸30 ཷ㸦㸲㹄ࣟࣅ࣮㸧 9㸸00㹼10㸸00 ࣮ࣔࢽࣥࢢࢭ࣑ࢼ࣮㸦41 ㆟ᐊ㸧 ࢧ࣮ࣔࣇࢵࢩ࣮ࣕࢧ࢚ࣥࢸࣇࢵࢡᰴᘧ♫ 㹋㹑-1 ࠕLC/MS/MS ࡢ⮫ᗋ᳨ᰝᛂ⏝ࡢྲྀࡾ⤌ࡳࠖ బ⸨ Ᏺ㸦༓ⴥᏛ་Ꮫ㒊㝃ᒓ㝔࣐ࢫࢫ࣌ࢡࢺ࣓ࣟࢺ᳨࣮ࣜᰝデ᩿Ꮫ㸧 10㸸00㹼12㸸00 ࢩ࣏ࣥࢪ࣒࢘㸱㸸 ࠕࢺࣛࣥࢫ࣑࢜ࢡࢫゎᯒࡀษࡾᣅࡃḟୡ௦་⒪࠾ࡅࡿࣂ࣐࣮࣮࢜࢝᥈⣴ࠖ 㸦41 ㆟ᐊ㸧 ࣮࢜࢞ࢼࢨ࣮࣭ᗙ㛗㸸୕ᯞ㍜㸦ᮾᏛ㸧 ᗙ㛗㸸ᯇ⏣ྐ⏕㸦㜰Ꮫ㸧 㹑3-1 ࠕࢺࣛࣥࢫ࣑࢜ࢡࢫゎᯒࡼࡿࣥࢫࣜࣥ௦ㅰไᚚࢿࢵࢺ࣮࣡ࢡࡢᵓ⠏ࠖ ᰆᮌඞஅ 1, ஂಖ⏣ᾈ⾜ 2,3, 㯮⏣┿ஓ 1,4㸦1 ᮾிᏛᏛ㝔⌮Ꮫ⣔◊✲⛉࣭⏕≀⛉Ꮫᑓ ᨷ, 2 ᕞᏛ࣭⏕య㜵ᚚ་Ꮫ◊✲ᡤ࣭ࢺࣛࣥࢫ࣑࢜ࢡࢫ་Ꮫ◊✲ࢭࣥࢱ࣮࣭⤫ྜ࣑࢜ ࢡࢫศ㔝, 3JST ࡉࡁࡀࡅ, 4JST CREST㸧 㹑3-2 ࠕ⬡㉁ࢡ࢜ࣜࢸࡽゎࡁ᫂ࡍែ࣭ࣂ࢜ࣟࢪ࣮◊✲ࠖ ᭷⏣ㄔ 1,2㸦1 ⌮Ꮫ◊✲ᡤ⤫ྜ⏕་⛉Ꮫ◊✲ࢭࣥࢱ࣮࣭࣓ࢱ࣮࣒࣎ࣟ◊✲ࢳ࣮࣒, 2 㹑3-3 ᶓᕷ❧ᏛᏛ㝔⏕་⛉Ꮫ◊✲⛉㸧 ࠕ௦ㅰࣇࣛࢵࢡࢫゎᯒ୰ᚰ௦ㅰࡢࢺࣛࣥࢫ࣑࢜ࢡࢫࠖ ᯇ⏣ྐ⏕, ΎỈ ᾈ㸦㜰ᏛᏛ㝔ሗ⛉Ꮫ◊✲⛉㸧 㹑3-4 ࠕつᶍࢥ࣮࣍ࢺ࣑࢜ࢡࢫゎᯒࡼࡿᝈண㜵࣐࣮࣮࢝᥈⣴ࠖ ୕ᯞ㍜ 1,2㸦1 ᮾᏛᮾ࣓ࢹ࣭࣓࢝ࣝ࢞ࣂࣥࢡᶵᵓ, 2 ᮾᏛᏛ㝔་Ꮫ⣔◊✲⛉㸧 12㸸00㹼13㸸00 ࣛࣥࢳࣙࣥࢭ࣑ࢼ࣮3㸦41 ㆟ᐊ㸧 ࢪࣞࣥࢺ㺃ࢸࢡࣀࣟࢪ࣮ᰴᘧ♫ 㹊㹑-3 ࠕLC-QTOF ࢆ⏝࠸ࡓ༴㝤ࢻࣛࢵࢢࡢศᯒࠖ ᇣᫀᙪ㸦ࢪࣞࣥࢺ㺃ࢸࢡࣀࣟࢪ࣮ᰴᘧ♫㸧 ́́ 13㸸00㹼14㸸00 㹎-2 ࣏ࢫࢱ࣮Ⓨ⾲㸦അᩘ₇㢟㸧 㸦43㸩44 ㆟ᐊ㸧 ࠕ⤌⧊ษ∦୰ࢪࣇ࢙ࢽࢪࣥࡢ MALDI-MS(/MS)ࡼࡿ┤᥋ศᯒࠖ ༡᪉ࡼᏊ 1, 㕥ᮌ㞞Ꮚ 2, 㔝⃝⚽ᶞ 1, ᒣᓊ ᱁ 1, 㛗㇂ᕝᘯኴ㑻 1, 㜿Ẹ᪥ 1, ᶒᏲ㑥ኵ 1, Ώ㒊ຍዉᏊ 1, 㕥ᮌಟ 1㸦1 ᯇ་⛉ᏛᏛἲ་Ꮫ, 2 ᯇ་⛉Ꮫᐇ㦂ᐇ ⩦ࢭࣥࢱ࣮ 㹎-4 ࠕἲ་ヨᩱ࠾ࡅࡿ⸆≀୰ẘࡢࣂ࣐࣮࣮࢜࢝᥈⣴ (2)ࠖ Ᏻ㒊ᐶᏊ 1, ᫍᒸభ⨾ 1, ᑠᲚဴ㞝 2, ዉⰋ᫂ዉ 1, Ọ⃝᫂ె 1, ▮ᓥ 1, ᒾ℩༤ኴ㑻 1,3 㸦1 ༓ⴥᏛᏛ㝔་Ꮫ◊✲㝔 ἲ་Ꮫᩍᐊ, 2 ᰴᘧ♫࢚࣮ࣅ࣮ࢧ࢚ࢵࢡࢫ, 3 ᮾி ᏛᏛ㝔་Ꮫ⣔◊✲⛉ ἲ་Ꮫᩍᐊ㸧 㹎-6 ࠕ㉁㔞ศᯒࡼࡿ௦ㅰ␗ᖖ⸆≀௦ㅰࡢ㚷ูࠖ ᙇ ⰼ, ᮤ ወ, ㉿ ᑀ, 㔠 ᫂ጲ, 㜲 ᐀ᾏ㸦࣑ࣝࢫࣥࢱ࣮ࢼࢩࣙࢼࣝ◊✲㛤Ⓨ㒊㸧 㹎-8 ࠕGCMS ࡼࡿ⣅౽୰⭉ᩋ⏘≀ࡢ ᐃࠖ ⅲ⹒ཧ, ⚟ཎ⨾௦Ꮚ, ஂ⏣㈗⩏㸦ᰴᘧ♫ࢸࢡࣀࢫ࣭ࣝ࢞ࣛ࣎㸧 㹎-10 ࠕLC-MS/MS ࡼࡿᒀ୰ࢥࣝࢳࢰ࣮ࣝཬࡧࢥࣝࢳࢰࣥࡢ 6Ș- / 6ș-Ỉ㓟௦ㅰ≀ࡢศ㞳 ᐃ㔞ἲࠖ ᶓᕝᙲ᭸ 1, ඵ㒓㞞ᘯ 1, ᖹ㔝Ⰻᖹ 1, ⣽⏣㤶⧊ 2, ▼ኵ 2, ྂ⏣ 㝯 1, ᰘᓮᾈ⨾ 1 㸦1 ᮾி⸆⛉Ꮫ⸆Ꮫ㒊, 2 ᮥᯘᏛಖᏛ㒊㸧 㹎-12 ࠕℐ⣬⾑ࢆ⏝࠸ࡓ᪂⏕ඣࡢࢡࣞࢳࢽࣥࢫࢡ࣮ࣜࢽࣥࢢ᳨ᰝ◊✲ࠖ ୰㔝 ඃ 1, ୖᮧ 2, ୰ᓥⴥᏊ 3, ఀ⸨ဴဢ 3, ᮏ⏣㞞ᩗ 4, 㰻⸨ఙ 1㸦1 ྡྂᒇᕷ ❧Ꮫᑠඣ⛉, 2 ࠶࠸ࡕᑠඣಖ་⒪⥲ྜࢭࣥࢱ࣮⭈⮚⛉, 3 ⸨⏣ಖ⾨⏕Ꮫᑠඣ⛉, 4 㹎-14 ᮾி㒔❧ᑠඣಖ་⒪ࢭࣥࢱ࣮㸧 ࠕUPLC-MS/MS ࡼࡿࣆ࣑ࣜࢪࣥሷᇶ௦ㅰ≀ࡢᐃ㔞ࡼࡿࣆ࣑ࣜࢪࣥ௦ㅰ␗ᖖࢫࢡࣜ ࣮ࢽࣥࢢࠖ ๓⏣ᗣ༤ 1, ⓙᕝ┿㔛 1, ୰ᓥⴥᏊ 2, ᚋ⸨ెዉ 1, ᇼ⏣♸ᚿ 1, ∦ᒸᬛဢ 3, ᕝฟ⩏ᾈ 1, ఀ⸨ဴဢ 2, ᮌᮧဴ 1,3㸦1 ྡྂᒇᕷ❧Ꮫ Ꮫ㝔⸆Ꮫ◊✲⛉, 2 ⸨⏣ಖ⾨⏕Ꮫ ་ Ꮫ㒊ᑠඣ⛉, 3 ྡྂᒇᕷ❧Ꮫ Ꮫ㝔་Ꮫ◊✲⛉㸧 㹎-16 ࠕ➽ࢪࢫࢺࣟࣇ࣮ᝈ⪅ࡢᒀ୰ࣉࣟࢫࢱࢢࣛࣥࢪࣥ D2 ࠾ࡼࡧ E2 ௦ㅰ≀ࡢኚືࠖ ➉ෆᩔᏊ 1, ฟⰋ༤ 2, ᯇᑿ㞞ᩥ 3㸦1 ⚄ᡞ⸆⛉Ꮫ, 2 ⟃ἼᏛᅜ㝿⤫ྜ╧╀་⛉Ꮫ◊ ✲ᶵᵓ, 3 ⚄ᡞᏛ㝔Ꮫ⥲ྜࣜࣁࣅࣜࢸ࣮ࢩࣙࣥᏛ㒊㸧 㹎-18 ࠕ㧗⬡⫫㣗ᦤྲྀࡀᘬࡁ㉳ࡇࡍ⭠ෆ⎔ቃࡢኚᑐࡍࡿ࣓ࢱ࣮࣒࣎ࣟゎᯒࡼࡿホ౯ࠖ すᾏ ಙ 1, ྜྷ⏣ ඃ 1,2㸦1 ⚄ᡞᏛᏛ㝔་Ꮫ◊✲⛉, 2 ᅜ❧◊✲㛤Ⓨἲே᪥ᮏ་⒪◊ ✲㛤Ⓨᶵᵓ, AMED-CREST㸧 㹎-20 ࠕUPLC/MS/MS ࡼࡿ᪥ᮏேࣉࣟࣆ࢜ࣥ㓟⾑ᝈ⪅ࡢࣉࣟࣆ࢜ࢽࣝ-CoA ࢝ࣝ࣎࢟ࢩ࣮ࣛ ࢮάᛶ ᐃࠖ ᚋ⸨ెዉ 1, ๓⏣ᗣ༤ 1, ୰ᓥⴥᏊ 2, ఀ⸨ဴဢ 2, ๓⏣㝧Ꮚ 1, ᇼ⏣♸ᚿ 1, ∦ᒸᬛဢ 3, ́́ ᕝฟ⩏ᾈ 1, ᮡᒣᡂྖ 4, ᮌᮧဴ 1,3㸦1 ྡྂᒇᕷ❧ᏛᏛ㝔⸆Ꮫ◊✲⛉, 2 ⸨⏣ಖ ⾨⏕Ꮫᑠඣ⛉, 3 ྡྂᒇᕷ❧ᏛᏛ㝔་Ꮫ◊✲⛉, 4 ឡ▱Ꮫ㝔Ꮫ⸆Ꮫ㒊㸧 㹎-22 ࠕࢫࢸࣟࢻ᳨ᰝヨᩱࡋ࡚ࡢ∎ࡢホ౯:ᕥྑࡢᡭࡢ∎୰ࢫࢸࣟࢻࡢྵ㔞ᕪࠖ ᑠᕝ⚈㑻1, ຍ⸨⏤㑣1, 㧗㔝 㤶1, ୰␁ຬኴ㑻1, ᒣᙧ᠇୍㑻1, 㛬 ಇဴ2, ᮾ 㐩ஓ1 㸦1ᮾி⌮⛉Ꮫ⸆Ꮫ㒊, 2㟼ᒸ┴❧Ꮫ⸆Ꮫ㒊㸧 㹎-24 ࠕLC/MS/MS ࡢ⮫ᗋ᳨ᰝᛂ⏝ ̿ࣅࢱ࣑ࣥ D ௦ㅰ≀ ᐃࢆᇶ┙̿ࠖ బ⸨Ᏺ 1, ▼ẟᓫஅ 2, ᑠᕝ⚈㑻 3, すᮧᇶ 2,4, ᯇୗ୍அ 2,4, ᮾ㐩ஓ 3, 㔝ᮧᩥኵ 1 㸦1 ༓ⴥᏛ་Ꮫ㒊㝃ᒓ㝔࣐ࢫࢫ࣌ࢡࢺ࣓ࣟࢺ᳨࣮ࣜᰝデ᩿Ꮫ, 2 ༓ⴥᏛ་Ꮫ㒊㝃ᒓ 㝔᳨ᰝ㒊, 3 ᮾி⌮⛉Ꮫ⸆Ꮫ㒊⮫ᗋศᯒ⛉Ꮫ◊✲ᐊ, 4 ༓ⴥᏛᏛ㝔་Ꮫ◊✲㝔 ศᏊែゎᯒᏛ㸧 㹎-26 ࠕ⺯ග࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈᢞ࣐࢘ࢫ⫢⤌⧊ᑐࡍࡿ LC/MS ࢆ⏝࠸ࡓ௦ㅰ≀୍ᩧศᯒࠖ ୰す , ᕤ⸨ᜤᙪ, ᕝྡಟ୍, ᒣཱྀ ு, ➉ෆ ྖ, ᑿᓥ⾜㸦ᰴᘧ♫ ᓥὠ〇సᡤ㸧 㹎-28 ࠕnano LC/MS/MS ࢆ⏝࠸ࡓࣛࢵࢺ⫢⮚୰⫹Ồ㓟୍ᩧศᯒἲࡢᵓ⠏ࠖ ὸ㔝⨾ 1,2 , ㈈ὠ ẸỤ 4, ᅵᶫ ᱇ 1, ℧ኴᮁ 1, ⲡ㔝㯞⾰Ꮚ 1, ᳃୍ဢ 2, ෆ⸨ஂ㞝 3, 㑣㡲 ᆒ 1, ▼ 1㸦1 ྡྂᒇᏛᏛ㝔་Ꮫ⣔◊✲⛉, 2 㔠ᇛᏛ㝔Ꮫ⏕ ά⎔ቃᏛ㒊, 3 ⸨⏣ಖ⾨⏕Ꮫ་Ꮫ㒊, 4 ୰㒊Ꮫ⏕ᗣ⛉Ꮫ㒊㸧 㹎-30 ࠕ⮫ᗋ᳨ᰝࢆ┠ⓗࡋࡓ LC-MS/MS ࡼࡿ⾑Ύ୰ࢩࣝ࢝ࣝࢽࢳࣥࡢᐃ㔞ศᯒἲࡢ㛤Ⓨࠖ ᑠᯘᘯ 1, ᒣ⏣ 1, ᆓ ு㍜ 1, 㛗㇂ᕝ᭷⣖ 1, ᒣཱྀΎḟ 1, ᇛୗ⩏ 2, ఀ⸨ᑗ 2, ᡭ㔝 2, ཎᡂ 2㸦1 ᓥ᰿Ꮫ་Ꮫ㒊ᑠඣ⛉, 2 ✚Ỉ࣓ࢹ࢝ࣝᰴᘧ♫㸧 㹎-32 ࠕLC-MS/MS ࡼࡿ⾑Ύ࢚ࢫࢺࣟࢤࣥ࠾ࡼࡧࣉࣟࢤࢫࢸࣟࣥࡢྠᐃ㔞ࠖ ᐑᯘభ⾰ 1, బ⸨ Ᏺ 2, ⬥ṇ㈗ 2, すᮧ ᇶ 1, ᯇୗ୍அ 1, 㔝ᮧᩥኵ 2㸦1 ༓ⴥᏛ Ꮫ㝔 ་Ꮫ◊✲㝔 ศᏊែゎᯒᏛ, 2 ༓ⴥᏛ་Ꮫ㒊㝃ᒓ㝔࣐ࢫࢫ࣌ࢡࢺ࣓ࣟࢺࣜ ᳨࣮ᰝデ᩿Ꮫ㸧 㹎-34 ࠕࣄࢺ㠌ᖏ࠾ࡅࡿࢢࣜࢥࢧ࣑ࣀࢢࣜ࢝ࣥࡢゎᯒࠖ 㛗Ꮚᬕ⨾ 1, ཎ ఙṇ 1, ᪥ྜྷᓠ㯇 1, Ἑ㔝㏻ᛌ 2, ෆᑿ♸ྖ 2, ᅵᒇ⨾ຍᏊ 1㸦ᓥ᰿Ꮫ ་Ꮫ㒊 㹎-36 1 ⏕Ꮫㅮᗙ, 2 ᩚᙧእ⛉Ꮫㅮᗙ㸧 ࠕAbcd1 ࣀࢵࢡ࢘ࢺ࣐࢘ࢫࡢ⬻ࡢࣜࣥ⬡㉁ゎᯒࠖ ℈ᘯኴ㑻 1, ⸨ཎඃᏊ 1, Ᏺ⏣㞞ᚿ 2, ୰ᖖ㞝 2, ୗ⃝ఙ⾜ 3, ᶓᒣ᫂ 1㸦1 ᖇி࣭ ⸆, 2 ᐩᒣ࣭⸆, 3 ᒱ㜧࣭⏕⛉Ꮫ⥲ྜ◊✲ᨭࢭࣥࢱ࣮㸧 㹎-38 ࠕEffects of preanalytical variables on serum peptidome profiling for long-term storage using matrix-assisted laser desorption/ionization time-of-flight mass spectrometryࠖ ᅵ⏣⚈ኸ 1, బ⸨Ᏺ 1, ᱵᮧၨྐ 2, ᭮ᕝ୍ᖾ 3, ⬥ṇ㈗ 1, ูᗓ⨾ዉᏊ 4, すᮧᇶ 4, ᑠ ᑎ⩏⏨ 5, ᯇୗ୍அ 4, 㔝ᮧᩥኵ 1㸦1 ༓ⴥᏛ་Ꮫ㒊ᒓ㝔࣐ࢫࢫ࣌ࢡࢺ࣓ࣟࢺ࣮ࣜ ́́ ᳨ᰝデ᩿Ꮫ, 2 ᒸᒣᏛᏛ㝔་ṑᏛ⥲ྜ◊✲⛉, 3 㯞ᕸᏛ⏕⎔ቃ⛉Ꮫ㒊⮫ᗋ᳨ᰝ ᢏᖌᏛ⛉, 4 ༓ⴥᏛ་Ꮫ㒊་Ꮫ◊✲㝔ศᏊែゎᯒᏛ, 5 㔛Ꮫ⌮Ꮫ㒊≀⌮Ꮫ⛉㸧 㹎-40 ࠕMALDI-TOF MS ࠾ࡅࡿ Neisseria meningitidis ࡢㄗྠᐃ୍ࠖ 㔝ᬛᏊ㸦ឡ▱་⛉Ꮫ㝔ឤᰁไᚚ㒊㸧 㹎-42 ࠕMALDI mass spectrometry imaging ࡼࡿ⤖⤌⧊ࣞໟᇙஙࡀࢇ⤌⧊ࡢపศᏊ௦ ㅰ⏘≀ࣉࣟࣇࣜࣥࢢࠖ ᐥ⏣ಙ༤ 1, ஂಖ ┿ 1, ୕ᾆ 3, ෆ⏣◊ᐂ 1, ᐑᓮဴஅ 2, ⸨ᮧ⏤⣖ 3, ᪩ᕝⱥ 3, ሯ㝯⏕ 1, ᐑᆏ⩏ᾈ 1, ┿㘠㐩ஓ 1, ᑠ⏣⩏┤ 2, Ỉඖ୍༤ 4, ୰ᮧ㞞ྐ 1㸦1 ᕞᏛ⮫ ᗋ࣭⭘⒆እ⛉, 2 ᕞᏛᙧែᶵ⬟⌮, 3 ᕞᏛඛ➃⼥ྜ་⒪ࣞࢻࢵࢡࢫࢼࣅ◊✲ᣐ Ⅼ, 4 ᕞᏛ㝔 ࡀࢇࢭࣥࢱ࣮㸧 㹎-44 ࠕࣄࢺ⫾┙࠾ࡅࡿ⤊ᮎ⤧ẟᖿ⤧ẟ࠾ࡅࡿࣜࣥ⬡㉁ศᕸࣃࢱ࣮ࣥࡢ≉ᚩ⫾┙ ⌮ᡤぢࡢ┦㛵ࡘ࠸࡚ࠖ ᒣ㷂㤶⧊ 1, ṇᮌ⣖㝯㸰, ᖾᮧᏘᏊ 1, ᪩ᆏᏕᏹ 3, ఀᮾᏹ 1, 㔠ᒣᑦ⿱ 1, ℩⸨ග㸰 㸦1 ᯇ་⛉Ꮫ⏘፬ே⛉Ꮫㅮᗙ, 2 ᯇ་⛉Ꮫゎ๗Ꮫㅮᗙ⣽⬊⏕≀Ꮫศ㔝, 3 ᾏ㐨Ꮫ Ꮫ㝔ಖ⛉Ꮫ◊✲㝔㸧 㹎-46 ࠕࢺࣜࣉࣝࢿ࢞ࢸࣈங⒴ࡢⓎண ᅉᏊࡢ㉁㔞㢧ᚤ㙾ࢆ⏝࠸ࡓ᥈ồࠖ ⣽ᕝඃᏊ 1, ṇᮌ⣖㝯 2, ᯇୗ⚈Ꮚ 2, ᮡᒣᰤ 2, ᑠ༤அ 1, ᳝㇂⣖ᙪ 1, ℩⸨ග 2 㸦1 ᯇ་⛉Ꮫ➨୍እ⛉, 2 ᯇ་⛉Ꮫゎ๗Ꮫㅮᗙ ⣽⬊⏕≀Ꮫศ㔝㸧 㹎-48 ࠕ⺯ග࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈᢞ࣐࢘ࢫ⫢⤌⧊ᑐࡍࡿྛ✀࣓࣮ࢪࣥࢢᢏ⾡ࡢ㐺⏝ࠖ ᒣཱྀ ு 1, ᒣᮏ༟ᚿ 1, ୰ᕝ ⸅ 1, Ώ㒊┤ᶞ 2, ➉ෆ 1 1 ྖ 1, ᑿᓥ⾜ 㸦 ᰴᘧ♫ ᓥὠ〇సᡤ, 2 ࣞࢽࢩ࣮ࣙᰴᘧ♫㸧 㹎-50 ࠕࣥࢺࢩࢽࣥࡢయෆືែゎᯒࠖ ㈈‶ಙᏹ 1, ✄ⴥᰭ㔛 1, ⸨᳃㝯㐨 1, Ⲯཝဴဢ 2, ᑠᯘἋ⧊ 2, ᳃ᒣ㐩ဢ 1㸦1 ㏆␥Ꮫ ㎰Ꮫ㒊, 2 ᰴᘧ♫࣡࢝ࢧ⏕ά㸧 㹎-52 ࠕ⾪✺᩿㠃✚ᇶ࡙ࡃ MALDI ࣓࣮ࢪࣥࢢཬࡧ MS/MS ࣇࣛࢢ࣓ࣥࢺࢹ࣮ࢱࡢ㛵㐃ࡅ ࡼࡿ⬡㉁ࡢྠᐃᒁᅾゎᯒࠖ ᑎᓮ┿ᶞ 1, Mark Towers 2, Emmanuelle Claude 2, Johannes PC Vissers 2㸦1 ᪥ᮏ࢛࢘ ࣮ࢱ࣮ࢬᰴᘧ♫, 2 ࢛࣮࢘ࢱ࣮ࢬ࣭ࢥ࣮࣏࣮ࣞࢩࣙࣥ㸧 㹎-54 ࠕ㉁㔞ศᯒ࣓࣮ࢪࣥࢢἲࢆ⏝࠸ࡓ࢜ࣜࢦࢹࣥࢻࣟࢧࢺศ㐣⛬ࡢྍどࠖ ᖹཎᖾᜨ㸯, ⱝᯘẎಇ㸯, ᳃ ᚭ⮬ 1,2, ▮ᑿ⫱Ꮚ 3, ὠ⏣㞞அ 4, ᮏᐙᏕ୍ 5, ᑠụኴ㑻㸯, ᚋ⸨ோᚿ 6, ᑠ㔝ᙪ 6, ᒣ⏣ஂኵ㸯㸦1 㛵す་࣭་࣭ゎ๗Ꮫ➨୍, 2 㫽ྲྀᏛ࣭་࣭ಖ Ꮫ⛉, 3 ᯇ་࣭࣓ࢹ࢝ࣝࣇ࢛ࢺࢽࢡࢫ◊✲ࢭࣥࢱ࣮, 4 㧘▱Ꮫ࣭⥲◊, 5 㧘▱ Ꮫ࣭་࣭⏕Ꮫ, 6 ி㒔ᗓ་࣭⏕≀Ꮫ㸧 㹎-56 ࠕ㉁㔞㢧ᚤ㙾ࡼࡿࢸࢫࢺࢫࢸࣟࣥ◲㓟࢚ࢫࢸࣝࡢ࣐࢘ࢫ⢭ᕢ࠾ࡅࡿྍどࠖ ⇃⏣ࣥࣜ࢜ࣂࢹ㸯, ㇂ཱྀஂဴ㸰, ▮ᑿ⫱Ꮚ㸱, ྂ⏣ாྐ㸲, ᯇ⏣බᚿ㸰, ఀ⸨ㄔ㸯 ́́ 㸦1 㛵す་⛉Ꮫ་Ꮫㅮᗙ, 2 ⭈Ἢᒀჾእ⛉Ꮫㅮᗙ, 3 ᯇ་⛉Ꮫ࣓ࢹ࢝ࣝࣇ࢛ࢺ 4 ࢽࢡࢫ◊✲ࢭࣥࢱ࣮, ᒱ㜧Ꮫ་Ꮫ⣔◊✲⛉㸧 㹎-58 ࠕ⚄⤒㞀ᐖᛶ⑊③ࣔࢹ࣐ࣝ࢘ࢫ࠾ࡅࡿ⬨㧊ᚋゅࡢ⬡㉁ኚࠖ ᆏ㔝ၨ 1, ṇᮌ⣖㝯㸯, ᮧጾኵ㸯, ୕ཎ၏ᬦ㸯, ᚎ㛼㸯, ᯇᒣᖾᘯ 1, ℩⸨ග㸯 㸦1 ᯇ་⛉Ꮫ་Ꮫ⣔◊✲⛉㸧 㹎-60 ࠕ㉁㔞࣓࣮ࢪࣥࢢἲࢆ⏝࠸ࡓࣁࣟ࣌ࣜࢻ࣮ࣝ⏤᮶ࣆࣜࢪࢽ࣒࢘௦ㅰ≀ࡢ⬻ෆศᕸ 㛵ࡍࡿྍどࡢ᳨ウࠖ 4 1 ㏆␥Ꮫ་Ꮫ㒊ἲ་Ꮫ, ྜྷ⏣ཎつ 1, ୰す㇏ᩥ 2, ᮡᮏ㤶ዉ 3, ᕴ ಙ 1, ༑ᔒ୍㞝㸦 2 㜰་⛉Ꮫ⮫ᗋ᳨ᰝ་Ꮫ, 㸱 㜰ᏛᏛ㝔་Ꮫ⣔◊✲⛉ἲ་Ꮫ, 4 ୍⯡♫ᅋἲே་ ⸆ศᯒ༠ 㹎-62 LC/MS ゎᯒࡼࡿ⾑୰ CRP 」ྜయࡘ࠸࡚ࡢ᳨ウ ᑠᙬୡᏊ 1,3, 㔛ᮧཌྖ 1, ᫍ㔝 ᛅ 1, Ⲩᓥᗣ 1, ᚿ᪉࠼ࡾࡉ 1, ⸨ᒸ⨾ 1, ୗ⃝ 㐩㞝 3, ୰ᒣᬛ⚈ 1㸦1 ᪥ᮏᏛ་Ꮫ㒊 ែ⌮Ꮫ⣔ ⮫ᗋ᳨ᰝ་Ꮫศ㔝, 2 ᪥ᮏᏛ 㝔 ⮫ᗋ᳨ᰝ་Ꮫ⛉, 3 ᮾிᏛ་Ꮫ㒊ᒓ㝔 ᳨ᰝ㒊) 14㸸00㹼15㸸30 ࢩ࣏ࣥࢪ࣒࢘㸲㸸ࠕ༴㝤ࢻࣛࢵࢢࡢ ㉁㔞ศᯒ◊✲ࡢ᭱๓⥺ࠖ㸦41 ㆟ᐊ㸧 ࣮࢜࢞ࢼࢨ࣮࣭ᗙ㛗㸸㕥ᮌ ಟ㸦ᯇ་⛉Ꮫ㸧 㹑4-1 ࠕ⌧ሙ࡛᥇ྲྀྍ⬟࡞ᚤ㔞ࡢ⾑ᾮ, ၚᾮཬࡧờࡽࡢ⸆≀᳨ᰝࠖ ᱓ᒣḟ㸦⛉Ꮫ㆙ᐹ◊✲ᡤ㸧 㹑4-2 ࠕ࢝ࢳࣀࣥ⣔༴㝤ࢻࣛࢵࢢࡢ௦ㅰ㸫Ꮫᵓ㐀ࡀ௦ㅰཬࡰࡍᙳ㡪ࡘ࠸࡚㸫ࠖ ᚿᦶ᫂ 1, 㙊⏣ᐶᜨ 1, ᯇ⏣㥴ኴᮁ 1, ᶫ⚽┤ 1, ୕ᮌᏹ 1, ∦ᮌ᐀ᘯ 1, ᅵᶫ ᆒ 2 㸦1 㜰ᗓ㆙⛉Ꮫᤚᰝ◊✲ᡤ, 2 ྡྂᒇᏛᏛ㝔་Ꮫ⣔◊✲⛉㸧 㹑4-3 ࠕ༴㝤ࢻࣛࢵࢢὶ㏻ᐇែㄪᰝ࠾ࡅࡿ㉁㔞ศᯒࡢᙺࠖ ⰼᑼ㸦ᮌ㸧⍠⌮㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ㸧 15㸸30㹼17㸸30 㹒㹄-1 ࢸࢡࣀࣟࢪ࣮ࣇ࢛࣮࣒ࣛ㸸㉁㔞ศᯒᢏ⾡㛵㐃ࡢᶵჾ࠾ࡼࡧᴗၟရࡢ⤂ 㸦41 ㆟ᐊ㸧 ᗙ㛗㸸ụୖᾈྖ㸦ᯇ་⛉Ꮫ㸧 ࠕ᭱᪂ࡢ㉁㔞ศᯒ࣓࣮ࢪࣥࢢ࢜ࣥࣔࣅࣜࢸ࣮QTofࠖ ᑎᓮ┿ᶞ 1, ࢱࢼ ࣃࢡࢫࢺࣥ 1㸦1 ᪥ᮏ࢛࣮࢘ࢱ࣮ࢬᰴᘧ♫㸧 㹒㹄-2 ࠕAgilent 6560 Ion Mobility Q-TOF LC/MSC-QTOF ࡢ⤂ࠖ ᇣᫀᙪ㸦ࢪࣞࣥࢺ㺃ࢸࢡࣀࣟࢪ࣮ᰴᘧ♫㸧 㹒㹄-3 ࠕ࣓࣮ࢪࣥࢢ㉁㔞ศᯒࡢ࣎ࢺࣝࢿࢵࢡࢆゎᾘࡍࡿ rapifleX™ MALDI Tissuetyper™ࠖ ๓⏣ᩧ㸦ࣈ࣮࣭ࣝ࢝ࢲࣝࢺࢽࢡࢫᰴᘧ♫㸧 㹒㹄-4 ࠕ㉁㔞ศᯒィࢆ᳨ฟჾࡍࡿయእデ᩿⏝་⒪ᶵჾ Prelude MD ࡢ⤂ࠖ ❑⏣㞞அ㸦ࢧ࣮ࣔࣇࢵࢩ࣮ࣕࢧ࢚ࣥࢸࣇࢵࢡᰴᘧ♫㸧 ́́ 㹒㹄-5 ࠕSWATH® Next-Generation Proteomics OneOmics™ࡼࡿ⥙⨶ⓗ࡞ࢱ࣮ࢤࢵࢺᐃ㔞ࣉ ࣟࢸ࣮࣒࢜ゎᯒࠖ ᰘ⏣ ⊛㸦ࢧ࢚ࢵࢡࢫ ࣉࣜࢣ࣮ࢩࣙࣥࢧ࣏࣮ࢺ㸧 㹒㹄-6 ࠕࣜࣥ⬡㉁ࡢ㝖ཤࣜࣥ⬡㉁ࢆᢳฟࡍࡿ๓ฎ⌮〇ရࡘ࠸࡚ࠖ 㕥ᮌ୍, ኴ⏣ⱱᚨ, ⏤ኤ†㸦ࢪ࣮࢚ࣝࢧ࢚ࣥࢫᰴᘧ♫㸧 㹒㹄-7 ࠕHybrid SPE®-Phospholipid ࢆ⏝࠸ࡓࣜࣥ⬡㉁㝖ཤࡼࡿ㧗ឤᗘศᯒࠖ ᯇᓥỤ㔛㤶㸦ࢩࢢ࣐ࣝࢻࣜࢵࢳ ࢪࣕࣃࣥྜྠ♫㸧 㹒㹄-8 ࠕLC-MS/MS ࡼࡿ⾑୰་⸆ရศᯒࡢࡓࡵࡢ⮬ື๓ฎ⌮ࢩࢫࢸ࣒ࠖ ᑿᓥ⾜ 1, ✄ᇉ▱Ꮚ 1, ሯᮏከ▴ 1, ᰘ⏣ග 1,2 , ᕝୖ㍜ 1㸦1(ᰴ)ᓥὠ〇సᡤศᯒィ ᴗ㒊, 2Shimadzu Scientific Instruments Inc.㸧 17㸸30㹼17㸸35 㛢ࡢ㎡㸦41 ㆟ᐊ㸧 ́́ ㅮ₇せ᪨ 㸦L-1㸸ᣍᚅㅮ₇࣭L-2㸸ᯇᮏຬ㈹ཷ㈹ㅮ₇࣭L-3㸸≉ูㅮ₇㸧 ́́ L-1 Systems Medicine in a Changing World : The Challenge of Measuring and Visualising Personal and Public Healthcare Data. Jeremy K. Nicholson Department of Surgery and Cancer Imperial College London Changes in climate and population densities and distribution plus increasing socioeconomic stresses placed on healthcare systems pose a unique series of challenges in 21st Century medicine. A tension exists between the development of new investigative, diagnostic and prognostic technologies and the ability of scientists and healthcare professionals to deliver effective translational solutions. Systems biology tools can be applied at both individual and population levels to understand integrated biochemical function in relation to disease pathogenesis but there are still barriers to the clinical actionability of these modelling tools that present barriers to translation. The complex gene-environment interactions that create individual and population disease risks are also responsible for the expression of metabolic phenotypes in different body compartments and fluids. Thus metabolic phenotyping offers an important window on human systemic activity and spectroscopic tools can be employed to help characterize personalised profiles, disease processes and responses to therapy (1). We have developed new scalable and translatable strategies for “phenotyping the patient journey” (2) using top-down systems biology tools that capitalize on the use of metabolic datasets (3) for diagnostic and prognostic biomarker generation to aid clinical decision-making at point-of-care. These have been shown to be of value in the development of prognostic marker models for both clinical efficacy and drug toxicity in cancer patients. Such approaches, including those for near real-time applications as in surgery, molecular pathology, oncology and critical-care, can be extremely sensitive for the detection of diagnostic and prognostic biomarkers in a variety conditions (4,5). These methods also provide a powerful adjunct to conventional procedures for disease assessment that are required for future developments in “precision medicine” including understanding of the symbiotic influences on patient state (6). Finally, the “Metabolome Wide Association Study” (7) concept provides powerful new tool to generate disease risk biomarkers (e.g. for cancer or cardiometabolic diseases) from epidemiological sample collections. Such population risk models can also link to individual patient healthcare models thus closing the personal and public healthcare modelling triangle. The ultimate challenge is to take complex validated data sets and models on human biology and to visualise these in engaging formats and forms that clinically actionable in an ever changing background of human health. ́́ 1. Nicholson J.K. and Lindon, J.C. (2008) Nature 455 1054-1056. 2. Nicholson, J.K. et al (2012) Nature 491 384-392. 3. Clayton, T.A. et al (2006) Nature 440 1073-1077. 4. Balog, J et al (2013) Science Translational Medicine 5 (194) 194ra93. 5. Veselkov, K.A. et al (2014) PNAS doi 10.1073pnas. 6. Mirnezami, R. Nicholson, J.K. and Darzi, A. (2012) New Eng. J. Med. 366 (6) 489-491. 7. Holmes, E. et al (2008) Nature 453 396-400. Professor Nicholson obtained his BSc from Liverpool University (1977) and his PhD from London University (1980) in Biochemistry working on the application of analytical electron microscopy and the applications of energy dispersive X-Ray microanalysis in molecular toxicology and inorganic biochemistry. He was appointed Lecturer in Chemistry (Birkbeck College, London University, 1981-83) and Lecturer in Experimental Pathology at The London University School of Pharmacy (1983-85) returning to Birkbeck as a Senior Lecturer in Chemistry, then Reader (1989) and Professor of Biological Chemistry (1992). In 1998 he became Head of Biological Chemistry at Imperial College London then Head of Biomolecular Medicine (2006). Since 2009 he has been Head of the Department of Surgery and Cancer at Imperial where he runs a series of programs in stratified medicine, molecular phenotyping and molecular systems biology. In 2012 he became the Director of world’s first National Phenome Centre specialising in large-scale phenotyping. Professor Nicholson is the author of over 600 peer-reviewed scientific papers and many other articles/patents on the development and application of novel spectroscopic and chemometric approaches to the investigation of metabolic systems failure, MWAS studies and pharmaocometabonomics. His research has been recognised by awards such as: the RSC Silver (1992) and Gold (1997) Medals for Analytical Chemistry; the Chromatographic Society Jubilee Silver Medal (1994); the Pfizer Prize for Chemical and Medicinal Technology (2002); the RSC medal for Chemical Biology (2003); the RSC Interdisciplinary Prize (200&) the RSC Theophilus Redwood Lectureship (2008); the Pfizer Global Research Prize for Chemistry (2006); the NIH Stars in Cancer and Nutrition Distinguished Lecturer (2010) and the Semelweiss-Budapest Prize for Biomedicine (2010). Professor Nicholson was also elected as a Fellow of the UK Academy of Medical Sciences in 2010. He was elected Lifetime honorary membership of the US Society of Toxicology (2013), Honorary lifetime membership of the International Metabolomics society (2013). He currently holds honorary professorships at 8 International Universities and in 2014 was Elected an Einstein Professor of the Chinese Academy of Sciences. ISi highly cited researcher (h= 99). He is a consultant to many pharmaceutical/healthcare companies in the UK, Europe and the USA and is a founder director of Metabometrix, an Imperial College spin-off company specializing in molecular phenotyping, clinical diagnostics and toxicological screening via metabonomics and metabolomics. ́́ L-2 ㉁㔞ศᯒᢏ⾡ࡢ⮫ᗋ᳨ᰝᛂ⏝㛵ࡍࡿ◊✲ 㔝ᮧᩥኵ ༓ⴥᏛ་Ꮫ㒊㝃ᒓ㝔࣐ࢫࢫ࣌ࢡࢺ࣓ࣟࢺ᳨࣮ࣜᰝデ᩿Ꮫ ≉௵ᩍᤵ Applications of mass spectrometry to laboratory medicine Fumio Nomura Division of Clinical Mass Spectrometry, Chiba University Hospital ㉁㔞ศᯒᢏ⾡ࡢ⮫ᗋ᳨ᰝᛂ⏝ࡣࡁࡃ 2 ࡘࡢࣉ࣮ࣟࢳࡀ࠶ࡿࠋ᪂つࣂ࣐࣮࣮࢜࢝ 㸦᳨ᰝ㡯┠㸧ࡢⓎぢࢆ┠ⓗࡋࡓࣉࣟࢸ࣮࣒࢜ゎᯒ࣭࣓ࢱ࣮࣒࣎ࣟゎᯒ࠾ࡅࡿ㉁㔞ศᯒἲ ࡢ⏝᪤Ꮡࡢ⮫ᗋ᳨ᰝ࠾ࡅࡿ㉁㔞ศᯒἲࡢά⏝࡛࠶ࡿࠋẚ㍑ࣉࣟࢸ࣮࣒࢜ゎᯒࡢࡓࡵ ࡢ㉁㔞ศᯒᢏ⾡ࡢ㐍Ṍࡣ┠ぬࡲࡋࡃࠊከࡃࡢデ᩿ࣂ࣐࣮࣮࢜࢝ೃ⿵ࡀぢฟࡉࢀ࡚࠸ࡿࡀࠊ ᐇ㝿ࡢ⮫ᗋᛂ⏝ࡲ࡛฿㐩ࡋ࡚࠸ࡿࡶࡢࡣ͆A drop in the ocean͇⾲⌧ࡉࢀࡿࡼ࠺ࡁࢃࡵ࡚ ᑡ࡞࠸ࠋ࣐࣮࣮࢝ࡢⓎぢࡽᐇ⏝ࡲ࡛ࡢ㐨ࡢࡾࡣ㛗࠸ࡀࠊ⏘Ꮫࡀᐦ㐃ᦠࡍࡿࡇࡼ ࡾࠊձᑐ㇟ᝈࡢ㐺ษ࡞㑅ᢥࠊղ⮫ᗋሗࡀࡉࢀࡓ⮫ᗋ᳨యࡢ㐺ษ࡞᥇ྲྀಖᏑࠊճ▱ ⓗ㈈⏘ࡢ☜ಖ⥔ᣢࠊ մయእデ᩿⸆ࡢᢎㄆ⏦ㄳࠊ ࡞ࡀྍ⬟࡞ࡿࠋ₇⪅ࡽࡣ SELDI-TOF MS ࢆ⏝࠸࡚ぢฟࡋࡓ⾑Ύ୰ࡢ 5.9kD ࣌ࣉࢳࢻࡀ࢘ࣝࢫᛶ៏ᛶ⫢㞀ᐖ࠾ࡅࡿ㗦ᩄ࡞⥺⥔ ࣐࣮࣮࢝࡞ࡿྍ⬟ᛶࢆ♧ࡋࡓࠋ⌧ᅾ⮫ᗋ᳨ᰝデ᩿⸆ࡋ࡚ࡢᢎㄆྥࡅ࡚ࠊ⊂❧⾜ᨻἲ ே་⸆ရ་⒪ᶵჾ⥲ྜᶵᵓ㸦PMDA㸧࡛ᑂᰝ୰࡛࠶ࡿࠋࡲࡓࠊཎⓎᛶ⫢⣽⬊⒴ (HCC)ᝈ⪅ ࡢ⫢ษ㝖⤌⧊ࡢ⒴㒊ࠊ㠀⒴㒊ࡢẚ㍑ࣉࣟࢸ࣮࣒࢜ゎᯒࡢ⤖ᯝࠊ⌮デ᩿᭷⏝࡞࣐࣮࣮࢝ ࡋ࡚ clathrin heavy chain formiminotransferase cyclodeaminase ࢆぢฟࡋࡓࠋ⒴㒊࡛㧗Ⓨ⌧ ࡋ࡚࠸ࡿ⺮ⓑ㉁࡛ࡣ⩻ヂᚋಟ㣭࡞ࡼࡿᢠཎᛶࡢኚࡀᐃࡉࢀࡿࡢ࡛ࠊࡇࢀࡽࡢ⺮ⓑ ㉁ᑐࡍࡿ⾑୰⮬ᕫᢠయ ᐃࡼࡿ HCC ࡢ᪩ᮇデ᩿ࡢྍ⬟ᛶࢆ᳨ウࡋ࡚࠸ࡿࠋ ୍᪉ࠊ⌧ᅾ㝔᳨ᰝᐊ࠾ࡅࡿ᪂ࡓ࡞᳨ᰝἲࡋ࡚ࡢ㉁㔞ศᯒἲࡢᙺࡀᛴ㏿㧗ࡲࡾ ࡘࡘ࠶ࡿࠋ᭱ࡶᡂຌࡋ࡚࠸ࡿࡢࡣ MALDI-TOF MS ࢆ⏝࠸ࡓ⳦యࡢࣉࣟࢸ࣮࣒࢜ゎᯒࡼࡿ ⣽⳦࣭┿⳦ࡢ㎿㏿ྠᐃ࡛࠶ࡿࠋᮏἲࡣ⡆౽ࠊṇ☜ࠊ㎿㏿࡛࠶ࡾࠊࡉࡽࣛࣥࢽࣥࢢࢥࢫࢺ ࡶపࡃࠊ⮫ᗋ⣽⳦᳨ᰝ㠉ⓗ࡞ኚࢆࡶࡓࡽࡋ࡚࠸ࡿࠋᡃࠎࡶ 2010 ᖺࡽᮏᢏ⾡ࢆඛࡎ ◊✲ᐊ࡛ࣞ࣋ࣝᑟධࡋࠊ2012 ᖺࡽࡣ㝔᳨ᰝ㒊ᑓ⏝ᶵჾࢆタ⨨ࡋ࡚࣮ࣝࢳ᳨ࣥᰝࡋ ࡚ᐇࡋ࡚࠸ࡿࠋin-house ࢹ࣮ࢱ࣮࣋ࢫࡢసᡂࡸࠊ⳦యᵓ㐀ྜࢃࡏࡓ๓ฎ⌮ࡢᕤኵ࡞ ࡼࡾྠᐃ⋡ࡢྥୖດࡵ࡚࠸ࡿࠋ≉⾑ᾮᇵ㣴⤖ᯝࡸ⣽⳦ᛶ㧊⭷⅖ࡢ㉳⅖⳦ࡢ㎿㏿ሗ࿌࡞ ࡼࡾឤᰁデ⒪㈉⊩ࡋ࡚࠸ࡿࠋࡋࡋࠊᢠ⳦⸆ᑐࡍࡿឤཷᛶ࣭⪏ᛶࡢุูࡀࡲࡔ ༑ศ࡛ࡁ࡞࠸ࡇࠊ」ᩘ⳦ࡢᑐᛂࡀᐜ࡛᫆࡞࠸ࡇࠊ࡞ㄢ㢟ࡶከ࠸ࠋ⌧ᅾࠊࢫࢸࣟ ࢻ࣍ࣝࣔࣥ࡞ࡢపศᏊྜ≀ࡢᐃ㔞ࡣ࣒ࣀࢵࢭࡀከ⏝ࡉࢀ࡚࠸ࡿࡀࠊഃ㙐ᵓ㐀 ࡢᚤᑠ࡞㐪࠸ࢆᢠయࡢࡳ࡛ ࡾศࡅࡿࡇࡣ㝈⏺ࡀ࠶ࡾࠊLC/MS/MS ࡢ⛣⾜ࡢᶵ㐠ࡀ㧗 ࡲࡗ࡚࠸ࡿࠊ௨ୖࡢࡼ࠺㉁㔞ศᯒᢏ⾡ࡢ⮫ᗋ᳨ᰝᛂ⏝ࡀᚋᛴ㏿ᬑཬࡍࡿࡇഛ࠼ ࡚ࠊᮏᢏ⾡ࡢᇶ♏ࢆᏛࡪྠ᳨ᰝἲࡢᶆ‽ࡢࡓࡵࡢඹ㏻ᇶ┙ࢆᣢࡘࡇࢆ┠ᶆࡋ ࡚ࠊ2013 ᖺࡼࡾᮏᏛ࠾࠸࡚་⏝㉁㔞ศᯒㄆᐃኈไᗘࡀࢫࢱ࣮ࢺࡋࠊ⌧Ⅼ࡛ 184 ྡࡀ ㄆᐃࡉࢀ࡚࠸ࡿࠋ ́́ Ӑ␎ Ṕӑ 50 ᖺ ༓ⴥᏛ་Ꮫ㒊༞ᴗࠊ➨㸯ෆ⛉ධᒁ 53 ᖺࡽ 4 ᖺ㛫 ࣓ ࣜ ࢝ ྜ ⾗ ᅜ ࢽ ࣗ ࣮ ࣚ ࣮ ࢡ ᕷ ❧ Ꮫ ་ Ꮫ 㒊 Mount Sinai Hospital ࣞࢪࢹࣥࢺ࠾ࡼࡧࣝࢥ࣮ࣝ⫢◊✲ᡤ◊✲ဨ 㸦Charles S. Lieber ᩍᤵ㸧 ᖐᅜᚋ ༓ⴥᏛ་Ꮫ㒊➨ 1 ෆ⛉࠾࠸࡚⫢ᝈࡢデ⒪◊✲ᚑ 58 ᖺ ༓ⴥᏛ་Ꮫ㒊➨ 1 ෆ⛉ຓᡭ ᖹᡂ 5 ᖺ ⟃ἼᏛ⮫ᗋ་Ꮫ⣔ㅮᖌ ᖹᡂ 6 ᖺ ྠຓᩍᤵ ᖹᡂ 11 ᖺ 10 ᭶ ༓ⴥᏛ་Ꮫ㒊⮫ᗋ᳨ᰝ་Ꮫㅮᗙ 㸦ᖹᡂ 13 ᖺ 4 ᭶ࡼࡾ༓ⴥᏛᏛ㝔་Ꮫ◊✲㝔ศᏊែゎᯒᏛ㸧ᩍᤵ࠾ࡼࡧ㝃ᒓ㝔᳨ᰝ㒊㛗 ᖹᡂ 18 ᖺ 5 ᭶ ࡼࡾ 㝃ᒓ㝔ᝈࣉࣟࢸ࣑࢜ࢡࢫࢭࣥࢱ࣮㛗වົ ᖹᡂ 20 ᖺ 4 ᭶ ࡼࡾ 㑇ఏᏊデ⒪㒊㛗වົ ᖹᡂ 27 ᖺ 3 ᭶ ༓ⴥᏛᩍᤵࢆᐃᖺ㏥௵ ᖹᡂ 27 ᖺ 4 ᭶ ~ ༓ⴥᏛ་Ꮫ㒊㝃ᒓ㝔࣐ࢫࢫ࣌ࢡࢺ࣓ࣟࢺ᳨࣮ࣜᰝデ᩿Ꮫᐤ ◊✲㒊㛛 ≉௵ᩍᤵ බ┈㈈ᅋἲேࡕࡤ┴Ẹಖண㜵㈈ᅋ Ꮫ⾡㢳ၥ ́́ L-3 ḟୡ௦ࣉࣟࢸ࣑࢜ࢡࢫࢆ⏝࠸ࡓࡀࢇ≉ᛶࡢゎ᫂ ୰ᒣᩗ୍ ᕞᏛ࣭⏕య㜵ᚚ་Ꮫ◊✲ᡤ࣭ศᏊ་⛉Ꮫศ㔝࣭ࣄࢺࣉࣟࢸ࣮࣒࢜◊✲ࢭࣥࢱ࣮ Next-generation proteomics unveils a global landscape of cancer Keiichi Nakayama Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University ࣄࢺࢤࣀ࣒ィ⏬ࡀ⤊ࡋ࡚ࡰ 10 ᖺࡀ⤒࠺ࡋ࡚࠸ࡿࡀࠊ⏕ࡢᇶᮏసືཎ⌮ࡣᮏ㉁ⓗ ᮍゎ᫂ࡢ㒊ศࡀከࡃṧࡉࢀ࡚࠸ࡿࠋࡑࢀࡣ⣽⬊άືࡢᐇ⾜㒊㝲ࡀࢱࣥࣃࢡ㉁࡛࠶ࡿࡽ࡛࠶ ࡿࠋ⏕࠸࠺ࢿࢵࢺ࣮࣡ࢡࢩࢫࢸ࣒ࢆ⌮ゎࡍࡿୖ࡛ࠊࢱࣥࣃࢡ㉁ࡢ㛫࣭✵㛫࣭㔞࠸࠺⥙ ⨶ⓗሗࡀ࡞࠸㝈ࡾࠊಶࠎࡢࣀ࣮ࢻࡀ」㞧㐃⤖ࡍࡿࢿࢵࢺ࣮࣡ࢡࢆ⌮ゎࡍࡿࡇࡣྍ⬟࡛ ࠶ࢁ࠺ࠋࡑࡇ࡛ࢃࢀࢃࢀࡣࣄࢺࢱࣥࣃࢡ㉁ࡢ⤯ᑐᐃ㔞࠸࠺ክࡢࣉࣟࢪ࢙ࢡࢺ㸦ࣄࢺࣉࣟࢸ ࣮࣒࢜ィ⏬㸧ᣮᡓࡋ࡚࠸ࡿࠋࡲࡓ࡚ࡢࢱࣥࣃࢡ㉁ࢆ⤯ᑐᐃ㔞ࡍࡿࡇࡼࡗ࡚ࠊ⢭ᐦ࡞ᩘ ⌮⛉Ꮫⓗ࡞ゎᯒࡢᑟධࢆ┠ᣦࡋ࡚࠸ࡿࠋ ࢃࢀࢃࢀࡣ 16 ྎࡢ㉁㔞ศᯒィࢆᑟධࡋࠊࣉࣟࢸ࣮࣒࢜ィ ࡢ㣕㌍ⓗ࡞ࢫ࣮ࣝࣉࢵࢺᣑດ ࡵ࡚࠸ࡿࠋྠࣄࢺࡢࣜࢥࣥࣅࢼࣥࢺࢱࣥࣃࢡ㉁ 25,000 ✀ࢆヨ㦂⟶ෆ࡛ྜᡂࡋࠊࡇࡢሗ ࢆᇶ㧗㏿ MRM ࡛▷㛫ከᩘࡢࢱࣥࣃࢡ㉁ࡢ⤯ᑐᐃ㔞ࢆྍ⬟ࡍࡿᢏ⾡㸦in vitro proteome-assisted MRM for Protein Absolute QuanTification: iMPAQT㸧࠸࠺᪉ἲࢆⓎ᫂ࡋ ࡓ㸦≉チ➨ 5468073 ྕ㸧 ࠋࡇࡢ iMPAQT ἲࡣࠊᢠయࢆ⏝ࡏࡎᩘ✀㢮ࡢࢱࣥࣃࢡ㉁ࢆ㉸㧗ឤ ᗘ࡛⤯ᑐᐃ㔞ࡍࡿࡇࡀྍ⬟࡛࠶ࡿࠋࡇࡢ iMPAQT ἲࢆ⏝࠸࡚ከࡃࡢࢱࣥࣃࢡ㉁ࡢ⤯ᑐᐃ㔞ࢆ⾜ ࡗࡓࠋ≉ṇᖖ⣽⬊ࡀࢇ⣽⬊ࡘ࠸࡚ࠊࡑࡢ௦ㅰ≧ែࡢኚࢆࡶࡓࡽࡍ࣮࢟㓝⣲ࢆ᥈⣴ࡋࡓࠋ ⣙ 90 ᖺ๓ࢻࢶࡢ⏕⌮Ꮫ⪅ Otto Warburg ࡼࡗ࡚Ⓨぢࡉࢀࡓࡀࢇ࠾ࡅࡿ௦ㅰࢩࣇࢺ ࠕ࣡ ࣮ࣝࣈࣝࢢຠᯝࠖࡣࠊࡀࢇ⣽⬊ࡀዲẼⓗ᮲௳ୗ࠾࠸࡚ࡶ᎘Ẽⓗ௦ㅰࢆ⾜࠺࠸࠺୍ぢወጁ࡞ ࡿ⯙࠸ࢆࡍࡿ⌧㇟࡛࠶ࡿࡀࠊከࡃࡢࡀࢇ⣽⬊ࡀࡇࡢᡓ␎ࢆ᥇ࡿ⌮⏤ࡣ⌧ᅾ࡛ࡶ᫂ࡽ࡛ࡣ࡞ ࠸ࠋࢃࢀࢃࢀࡣ࣮࣡ࣝࣈࣝࢢຠᯝࡢᮏ㉁ࢆゎ᫂ࡍࡿࡓࡵࠊiMPAQT ἲࡼࡗ࡚ṇᖖ⣽⬊ࡀࢇ⣽ ⬊࠾࠸࡚ࠊ࡚ࡢ௦ㅰ㓝⣲㸦⣙ 1000 ✀㢮㸧࠾ࡼࡧ௦ㅰ⏘≀ࢆ⤯ᑐᐃ㔞ࡋࠊࢩࢫࢸ࣒⏕≀Ꮫⓗ ᡭἲࢆྲྀࡾධࢀ࡞ࡀࡽࠊ࣮࣡ࣝࣈࣝࢢຠᯝࡢ࣮࢟㓝⣲ࢆྠᐃࡋࡓࠋࡇࡢ⤖ᯝࠊࡀࢇ࠾ࡅࡿ௦ ㅰࢩࣇࢺࡣࠊ࣮࢝࣎ࣥࢯ࣮ࢫ⏝ࢆ࢚ࢿࣝࢠ࣮⏘⏕ࡽ㧗ศᏊྜ≀ྜᡂࣜࣔࢹࣜࣥࢢࡍࡿ 㐺ᛂᡓ␎࡛࠶ࡿࡇࡀ᫂ࡽ࡞ࡗࡓࠋᚋࡣ iMPAQT ἲࡼࡗ࡚ከࡃࡢศ㔝ࡢ◊✲ࢆ㠉᪂ⓗ 㐍Ṍࡉࡏࡿྠࠊ⮫ᗋ᳨ᰝࡢᛂ⏝ࡸࣂ࣐࣮࣮࢜࢝᥈⣴࡞ࠊ་Ꮫ⏕≀Ꮫ㛗㊊ࡢ㐍Ṍ ࢆࡶࡓࡽࡍࡇࡀᮇᚅࡉࢀࡿࠋ ࡇࡢࡼ࠺ṇᖖᝈ࠾ࡅࡿࢿࢵࢺ࣮࣡ࢡᵓ㐀ࡢᕪ␗ࡀ᫂ࡽ࡞ࢀࡤࠊᝈࢿࢵࢺ࣮࣡ ࢡ࠾ࡅࡿࣁࣈศᏊࢆ✺ࡁṆࡵࠊࡑࢀࢆᶆⓗࡋࡓ⸆ࡀྍ⬟࡞ࡿࠋࢃࢀࢃࢀࡣࡇࡢ⪃࠼᪉ ࢆࠕࢿࢵࢺ࣮࣡ࢡᶆⓗ⸆ࠖࢆࡧࠊᚑ᮶ࡢศᏊᶆⓗ⸆ࡣ୍⥺ࢆ⏬ࡋ࡚⪃࠼࡚࠸ࡿࠋࢿࢵ ࢺ࣮࣡ࢡᶆⓗ⸆ࢆྍ⬟ࡍࡿࡓࡵࡣࠊ⢭ᐦ࡞ᐃ㔞ィ 㧗ᗘ࡞ሗᩘ⌮⛉Ꮫࡢ㐃ᦠࡀᚲせ ࡛࠶ࡾࠊ⌧ᅾୖグࡢࡀࢇ࠾ࡅࡿ௦ㅰࢩࣇࢺࢆࣃࣟࢵࢺࢣ࣮ࢫࡋ࡚ᐇド◊✲ࢆ㐍ࡵ࡚࠸ࡿࠋ ́́ Ӑ␎ Ṕӑ 1980 ᖺ 3 ᭶ 㸸⚄ዉᕝ┴❧•༡㧗➼Ꮫᰯ ༞ᴗ 1980 ᖺ 4 ᭶ 㸸ᮾி་⛉ṑ⛉Ꮫ་Ꮫ㒊་Ꮫ⛉ ධᏛ 1986 ᖺ 3 ᭶ 㸸ྠ ༞ᴗ 1986 ᖺ 4 ᭶ 㸸㡰ኳᇽᏛᏛ㝔་Ꮫ◊✲⛉ ධᏛ㸦චᏛᑓᨷ㸧 1990 ᖺ 3 ᭶ 㸸ྠ ༞ᴗ 1990 ᖺ 4 ᭶ 㸸⌮Ꮫ◊✲ᡤ ࣇࣟࣥࢸ◊✲ဨ 1990 ᖺ 12 ᭶ 㸸࣡ࢩࣥࢺࣥᏛ་Ꮫ㒊 ࣏ࢫࢺࢻࢡࢺࣛࣝࣇ࢙࣮ࣟ 1992 ᖺ 3 ᭶ 㸸࣡ࢩࣥࢺࣥᏛࣁ࣮࣡ࢻࣄ࣮ࣗࢬ◊✲ᡤ ༤ኈ◊✲ဨ 1995 ᖺ 7 ᭶ 㸸᪥ᮏࣟࢩࣗ◊✲ᡤ⏕≀Ꮫ㒊 ᖿ◊✲ဨ 1996 ᖺ 10 ᭶ 㸸ᕞᏛ⏕య㜵ᚚ་Ꮫ◊✲ᡤ⣽⬊Ꮫ㒊㛛 ᩍᤵ ⌧ᅾ⮳ࡿ ́́ ㅮ₇せ᪨ 㸦S1㹼S4㸸ࢩ࣏ࣥࢪ࣒࢘㸧 ́́ S1-1 ࢥࣥࢧࣝࢱࣥࢺ་ᖌࡀ⾜࠺㝧ᛶࡢホ౯ᑐᛂ ❑⏣ ‶ ᅜ❧ᡂ⫱་⒪◊✲ࢭࣥࢱ࣮⥲ྜデ⒪㒊 How should consultant doctors evaluate and respond to MS/MS positive results? Mitsuru Kubota Department of General Pediatrics & Interdisciplinary Medicine, National Center for Child Health and Development ࠙ࡣࡌࡵࠚ ⌧ᅾࠊ᪥ᮏᅜ࡛⏕ࡲࢀࡿࡍ࡚ࡢ᪂⏕ඣᑐࡋࠊࢱࣥࢹ࣒࣐ࢫ࣭ࢫࢡ࣮ࣜ ࢽࣥࢢ㸦௨ୗ TMS㸧ࡀᐇࡉࢀ࡚࠸ࡿࠋࡋࡋࠊᐇయ࡛࠶ࡿ 67 㒔㐨ᗓ┴࣭ᨻ௧ᣦᐃ㒔 ᕷࡍ࡚ TMS ࢆᑓ㛛ࡋ࡚࠸ࡿ་ᖌࡀ࠸ࡿࢃࡅ࡛ࡣ࡞ࡃࠊࢥࣥࢧࣝࢱࣥࢺ་ᖌࡀඛኳᛶ ⏥≧⭢ᶵ⬟పୗ࡞ࡢෆศἪᝈࢆᑓ㛛ࡋ࡚࠾ࡾࠊTMS ࡢᑓ㛛ᐙ࡛ࡣ࡞࠸ࡇࡶከ࠸ࠋ ᳨࠙ᰝࠚ᳨ᰝࡢุ᩿ࡣᇶᮏⓗ TMS ᢸᙜࡢᢏ⾡⪅ࡀ⾜ࡗ࡚࠸ࡿࠋ TMS ᴗࡢ୍㒊࡛࠶ࡾࠊ ࡲࡔࠕ་⒪࡛ࠖࡣ࡞࠸ࠋ⢭ᐦ᳨ᰝࡍࡿࠊ᳨ᰝࡍࡿࡢุ᩿ࡣ༢⣧࡞ࡶࡢ࡛ࡣ࡞ࡃࠊ ඣࡢ့ங≧ἣࠊᢠ⳦⸆⏝ࡢ᭷↓ࠊ࿘⏘ᮇࡢ≧ែ࡞ࡶຍࡋ࡚Ỵᐃࡋ࡚࠸ࡿࠋTMS ᢏ⾡⪅ ࡣࠊṇ☜࡞ࢹ࣮ࢱࢆ᪥ࠎࡢᴗົ࡛ฟࡋ⥆ࡅࡿࡇࡢࡳ࡞ࡽࡎࠊࡇࡢࠕุ᩿ࠖࡀせồࡉࢀࠊ ࢥࣥࢧࣝࢱࣥࢺ་ᖌࡣᑓ㛛ᐙඹࡑࡢᣦᑟࢆ⾜࠺ᚲせࡀ࠶ࡿࠋ ࠙⢭ᐦ᳨ᰝࠚ ࡇࡇࡽࡀࢥࣥࢧࣝࢱࣥࢺ་ᖌࡀ┤᥋ᢸᙜࡍࡿࠕ་⒪࡛ࠖ࠶ࡿࠋTMS ࡼࡗ࡚ࠊ ⣙ 10,000 ே୍ேࡢᝈ⪅ࡀⓎぢࡉࢀ࡚࠸ࡿࠋࡑࡢ⣙ 3 ಸࡢேᩘࡀ TMS 㝧ᛶࡢ⢭ᰝᑐ㇟⪅ ⪃࠼ࡽࢀࠊ⢭ᰝ་⒪ᶵ㛵ᣦᐃࡉࢀࢀࡤࠊ୍ᐃࡢᩘࡢ⢭ᰝࢆ⾜࠺ᚲせࡀ࡛࡚ࡃࡿࠋࡑࡢࡓ ࡵࠊᑓ㛛ᐙ࡛࡞ࡃ࡚ࡶデ⒪࡛ࡁࡿࡼ࠺ࠊ᪥ᮏඛኳ௦ㅰ␗ᖖᏛࡣࠊTMS ᑐ㇟ᝈ㛵ࡍࡿ デ⒪࢞ࢻࣛࣥࢆసᡂࡋࡓࠋࡋࡋࠊ࢞ࢻࣛࣥࡀᏑᅾࡋ࡚࠸࡚ࡶࠊࡑࢀࡔࡅ࡛デ⒪ ࡛ࡁࡿࢃࡅ࡛ࡣ࡞࠸ࠋᑓ㛛ᐙࢥࣥࢧࣝࢺ࡛ࡁࡿࢩࢫࢸ࣒ࡀᚲせ࡛࠶ࡾࠊNPO ἲேࢱࣥࢹ࣒ ࣐ࢫ࣭ࢫࢡ࣮ࣜࢽࣥࢢᬑཬ༠࡛ࡣࠊࢱࣥࢹ࣒࣐ࢫ࣭ࢫࢡ࣮ࣜࢽࣥࢢ࣭ࢥࣥࢧࣝࢸ࣮ࢩࣙ ࣥࢭࣥࢱ࣮ࢆタ⨨ࡋ࡚࠸ࡿࠋࡋࡋࠊface to face ࡢࢥࣥࢧࣝࢸ࣮ࢩࣙࣥࡶ㔜せ࡛࠶ࡾࠊ ₇⪅ࡣ」ᩘࡢ⮬యዎ⣙ࡋࠊࢥࣥࢧࣝࢺᴗົࢆ⾜ࡗ࡚࠸ࡿࠋࡲࡓࠊᖺࡽ㛵ᮾᆅ༊࡛ࠊ ࠕ㛵ᮾࢱࣥࢹ࣒࣐ࢫ࣭ࢫࢡ࣮ࣜࢽࣥࢢ࣭ࣇ࢛࣮࣒ࣛࠖࢆ㛤ദࡋ࡚࠸ࡿࠋ ࠙་⒪ୖࡢၥ㢟Ⅼࠚ ๓㏙ࡢࢩࢫࢸ࣒࡛⢭ᰝ᪉㔪ࡀỴࡲࡗ࡚ࡶࠊ☜ᐃデ᩿ࡢࡓࡵᚲせ࡞᳨ ᰝࡢ୰࡛ࠊಖ㝤㍕ࡉࢀ࡚࠸ࡿ᳨ᰝࡣഹ࡛࠶ࡿࡇࡀၥ㢟࡛࠶ࡿࠋ ࠕಖ㝤་⒪ᶵ㛵ෆ࡛ࡢ ᳨ᰝࠖ࠸࠺ไ⣙ࡀ࠶ࡿ㡯┠ࡶ࠶ࡾࠊᮍࡔⰋ࠸デ⒪యไ࡞ࡗ࡚࠸࡞࠸ࠋ ࠙ࡲࡵࠚ ఱࡼࡾࡶ㔜せ࡞ࡇࡣࠊᆅᇦࡢࢥࣥࢧࣝࢱࣥࢺ་ᖌࢆᨭ࠼ࡿࢩࢫࢸ࣒ࡢᵓ⠏࡛ ࠶ࡿࠋTMS ࡢᑓ㛛ᐙࡣࠊ་ᖌ࡛࠶ࡗ࡚ࡶᢏ⾡⪅࡛࠶ࡗ࡚ࡶࠊ✚ᴟⓗࢥࣥࢧࣝࢱࣥࢺ་ᖌ 㛵ࢃࡾࠊࡼࡾⰋ࠸ TMS ࢆᐇ⌧࡛ࡁࡿࡼ࠺ດຊࡋ࡞ࡅࢀࡤ࡞ࡽ࡞࠸ࠋ ́́ S1-2 ࠕᅜ⮬య࡛ᴗࡉࢀࡓࢱࣥࢹ࣒࣐ࢫ࣭ࢫࢡ࣮ࣜࢽࣥࢢࡢᑐᛂࠖ ⢭ᐦ᳨ᰝࡢᑐᛂࡢ⌧ἣ 㛗㇂ᕝ᭷⣖ 1 1 ᓥ᰿Ꮫ་Ꮫ㒊ᑠඣ⛉ Management of second-tier tests in newborn screening using tandem mass spectrometry in Shimane University Yuki Omura-Hasegawa1 1 Department of Pediatrics, Shimane University School of Medicine ࢱࣥࢹ࣒࣐ࢫ㉁㔞ศᯒィ㸦MS/MS㸧ࢆ⏝࠸ࡓ᪂ࡋ࠸᪂⏕ඣ࣐ࢫ࣭ࢫࢡ࣮ࣜࢽࣥࢢ㸦NBS㸧 ࡣ≉⬡⫫㓟࣭᭷ᶵ㓟௦ㅰ␗ᖖࡢデ᩿᭷⏝ࡔࡀࠊඣࡢ᪩ᮇ⒪ࡸ㞀ᐖண㜵ᙺ❧࡚ࡿ ࡓࡵࡣࠊ⢭ᐦ᳨ᰝࡢᑐᛂࡸデ᩿ᚋࡢࣇ࢛࣮ࣟ࠸ࡗࡓࢩࢫࢸ࣒ᵓ⠏ࡀ㔜せ࡛࠶ࡿࠋ☜ ᐃデ᩿ࡣ MS/MS ࡼࡿ⾑୰ࢩࣝ࢝ࣝࢽࢳࣥศᯒຍ࠼࡚ࠊ࢞ࢫࢡ࣐ࣟࢺࢢࣛࣇ㉁㔞ศ ᯒィ㸦GC/MS㸧ࢆ⏝࠸ࡓᒀ୰᭷ᶵ㓟ศᯒࡸ㑇ఏᏊゎᯒࠊ㓝⣲άᛶ ᐃ࡞ࡢ᳨ᰝࡀᚲせࡔࡀࠊ ࡇࢀࡽࡢḟ᳨ᰝࢆᐇ࡛ࡁࡿタࡣ㝈ࡽࢀ࡚࠸ࡿࡢࡀ⌧≧࡛࠶ࡿࠋ ᓥ᰿Ꮫ࡛ࡣ 1995 ᖺࡽᒀ୰᭷ᶵ㓟ศᯒࢆࠊ2003 ᖺࡽࡣ⾑୰ࢩࣝ࢝ࣝࢽࢳࣥศᯒࢆ 㛤ጞࡋࡓࠋ2014 ᖺ 12 ᭶ࡲ࡛ࠊNBS ࢆ㝖࠸ࡓࡢศᯒ᳨యᩘࡣᒀ୰᭷ᶵ㓟ศᯒࡀ 23,496 ᳨యࠊࢩࣝ࢝ࣝࢽࢳࣥศᯒ 20,255 ᳨యࠊ㑇ఏᏊゎᯒ 532 ᳨యࠊ㓝⣲άᛶ/immunoblotting 884 ᳨యࠊᅜෆእࡽከᩘࡢࣁࣜࢫࢡඣࡢデ᩿౫㢗ᑐᛂࡋࠊ⤒㦂ࢆ㔜ࡡ࡚ࡁࡓࠋ ᓥ᰿Ꮫ࡛ NBS ࢆ⾜ࡗࡓࡘ࠸࡚ࡣࠊ2005 ᖺ 4 ᭶ࡽ 2014 ᖺ 12 ᭶ࡲ࡛ࡢศᯒᩘࡀ ィ 224,352 ᳨య࡛ࠊ࠺ࡕ⢭ᐦ᳨ᰝ࡞ࡗࡓࡀ 199 㸦0.09%㸧 ࠊࡉࡽ࡞ࡿ᳨ᰝࢆ⾜ࡗࡓ 㸦㝧ᛶ㸧ࡣ 77 㸦0.03㸣㸧࡛ࠊ᭱⤊ⓗ௦ㅰ␗ᖖデ᩿ࡉࢀࡓࡢࡣ 32 㸦0.01%㸧 ࡛࠶ࡗࡓࠋᝈࡣࣇ࢙ࢽࣝࢣࢺࣥᒀ㸦PKU㸧5 ࠊ㍍ࢆྵࡴࣉࣟࣆ࢜ࣥ㓟⾑ᴟ㛗㙐 ࢩࣝ CoA ⬺Ỉ⣲㓝⣲㸦VLCAD㸧Ḟᦆࡀࡑࢀࡒࢀ 4 ࠊ࣓ࢳ࣐ࣝࣟࣥ㓟⾑ࠊ୰㙐ࢩࣝ CoA ⬺Ỉ⣲㓝⣲㸦MCAD㸧Ḟᦆ࡞ࡀ 2 ࡎࡘⓎぢࡉࢀࡓࠋඛኳᛶᝈ௨እࡶࣅࢱ࣑ࣥ 12 ㊊ࡼࡿᛮࢃࢀࡿ୍㐣ᛶࡢ࣓ࢳ࣐ࣝࣟࣥ㓟⾑ 12 ࠊࣅ࢜ࢳࣥḞஈ 1 ࡞ࡶデ᩿ ࡋ࠼ࡓࠋࡉࡽ⾑Ύࢩࣝ࢝ࣝࢽࢳࣥศᯒ࡛㍍ᗘࡢ␗ᖖࡀ⥆ࡃᑐࡋ࡚ࡣࠊ㑇ఏᏊゎ ᯒࡸ㓝⣲άᛶ ᐃࢆ⾜࠸ࠊィ 7 ࡀ VLCAD Ḟᦆࡸ MCAD Ḟᦆࡢಖᅉ⪅デ᩿ࡉࢀࡓࠋ ࡇࡢࡼ࠺ NBS ࡽデ᩿☜ᐃࡲ࡛ࡢࢩࢫࢸ࣒ࡀ☜❧ࡋ࡚࠸ࢀࡤࠊ ⢭ᐦ᳨ᰝࡢᚲせ࡞ ⣲᪩ࡃᑐᛂ࡛ࡁࡿࡔࡅ࡛࡞ࡃࠊࡈࢹ࣮ࢱࢆヲ⣽ゎᯒ࡛ࡁࠊ⢭ᐦ᳨ᰝ⋡ࢆ୍ᐃಖ ࡕ࡞ࡀࡽぢ㏨ࡋࢆῶࡽࡍࡓࡵࡢࡼࡾ㐺ษ࡞ᣦᶆࡢ᳨ウࡶᙺ❧ࡘࠋデ᩿⤒㦂ࢆάࡋࠊ ḟ᳨ᰝタࢆᣢࡓ࡞࠸⮬య࡛ࡶࡼࡾ㎿㏿࡞デ᩿ࡀ࡛ࡁࡿࡼ࠺ࠊNPO ἲேࢱࣥࢹ࣒࣐ࢫᬑཬ ༠ࢆタ❧ࡋデ᩿ᨭࡢ㐃ᦠࢆᅗࡗ࡚࠾ࡾࠊࡇࢀࡽࢆྵࡵࡓᑐᛂࡢ⌧≧ࢆ࠾ヰࡋࡍࡿࠋ ́́ S1-3 ṇᖖ᳨యᝈ⪅ࢹ࣮ࢱሗ㞟ࡼࡿࢱࣥࢹ࣒࣐ࢫࢫࢡ࣮ࣜࢽࣥࢢࡢ⢭ᗘ⟶⌮ ⰼ₶ᖌ 1, ⚟ኈ 2, ▼ẟಙஅ 3, ⏣ᓮ㝯 4 1 ᮐᖠᕷ⾨⏕◊✲ᡤ, 2 ᮐᖠ࣒ࣀࢲࢢࣀࢫࢸࢵࢡࣛ࣎ࣛࢺ࣮ࣜ, 3(බ㈈)ᮾி㒔ண㜵 ་Ꮫ༠, 4(୍㈈)Ꮫཬ⾑Ύ⒪ἲ◊✲ᡤ Quality control utilizing screening data from the normal babies and the patients in newborn screening using tandem mass spectrometry Junji Hanai1, Masaru Fukushi2, Nobuyuki Ishige3, Ryuji Tasaki4 1 Sapporo City Institute of Public Health, 2Sapporo Immuno diagnostic laboratory, 3Tokyo Health Service Association, 4The Chemo Sero-Therapeutic Research Institute ࠙┠ⓗࠚࢱࣥࢹ࣒㉁㔞ศᯒィࢆ⏝࠸ࡿ᪂⏕ඣ௦ㅰ␗ᖖ࣐ࢫࢫࢡ࣮ࣜࢽࣥࢢ(௨ୗࠊࢱࣥࢹ࣒࣭ ࣐ࢫࢫࢡ࣮ࣜࢽࣥࢢ㸸TMS)ࡣᅜࡢ⮬య࡛ᐇࡉࢀ࡚࠾ࡾࠊ᳨ᰝタࡣ 38 ᡤ࡞ࡗ࡚ ࠸ࡿࠋTMS ࡣከᣦᶆࡼࡿከ✀㢮ࡢᝈࡢࢫࢡ࣮ࣜࢽࣥࢢ࡛࠶ࡿࡇࡽࠊྛᝈᛂࡌ ࡓ㐺ษ࡞࢝ࢵࢺ࢜ࣇ್ࡢタᐃࡀᚲせ࡛࠶ࡾࠊ ᅜᆒ㉁࡞⢭ᗘࡢ㧗࠸ࢫࢡ࣮ࣜࢽࣥࢢࢆ┠ᣦࡍ ୖࡽࡶࠊタ㛫ᕪࡢゎᾘࡣ㔜せ࡞ㄢ㢟࡛࠶ࡿࠋࡑࡇ࡛ࠊࢫࢡ࣮ࣜࢽࣥࢢ⢭ᗘࡢᨵၿタ 㛫ᕪࡢゎᾘࢆᅗࡿࡓࡵࠊTMS ࡢ⢭ᗘྥୖᡂᯝࢆୖࡆ࡚࠸ࡿ࣓ࣜ࢝ࠕThe Region 4 Stork collaborative projectࠖ(௨ୗࠊR4S)ࡢゎᯒࢩࢫࢸ࣒ࢆཧ⪃ࠊྛᣦᶆࡢṇᖖ್ศᕸ࢝ࢵࢺ࢜ ࣇ್ࡢㄪᰝ⤖ᯝຍ࠼࡚ࠊ ࢫࢡ࣮ࣜࢽࣥࢢⓎぢ࠾ࡼࡧഇ㝧ᛶࡢ᳨ᰝࢹ࣮ࢱࢆ⏝ࡋࡓ᪥ ᮏ∧ R4S ࢆᐃࡋࡓ TMS Web ゎᯒࢩࢫࢸ࣒ࡢᵓ⠏ࢆ᳨ウࡋࡓࠋ ࠙᪉ἲࠚᖹᡂ 26 ᖺ 9 ᭶ࡽ 12 ᭶ࠊ᪥ᮏ࣐ࢫࢫࢡ࣮ࣜࢽࣥࢢᏛᢏ⾡㒊ࡀసᡂࡋࡓෆ㒊 ⢭ᗘ⟶⌮ࢶ࣮ࣝࢆ⏝࠸࡚ࠊTMS ࢫࢡ࣮ࣜࢽࣥࢢタṇᖖ್ศᕸㄪᰝࢆ⾜ࡗࡓࠋࡲࡓࠊཌ ປ⛉◊◊✲⌜ࠕ࣐ࢫࢫࢡ࣮ࣜࢽࣥࢢ᳨ᰝ⢭ᗘྥୖ㛵ࡍࡿ◊✲ࠖ 㸦◊✲௦⾲⪅㸸ᓥ᰿Ꮫ་ Ꮫ㒊ᑠඣ⛉ᩍᤵᒣཱྀΎḟ㸧ࡢ୍⎔ࡋ࡚ TMS Ⓨぢᝈ⪅ㄪᰝࢆᐇࡋࠊࢫࢡ࣮ࣜࢽࣥࢢࡢ TMS ࢹ࣮ࢱࢆ㞟ࡋࡓࠋ ࠙⤖ᯝࠚR4S ࡢ Analyte Comparison ゎᯒࢆཧ⪃ EXCEL ࡛సᡂࡋࡓෆ㒊⢭ᗘ⟶⌮ࢶ࣮ࣝ ࡼࡾྛタࡢṇᖖ್ศᕸࠊ࢝ࢵࢺ࢜ࣇ್ࠊᝈ⪅ࢹ࣮ࢱ࡞ࢆ⟽ࡦࡆᅗ࡛⾲♧࡛ࡁࡿࡼ࠺ࡋ ࡓࠋࡇࡢゎᯒࢶ࣮ࣝࢆⓎᒎࡉࡏࠊࢡࣛ࢘ࢻࢧ࣮ࣂ࣮ୖ TMS ᑓ⏝ࡢ Web ゎᯒࢩࢫࢸ࣒ࢆᵓ ⠏ࡍࡿࡇࡼࡾࠊྛ᳨ᰝタ࡛ࡣᐃᮇⓗࡲࡓࡣ㝶ࠊṇᖖ್ศᕸ㞟ィ⤖ᯝࡸᝈ⪅ࢹ࣮ ࢱࢆ᭦᪂ࡋࠊᚲせ࡞ṇᖖ್ศᕸࡢタ㛫ᕪࡸ࢝ࢵࢺ࢜ࣇ್ࡢጇᙜᛶࢆ᳨ド࡛ࡁࡿࠋ ࠙⪃ᐹࠚᡃࡀᅜࡢ TMS ࡣᖺ㛫᳨యᩘࡀ 2 ௳‶ࡓ࡞࠸タࡀ⣙༙ᩘ࠶ࡾࠊᅜᆒ㉁࡞ࢫ ࢡ࣮ࣜࢽࣥࢢ⢭ᗘࡢ☜ಖࡀ㔜せ࡞ㄢ㢟࡛࠶ࡿࡀࠊWeb ゎᯒࢩࢫࢸ࣒ࢆ⏝࠸ࡿࡇ࡛ࠊᅜ ࡢ᳨ᰝタࡀࠊ ᚲせ࡞࠸ࡘ࡛ࡶࠊ ᳨ᰝࢹ࣮ࢱࡢタ㛫ᕪࡸ࢝ࢵࢺ࢜ࣇ್ࡢጇᙜᛶࢆ᳨ドࠊ ゎᯒ࡛ࡁࡿࡇࡽࠊTMS ࠾ࡅࡿ᳨ᰝ⢭ᗘࡢࡉࡽ࡞ࡿྥୖ㈉⊩ࡍࡿࡇࡀᮇᚅࡉࢀࡿࠋ ́́ S1-4 LC-MS/MS ࡼࡿḟ᳨ᰝἲࡢ㛤Ⓨ 㔜ᯇ㝧 1, ⏿ 㑳Ụ 2, ୰ᓥⱥつ 3 1 ⚟Ꮫ་Ꮫ㒊ᗣ⛉Ꮫ, 2 ⚟Ꮫ་Ꮫ㒊ᑠඣ⛉Ꮫ, 3 ᅜ❧ᡂ⫱་⒪◊✲ࢭࣥࢱ࣮࣭࣐ࢫ ࢫࢡ࣮ࣜࢽࣥࢢ◊✲ᐊ Development of second-tier tests using LC-MS/MS for newborn screening Yosuke Shigematsu1, Ikue Hata2, Hideki Nakajima3 1 Department of Health Science, University of Fukui 2 Department of Pediatrics, University of Fukui 3 Mass screening laboratory, National Research Institute for Child Health and Development ࠙┠ⓗࠚ ᪂⏕ඣ࣐ࢫࢫࢡ࣮ࣜࢽࣥࢢࡢࢩࣝ࢝ࣝࢽࢳ࣭࣑ࣥࣀ㓟 flow-injection ESI-MS/MS ศᯒ࡛ࡣࠊ␗ᛶయࡢศูᐃ㔞ࡀᅔ㞴࡛࠶ࡾࠊࢫࢡ࣮ࣜࢽࣥࢢᣦᶆ≀㉁ࡢデ᩿≉␗ ᛶࡀప࠸ࡓࡵഇ㝧ᛶࡀከࡃⓎ⏕ࡍࡿࠋ୍᪉ࠊℐ⣬⾑୰ࡣ㏻ᖖࡢᣦᶆ≀㉁௨እデ᩿≉␗ⓗ ࡞௦ㅰ≀ࡀྵࡲࢀ࡚࠸ࡿࡢ࡛ࠊࡑࡢᐃ㔞ࢆ┠ⓗࡋࡓ LC-MS/MS ἲࢆ㛤Ⓨࡋࡓࠋ ࠙᪉ἲࠚAB Sciex ♫〇 API4000 MS/MS system ᓥὠ〇సᡤ〇 LC system ࢆ᥋⥆ࡋ࡚ LC-MS/MS ศᯒࢆ⾜ࡗࡓࠋLC ࣒࢝ࣛࡣ Imtakt ♫〇࣐ࣝࢳ࣮ࣔࢻࢡ࣐ࣟࢺࢢࣛࣇ࣮࣒࢝ࣛ Scherzo SS-C18 (3.0㹶150 mm)ࢆ⏝ࡋࡓࠋ ࠙⤖ᯝࠚ ࣑ࣀ㓟ࢩࣝ࢝ࣝࢽࢳࣥࡣࢫࢡ࣮ࣜࢽࣥࢢ⏝ࡢᢳฟᾮࢆᾲࡋ 2%ࢠ㓟⁐ ゎࡋ࡚ศᯒྍ⬟࡛࠶ࡾࠊࢩࣝࢢࣜࢩࣥࡣᏳᐃྠయᶆ㆑యࢆู㏵ຍ࠼ࡿࡇ࡛ࠊྠ ศᯒྍ⬟࡛࠶ࡗࡓࡀࠊ㧗ឤᗘ࡛▷㛫ศᯒࡍࡿࡣࠊᑐ㇟ᝈࡈࡢศᯒ࣓ࢯࢵࢻࢆ ⏝ࡍࡿᚲせࡀ࠶ࡗࡓࠋ᭷ᶵ㓟௦ㅰ␗ᖖ࡛デ᩿⏝ࡉࢀࡿ᭷ᶵ㓟ࡋ࡚ࠊ࣓ࢳ࣐ࣝࣟࣥ 㓟ࠊ3-ࣄࢻࣟ࢟ࢩࣉࣟࣆ࢜ࣥ㓟ࠊࢢࣝࢱࣝ㓟ࠊ3-ࣄࢻࣟ࢟ࢩࢢࣝࢱࣝ㓟ࠊ3-ࣄࢻࣟ࢟ࢩ-3࣓ࢳࣝࢢࣝࢱࣝ㓟ࠊ3-ࣄࢻࣟ࢟ࢩࢯྜྷⲡ㓟ࡀ stable-isotope dilution ἲ࡛ℐ⣬⾑ 1 ࣃࣥࢳࢆ ⏝࠸࡚ᐃ㔞ฟ᮶ࡓࡀࠊ⁐ゎᾮࡸ⛣ື┦ᕤኵࡀᚲせ࡛࠶ࡗࡓࠋ ࠙⪃ᐹࠚ ཝ᱁࡞ẕஙᰤ㣴⩏ࡼࡾ㔜ᗘࡢ㣚㣹≧ែ㝗ࡗ࡚࠸ࡿ᪂⏕ඣ࡛ࡣ␗ஹ㐍ࡼ ࡾᑐ㇟ᝈࡢഇ㝧ᛶ࡞ࡿࡇࡀከࠎ࠶ࡾࠊ᪩ᮇࡢ᳨ᰝ࡛㐺ษ≧ែホ౯⾜࠺ࡇࡣ㔜せ ࡛࠶ࡿࠋ࣓࣮ࣉࣝࢩࣟࢵࣉᒀࡣ allo-isoleucine ࡢቑຍ࡛Ꮫデ᩿ࡀྍ⬟࡛࠶ࡾࠊ㣚㣹ࡼ ࡿ␗ஹ㐍≧ែ༊ูฟ᮶ࡿࠋ࣓ࢳ࣐ࣝࣟࣥ㓟⾑࣭ࣉࣟࣆ࢜ࣥ㓟⾑ࡢഇ㝧ᛶࡶ㉳ࡇࡾ ࠺ࡿࡀࠊࡇࢀࡶ࣓ࢳ࣐ࣝࣟࣥ㓟⃰ᗘᐃ㔞࡛Ꮫデ᩿ࡀྍ⬟࡛࠶ࡿࠋ୰㛗㙐ࢩࣝ࢝ࣝࢽࢳ ࣥࡢቑຍࡼࡿ⬡⫫㓟㓟␗ᖖࡢഇ㝧ᛶࡘ࠸࡚ࡣࠊᅇࡢ͆ḟ᳨ᰝ͇࡛㚷ูࡍࡿࡢ ࡣ㞴ࡋ࠸ࡢ࡛ࠊูࡢࣝࢦࣜࢬ࣒࡛ᑐᛂࡍࡿࡇ࡞ࢁ࠺ࠋྠቑຍࡍࡿ C5-DC ࢝ࣝࢽ ࢳࣥᑐࡋ࡚ࡣ 3-ࣄࢻࣟ࢟ࢩࢢࣝࢱࣝ㓟࡞ࡢ᭷ᶵ㓟ᐃ㔞ࡀᏛデ᩿᭷⏝࡛࠶ࡿࠋࡇࡢ ࡼ࠺࡞ LC-MS/MS ἲࡀࢫࢡ࣮ࣜࢽࣥࢢ᳨ᰝタࢫ࣒࣮ࢬᑟධฟ᮶ࡿయไࢆࡘࡃࡿࡇ ࡀồࡵࡽࢀ࡚࠸ࡿࠋ ́́ S2-1 ࣓࣮ࢪࣥࢢ㉁㔞ศᯒ࠾ࡅࡿ㧗ឤᗘ ᐃࡢࡓࡵࡢẁ㝵࣐ࢺࣜࢵࢡࢫ౪⤥ἲ ᡭἲ᭱㐺 ᪂㛫⚽୍ 1 1 㜰ᏛᏛ㝔ᕤᏛ◊✲⛉ Methodology of two-step matrix application procedure for imaging mass spectrometry Shuichi Shimma1 1 Osaka University Graduate School of Engineering IMS 䛿䚸㏆ᖺ䚸⸆◊✲䛻䛚䛡䜛⏕యෆ⸆≀ືែ䛾ホ౯䜔ẘᛶホ౯䛾䛯䜑䛾⸆≀௦ㅰ≀䜲䝯 䞊䝆䞁䜾䛺䛹䛻ᑟධ䛥䜜䛴䛴䛒䜛㐣Ώᮇ䛷䛒䜛䛸䛔䛘䜛䚹ᚋ䠈་⸆ရ䛾 IMS 䛜┿䛻䛘䜛ᢏ⾡䛸 䛺䜛䛯䜑䛻䛿ከタ䛷䛾ホ౯䛜ྍ⬟䛺ᶆ‽ᡭ㡰䜢䛿䛨䜑䛸䛩䜛ホ౯ᇶ‽䛜ᚲせ䛷䛒䜛䛸⪃䛘䛶䛔 䜛䚹䛧䛛䛧䛺䛜䜙䚸⌧Ⅼ䛷䛾་⸆ရ䛻䛚䛡䜛 IMS 䛷䛿䛂┠ⓗ䛾⸆≀⏤᮶䝅䜾䝘䝹䛜ぢ䛘䛺䛔䛃䚸 䛂་⸆ရ䛾⏕యෆศᕸ䜢ぢ䜛䛻䛿⸆ຠホ౯䛷䛾ᢞ㔞䛷䛿ឤᗘ༑ศ䛃䛸䛔䛳䛯ึṌⓗ䛷䛒䜛䛜 ゎỴ䛜㠀ᖖ䛻㞴䛧䛔ၥ㢟䛻┤㠃䛩䜛䛣䛸䛜䛒䜛䚹䛧䛯䛜䛳䛶䚸ỗ⏝ⓗᢏ⾡䛸䛧䛶ᡂ⇍䛩䜛䛻䛿䜎䛰 䜎䛰ᵝ䚻䛺㞀ቨ䜢䜚㉺䛘䜛ᚲせ䛜䛒䜛䚹 㞀ቨ䛾୍䛴䛾せᅉ䛸䛧䛶䚸⸆≀䜢ྍど䛩䜛䛯䜑䛻⾜䛖ヨᩱ๓ฎ⌮ἲ䛾༑ศ䛥䚸㐺ษ䛥䛜 ᣲ䛢䜙䜜䜛䚹་⸆ရ䛾 IMS 䛻䛚䛔䛶䛿䚸㐣ཤ䛻ሗ࿌䛥䜜䛶䛔䜛䝸䞁⬡㉁ྍど䛾䛯䜑䛾๓ฎ⌮ἲ 䛸䛿䛟ู䛾᮲௳タᐃ䛜ᚲせ䛷䛒䜛䛜䚸䛹䛾䜘䛖䛺ᡓ␎䛷๓ฎ⌮ἲ䜢㛤Ⓨ䛩䜛䛣䛸䛜ᮃ䜎䛧䛔䛛᫂ ☜䛷䛿䛺䛔䚹 IMS ๓ฎ⌮䛻䛚䛡䜛䝟䝷䝯䞊䝍䞊䛿䝬䝖䝸䝑䜽䝇౪⤥ἲ䛻㝈䛳䛶䜒ᩘከ䛟Ꮡᅾ䛩䜛䚹ᐃ䛥䜜䜛 䝟䝷䝯䞊䝍䞊䛜᭱⤊⤖ᯝ䛻䛹䛾⛬ᗘ䛾ᙳ㡪䜢䛘䜛䛛䚸䛸䛔䛖ሗ䜢ಖ᭷䛧䛶䛔䜛䛛ಖ᭷䛧䛶䛔䛺 䛔䛛䛿䝯䝋䝑䝗㛤Ⓨ䜢⾜䛖ୖ䛷㠀ᖖ䛻㔜せ䛷䛒䜛䛸⪃䛘䛶䛔䜛䚹ᮏⓎ⾲䛷䛿䚸䜲䝯䞊䝆䞁䜾㉁㔞ศᯒ 䛾㧗ឤᗘ ᐃ⏝䛻㛤Ⓨ䛥䜜䛯ẁ㝵䝬䝖䝸䝑䜽䝇౪⤥ᡭἲ䛾ᴫせ䛻䛴䛔䛶ㄝ᫂䛧䚸ᮏᡭἲ䜢ᐇ 䛩䜛䛻䛒䛯䜚ᐃ䛥䜜䜛ᵝ䚻䛺䝟䝷䝯䞊䝍䞊䛻䛴䛔䛶ᩚ⌮䛩䜛䚹䜎䛯䚸ᥦ♧䛧䛯䝟䝷䝯䞊䝍䞊䛜ᐇ㝿 䛻⤌⧊ୖ䛛䜙ᚓ䜙䜜䜛䝬䝇䝇䝨䜽䝖䝹䛻䚸䛹䛾䜘䛖䛺ᙳ㡪䜢䛘䛶䛔䜛䛛䛻䛴䛔䛶䜢䛒䛢䛶⪃ᐹ䛧 䛯䛔䚹 ́́ S2-2 ࣓࣮ࢪࣥࢢ㉁㔞ศᯒࡼࡿ᳜≀ྵ᭷ᡂศࡢゎᯒ ᖹ ಟ 1, ➃ᓮ㔛ᕹ 1, ∦㔝 ⫕ 1, 㔠Ꮚస 2, ୰す㇏ᩥ 3 1 ⚟┴❧Ꮫ⏕≀㈨※Ꮫ㒊ࠊ2 ᕞᕤᴗᏛࠊ3 㜰་⛉Ꮫ Nano-PALDI MS for Plant hormone Shu TAIRA1, Riho HASHIZAKI1, Hajime KATANO1, Daisaku KANEKO2, Toyofumi NAKANISHI2 1 Fukui Prefectural University Department of Bioscience, 2 Kyushu Institute of Technology, 3 Osaka Medical College, Faculty of Medicine ࠙┠ⓗࠚ ᭱㏆ࡣࠊ࣓࣮ࢪࣥࢢ MS ࡶ་⸆௨እࡢศ㔝ࠊ㎰ࠊᕤศ㔝ࡶ✚ᴟⓗᛂ⏝ࡉࢀ࡚࠸ࡿ ᛮ࠸ࡲࡍࠋ₇⪅ࡣࠊ㎰Ꮫ㒊ࡢ❧ሙࡽ㣗ရ㸦᳜≀㸧↔Ⅼࢆᙜ࡚࡚≀㉁ࡢᒁᅾࢆ᫂ࡽ ࡋ࡚࠸ࡲࡍࠋᅇࠊ 1. ࢺ࢘࢞ࣛࢩࡢ࢝ࣉࢧࢩࣥࡢᒁᅾ㸦ᅗ㸯㸧1 2. ࢟ࣗ࢘ࣜࡢࣅࢱ࣑ࣥ C ⏝ࡍࡿ㎰⸆ࡢᒁᅾ 2 3. ⏕⸆㸦㯤㸧ྵࡲࢀࡿࢭࣥࣀࢩࢻ㢮ࡢᒁᅾ ࡞ࡘ࠸࡚ࡈ⤂ࡋࠊⓙᵝ㆟ㄽࡋࠊⓙᵝࡢ◊✲ࡢ୍ຓ࡞ࢀࢀࡤᛮࡗ࡚࠾ࡾࡲࡍࠋ ࠙᪉ἲࠚ ྛࢧࣥࣉࣝࡢ⤖ษ∦ࢆసᡂᚋࠊ࢜ࣥᨭࢆሬᕸࡋࠊ࣓࣮ࢪࣥࢢ㉁㔞ศᯒࢆ⾜ ࡗࡓࠋ⏝࠸ࡓ࢜ࣥᨭࡣࠊCHCAࠊDHBࠊࢼࣀᚤ⢏Ꮚ࡛࠶ࡿࠋ ࠙⤖ᯝࠚ 1. ࢝ࣉࢧࢩࣥࡣ✀Ꮚከ࠸ࡉࢀࡿࡀᐇ㝿ࡣ⫾ᗙࡼࡤࢀࡿⰺࡢ⾲㠃ᒁᅾࡋ࡚࠸ࡿࠋ 2. ࣅࢱ࣑ࣥ C ࡣ࢟ࣗ࢘ࣜࡢእⰺᒁᅾࡋ࡚࠾ࡾࠊ㎰⸆ࡣ้ࠎෆ㒊ᾐ㏱ࡋ࡚࠸ࡓࠋ 3. ࢭࣥࣀࢩࢻ㢮ࡣ㧊㒊ᒁᅾࡋ࡚࠸ࡓࠋࡇࢀࡣྂ᮶ࡼࡾࠊ㧊㒊ࡢࡳࢆ⏝ࡍࡿ࠸࠺ಟ ຍᕤἲ⛉Ꮫⓗ᰿ᣐࢆ࠼ࡓࠋ ࠙⪃ᐹࠚ ᳜≀ࡢᶵ⬟ᛶᡂศ࡞ࢆྍどࡍࡿࡇࡣࠊ⏕⌮Ꮫⓗព⩏ࡢ࠶ࡿࡇ࡛ࡶ࠶ࡿࡀࠊ㣗 ရࡋ࡚ぢࡓሙྜࠊရ㉁ࢆド᫂ࡍࡿࢹ࣮ࢱࡋ࡚⌮ゎࡋࡸࡍ࠸ࠋࡲࡓࠊṧ␃㎰⸆ࡢ༴㝤ᛶ ࢆどぬⓗ♧ࡍࡶ㣗ရ⾨⏕Ꮫⓗ౯್ࡢ࠶ࡿࡇ࡛࠶ࡿࠋ ࠙ㅰ㎡ࠚ ࡇࡢᡂᯝࡣ NEDO ⱝᡭࢢࣛࣥࢺ㸦Project ID: 11B16002d㸧ࡢᨭࡼࡗ࡚ᚓࡽࢀࡲࡋࡓࠋ ࠙ཧ⪃ᩥ⊩ࠚ -----------------------------------------------------------------------------------------------------------1. S. Taira, et al. ” Mass spectrometry imaging of the capsaicin localization in the capsicum fruits” International Journal of Biotechnology for Wellness Industries 1, 61-65 (2012) 2. S. Taira, et al. ‘Mass Spectrometry Imaging Analysis of Location of Procymidone in Cucumber Sample’ Journal of Agricultural and Food Chemistry 63, 6109-6112 (2015) ́́ S2-3 ⤫ྜኻㄪ⒪⸆ࣁࣟ࣌ࣜࢻ࣮ࣝࡼࡿ⚄⤒ẘᛶⓎ⌧ᶵᵓࡢゎᯒ㸸㉁㔞࣓࣮ ࢪࣥࢢᡭἲࡼࡿ⬻ෆࣆࣜࢪࢽ࣒࢘௦ㅰ≀ࡢྍど ྜྷ⏣ཎつ 1, ୰す㇏ᩥ 2, ᮡᮏ㤶ዉ㸱, ༑ᔒ୍㞝㸲 1 ㏆␥Ꮫ་Ꮫ㒊ἲ་Ꮫ, 2 㜰་⛉Ꮫ⮫ᗋ᳨ᰝ་Ꮫ, 3 㜰ᏛᏛ㝔་Ꮫ⣔◊✲⛉ἲ་Ꮫ, 4 ୍⯡♫ᅋἲே་⸆ศᯒ༠ Brain distribution studies of the neurotoxic pyridinium metabolite (HPP+) of haloperidol with MALDI mass spectrometry imaging Motonari Yoshida1, Toyofumi Nakanishi2, Kana Sugimoto3 , Kazuo Igarashi4 Department of Legal Medicine, Faculty of Medicine, Kinki University, 2Department of Clinical and 3 Laboratory Medicine, Osaka Medical College, Department of Legal Medicine, Osaka University 4 Graduate School of Medicine, Department of Research Development, Association of Medicinal Analysis 1 ⸆≀ࡢయෆศᕸ◊✲࠾࠸࡚ࠊᚑ᮶ࡢᨺᑕᛶᶆ㆑యࢆ⏝࠸ࡿ࣮࢜ࢺࣛࢪ࢜ࢢࣛࣇ࣮ ࡣ␗࡞ࡗ࡚ࠊ㉁㔞ศᯒࡼࡾ⤌⧊ษ∦ୖࡢ⸆≀ศᕸ≧ែࢆ ᐃ࡛ࡁࡿ㉁㔞࣓࣮ࢪࣥࢢἲ ࡢ⏝ࡋࡓሗ࿌ࡀ㏆ᖺᑡࡋࡎࡘቑຍࡋ࡚࠸ࡿࠋࡇࡢ᪉ἲࡣࠊᨺᑕᛶᶆ㆑యࢆᚲせࡋ࡞࠸ ࡇࠊ㉁㔞ศᯒࡢ≉ᛶࢆ⏝ࡋࠊ⸆≀ࡸࡑࡢ௦ㅰ≀ࡢศᕸ≧ἣࢆ㑅ᢥⓗྍど࡛ࡁࡿ Ⅼࢆ᭷ࡋ࡚࠸ࡿࠋᚋࠊ⸆≀ࡢయෆศᕸ◊✲ศ㔝ࡢᛂ⏝ࡀࡲࡍࡲࡍᮇᚅࡉࢀࡿࠋ ⤫ྜኻㄪ⒪⸆࡛࠶ࡿࣁࣟ࣌ࣜࢻ࣮ࣝ㸦HP㸧ࡣࠊ➨୍ୡ௦ࡢᢠ⢭⚄⸆࡛࠶ࡿࡀࠊ⤫ ྜኻㄪࡢ୰࡛ࡶᗁ⫈ࡸዶ࡞ࡢ≧ᨵၿࡢࡓࡵ࡞࠾ᗈࡃ⏝࠸ࡽࢀ࡚࠸ࡿࠋ୍᪉ࠊ ࡇࡢ⒪⸆ࡢ㛗ᮇ⏝ࡼࡾࠊస⏝ࡋ࡚⸆ᛶࣃ࣮࢟ࣥࢯࢽࢬ࣒ࡀㄏᑟࡉࢀࡿࡇࡶ ▱ࡽࢀ࡚࠸ࡿࠋࡇࡢ HP ࡼࡿ⸆ᛶࣃ࣮࢟ࣥࢯࢽࢬ࣒Ⓨ⌧ࡢせᅉࡋ࡚ࠊHP ࡼࡿ⚄⤒ẘ ᛶ௦ㅰ≀ࣆࣜࢪࢽ࣒࢘㸦HPP+㸧ࡢ㛵ࡀሗ࿌ࡉࢀ࡚࠸ࡿࠋࡇࡢ௦ㅰ≀ HPP+ࡣᏛᵓ㐀ⓗࠊ ⚄⤒ẘᛶㄏⓎ≀㉁ MPTP ࡢࣆࣜࢪࢽ࣒࢘௦ㅰ≀ MPP+㢮ఝࡋ࡚࠸ࡿࡇࡽࠊ㢮ఝࡋࡓ⬻⚄ ⤒ẘᛶࢆ᭷ࡍࡿ⪃࠼ࡽࢀ࡚࠸ࡿࠋḟ HP ᢞᚋࡢయෆືែࡋ࡚ࠊࡲࡎ⫢⮚ CYP3A ࡼ ࠊ ࡾࣆࣜࢪࢽ࣒࢘௦ㅰ≀ HPP+ࡀ⏕ᡂࡉࢀࠊ⬻ෆ㍺㏦ࡉࢀࡿࡇࡀࠊIgarashi ➼㸦1998㸧 Crowley ➼㸦2013㸧ࡼࡾሗ࿌ࡉࢀ࡚࠸ࡿࠋࡲࡓ Igarashi ➼㸦2002㸧ࡣ HP ᢞື≀ࡢ⬻⤌ ⧊࠾ࡅࡿࣆࣜࢪࢽ࣒࢘௦ㅰ≀ HPP+⃰ᗘࡀᢞᅇᩘ౫Ꮡࡋ࡚ቑຍࡍࡿഴྥ࠶ࡿࡇࡶ ሗ࿌ࡋ࡚࠸ࡿࠋ ࡇࢀࡽࡢሗ࿌ࡼࡾࠊ⤫ྜኻㄪ⒪⸆ࣁࣟ࣌ࣜࢻ࣮ࣝ HP ᢞ⏤᮶ࡍࡿ⸆ᛶࣃ࣮࢟ࣥ ࢯࢽࢬ࣒Ⓨ⌧ᶵᵓࢆゎ᫂ࡍࡿࡓࡵࠊ㉁㔞࣓࣮ࢪࣥࢢᡭἲࢆ⏝ࡋࡓ⚄⤒ẘᛶ௦ㅰ≀ࣆ ࣜࢪࢽ࣒࢘㸦HPP+㸧ࡢ⬻ෆศᕸ㒊㛵ࡍࡿྍどࢆ᳨ウࡋࡓࠋ ́́ S2-4 ࣝࢶࣁ࣐࣮⬻◊✲ࡢࡓࡵࡢ㉁㔞࣓࣮ࢪࣥࢢゎᯒ ụᕝ㞞ဢ 1, ᐑᆏ▱ᏹ 1, ゅ⏣ఙே 1, ᒾᓮᩍ 2, 㡞⃝ ᓫ 2, 㝮ⶶᖾ 3, ᮧᒣ⦾㞝 3, ཎᗣኵ 4 1 ྠᚿ♫Ꮫ⏕་⛉Ꮫ㒊, 2 ࣈ࣮࣭ࣝ࢝ࢲࣝࢺࢽࢡࢫओ, 3 ᮾி㒔ᗣ㛗ᑑ་⒪ࢭࣥࢱ࣮◊ ✲ᡤ㧗㱋⪅ࣈࣞࣥࣂࣥࢡ, 4 ྠᚿ♫Ꮫ⬻⛉Ꮫ◊✲⛉ Imaging Mass Spectroscopy for the study of Alzheimer’s disease (AD) Brain Masaya Ikegawa1, Tomohiro Miyasaka1, Nobuto Kakuda1, Noriyuki Iwasaki2, Takashi Nirasawa2, Hiroyuki Sumikura3, Shigeo Murayama3, Yasuo Ihara4 1 Doshisha University Faculty of Life and Medical Sciences 2 Bruker Daltonics K.K. 3 The Brain Bank for Aging Research, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology 4 Doshisha University, Graduate School of Brain Science ࣝࢶࣁ࣐࣮ࡢᝈ⪅⬻࡛ࡣࠊ⪁ேᩬࡤࢀࡿ࣑ࣟࢻE (AE)ࢆᡂศࡍࡿ␗ᖖ ᵓ㐀≀ࡢỿ╔ࡀែࡢ୰ᚰⓗᙺࢆᯝࡓࡍ⪃࠼ࡽࢀ࡚࠸ࡿࠋࡇࡢᵓ㐀≀ࡢᵓᡂᡂศࡣࠊ ࡇࢀࡲ࡛㉁㔞ᩘ 4000 ࡽ 5000 ࡢ AE࣌ࣉࢳࢻ⩌࡛ࠊ࣑ࣟࢻ๓㥑యࢱࣥࣃࢡ㉁ (amyloid precursor protein: APP) ⏤᮶ࡍࡿࡇࡀ᫂ࡽࡉࢀ࡚࠸ࡿࠋ୍᪉ࠊㄆ▱⬻࠾࠸࡚⚄ ⤒ཎ⥺⥔ኚࡋ࡚▱ࡽࢀࡿ⣽⬊ෆจ㞟యࡢᵓᡂᡂศ࡛࠶ࡿࢱ࢘ࢱࣥࣃࢡ㉁ࡣࠊࡑࡢจ㞟 㐣⛬࡛ࢩࢼࣉࢫᾘኻࠊ⚄⤒⣽⬊Ṛࡼࡗ࡚⬻ᶵ⬟పୗࢆᘬࡁ㉳ࡇࡍࡉࢀࠊࣝࢶࣁ࣐ ࣮⬻ࡢ◊✲⬻ࢱࣥࣃࢡ㉁⪁ࡢほⅬࡽ࠾ࡇ࡞࠺ࣉࣟࢸ࣮࣒࢜ゎᯒࡢᯝࡓࡍᙺࡣ ࡁ࠸ᮇᚅࡉࢀ࡚࠸ࡿࠋᮏ◊✲࡛ࡣࠊAD ࣐࢘ࢫࣔࢹࣝࡋ࡚☜❧ࡉࢀ࡚࠸ࡿ APP23 ࢺࣛ ࣥࢫࢪ࢙ࢽࢵࢡ࣐࢘ࢫ⬻ࢆᑐ㇟ࡋ࡚ MALDI-TOF MS ࡸ FT-MS ࢆ⏝࠸ࡓࣉࣟࢸ࣮࣒࢜ࣞ ࣋ࣝࡢ㉁㔞࣓࣮ࢪࣥࢢゎᯒࢆヨࡳࡓࠋࡇࡢࣔࢹࣝࡣࠊAPP 㑇ఏᏊࢫ࢙࣮࢘ࢹࣥᆺኚ␗ ࢆධࢀࡓࢺࣛࣥࢫࢪ࢙ࢽࢵࢡ࣐࢘ࢫ࡛ࠊ㢧ⴭ࡞ࣉ࣮ࣛࢡ✚ࡀච⤌⧊Ꮫⓗ᪉ἲࡼࡗ࡚ ☜ㄆࡉࢀ࡚࠸ࡿࠋࡑࡢ⤖ᯝࠊ㐌㱋ࢆྜࢃࡏࡓࢥࣥࢺ࣮࣐ࣟࣝ࢘ࢫࡣㄆࡵࡽࢀ࡞࠸ AE࣌ࣉ ࢳࢻ⩌ࡢ⬻ෆศᕸࡀ࠶ࡁࡽ࡞ࡗࡓࠋࡉࡽࠊࣄࢺ AD ⬻ࢆᑐ㇟ࡋࡓ⮫ᗋ⌮Ꮫⓗゎᯒ ࡢᛂ⏝ࡘ࠸࡚ࡶ㉁㔞࣓࣮ࢪࣥࢢゎᯒࡢ⌧≧ㄢ㢟ࡘ࠸࡚ⱝᖸࡢ⪃ᐹࢆヨࡳࡓࠋ ́́ S3-1 ࢺࣛࣥࢫ࣑࢜ࢡࢫゎᯒࡼࡿࣥࢫࣜࣥ௦ㅰไᚚࢿࢵࢺ࣮࣡ࢡࡢᵓ⠏ ᰆᮌඞஅ 1, ஂಖ⏣ᾈ⾜ 2, 3, 㯮⏣┿ஓ 1, 4 1 ᮾிᏛᏛ㝔⌮Ꮫ⣔◊✲⛉࣭⏕≀⛉Ꮫᑓᨷ, 2 ᕞᏛ࣭⏕య㜵ᚚ་Ꮫ◊✲ᡤ࣭ࢺࣛࣥࢫ ࣑࢜ࢡࢫ་Ꮫ◊✲ࢭࣥࢱ࣮࣭⤫ྜ࣑࢜ࢡࢫศ㔝, 3 JST ࡉࡁࡀࡅ, 4JST CREST Reconstruction of insulin signal flow in global phosphorylation and metabolic network Katsuyuki Yugi1, Hiroyuki Kubota 2,3, Shinya Kuroda1,4 1 University of Tokyo, 2Kyushu University, 3JST PRESTO, 4JST CREST ࠙┠ⓗࠚ ࣥࢫࣜࣥస⏝ࡢศᏊࢿࢵࢺ࣮࣡ࢡࡣ」ᩘࡢ࣑࢜ࢡࢫ㝵ᒙࡲࡓࡀࡿࡇࡀ▱ࡽࢀ࡚࠸ ࡿࡀࠊࡑࡢㇺࡣᮍࡔ᫂ࡽ࡞ࡗ࡚࠸࡞࠸ࠋ ࠙᪉ἲࠚ ᡃࠎࡣࠊࣜࣥ㓟ࣉࣟࢸ࣮࣒࣓࢜ࢱ࣮࣒࣎ࣟࡢ 2 ࡘࡢ࣑࢜ࢡࢫ㝵ᒙࡲࡓࡀࡿࢿࢵࢺ ࣮࣡ࢡࢆᵓ⠏ࡍࡿ᪉ἲㄽࠕࢺࣛࣥࢫ࣑࢜ࢡࢫゎᯒࠖࢆ☜❧ࡋࠊࣥࢫࣜࣥస⏝ᛂ⏝ࡋ ࡓࠋᮏゎᯒࡢ᭱ࡢ≉Ⰽࡣࠊ่⃭ᛂ⟅ࡋ࡚⃰ᗘࡀ᭷ពኚືࡋࡓ௦ㅰ≀ࢆ㉳Ⅼࠊࡑࡢ ኚືࡢ᰿ᮏⓗཎᅉ࡛࠶ࡿ่⃭ࢩࢢࢼࣝࡢ㏻ࡾ㐨ࢆࡉࡢࡰࡿࡇ࡛ከ㝵ᒙ௦ㅰไᚚࢿ ࢵࢺ࣮࣡ࢡࢆᵓ⠏ࡍࡿࡇࢁ࠶ࡿࠋ ࠙⤖ᯝࠚ ྠ୍᮲௳ୗ࡛ㄪ〇 ࡋࡓࣛࢵࢺ⫢ࡀࢇ⏤ ᮶ Fao ⣽⬊ࡽᚓࡽ ࢀࡓ࣑࢜ࢡࢫࢹ࣮ࢱ ࡽࠊࣥࢫ่⃭ࣜࣥ ᚋ 60 ศ௨ෆᛂ⟅ࡍ ࡿከ㝵ᒙ௦ㅰไᚚࢿ ࢵࢺ࣮࣡ࢡࢆᵓ⠏ ࡍࡿࡇᡂຌࡋࡓ [1, ྑᅗ]ࠋ ᅗ ࠕࢺ࣑ࣛࣥ࢜ࢡࢫゎᯒࠖࡼࡾᵓ⠏ࡋࡓࣥࢫࣜࣥࡼࡿ ከ㝵ᒙ௦ㅰไᚚࢿࢵࢺ࣮࣡ࢡ [1]ࠋ ࠙⪃ᐹࠚ ᵓ⠏ࡉࢀࡓࣥࢫࣜࣥస⏝ࡢࢿࢵࢺ࣮࣡ࢡࡣࠊಶูศᏊゎᯒࡢࣃࢵࢳ࣮࣡ࢡࡋ࡚▱ ࡽࢀ࡚࠸ࡓ⤒㊰௨እࡶከᩘࡢ᪂つ⤒㊰ࢆྵࡳࠊࣥࢫࣜࣥࢩࢢࢼࣝࡀᚑ᮶▱ࡽࢀ࡚࠸ࡿ ࡼࡾࡶࡣࡿᗈ࠸⠊ᅖఏ㐩ࡉࢀ࡚࠸ࡿࡇࢆ♧၀ࡍࡿࠋ Reference 1) Yugi et al. Cell Reports 8, 1171–1183 (2014). ́́ S3-2 ⬡㉁ࢡ࢜ࣜࢸࡽゎࡁ᫂ࡍែ࣭ࣂ࢜ࣟࢪ࣮◊✲ ᭷⏣ ㄔ 1,2 1 ⌮Ꮫ◊✲ᡤ⤫ྜ⏕་⛉Ꮫ◊✲ࢭࣥࢱ࣮࣭࣓ࢱ࣮࣒࣎ࣟ◊✲ࢳ࣮࣒ 2 ᶓᕷ❧ᏛᏛ㝔⏕་⛉Ꮫ◊✲⛉ Quality of lipids in health and disease Makoto Arita1, 2 1 Laboratory for Metabolomics, RIKEN Center for Integrative Medical Sciences 2 Graduate School of Medical Life Science, Yokohama City University ᚑ᮶ࡢ⏕⛉Ꮫ࠾ࡅࡿ⬡㉁◊✲ࡣࠊ⬡㉁ࡢࠕ㔞ࠖࢆ㔜どࡋ࡚⾜ࢃࢀ࡚ࡁࡓࡀࠊ⬡㉁ ࡣከࡃࡢ✀㢮ࠊࡍ࡞ࢃࡕࠕ㉁ࠖࡢ㐪࠸ࡀᏑᅾࡍࡿࠋ⏕యෆࡣከᵝ࡞⬡⫫㓟ศᏊ✀ࡀᏑᅾ ࡋࠊࡑࡢ㉁ࡢ㐪࠸ࡸ௦ㅰࣂࣛࣥࢫࡢኚࡀࠊᵝࠎ࡞⅖࣭௦ㅰᛶᝈ㛵ࢃࡿࡇࡀ♧၀ ࡉࢀ࡚࠸ࡿࠋࡇࢀࡽ⬡㉁ศᏊࡢᵓ㐀ⓗ࡞≉㉁ࢆࠕ⬡㉁ࢡ࢜ࣜࢸࠖᤊ࠼ࠊ⬡㉁ࢡ࢜ࣜࢸ ࡢከᵝᛶࡀᯝࡓࡍ⏕≀Ꮫⓗព⩏ࡘ࠸࡚⪃࠼ࡿᚲせࡀ࠶ࡿࠋࡋࡋ࡞ࡀࡽࠊ⬡㉁ࢡ࢜ࣜ ࢸࢆ⥙⨶ⓗࡘ᫂☜༊ูࡍࡿゎᯒᢏ⾡ࡣᮍࡔⓎᒎ㏵ୖ࠶ࡾࠊࡲࡓ⬡㉁ࢡ࢜ࣜࢸࢆ ไᚚ࣭㆑ูࡍࡿศᏊᶵᵓࡸࡑࡢ⏕≀Ꮫⓗព⩏㛵ࡍࡿ⌮ゎࡣⴌⱆⓗ࡞ẁ㝵࠶ࡿࠋ ⬡㉁ࢡ࢜ࣜࢸࡢኚࡀࡶࡓࡽࡍᵝࠎ࡞⾲⌧ᆺࡘ࠸࡚ࠊࡑࡢ⌮ゎࢆ㐍ࡵࡿୖ࡛㔜せ࡞ ࡶࡢࡢ୍ࡘࡀࠊ⬡㉁ศᏊࡢᵓ㐀ⓗ࡞≉㉁ࢆᗈ⠊ᅖࡘ᫂☜༊ู࡛ࡁࡿ࣓ࢱ࣮࣒࣎ࣟゎᯒ ࢩࢫࢸ࣒࡛࠶ࡿࠋᡃࠎࡣࡇࢀࡲ࡛ࠊ⬡⫫㓟௦ㅰ≀ࢆໟᣓⓗゎᯒࡍࡿࡓࡵࡢ࣓ࢱ࣮࣎ࣟ ࣒ゎᯒࢩࢫࢸ࣒ࢆ☜❧ࡋࠊ⅖ࡢไᚚ࠾࠸࡚⬡⫫㓟௦ㅰࡢ㉁ⓗኚࡀ㛵ࡍࡿྍ⬟ᛶࢆ ぢ࠸ࡔࡋ࡚ࡁࡓࠋࡉࡽࠊ≉ᐃࡢ⬡㉁ศᏊ✀ࢆ㑅ᢥⓗ ᐃࡍࡿᚑ᮶ᆺࡢࢱ࣮ࢤࢵࢺゎᯒ ຍ࠼ࠊศᏊ✀ࢆ≉ᐃࡋ࡞࠸ࣀࣥࢱ࣮ࢤࢵࢺゎᯒࢆᐇ⌧ࡍࡿࡇ࡛ࠊඛධほࡢ࡞࠸᥈⣴⠊ ᅖࡢᣑ࠾ࡼࡧゎᯒࢹ࣮ࢱࡢ㉁ࡢྥୖࢆ┠ᣦࡋ࡚࠸ࡿࠋᡃࠎࡣࠊྛ✀⬡⫫㓟ࡢྜᡂ࣭௦ㅰ 㓝⣲ࡢ㑇ఏᏊᨵኚື≀ࠊ࠶ࡿ࠸ࡣ␗࡞ࡿ⬡⫫㓟ࢆྵࡴᰤ㣴せᅉࡼࡗ࡚⬡⫫㓟௦ㅰࣂࣛࣥ ࢫࡀኚࡋࡓ≧ἣࢆ㐀ࡾฟࡋࠊࡇࢀࡽࡢ࣓ࢱ࣮࣒࣎ࣟゎᯒࡸ㑇ఏᏊⓎ⌧ゎᯒ࡞ࢆ⤌ࡳྜ ࢃࡏࡿࡇࡼࡾࠊᵝࠎ࡞⏕⌧㇟㛵ࢃࡿศᏊ࣓࢝ࢽࢬ࣒ࢆ⬡⫫㓟௦ㅰࡢ㉁ࡢ㐪࠸࠸ ࠺ほⅬࡽ᫂ࡽࡋࠊࡉࡽ⬡㉁ࢡ࢜ࣜࢸࡢ㐪࠸ࢆᶵ⬟ⓗᫎࡍࡿ⏕⌮άᛶ⬡㉁ࡢ ྠᐃࢆ┠ᣦࡋ࡚࠸ࡿࠋ ́́ S3-3 ௦ㅰࣇࣛࢵࢡࢫゎᯒ୰ᚰ௦ㅰࡢࢺࣛࣥࢫ࣑࢜ࢡࢫ ᯇ⏣ྐ⏕ 1, ΎỈ ᾈ 1 1 㜰ᏛᏛ㝔ሗ⛉Ꮫ◊✲⛉ Trans-omics analysis of central metabolism using metabolic flux information Fumio Matsuda1, Hiroshi Shimizu1 1 Graduate school of information science and technologies, Osaka University ⣽⬊ෆ௦ㅰ⤒㊰ࢆὶࢀࡿྜ≀ὶ㔞㸦௦ㅰࣇࣛࢵࢡࢫ㸧ࡣ┤᥋ィ ࡍࡿࡇࡀ࡛ࡁ࡞࠸ࠋ ࡑࡇ࡛ 13 C ௦ㅰࣇࣛࢵࢡࢫゎᯒ (13C-MFA)ࡤࢀࡿィ ἲࡀᚤ⏕≀௦ㅰᕤᏛศ㔝࡛Ⓨᒎ ࡋ࡚ࡁࡓࠋィ ᑐ㇟ࡢ⣽⬊ᰴࢆ 13C ᶆ㆑Ⅳ⣲※㸦[1-13C]ࢢࣝࢥ࣮ࢫࠊ[1-13C]ࢢࣝࢱ࣑ࣥ࡞㸧 ࢆྵ᭷ࡍࡿᇵᆅ࡛ᶆ㆑ᇵ㣴ࡍࡿࠋ⣽⬊ෆ௦ㅰ≀㉁ࡢྠయᶆ㆑ࣃࢱ࣮ࣥࡣࠊ㏻㐣ࡋ࡚ࡁ ࡓ௦ㅰ⤒㊰ࡢሗࡀᫎࡍࡿࠋࡇࢀࢆ㉁㔞ศᯒ⨨࡛ ᐃࡋࠊࢹ࣮ࢱゎᯒࢆ⾜࡞࠺ࡇ࡛ࠊ ௦ㅰࣇࣛࢵࢡࢫศᕸࢆ ᐃࡍࡿࠋࢃࢀࢃࢀࡣ 13 C-MFA ᑓ⏝ࢹ࣮ࢱゎᯒࢯࣇࢺ࢙࢘ OpenMebius ࢆ㛤Ⓨࡋ (http://www-shimizu.ist.osaka-u.ac.jp/)ࠊ┿᰾ࣔࢹࣝ⏕≀ࡢฟⱆ㓝ẕࡽ ື≀ᇵ㣴⣽⬊ࡲ࡛ゎᯒᑐ㇟ࡢᣑࢆ⾜࡞ࡗ࡚ࡁࡓࠋ13C-MFA ࡽࡣࠊNAD(P)H ࡸ ATP ࡢ ᨭࢆぢ✚ࡶࡿࡇࡀ࡛ࡁࡿࡓࡵࠊ⣽⬊ෆࡢ㓟㑏ඖࠊ࢚ࢿࣝࢠ࣮≧ែࡀ᥎ᐃ࡛ࡁࡿࠋࡲࡓࠊ ࡀࢇ≉␗ⓗ࡞௦ㅰࡢάᛶࢆ┤᥋᥎ᐃࡋࡓࡾࠊ࠶ࡿ௦ㅰ⤒㊰ࡢάᛶኚࢆㄪࡿ࣐࣮࣮࢝ ࡋ࡚⏝࡛ࡁࡿࠋࡉࡽ௦ㅰࣇࣛࢵࢡࢫሗࡣࠊ௦ㅰไᚚᶵᵓࡢࢩࢫࢸ࣒⏕≀Ꮫⓗゎᯒ ࠾࠸࡚㔜せ࡞ᙺࢆᯝࡓࡍᮇᚅࡉࢀ࡚࠾ࡾࠊᝈࣂ࣐࣮࣮࢜࢝ࡢᅉᯝ㛵ಀࡢゎᯒ ࡶ᭷⏝࡛࠶ࡿࠋ㉁㔞ศᯒᢏ⾡ࡢⓎᒎࡼࡾࠊ௦ㅰ୰㛫యࡢ⃰ᗘࡸ㓝⣲ࢱࣥࣃࢡࡢ୍ᩧᐃ 㔞ࡀྍ⬟࡞ࡾࠊࢺࣛࣥࢫ࣑࢜ࢡࢫࢹ࣮ࢱࢆࡶ௦ㅰไᚚࢆᐃ㔞ⓗ⌮ゎࡍࡿ⣲ᆅࡀᩚ ࠸ࡘࡘ࠶ࡿࠋࡑࡇ࡛ࠊ13C ௦ㅰࣇࣛࢵࢡࢫゎᯒἲࡢᴫせࢆ⤂ࡋࠊࡉࡽ㓝ẕ୰ᚰ௦ㅰࡢࢺ ࣛࣥࢫ࣑࢜ࢡࢫゎᯒࡽぢ࠼࡚ࡁࡓ௦ㅰไᚚᶵᵓࡘ࠸࡚㆟ㄽࡋࡓ࠸ࠋ ́́ S3-4 つᶍࢥ࣮࣍ࢺ࣑࢜ࢡࢫゎᯒࡼࡿᝈண㜵࣐࣮࣮࢝᥈⣴ ୕ᯞ㍜ 1,2 1 ᮾᏛᮾ࣓ࢹ࣭࣓࢝ࣝ࢞ࣂࣥࢡᶵᵓ, 2 ᮾᏛᏛ㝔་Ꮫ⣔◊✲⛉ Researching Predictive Biomarker in a Large Scale Cohort Study Daisuke Saigusa1 1 Tohoku Medical Megabank Organization, Tohoku University 2 School of Medicine, Tohoku University ḟୡ௦་⒪࡛ࡣࠊಶูࡉࢀࡓᝈࣜࢫࢡุᐃᇶ࡙ࡃண㜵་⒪ࡀồࡵࡽࢀ࡚࠾ࡾࠊ᪂ ࡓ࡞ᝈࣂ࣐࣮࣮࢜࢝ࡢⓎぢࡑࡢ⮫ᗋᛂ⏝ࡀᮇᚅࡉࢀ࡚࠸ࡿࠋࣂ࣐࣮࣮࢜࢝᥈⣴ ࠾࠸࡚ࡣࠊࢤࣀ࣒ࠊࢺࣛࣥࢫࢡࣜࣉࢺ࣮࣒ࠊࣉࣟࢸ࣮࣒࢜ཬࡧ࣓ࢱ࣮࣒࣎ࣟࢆከ㝵ᒙⓗ ゎᯒࡍࡿᡭἲࠊ ࠕࢺࣛࣥࢫ࣑࢜ࢡࢫゎᯒࠖࡀ᭷ຠ࡞ᡭẁ⪃࠼ࡽࢀ࡚࠸ࡿࠋ≉ࠊ࣓ࢱ࣎ࣟ ࣮࣒ゎᯒࡣࠊࢤࣀ࣒⎔ቃせᅉࡼࡾᙧᡂࡉࢀࡿಶேࡢ⾲⌧ᆺࢆ㔞ⓗᙧ㉁ࡋ࡚グ㏙࣭ ᐃ⩏ࡋ࠺ࡿ⪃࠼ࡽࢀ࡚࠸ࡿࠋ㏆ᖺࠊ㉁㔞ศᯒィ (MS) ࢆ⏝࠸ࡿ࣓ࢱ࣮࣒࣎ࣟゎᯒᢏ⾡ࡀ ࡁࡃ㐍Ṍࡋࠊ୍ḟཬࡧḟ௦ㅰ≀ࢆᶆⓗࡋࡓ Targeted Metabolomics (TMet) ࡀࠊᝈ ࣂ࣐࣮࣮࢜࢝᥈⣴ཬࡧⓎ࣓࢝ࢽࢬ࣒ࡢゎ୍᫂ᐃࡢᡂᯝࢆࡶࡓࡽࡋ࡚࠸ࡿࠋࡋࡋ࡞ ࡀࡽࠊᶆⓗࢆ⤠ࡽࡎ௦ㅰ≀ゎᯒࢆ⾜࠺ Global Metabolomics (GMet) ࡣࠊᮍ▱ࡢᝈࣂ ࣐࣮࣮࢜࢝ྠᐃ࠾ࡅࡿ᭷⏝ᛶࡣホ౯ࡉࢀ࡚࠸ࡿࡶࡢࡢࠊ᳨య๓ฎ⌮ࡢࣁࢫ࣮ࣝࣉࢵࢺ ࠊMS ᐃࡢ⌧ᛶࠊྜ≀ࡢྠᐃ⢭ᗘࠊࢹ࣮ࢱゎᯒࡢ↹㞧ࡉㄢ㢟ࡀᣦࡉࢀ࡚࠸ࡿࠋ ࡉࡽࠊ⮫ᗋ㡿ᇦࡅࡿࢺࣛࣥࢫ࣑࢜ࢡࢫゎᯒࡣࠊࢤࣀ࣒ࡸ⮫ᗋሗ➼ࡢࣅࢵࢡࢹ࣮ࢱ ࡼࡿ┦㛵ゎᯒࢆᐇࡍࡿࡇࡀᚲせ࡛࠶ࡿⅭࠊᚓࡽࢀࡓゎᯒ⤖ᯝࡽ᭷ព⩏࡞ᅉᏊࢆᢳฟ ࡍࡿࡇࡀᅔ㞴࡛࠶ࡿ⪃࠼ࡽࢀ࡚࠸ࡿࠋᚑࡗ࡚ࠊࡇࢀࡽࡢㄢ㢟ࢆゎỴࡍࡿᇶ┙ᢏ⾡ཬࡧ ࣥࣇ࢛࣐ࢸࢡࢫゎᯒᇶ┙ࡢᵓ⠏ࡀồࡵࡽࢀ࡚࠸ࡿࠋ ᡃࠎ ࡣࠊጞࡵ ⮫ᗋ᳨యࡢ ࣁࢫࣝ ࣮ࣉࢵࢺ࡞ ⮬ື๓ฎ ⌮ࢩࢫࢸ࣒ࢆ ᵓ⠏ࡋ ࠊ UPLC-Q-TOF/MS ཬࡧ LC-Q-FT/MS ࡼࡿ GMet ゎᯒࣉࣟࢺࢥࣝࢆᵓ⠏ࡋࡓࠋࡲࡓࠊLC-MS/MS ࢆ⏝࠸࡚ 300 ྜ≀⛬ᗘࡢ ᐃࢆྍ⬟ࡍࡿ TMet ᐃᡭἲࢆᵓ⠏ࡋࡓࠋḟࠊᵓ⠏ࡋࡓ GMet ཬࡧ TMet ゎᯒᡭἲࡼࡿ⮫ᗋ᳨యࡢᑠつᶍゎᯒཬࡧఫẸࢥ࣮࣍ࢺ᳨య㸦500 ே㸧ࡢ ゎᯒࢆᐇࡋࡓࠋ⌧ᅾࠊᚓࡽࢀࡓゎᯒ⤖ᯝࢆ⏝࠸ࡿࢺࣛࣥࢫ࣑࢜ࢡࢫゎᯒࢆᐇࡋ࡚࠾ࡾࠊ ࣂ࢜ࣥࣇ࢛࣐ࢸࢡࢫゎᯒࢆ㥑ࡋࡓ᪂つᝈࣂ࣐࣮࣮࢜࢝ೃ⿵ྜ≀ࡢᢳฟࢆヨ ࡳ࡚࠸ࡿࠋ ́́ S4-1 ⌧ሙ࡛᥇ྲྀྍ⬟࡞ᚤ㔞ࡢ⾑ᾮࠊၚᾮཬࡧờࡽࡢ⸆≀᳨ᰝ ᱓ᒣḟ ⛉Ꮫ㆙ᐹ◊✲ᡤ Drug test using blood, saliva, and sweat collected on site Kenji Kuwayama National Research Institute of Police Science ࠙◊✲ࡢ⫼ᬒࠚ༴㝤ࢻࣛࢵࢢᑐ⟇ࡢᙉࡢࡓࡵࠊᣦᐃ⸆≀ࡢ⏝ࡀつไࡉࢀࡓࡇక࠸ࠊ ᦤྲྀ⸆≀ࡢ≉ᐃࡀࡲࡍࡲࡍ㔜せ࡞ࡗ࡚࠸ࡿࠋ⸆≀ᦤྲྀࡢド᫂ࡣᒀࡀ୍⯡ⓗ⏝࠸ࡽࢀ ࡿࡀࠊ㏿ࡸ௦ㅰࡉࢀࠊᒀࡽᮍኚయࡀ᳨ฟࡉࢀ࡞࠸⸆≀ࡀᏑᅾࡍࡿࠋࡲࡓࠊ㢮ఝᵓ 㐀≀ࡀඹ㏻ࡢ௦ㅰ≀ࢆ⏕ᡂࡍࡿྍ⬟ᛶࡀ࠶ࡿࡓࡵࠊᦤྲྀ⸆≀ࡢ≉ᐃࡀᅔ㞴࡞ሙྜࡀ࠶ࡿࠋ ⸆≀ᦤྲྀࡽᩘ㛫௨ෆ⾑ᾮࢆ᥇ྲྀ࡛ࡁࢀࡤࠊᮍኚయࢆ᳨ฟ࡛ࡁࡿྍ⬟ᛶࡀ㧗ࡲࡿࡀࠊ ⿕⪅➼ࢆ☜ಖࡋࡓ⌧ሙ࡛ᤚᰝဨࡀᙉไⓗ⾑ᾮࢆ᥇ྲྀࡍࡿࡇࡣ࡛ࡁ࡞࠸ࠋุࡢドᣐ ࡞ࡾᚓࡿ㈨ᩱࡢ㐺ṇ࡞᥇ྲྀࡢࡓࡵࠊἲⓗ࡞ᡭ⥆ࡁࡸ་ົᐊࡢ⛣ື➼㛫ࡀࡾࠊ ࡑࡢ㛫ࡶయෆࡢ⸆≀ࡣ௦ㅰ࣭ἥࡉࢀࡿࠋ⌧ሙ࡛⾑ᾮࢆ᥇ྲྀࡍࡿࡣࠊ⿕⪅➼ࡽࡢ ྠពࢆᚓࡓୖ࡛ࠊ་⒪⏝✸่ჾࢆ⏝࠸࡚⿕⪅➼ࡀ⮬ࡽࡢయയࢆࡅ࡚ᚤ㔞ࡢ⾑ᾮࢆᥦ ౪ࡍࡿࡋ࡞࠸ࠋ୍᪉ࠊᦤྲྀࡋࡓ⸆≀ࡢ୍㒊ࡀၚᾮࡸờࡶศἪࡉࢀࡿࡇࡀ▱ࡽࢀ࡚࠾ ࡾࠊၚᾮࡸờࡣ⾑ᾮẚ࡚ࠊ≉ู࡞ᢏ⾡ࡸタࢆᚲせࡏࡎ᥇ྲྀ࡛ࡁࡿࡓࡵࠊ௦᭰㈨ ᩱࡋ࡚᭷ຠ࡛࠶ࡿ⪃࠼ࡽࢀࡿࠋ࠸ࡎࢀࡋ࡚ࡶࠊ⌧ሙ࡛⏕య㈨ᩱࢆ᥇ྲྀࡍࡿࡣࠊ⿕ ⪅➼ࡽ㈨ᩱᥦ౪ࡢྠពࢆᚓ࡞ࡅࢀࡤ࡞ࡽ࡞࠸ࡀࠊࡇࡢࡼ࠺࡞ไ⣙ࡀ࠶ࡗ࡚ࡶ࡞࠾ࠊ⏕ య㈨ᩱࢆ㎿㏿᥇ྲྀࡍࡿࡇࡀᦤྲྀࡋࡓ⸆≀ࡢ≉ᐃ㔜せ࡛࠶ࡿ⪃࠼ࡽࢀࡿࠋ ࠙⌧ሙ࡛ࡢ⏕య㈨ᩱ᥇ྲྀἲࠚ㈨ᩱᥦ౪⪅ࠊ㈨ᩱ᥇ྲྀ⪅ࠊ⸆≀᳨ᰝ⪅ࡑࢀࡒࢀࡢ❧ሙࠊ᥇ྲྀࡸ ศᯒ๓ฎ⌮ࡢ⡆౽ᛶࠊ㎿㏿ᛶࠊ⤒῭ᛶ➼ࢆ⪃៖ࡋࠊྛ㈨ᩱࡢ᥇ྲྀἲࢆ㑅ᐃࡋࡓࠋࡲࡓࠊࡑ ࡢ᪉ἲ࡛᥇ྲྀࡋࡓ⾑ᾮཬࡧၚᾮࡽ༴㝤ࢻࣛࢵࢢ➼ࢆ᳨ฟࡍࡿࡓࡵᚲせ࡞⸆≀⃰ᗘࢆぢ ✚ࡶࡗࡓࠋ⌧ሙ࡛᥇ྲྀ࡛ࡁࡿ⾑ᾮࡣᚤ㔞࡛࠶ࡿࡓࡵࠊẚ㍑ⓗ㧗⃰ᗘࡢ⸆≀࡛࡞ࡅࢀࡤࠊࡑ ࡢ᳨ฟࡀᅔ㞴࡛࠶ࡿࠋၚᾮࡣ㔞᥇ྲྀ࡛ࡁࡿࡓࡵࠊ⾑ᾮ୰ࡼࡾࡶప࠸⃰ᗘࡢ⸆≀ࢆ᳨ฟ ࡛ࡁࡿࡀࠊ⥥Წ➼ࡢ᥇ྲྀჾල྾╔ࡋࡸࡍ࠸⸆≀ࡀ࠶ࡿࡓࡵࠊ᥇ྲྀἲࡸᢳฟἲὀពࡀᚲ せ࡛࠶ࡿࠋ ࠙ྛ⏕య㈨ᩱࡢ᭷⏝ᛶࠚ⸆≀ᢞᚋࠊᒀࠊ⾑ᾮࠊၚᾮཬࡧờࢆ᥇ྲྀࡋࠊ⸆≀᳨ᰝ࠾ࡅࡿྛ ㈨ᩱࡢ᭷⏝ᛶࢆホ౯ࡋࡓࠋ᥇ྲྀࡢᐜ᫆ࡉࠊ᥇ྲྀ㔞ࠊ⸆≀⃰ᗘࠊ⸆≀ࡢ᳨ฟྍ⬟࡞ᮇ㛫➼ࢆ ẚ㍑ࡍࡿࠊ࠸ࡎࢀࡢ㈨ᩱࡶ᭷⏝࡞Ⅼࡀ࠶ࡗࡓࠋᒀࢆ⏝࠸ࡓ⸆≀᳨ᰝࢆᇶᮏࡋ࡚ࠊᒀ ࡢ᥇ྲྀ๓⌧ሙ࡛ࡇࢀࡽࡢ⏕య㈨ᩱࡶ᥇ྲྀ࡛ࡁࢀࡤࠊᦤྲྀ⸆≀ࡢ≉ᐃࡢྍ⬟ᛶࡀ㧗ࡲࡿ ⪃࠼ࡽࢀࡿࠋ ́́ S4-2 ࢝ࢳࣀࣥ⣔༴㝤ࢻࣛࢵࢢࡢ௦ㅰ 㸫Ꮫᵓ㐀ࡀ௦ㅰཬࡰࡍᙳ㡪ࡘ࠸࡚㸫 ᚿᦶ᫂ 1, 㙊⏣ᐶᜨ 1, ᯇ⏣㥴ኴᮁ 1, ᶫ⚽┤ 1, ୕ᮌᏹ 1, ∦ᮌ᐀ᘯ 1, ᅵᶫ ᆒ 2 1 㜰ᗓ㆙⛉Ꮫᤚᰝ◊✲ᡤ, 2 ྡྂᒇᏛᏛ㝔་Ꮫ⣔◊✲⛉ Metabolism of cathinone-derived drugs of abuse̿Influences of the chemical structures on the metabolism̿ Noriaki Shima1, Hiroe Kamata1, Shuntaro Matsuta1, Hidenao Kakehashi1, Akihiro Miki1, Munehiro Katagi1, Hitoshi Tsuchihashi2 1 Forensic Science Laboratory, Osaka Prefectural Police Headquarters, Osaka 2 Nagoya University Graduate School of Medicine ࠕ༴㝤ࢻࣛࢵࢢࠖࡋ࡚ὶ㏻ࡍࡿ࢝ࢳࣀࣥ⣔⸆≀ࡣࠊྜᡂ࢝ࣥࢼࣅࣀࢻ⣔⸆≀ඹࡑ ࡢὶ㏻ࡣ㝿❧ࡗ࡚ከࡃࠊᦤྲྀド᫂ࡀồࡵࡽࢀࡿࡀᅜⓗከⓎࡋ࡚࠸ࡿࠋ2015 ᖺ 5 ᭶ ࡣ➨୕ᅇໟᣓつไ㸦࢝ࢳࣀࣥ㢮ࡀᑐ㇟㸧ࡀ⾜ࡉࢀࠊ1300 ✀௨ୖࡢ࢝ࢳࣀࣥ⣔⸆≀ࡀࠊ 㯞⸆࠶ࡿ࠸ࡣ་⸆ရ་⒪ᶵჾ➼ἲ㸦ᪧ⸆ἲ㸧ࡢᣦᐃ⸆≀ࡋ࡚つไࡉࢀ࡚࠸ࡿࡢࡀ⌧≧ ࡛࠶ࡿࠋ࢝ࢳࣀࣥ⣔⸆≀ࡣࠊぬ㓰➼ẚ㍑ࡋ࡚௦ㅰࡀ㏿࠸ࡇࡀ♧၀ࡉࢀ࡚࠾ࡾࠊ⏕య ヨᩱࢆᑐ㇟ࡋࡓศᯒ࡛ࡣࠊᮍኚయඹ௦ㅰ≀ࢆ᥈⣴ࡍࡿࡇࡀ㔜せ࡞ࡿࠋ ࢝ࢳࣀࣥ⣔⸆≀ࡢ௦ㅰࡣࠊࡑࡢඹ㏻ࡢ㦵᱁࡛࠶ࡿ࢝ࣝ࣎ࢽࣝᇶࡢ㑏ඖࡀᇶᮏ࡞ࡿࠋከ ࡃࡢ⸆≀࠾࠸࡚ࡑࡢ㑏ඖయ㸦ࢪࢫࢸ࣐࣮ࣞ࢜㸧ࡀ☜ㄆࡉࢀ࡚࠾ࡾ 1-3) ࠊᦤྲྀド᫂ࡢᣦᶆ ࡋ࡚᭷⏝࡞௦ㅰ≀࡞ࡿࠋ୍᪉ࠊ࢝ࣝ࣎ࢽࣝ㑏ඖ௨እࡢ௦ㅰ⤒㊰㛵ࡋ࡚ࡣࠊ࣑ࣀᇶࠊ ࣋ࣥࢮࣥ⎔ୖࡢ⨨ᇶ࠶ࡿ࠸ࡣࣝ࢟ࣝ㙐㸦㙐㸧ࡢ㛗ࡉࡼࡗ࡚␗࡞ࡾࠊせ࡞ࡿ௦ ㅰ⤒㊰ࡶࡑࡢᵓ㐀౫Ꮡࡍࡿࡇࡀ♧၀ࡉࢀ࡚࠸ࡿࠋࡍ࡞ࢃࡕࠊN-࣑ࣝ࢟ࣝࣀᇶࢆ᭷ ࡍࡿྜ≀࡛ࡣ N-⬺ࣝ࢟ࣝࡀ㐍ࡴ୍᪉ࠊࣆࣟࣜࢪࣥ⎔ࢆ᭷ࡍࡿ Į-PVP ࡸ Į-PBP ➼ࡣࠊ ࣆࣟࣜࢪࣥ⎔ࡢ㓟ࡼࡾ࢜࢟ࢯయ௦ㅰࡉࢀࡿࡇࡀ♧ࡉࢀ࡚࠸ࡿ 1,2)ࠋࡲࡓࠊ࣋ࣥࢮࣥ⎔ ࡢ࣓ࢺ࢟ࢩᇶ⨨య࡛ࡣࠊO-⬺࣓ࢳࣝࡉࢀࡿ⤒㊰ࡀ࡞ࡾࠊࣝ࢟ࣝ㙐㸦㙐㸧ࡢ㛗 ࠸ྜ≀࡛ࡣࠊȦ-1 ཬࡧ Ȧ ࡢ㓟ࡀ௦ㅰ⤒㊰࡞ࡿࡇࡀ♧၀ࡉࢀ࡚࠸ࡿ 3)ࠋࡇࡢࡼ࠺ ࡞௦ㅰ⤒㊰ࡢண ࡣࠊ᪂つ⸆≀ࢆᑐ㇟ࡋࡓศᯒ࡛ࡣᚲせྍḞ࡞ࡿࠋ ᮏⓎ⾲࡛ࡣࠊࣆࣟࣜࢪࣥ⎔ࢆ᭷ࡍࡿ࢝ࢳࣀࣥ⣔⸆≀ࢆ୰ᚰࠊ㉁㔞ศᯒࡼࡿᮍኚయ ཬࡧ௦ㅰ≀ࡢᵓ㐀᥎ᐃࢆ♧ࡍඹࠊࣝ࢟ࣝ㙐㸦㙐㸧ࡢ㛗ࡉࡸ࣋ࣥࢮࣥ⎔⨨ᇶ➼ࠊ ᵓ㐀ࡢ㐪࠸ࡀ௦ㅰ⤒㊰ཬࡰࡍᙳ㡪ࡘ࠸࡚⤂ࡍࡿࠋ ࠙ཧ⪃ᩥ⊩ࠚ -----------------------------------------------------------------------------------------------------------1. Shima, N., et al., Forensic Toxicol., 32, 59-67 (2014). 2. Matsuta, S., et al., Forensic Sci. Int., 249, 181-188 (2015). 3. Shima, N., et al., Forensic Toxicol., 33, 279-294 (2015). ́́ S4-3 ༴㝤ࢻࣛࢵࢢὶ㏻ᐇែㄪᰝ࠾ࡅࡿ㉁㔞ศᯒࡢᙺ ⰼᑼ㸦ᮌ㸧⍠⌮ ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ Mass spectrometry for a survey of the prevalence of new psychoactive substances in Japan Ruri Kikura-Hanajiri National Institute of Health Sciences ༴㝤ࢻࣛࢵࢢࡣࠊ㯞⸆ࡸぬࡏ࠸ࡢࡼ࠺ἲつไࡉࢀ࡚࠸࡞࠸ࡀࠊࡑࢀࡽ㢮ఝࡢ᭷ᐖ ᛶࢆ᭷ࡍࡿࡇࡀࢃࢀࡿྜ≀࡛࠶ࡾࠊ⏝┠ⓗ࡛〇㐀ࠊ㈍ࡉࢀࡿࡶࡢࢆ♧ࡍࠋࡇࢀ ࡽྜ≀ࢆྵࡴ〇ရࡢὶ㏻ࡣࠊᖹᡂ 10 ᖺ㡭ࡼࡾ㢧ᅾࡋࠊᅛᙧࠊ⢊ᮎࠊᾮయࠊ࢝ࣉࢭࣝ➼ࠊ ᵝࠎ࡞ᙧែ࡛㈍ࡉࢀࡓࠋᖹᡂ 18 ᖺࠊ⸆ἲ㸦⌧་⸆ရ་⒪ᶵჾ➼ἲ㸧ࡀᨵṇࡉࢀࠊᣦ ᐃ⸆≀ไᗘࡀᑟධࡉࢀࡓᚋࡣࠊ୍ᮇࠊࡑࡢ㈍ᩘࡀῶᑡࡋࡓࠋࡋࡋࠊᖹᡂ 24 ᖺ๓ᚋ ࡽࠊ࢝ࣥࢼࣅࣀࢻཷᐜయᙉ࠸άᛶࢆ♧ࡍྜ≀⩌㸦ྜᡂ࢝ࣥࢼࣅࣀࢻ㢮㸧ࢆ⇱᳜ ≀⣽∦ΰྜࡋࡓࠕ⬺ἲࣁ࣮ࣈࠖࡸࠊࠕ࣐ࣟࣜ࢟ࢵࢻࠖ㸦ᾮయ㸧➼ࡋ࡚㈍ࡉࢀࡿ⯆ዧ ᛶ࣑ࣥ㢮㸦࢝ࢳࣀࣥ㢮㸧ྵ᭷〇ရࡼࡿᗣ⿕ᐖࡀᛴቑࡋࠊ῝้࡞♫ၥ㢟࡞ࡗࡓࠋ ᅜ❧⾨◊࡛ࡣ༴㝤ࢻࣛࢵࢢ〇ရࡢὶ㏻ᐇែኚࢆᢕᥱࡍࡿࡇࢆ┠ⓗࡋࠊᖹᡂ 14 ᖺᗘ ࡼࡾ༴㝤ࢻࣛࢵࢢ〇ရࡢྵ᭷ᡂศㄪᰝࢆᐇࡋ࡚࠸ࡿࠋᖹᡂ 26 ᖺᗘࡲ࡛ᅜ❧⾨◊ࡀㄪᰝ ࡋࡓ༴㝤ࢻࣛࢵࢢ〇ရࡣ⣙ 3500 ✀㢮ࡶ࠾ࡼࡪࠋ༴㝤ࢻࣛࢵࢢ〇ရศᯒ࡛ࡣࠊGC-MSࠊ LC-PDA-MSࠊDART-Orbitrap ➼ࡼࡾࢫࢡ࣮ࣜࢽࣥࢢศᯒࢆ⾜࠸ࠊ᪂つὶ㏻ྜ≀ࡀ᳨ฟࡉ ࢀࡓሙྜࡣࠊLC-QTOF ཬࡧ NMR ศᯒࡼࡾᵓ㐀ࢆྠᐃࡋ࡚࠸ࡿࠋ୍᪉ࠊ༴㝤ࢻࣛࢵࢢࡀ 㛵ࡋࡓᩆᛴᦙ㏦࣭Ṛஸ➼࠾࠸࡚ࡣࠊLC-QTOF ཬࡧ LC-MS/MS ࡢ୧ᡭἲࢆ⏝࠸࡚ࠊ ⾑ᾮࠊᒀࠊẟ㧥➼ࡢ⏕యヨᩱ୰⸆≀ࡢࢫࢡ࣮ࣜࢽࣥࢢศᯒ࣭ᐃ㔞ศᯒࢆ⾜ࡗ࡚࠸ࡿࠋ࡞࠾ࠊ ḟࡽḟ᪂つὶ㏻ྜ≀ࡀฟ⌧ࡍࡿ༴㝤ࢻࣛࢵࢢ࠾࠸࡚ࡣࠊᅜෆእࡢ◊✲ᶵ㛵㛫 ࠾ࡅࡿሗࡢඹ᭷ࡀ㔜せ࡞ࡿࠋᅜ❧⾨◊࡛ࡣࠊᖹᡂ 26 ᖺ 3 ᭶ࡽࠕ㐪ἲࢻࣛࢵࢢࢹ࣮ ࢱ㜀ぴࢩࢫࢸ࣒ࠖ 㸦http://npsdb.nihs.go.jp/Search/㸧࠾࠸࡚ࠊ༴㝤ࢻࣛࢵࢢ㛵ࡍࡿ ᐃࢹ࣮ ࢱ➼ࡢሗࢆබ㛤ࡋ࡚࠸ࡿࠋᖹᡂ 27 ᖺ 3 ᭶ᮎⅬ࡛ࠊ656 ྜ≀ࠊ1980 〇ရࡢሗࡀ㍕ ࡉࢀ࡚࠾ࡾࠊᅜ㐃➼ࡢᅜ㝿ᶵ㛵ࢆྵࡴ⣙ 310 ᶵ㛵㸦㒊⨫㸧ࡀⓏ㘓ࢆࡋ࡚࠸ࡿࠋ ᖹᡂ 26 ᖺᗘᚋ༙௨㝆ࠊ༴㝤ࢻࣛࢵࢢᑐࡍࡿつไཬࡧྲྀ⥾ࡾᙉࡀᐇࡉࢀࠊᖹᡂ 27 ᖺ 7 ᭶ࡣ㈍ᗑ⯒ᩘࡣࡘ࠸ࢮࣟ࡞ࡗࡓࠋࡋࡋࠊ༴㝤ࢻࣛࢵࢢࡽ㏨ࢀࡽࢀ࡞࠸ ⏝⪅ࡶᮍࡔከᩘᏑᅾࡋ࡚࠸ࡿࡇࡀ᥎ ࡉࢀࠊண᩿ࢆチࡉ࡞࠸≧ἣୗ࠶ࡿࠋᮏࢩ࣏ࣥࢪ ࣒࡛࢘ࡣࠊ༴㝤ࢻࣛࢵࢢࡘ࠸࡚ࠊࡇࡢ 10 ᖺ㛫ࡢὶ㏻ࡢኚࢆゎㄝࡍࡿඹࠊ༴㝤ࢻࣛ ࢵࢢὶ㏻ᐇែㄪᰝ㸦⏕యヨᩱ୰⸆≀ศᯒࢆྵࡴ㸧࠾ࡅࡿ㉁㔞ศᯒࡢᙺࡘ࠸࡚ㄽࡌࡿࠋ ́́ ㅮ₇せ᪨ 㸦P1㹼P62㸸࣏ࢫࢱ࣮Ⓨ⾲㸧 ́́ P-1 HILIC-MS/MS ἲࡼࡿࣄࢺయᾮ୰ tegafur ཬࡧ 5-fluorouracil ࡢ㧗ឤᗘศᯒἲ ᑠῲᚊᏊ 1,2, ᮤ ᬡ㭉 1, ⇃⃝Ṋᚿ 1, ᘅ⃝ᵞᏊ 2, 㛗㇂ᕝᬛ⳹ 3, ධᡞ㔝 1, 㧗ᶫ⏨ 2, బ⸨ၨ㐀 1 1 Ꮫ་Ꮫ㒊ἲ་Ꮫㅮᗙ 2 Ꮫ་Ꮫ㒊║⛉Ꮫㅮᗙ 3 ᮾ㑥Ꮫ་Ꮫ㒊ἲ་Ꮫㅮᗙ High sensitive analysis of tegafur and 5-fluorouracil in human body fluids by HILIC-MS/MS Ritsuko Obuchi1,2, Xiao-Pen Lee1, Takeshi Kumazawa1, Makiko Hirosawa2, Chika Hasegawa3, Susumu Nittono1, Haruo Takahashi2, Keizo Sato1 1 Department of Legal Medicine, Showa University School of Medicine 2 Department of Ophthalmology, Showa University School of Medicine 3 Department of Legal Medicine, Toho University School of Medicine ࠙┠ⓗࠚ⤒ཱྀᢠࡀࢇࢸ࣮࢚ࢫ࣡ࣥ®ࡣࠊᡂศࡀࢸ࢞ࣇ࣮ࣝ㸸5-fluoro-1-[(2RS)- tetrahydrofuran-2-yl] uracil (FT)࡛࠶ࡾࠊ5-fluorouracil㸦5-FU㸧ࡣ FT ࡢ௦ㅰయ࡛࠶ࡿࠋFT ࠾ࡼࡧ 5-FU ࡣࠊࢸ࣮࢚ࢫ࣡ࣥ®ᢞᝈ⪅ࡢゅ⭷㞀ᐖࠊᾦ㐨㞀ᐖ࡞║ྜేࡢ㛵ࡀᣦࡉࢀ࡚࠸ ࡿࠋᅇᡃࠎࡣࠊ㡰┦࣒࢝ࣛࢆ⏝࠸ࡓ㉸㧗㏿ᾮయࢡ࣐ࣟࢺࢢࣛࣇ࣮㸦UFLC㸧íࢱࣥࢹ࣒ ㉁㔞ศᯒ㸦MS/MS㸧ࡼࡿࣄࢺᾦᾮ࠾ࡼࡧ⾑₢୰ FT 5-FU ࡢ⡆౽ࡘ㧗ឤᗘ࡞ศᯒ᮲௳ ࢆタᐃࡋࡓࡢ࡛ሗ࿌ࡍࡿࠋ ࠙᪉ἲࠚᮏศᯒࢩࢫࢸ࣒ࡣ Prominence UFLC ⨨㸦ᓥὠ〇సᡤ㸧࠾ࡼࡧࢺࣜࣉࣝᅄ㔜ᴟ ࣜࢽ࢜ࣥࢺࣛࢵࣉᶵ⬟ࢆᦚ㍕ࡋࡓ API4000 Q Trap MS/MS ⨨㸦AB SCIEX㸧ࢆ⏝࠸ࡓࠋ ࡲࡓࠊᕷ㈍Ⅼ║⸆ࢸ࣮ࣞ W®㸦࢜ࣇࢸࢡࢫ〇㸧ࢆேᕤᾦᾮࡋ࡚⏝࠸ࡓࠋ⸆≀ῧຍᾦᾮ ࡣࠊࣄࢺᾦᾮࡲࡓࡣேᕤᾦᾮ 10 μL FTࠊ5-FU ࠾ࡼࡧ 5-chlorouracil (IS) ࢆῧຍࡋࡓᚋࠊ2M 㓑㓟ࣥࣔࢽ࣒࢘⁐ᾮ 40 μLࠊ2%ࢠ㓟ࢭࢺࢽࢺࣜࣝ 250 μL ࢆຍ࠼࡚ㄪ〇ࡋࡓࠋヨᩱᾮࡣࠊ 㐲ᚰศ㞳ࡋࡓᚋࠊࡑࡢୖΎ 15 μL ࢆศᯒࢩࢫࢸ࣒ࣉࣛࡋࡓࠋࡲࡓࠊ⸆≀ῧຍࣄࢺ⾑₢ ࡣࠊ20 μL ྛ⸆≀ࢆῧຍࡋࡓᚋࠊ2M 㓑㓟ࣥࣔࢽ࣒࢘⁐ᾮ 80 μLࠊ2%ࢠ㓟ࢭࢺࢽࢺࣜ ࣝ 500 μL ࢆຍ࠼࡚ㄪ〇ࡋࡓࠋヨᩱᾮࡣࠊ㐲ᚰศ㞳ࡋࡓᚋࠊࡑࡢୖΎ 15 μL ࢆศᯒࢩࢫࢸ࣒ ࣉࣛࡋࡓࠋHILIC-MS/MS ศᯒࡢศ㞳࣒࢝ࣛࡣ Imtakt ♫〇ࡢ㡰┦࣒࢝ࣛ UK-Amino 㸦㛗ࡉ 50 mmࠊෆᚄ 3 mmࠊ⢏ᚄ 3 μm㸧ࢆ⏝ࡋࠊ⛣ື┦ࡣࢭࢺࢽࢺࣜࣝࢆ࣮࣋ࢫࡋࡓ 10 mM 㓑㓟ࣥࣔࢽ࣒࢘⁐ᾮࡢࣜࢽࢢࣛࢪ࢚ࣥࢺࢆ⏝࠸ࡓࠋ ࠙⤖ᯝࠚẼᅽᏛ࢜ࣥἲ㸦APCI㸧ࢆ⏝࠸ࡓ SRM ᐃࡼࡾࠊFT ࠾ࡼࡧ 5-FU ࡣࠊᾦ ᾮ࠾ࡼࡧ⾑₢ࡽ 1 ศ௨ෆឤᗘࡼࡃ᳨ฟࡉࢀࡓࠋࡲࡓࠊFT 5-FU ࡢᅇ⋡ࡣᾦᾮ࡛ 87-104 %ࠊ ⾑₢࡛ 94-106 %࡛࠶ࡗࡓࠋ ᳨㔞⥺ࡣᾦᾮ࡛ 0.08㹼4.0 μg/mLࠊ⾑₢࡛ 0.1㹼4.0 μg/mL ࡢ⠊ᅖ࡛୧⪅ࡶⰋዲ࡞┤⥺ᛶࡀᚓࡽࢀࡓࠋ᳨ฟ㝈⏺㸦LOD㸧ࡣᾦᾮࡀ 0.04 μg/mLࠊ⾑ ₢ࡀ 0.02-0.04 μg/mL ࡛࠶ࡗࡓࠋ ࠙⪃ᐹࠚᮏ◊✲࡛ࡣࠊ10 μL ᾦᾮࡲࡓࡣ 20 μL ⾑₢࠸࠺ᚤ㔞ࡢ⏕యヨᩱࡽ FT ࠾ࡼࡧ 5-FU ࢆ⡆౽ࡘ㧗ឤᗘศᯒ࡛ࡁࡓࠋᮏἲࡣᚤ㔞࡞⏕యヨᩱ࠾ࡅࡿᚤ㔞ࡢ⸆≀ᡂศࢆᑐ㇟ ࡍࡿ㧗ឤᗘࣁࢫ࣮ࣝࣉࢵࢺศᯒ᭷⏝࡛࠶ࡾࠊ║⛉㡿ᇦࢆጞࡵࡍࡿ⮫ᗋ㡿ᇦ࠾ࡼࡧἲ ་Ꮫ㡿ᇦ࠾ࡅࡿ⸆≀࠾ࡼࡧ௦ㅰ≀ࡢᚤ㔞ศᯒጾຊࢆⓎࡍࡿࡶࡢᛮࢃࢀࡿࠋ ́́ P-2 ⤌⧊ษ∦୰ࢪࣇ࢙ࢽࢪࣥࡢ MALDI-MS(/MS)ࡼࡿ┤᥋ศᯒ ༡᪉ࡼᏊ 1, 㕥ᮌ㞞Ꮚ 2, 㔝⃝⚽ᶞ 1, ᒣᓊ ᱁ 1, 㛗㇂ᕝᘯኴ㑻 1, 㜿Ẹ᪥ 1, ᶒᏲ㑥ኵ 1, Ώ㒊ຍዉᏊ 1, 㕥ᮌ ಟ 1 1 ᯇ་⛉ᏛᏛἲ་Ꮫ, 2 ᯇ་⛉Ꮫᐇ㦂ᐇ⩦ࢭࣥࢱ࣮ Direct MALDI mass spectrometric analysis of diphenidine in several tissues Kayoko Minakata1, Masako Suzuki2, Hideki Nozawa1, Itaru Yamagishi1, Koutaro Hasegawa1, Amin Wurita1, Kunio Gonmori1, Kanako Watanabe1, Osamu Suzuki1 1 Department of Legal Medicine, Hamamatsu University School of Medicine 2 Research Equipment Center, Hamamatsu University School of Medicine ࠙┠ⓗࠚ㏆ᖺ, ྜᡂ࢝ࣥࢼࣅࣀࢻ㢮ࡸ࢝ࢳࣀࣥ㢮ࡢ༴㝤ࢻࣛࢵࢢࡀᘏࡋࡓࡓࡵࠊࡑࢀࡽ ࡣໟᣓつไࡉࢀࡓࠋࡑࡢࡓࡵࡑࢀࡽᒓࡉ࡞࠸⸆≀ࡀ᳨ฟࡉࢀጞࡵࡓࠋࢪࣇ࢙ࢽࢪࣥࡶࡑ ࠺ࡋࡓ⸆≀ࡢ 1 ࡘ࡛࠶ࡾ, 2014 ᖺࡽሗ࿌ࡉࢀጞࡵ, ᙜᩍᐊ࡛ࡶࢪࣇ࢙ࢽࢪࣥ୰ẘ⪃࠼ࡽ ࢀࡿゎ๗㐼㐝ࡋࡓࠋ⤌⧊ษ∦ࢆ⏝࠸ࡓࢪࣇ࢙ࢽࢪࣥࡢ MALDI-M(/MS) ࡼࡿ┤᥋ศᯒ ࡘ࠸࡚ࡢሗ࿌ࡣࡲࡔ࡞ࡉࢀ࡚࠸࡞࠸ࠋᅇࡣࢪࣇ࢙ࢽࢪࣥ ᐃࡢ᭱㐺᮲௳ࡢ᳨ウࢆ⾜࠸, ᚋࡢ⤌⧊ษ∦ࡽࡢࡢ⸆≀᳨ฟࡢ㐺⏝ࢆ┠ⓗࡍࡿࠋ ࠙᪉ἲࠚゎ๗ฟࡉࢀࡓ✀ࠎࡢ⤌⧊ࡽᚄ 5mm ⛬ᗘࡢ⤌⧊ሢࢆ᥇ྲྀࡋ, -80 ᗘ࡛⤖ಖ ᏑࡋࡓࠋMS ᐃ㝿ࡋ, ࡑࡢሢࡽ 20 Pm ཌࡢ⤖ษ∦ࢆసᡂࡋ, MALDI-MS ᐃ⏝ࡢࢫ ࢸࣥࣞࢫࣉ࣮ࣞࢺୖ 20 ᯛ⛬ࡢࡏ, ᥋╔ࡉࡏࡓࠋ ࡑࢀࢆࢩࣜ࢝ࢤࣝධࡾࡢࣃࢵࢡᐦ㛢ࡋ, ᐊ 1 ᬌᨺ⨨ࡋࡓࠋෆ㒊ᶆ‽(imipramine) ࡣ⤌⧊ษ∦ࢆࡢࡏࡿ๓ࣉ࣮ࣞࢺୖῧࡋࡓࠋ ḟ⤌⧊⾲㠃 matrix ⁐ᾮࢆ࢚ࣈࣛࢩ࡛ሬᕸࡋࡓࠋ⇱ᚋ reflector type-TOF-MS, QSTAR Eliet Hybrid (AB SCIEX) ࡚ MS MS/MS ࢆ ᐃࡋࡓࠋ⨨ࡢ mass resolution ࡣ 15,000, mass accuracy ࡣ 5 ppm ࡛࠶ࡿࠋ355-nm Nd:YAG laser ࢆ power level 10.6 PJ, 1000 Hz, 20 cycle ࡛↷ᑕࡋࡓࠋྖἲゎ๗కࡗࡓ⤌⧊୰ࡢ⸆≀᳨ฟࡣබⓗせㄳࡉࢀ࡚࠸ࡿࠋ ࠙⤖ᯝࠚ⸆≀᳨ฟࡢሙྜ, ⤌⧊ษ∦ࡢᚄࡣࡑࢀࡁ࠸ᚲせࡣ࡞࠸ࡀ, ᚄ 3mm ௨ୗ࡛ࡣ ษ∦ࢆࣉ࣮ࣞࢺୖ࣊⛣ືࡉࡏࡿࡢࡀᅔ㞴࡛࠶ࡗࡓࡢ࡛, ᚄࡣ 5mm ⛬ᗘࡋࡓࠋmatrix ࡋ࡚ Į-cyano-4-hydroxy cinnamic acid (CHCA)ࢆ⏝࠸ࡓሙྜ, CHCA 10mg ࢆࢭࢺࢽࢺࣜࣝ㸸 Ỉ (1 ml : 0.2 ml) ⁐ゎࡋࡓ⁐ᾮࡀ㐺ᙜ࡛࠶ࡗࡓࠋ⬡⫫୰ࡢࢪࣇ࢙ࢽࢪࣥࡣ⮚ჾࡼࡾࡶ㠀 ᖖ㧗⃰ᗘ࡛࠶ࡗࡓࠋ ࠙⪃ᐹࠚ⤌⧊ࡼࡿ ion suppression ࡣࡁࡃ, ࡲࡓ⤌⧊㸦㒊㸧ࡼࡗ࡚␗࡞ࡿࡢ࡛, ᮏἲ ࡼࡿ⢭ᐦ࡞ᐃ㔞ࡣᅔ㞴ᛮࢃࢀࡿࠋࡋࡋ⸆≀⃰ᗘࡀ࣮࢜ࢲ࣮ⓗṇࡋࡃ ᐃྍ⬟࡛࠶ ࢀࡤ୰ẘࡸ⮴Ṛࡢุ᩿ᮦᩱ࡞ࡾᚓࡿࡢ࡛, ἲ་Ꮫศ㔝࠾ࡅࡿ⸆ẘ≀ࡢ㎿㏿࡞ุู ⏝࡛ࡁࡿ᭷ຊ࡞᪉ἲ࡛࠶ࡿᛮࢃࢀࡿࠋ ́́ P-3 ḟளሷ⣲㓟ࡼࡾ㓟ࡉࢀࡓ࣍ࢫࣇࢳࢪࣝࢥࣜࣥࡢ LC/QTOF-MS ࢆ⏝࠸ࡓศᯒ ᫍᒸభ⨾ 1, Ᏻ㒊ᐶᏊ 1, ▮ᓥ 1, ᒾ℩༤ኴ㑻 1,2 1 ༓ⴥᏛᏛ㝔་Ꮫ◊✲㝔 ἲ་Ꮫᩍᐊ, 2 ᮾிᏛᏛ㝔་Ꮫ⣔◊✲⛉ ἲ་Ꮫᩍᐊ Analysis of hypochlorite-oxidized phosphatidylcholines using LC/QTOF-MS Yumi Hoshioka1, Hiroko Abe1, Daisuke Yajima1, Hirotaro Iwase1, 2 1 Department of Legal Medicine, Graduate School of Medicine, Chiba University 2 Department of Forensic Medicine, Graduate School of Medicine, The University of Tokyo ࠙⫼ᬒ࣭┠ⓗࠚዲ୰⌫ෆࡢ㓝⣲ࡢ୍ࡘ࡛࠶ࡿ࣑࢚ࣟ࣌ࣝ࢜࢟ࢩࢲ࣮ࢮ(MPO)ࡣࠊ⣽⳦➼ࡢ␗ ≀㈎㣗ࢆࡁࡗࡅ⏘⏕ࡉࢀࡓ㐣㓟Ỉ⣲ࡽḟளሷ⣲㓟ࢆ⏘⏕ࡍࡿᛂࢆゐ፹ࡍࡿࡉ ࢀࡿࠋ⏘⏕ࡉࢀࡓḟளሷ⣲㓟ࡣࠊ㈎㣗ࡉࢀࡓ⣽⳦➼ࡢ⬡㉁ࡸ⺮ⓑ㉁ࠊDNA ➼ࢆ㓟യᐖࡋ ẅ⳦㛵ࡍࡿゝࢃࢀ࡚࠸ࡿࠋࡇࡢస⏝ࡣࠊᚰ➽᱾ሰᕢ࡞␗≀ฎ⌮ࡀ⾜ࢃࢀࡿቯṚᕢ ࡸࠊ⅖࣭ಟࡢ࣓࢝ࢽࢬ࣒ࡀ㛵ࡍࡿ⪃࠼ࡽࢀ࡚࠸ࡿື⬦◳ᕢ࠾࠸࡚ࡶാ࠸࡚࠸ ࡿ⪃࠼ࡽࢀࡿࠋᮏ◊✲ࡣࠊዲ୰⌫ MPO ࡼࡿ␗≀ฎ⌮ࡢ࣓࢝ࢽࢬ࣒ࡢ࠺ࡕ⏕య⭷ࡢ⬡㉁ 㓟ὀ┠ࡋࠊࡑࡢศᯒࢆ⾜࠺ࡇ࡛⏕య⭷࠾ࡅࡿ⬡㉁㓟ࡢᐇែゎ᫂ࢆ┠ⓗࡍࡿࠋ ᅇࡣࠊ࣍ࢫࣇࢳࢪࣝࢥࣜࣥ(PC)ᶆ‽ရḟளሷ⣲㓟ࢆຍ࠼ࠊ ᛂࡋࡓ PC ࢆ LC/QTOF-MS ࡛ศᯒࡋࠊࡢࡼ࠺࡞ PC 㓟≀ࡀ⏘⏕ࡉࢀࡿ᳨ウࡋࡓࠋ ࠙᪉ἲࠚPC ᶆ‽ရࢆ 0.14mol/l NaCl ࣜࣥ㓟⦆⾪ᾮ(pH 6.9)ࢆ⏝࠸࡚ㄪᩚࡋࠊࡇࢀḟளሷ⣲ 㓟ࢼࢺ࣒ࣜ࢘(NaOCl)Ỉ⁐ᾮࢆῧຍࡋࡓࠋ37Υ࡛ᛂᚋࠊࢡ࣒ࣟࣟ࣍ࣝ/࣓ࢱࣀ࣮ࣝ(2:1, v/v) ࢆຍ࠼࡚ᛂࢆṆࡉࡏࠊࢡ࣒ࣟࣟ࣍ࣝᒙࢆศྲྀࡋࡓࠋศྲྀ⁐ᾮࢆヨᩱࡋ࡚ LC (Nexera system㸸ᓥὠ〇సᡤ) / QTOF-MS (TripleTOF5600+㸸AB SCIEX)࡛ศᯒࡋࡓࠋ࣒࢝ࣛࡣ Acquity HSS T3 C18 ȝPmm×100mm) (Waters)ࢆ⏝ࡋࠊ⛣ື┦ࡣ A ᾮ㸸10mM 㓑㓟ࣥࣔࢽ ࣒࢘, 0.2%㓑㓟, 50%࣓ࢱࣀ࣮ࣝỈ⁐ᾮࠊB ᾮ㸸2-ࣉࣟࣃࣀ࣮ࣝ:ࢭࢺࣥ=1:1ࠊὶ㏿ 0.35ȝl/min ࡋࡓࠋ ῧຍࡍࡿ NaOCl ࡢ⃰ᗘཬࡧᛂ㛫ࢆኚࡉࡏ᳨ウࡋࡓࠋ ࠙⤖ᯝ࣭⪃ᐹࠚ㣬⬡⫫㓟ᇶࢆࡶࡘ PC ࠾࠸࡚ࡣࠊࣔࣀࢡࣟࣟࣄࢻࣜࣥయ(+OH+Cl)ࠊሷ ⣲⨨య(+Cl-H)ࠊ㓟⣲ຍయ(+O, +2O)➼ࡀ⏘⏕ࡉࢀࡓࠋ㣬⬡⫫㓟ᇶࢆࡶࡓ࡞࠸ PC ࠾࠸࡚ࡣࡇࢀࡽࡢ⏘⏕≀ࡣㄆࡵ࡞ࡗࡓࠋḟளሷ⣲㓟ࡢ⃰ᗘࡀ㧗ࡃ࡞ࡿࡘࢀࠊࣔࣀࢡࣟ ࣟࣄࢻࣜࣥయཬࡧሷ⣲⨨యࡢ㔞ࡣቑຍࡋࡓࡀࠊ+O ࡘ࠸࡚ࡣࣉࣛࢺ࣮࡞ࡾࠊ+2O ࡘ ࠸࡚ࡣప⃰ᗘᇦ୍࡛ᗘቑຍࡋࡓᚋῶᑡࡋࡓࠋPC+2O ࡽ PC+O ࡢᛂࡀᏑᅾࡍࡿྍ⬟ᛶ ࡀ♧၀ࡉࢀࡓࠋࡑࡢヲ⣽ࡣᙜ᪥ሗ࿌ࡍࡿࠋ ᚋࡣἲ་ゎ๗࠾࠸࡚ᚓࡽࢀࡿࠊᚰ➽᱾ሰᕢ➼ࣄࢺ⏤᮶ࡢヨᩱࡽ⬡㉁ࢆᢳฟࡋࠊ᳨ ウࢆ㐍ࡵࡿணᐃ࡛࠶ࡿࠋ ́́ P-4 ἲ་ヨᩱ࠾ࡅࡿ⸆≀୰ẘࡢࣂ࣐࣮࣮࢜࢝᥈⣴ (2) Ᏻ㒊ᐶᏊ 1, ᫍᒸభ⨾ 1, ᑠᲚဴ㞝 2, ዉⰋ᫂ዉ 1, Ọ⃝᫂ె 1, ▮ᓥ 1, ᒾ℩༤ኴ㑻 1,3 1 ༓ⴥᏛᏛ㝔་Ꮫ◊✲㝔 ἲ་Ꮫᩍᐊ, 2 ᰴᘧ♫࢚࣮ࣅ࣮ࢧ࢚ࢵࢡࢫ 3 ᮾிᏛᏛ㝔་Ꮫ⣔◊✲⛉ ἲ་Ꮫᩍᐊ Search for biomarkers of drug intoxication cases of postmortem (2) Hiroko Abe1, Yumi Hoshioka1, Tetsuo Kokaji2, Akina Nara1, Sayaka Nagasawa1, Daisuke Yajima1, Hirotaro Iwase1,3 1 Department of Legal Medicine, Graduate School of Medicine, Chiba University 2 AB SCIEX 3 Department of Forensic Medicine, Graduate School of Medicine, The University of Tokyo ࠙┠ⓗࠚἲ་ศ㔝࠾࠸࡚ࠊ⸆≀㛵㐃Ṛࡢぢᴟࡵࡢࡓࡵࡶ⸆≀ศᯒࡣᚲ㡲ࡢศᯒ࡛࠶ࡿࠋ ࡋࡋࠊ ἲ་ヨᩱࡣ⭉ᩋࡢᙳ㡪ࡸ⸆≀ࡢṚᚋศᕸ࠸ࡗࡓᙳ㡪ࢆᙉࡃཷࡅ࡚࠸ࡿࡇࡽࠊ ⸆≀⾑୰⃰ᗘࡣཧ⪃್⛬ᗘࡋ࡞ࡽ࡞࠸ࠋࡑࡇ࡛ࠊᡃࠎࡣ⾑୰⃰ᗘຍ࠼࡚⭉ᩋࡸṚᚋ ศᕸࡢᙳ㡪ࢆཷࡅ࡞࠸⸆≀୰ẘᣦᶆ≀㉁ࡢ᥈⣴ࢆ㐍ࡵ࡚࠸ࡿࠋ➨ 39 ᅇ་⏝࣐ࢫࢫ࣌ࢡࢺࣝ Ꮫᖺ࠾࠸࡚ࡣࠊぬࡏ࠸ᡂศ↔Ⅼࢆ⤠ࡾࠊぬࡏ࠸ࡀ᳨ฟࡉࢀࡓヨᩱ୰ぬࡏ࠸ ᡂศ௨እࡢ࣐࣮࣮࢝࡞ࡾ࠺ࡿ≉ᚩⓗ࡞≀㉁ࡀ᳨ฟࡉࢀࡿ᪨ሗ࿌ࡋࡓࡀࠊ ࡑࡢ≀㉁ࡢྠᐃࡲ ࡛ࡣ⮳ࡽ࡞ࡗࡓࠋᅇࠊྠᵝࡢ࠾࠸࡚ࠊ᭦⬡㉁ࡶศᯒᑐ㇟ࡋ࡚ホ౯ࢆ⾜ࡗࡓ ࡢ࡛ሗ࿌ࡍࡿࠋ ࠙᪉ἲࠚ༓ⴥᏛἲ་Ꮫᩍᐊ࠾࠸࡚ࠊ㐣ཤぬࡏ࠸ࡀ᳨ฟࡉࢀࡓ⾑ᾮヨᩱ㸦MP ⩌㸧 ࠊᑐ↷ ⩌ࡋ࡚་⸆ရ㸦ྥ⢭⚄⸆㸧ࡀ᳨ฟࡉࢀࡓ⾑ᾮヨᩱ㸦PC ⩌㸧 ࠊ⸆≀ࢫࢡ࣮ࣜࢽࣥࢢ᳨ᰝ ࡼࡗ࡚⸆≀ࡀ᳨ฟࡉࢀ࡞ࡗࡓ⾑ᾮヨᩱ㸦NG ⩌㸧ࢆ⏝࠸ࡓࠋࡲࡓ࠶ࡿ✀ࡢ⸆≀࡛ࡣ㧗࣑ ࢜ࢢࣟࣅࣥ⾑ࢆⓎࡍࡿࡇࡀ▱ࡽࢀ࡚࠾ࡾࠊ ᥈⣴࣐࣮࣮࢝ࡀ࣑࢜ࢢࣟࣅࣥ⏤᮶࡛࠶ࡿ ྰࢆุ᩿ࡍࡿࡓࡵࠊ⸆≀㛵㐃ࡏࡎ࣑࢜ࢢࣟࣅࣥࡀ㧗್ࢆ♧ࡋࡓ⾑ᾮヨᩱ㸦HG ⩌㸧ࡶ ᅇᑐ↷ヨᩱࡋ࡚㏣ຍࡋࡓࠋBligh & Dyer ἲ࡚ྛ⾑ᾮ୰ࡢᡂศࢆᢳฟࡋࠊࢡ࣒ࣟࣟ࣍ࣝᒙ ࢆ ศ ྲྀ ࠋ ࡑ ࢀ ࡽ ࢆ ศ ᯒ ヨ ᩱ ࡋ LC 㸦 Nexera system 㸸 ᓥ ὠ 〇 స ᡤ 㸧 /QTOF-MS 㸦TripleTOF5600+㸸AB SCIEX)࡛ศᯒࡋࠊከኚ㔞ゎᯒ㸦MarkerView㸸AB SCIEX㸧ࢆ⾜ࡗࡓࠋ ࠙⤖ᯝ࣭⪃ᐹࠚPCA ゎᯒࡢ⤖ᯝࠊMP ⩌ࠊHG ⩌ࠊPC ⩌+NG ⩌ࡢ 3 ⩌ศ㞳ࡉࢀࠊࡑࢀࡒࢀ ࡢ⩌≉ᚩⓗ࡞≀㉁ࡀᏑᅾࡋࡓࠋྜ≀ྠᐃࡢ⤖ᯝࠊࡇࢀࡽࡢ≀㉁ࡣ⸆ᡂศ࠾ࡼࡧ⸆ ᡂศ௦ㅰ≀⏤᮶࡛ࡣ࡞࠸⪃࠼ࡽࢀࠊ⏕యෆ௦ㅰ⏘≀࡛࠶ࡿྍ⬟ᛶࡀ♧၀ࡉࢀࡓࠋ≉ HG ⩌ MP ⩌ࡀศ㞳ࡋࡓࡇࡽࠊMP ⩌≉ᚩⓗ࡞≀㉁ࡣ࣑࢜ࢢࣟࣅࣥ⏤᮶࡛ࡣ࡞࠸ྍ⬟ᛶ ࡀ♧၀ࡉࢀࡓࠋᚋࡇࢀࡽ≀㉁ࡢྠᐃࢆ㐍ࡵ࡚࠸ࡁࠊ≉ᐃࡢ⸆≀୰ẘ≉␗ⓗ࡞≀㉁࡛࠶ ࡿྰࠊ᳨ウࢆ㐍ࡵࡿࠋ ́́ P-5 HSD10 ࡢ⾑୰ࢩࣝ࢝ࣝࢽࢳࣥศᯒࡼࡿᏛデ᩿ 㔜ᯇ㝧 1, ⏿ 㑳Ụ 2, ୰ᓥⱥつ 3, ణ㤿 ๛ 4, ▼ẟಙஅ 5 1 ⚟Ꮫ་Ꮫ㒊ᗣ⛉Ꮫ, 2 ⚟Ꮫ་Ꮫ㒊ᑠඣ⛉Ꮫ, 3 ᅜ❧ᡂ⫱་⒪◊✲ࢭࣥࢱ࣮࣭࣐ࢫ ࢫࢡ࣮ࣜࢽࣥࢢ◊✲ᐊ, 4 ᗈᓥᏛᏛ㝔ᑠඣ⛉Ꮫ◊✲ᐊ, 5 ᮾி㒔ண㜵་Ꮫ༠ᑠඣࢫࢡࣜ ࣮ࢽࣥࢢ⛉ Chemical diagnosis of HSD10 disease by LC-MS/MS analysis of acylcarnitines in blood Yosuke Shigematsu1, Ikue Hata2, Hideki Nakajima3, Go Tajima4, Nobuyuki Ishige5 1 Department of Health Science, University of Fukui 2 Department of Pediatrics, University of Fukui 3 Mass screening laboratory, National Research Institute for Child Health and Development 4 Department of Pediatrics, Hiroshima University 5 Tokyo Health Service Association ࠙┠ⓗࠚHSD10 șࢣࢺࢳ࣮࢜ࣛࢮḞᦆࡢ㓝⣲␗ᖖ㒊ࡣ㏆᥋ࡋ࡚࠾ࡾࠊࡑࡢ㚷ูデ᩿ ࡣ㏻ᖖ GC/MS ᒀ᭷ᶵ㓟ศᯒ࡛࣓ࢳࣝࢭࢺ㓑㓟ࡀ␗ᖖἥࡉࢀ࡚࠸ࡿྰࡼࡾ⾜ࢃࢀ ࡿࠋᒀ୰࣓ࢳࣝࢭࢺ㓑㓟ࡣಖᏑࡼࡾ᳨ฟࡉࢀࡃࡃ࡞ࡿࡇࡸࠊᒀࡀ᥇ྲྀࡉࢀ࡚࠾ࡽࡎ ⾑ᾮℐ⣬ࡀ၏୍ࡢ᳨ᰝᮦᩱ࡛࠶ࡿࡇࡶ࠶ࡿࡓࡵࠊLC-MS/MS ࡼࡿ⾑୰ࢩࣝ࢝ࣝࢽࢳࣥ ศᯒࢆヨࡳࡓࠋ ࠙᪉ἲࠚHSD10 ࠾ࡼࡧșࢣࢺࢳ࣮࢜ࣛࢮḞᦆ㑇ఏᏊゎᯒ࡛☜ᐃデ᩿ࡉࢀࡓᝈ⪅ࡢℐ⣬ ⾑࠶ࡿ࠸ࡣ⾑Ύ㸦෭ᗜಖᏑ㸧ࢆศᯒࡋࡓࠋAB Sciex ♫〇 API4000 MS/MS system ᓥὠ〇 సᡤ〇 LC system ࢆ᥋⥆ࡋ࡚ LC-MS/MS ศᯒࢆ⾜ࡗࡓࠋLC ࣒࢝ࣛࡣ Imtakt ♫〇࣐ࣝࢳ࣮ࣔ ࢻࢡ࣐ࣟࢺࢢࣛࣇ࣮࣒࢝ࣛ Scherzo SS-C18 (3.0㹶150 mm)ࢆ⏝ࡋࡓࠋᐃ㔞ࡢࡓࡵࡢෆ 㒊ᶆ‽≀㉁ࡋ࡚ d9-3-hydroxyisovalerylcarnitine ࢆ⏝ࡋࡓࠋ ࠙ ⤖ ᯝ ࠚ 2-methyl-3-hydroxybutyrylcarnitine (MHBC) ࠾ ࡼ ࡧ 2-methylacetoacetylcarnitine㸦MAAC㸧ࡢᶆရࡣධᡭฟ᮶࡞ࡗࡓࡀࠊ[M+H]+ཬࡧࡑࡢ product ion ࡢศᯒࡽ ࡇࢀࡽ᥎ᐃࡉࢀࡿࢩࣝ࢝ࣝࢽࢳࣥࢆ᳨ฟ࡛ࡁࡓࠋࡇࢀࡽࢆ[M+H]+㸼85 ࡢࢺࣛࣥࢪࢩࣙ ࣥࢆ⏝࠸࡚ MRM ศᯒࡋࡓࡇࢁࠊșࢣࢺࢳ࣮࢜ࣛࢮḞᦆ࡛ࡣ MHBC MAAC ࡀቑຍࡋ࡚࠾ ࡾࠊHSD10 ࡛ࡣ MHBC ࡢࡳቑຍࡋ࡚࠸ࡓࠋ ࠙⪃ᐹࠚ⾑୰ࢩࣝ࢝ࣝࢽࢳࣥ⃰ᗘࡣᴟࡵ࡚ప࠸ࡶࡢࡢࠊ≉ᚩⓗ࡞ CID product ion m/z 85 ࡀ ඹ㏻ࡋ࡚ࡳࡽࢀࡿࡢ࡛ࠊdioylcarnitine ࡛࡞ࡅࢀࡤࠊᶆရࡀධᡭฟ᮶࡞࠸ࢩࣝ࢝ࣝࢽࢳ࡛ࣥ ࡶ MRM ศᯒ࡛⌧ᐇⓗ࡞⃰ᗘホ౯ࡀྍ⬟࡛࠶ࡿࠋ୧ᝈࡶ㔜ᗘࡢᖜࡀࡁࡃࠊ㍍࡛ ࡢ MAAC ࡣࠊ≉↓≧ࡢ㛫Ḟᮇࡣࠊᑐ㇟⪅ࡢ⃰ᗘᇦపୗࡍࡿࡇࡀ࠶ࡿࡢ࡛ࠊࡑࡢ᭷ ⏝ᛶࡘ࠸࡚ࡣ᭦᳨ウࡀᚲせ࡛࠶ࡿࠋ୍᪉⾑୰ࡢ᭷ᶵ㓟ࡘ࠸࡚ࡣࠊࢩࣝ࢝ࣝࢽࢳࣥ ␗࡞ࡾ CID product ion ࡀ୍ᐃࡋ࡚࠸࡞࠸ࡢ࡛ࠊᶆရࡀᚓࡽࢀ࡞࠸࣓ࢳࣝࢭࢺ㓑㓟ࡢศ ᯒࡣᅔ㞴࡛࠶ࡗࡓࠋ ́́ P-6 ㉁㔞ศᯒࡼࡿ௦ㅰ␗ᖖ⸆≀௦ㅰࡢ㚷ู ᙇ ⰼ, ᮤ ወ, ㉿ ᑀ, 㔠 ᫂ጲ, 㜲 ᐀ᾏ ࣑ࣝࢫࣥࢱ࣮ࢼࢩࣙࢼࣝ ◊✲㛤Ⓨ㒊 Distinguishing of metabolic disorder or drug metabolism by mass spectrometry analysis Chunhua Zhang, Qi Li, Ning Zhao, Mingji Jin and Zonghai Ruan Department of research & development of MILS International ࠙┠ⓗࠚ㉁㔞ศᯒࡼࡿ௦ㅰࣉࣟࣇࣝゎᯒࡣࠊ᳨ࣜࣝయ᥇ྲྀࡢయෆ௦ㅰືែࢆ ᫎࡋࠊែゎᯒࢶ࣮ࣝࡋ࡚௦ㅰ␗ᖖࡢᏛデ᩿ࡶ㛵ࢃࡽࡎࠊ⸆≀௦ㅰࠊ㓟ࢫࢺࣞ ࢫホ౯ࠊ⒴᳨デࡶᛂ⏝ࡉࢀ࡚࠸ࡿࠋࢃࢀࢃࢀࡣࠊ௦ㅰ␗ᖖࢆ࠺ᝈ⪅ࡢ௦ㅰែゎᯒ ࢆᐇࡋ࡚࠸ࡿ࡞ࠊᗄࡘࡢ་※ᛶ⸆≀ࡢ⏝ࡼࡿ௦ㅰࣉࣟࣇࣝࡢኚࡣ௦ㅰ␗ᖖ ㄗㄆࡍࡿྍ⬟ᛶࡸᆺⓗ࡞௦ㅰ␗ᖖࡢ≉ᚩⓗ࡞ኚࢆぢ࠼࡞ࡃᝈࡢデ᩿ࢆぢⴠ ࡍᜍࢀࡶࡋࡤࡋࡤ㐼㐝ࡋࠊ┿ࡢඛኳᛶ௦ㅰ␗ᖖࡢែゎᯒᝨࢃࡏࡿࡇࡀከࡗࡓࠋ ᅇࡇࢀࡽࡢ⸆≀⏤᮶௦ㅰࣉࣟࣇࣝࡢ≉ᚩࢆศᯒࡋࠊᗄࡘΰࡋࡸࡍ࠸ᝈࡢゎᯒ 㓄៖ࡍࡁⅬࡀぢࡘࡅࡓࠋࡇࡢ⤒㦂ࢆ⏕ࡋࡓ᪂ࡋ࠸ᢞ⸆ሗ⮫ᗋែࢆ㓄៖ࡋࡓ௦ㅰ ␗ᖖࡢࣉࣟࣇࣝゎᯒࢆᥦၐࡍࡿࠋ ࠙᪉ἲࠚ㐣ཤ௦ㅰ␗ᖖࡢཷク᳨ᰝࡋ࡚ࡁࡓᝈ⪅ࡢ௦ㅰែゎᯒࡢ࠺ࡕࠊᆺⓗ࡞௦ㅰ␗ᖖ ࣉࣟࣇࣝࢆ㞳ࡋࡓኚࢆ࿊ࡋࡓࡢ⮫ᗋሗྜࢃࡏ᳨࡚ウࡋࡓࠋୗグ 4 ✀ࡢ ⸆≀㛵ࡍࡿ௦ㅰࣉࣟࣇࣝࡢኚࢆゎᯒࡋࠊࡑࡢ≉ᚩࢆ⧳ࡵࡓࠋձ⮫ᗋデ᩿ࡢࡓࡵࡢ ࣝࢠࢽࣥ㈇Ⲵᝈ⪅⒪ࡢࡓࡵࡢࣝࢠࢽࣥᢞࡋࡓࢩࢺࣝࣜࣥ⾑ᝈ⪅ࡢᒀ⾑ᾮ㸹 ղᒀ㓟್ࢆୗࡆࡿࡓࡵࡢࣟࣉࣜࣀ࣮ࣝᢞ⸆ᝈ⪅ࡢᒀ⾑ᾮ㸹ճࡃࡿண㜵⒪ࡍࡿࡓࡵ ࡢ㨶⫢Ἔ⏝୰ᝈ⪅ࡢᒀ⾑ᾮ㸹մ㛗ᮇࢺ࣓ࣜࢳࣝࢢࣜࢩࣥᢞ୰ࡢ࣓ࢳ࣐ࣝࣟࣥ㓟⾑ ᝈ⪅ࡢᒀࠋ ࠙⤖ᯝࠚࣝࢠࢽࣥᢞࡼࡿ࢜ࣝࢽࢳࣥ⎔≧ࢩࢺࣝࣜࣥ㢮ఝᡂศࡢᒀ୰ἥቑຍࠊ ࣟࣉࣜࣀ࣮ࣝᢞ⸆ࡼࡿ࢟ࢧࣥࢳࣥᒀᵝ௦ㅰኚࠊ㨶⫢Ἔ⏝ࡼࡿ⾑୰㛗㙐ࣄࢻࣟ࢟ ࢩࢩࣝ-CoA ⬺Ỉ⣲㓝⣲Ḟᦆᵝࢩࣝ࢝ࣝࢽࢳࣥࡢኚࠊࢺ࣓ࣜࢳࣝࢢࣜࢩࣥᢞࡼ ࡿ࣓ࢳ࣐ࣝࣟࣥ㓟⾑ᝈ⪅ࡢᒀ୰ࢨࣝࢥࢩࣥࡢୖ᪼࡞ࢆุ᫂ࡋࡓࠋ ࠙⪃ᐹࠚ᪤ሗࡋࡓ࢚ࢳࣞࣥࢢࣜࢥ࣮ࣝㄗ㣧ࡼࡿ㧗ⶃ㓟ᒀᵝ௦ㅰࣉࣟࣇࣝࡢฟ⌧ࠊୖ グ 4 ✀ࡢ⸆≀ᢞࡢ௦ㅰኚࡣࡑࢀࡒࢀ┦ᛂࡍࡿ✀ࡢ௦ㅰ␗ᖖ㢮ఝࡍࡿࡇࢆ᫂ࡽ ࡋࡓࠋࡇࢀࡽࡢ⤒㦂ࢆάࡋ࡚ࡉࡽࡉࡲࡊࡲ࡞⸆ရᢞࡼࡿ௦ㅰࣉࣟࣇࣝࡢኚ ࢆ᳨ドࡋࠊࡼࡾヲ⣽࡞ୟࡘṇ☜࡞ែゎᯒ⧅ࡀࢀࠊ᳨య᥇ྲྀࡢᢞ⸆ࡸ⮫ᗋែࢆ㓄 ៖ࡋࡓᚋࡢ௦ㅰࣉࣟࣇࣝゎᯒࡢ⮫ᗋᛂ⏝㐍ࡵ࡚ࡺࡁࡓ࠸ࠋ ́́ P-7 GC/MS ศᯒࡼࡿࢩࢺࣝࣜࣥ⾑ᝈ⪅ᒀ୰࢜ࣝࢽࢳ᳨ࣥฟࡢ⮫ᗋព⩏ 㜲 ᐀ᾏ, ᮤ ወ, 㔠 ᫂ጲ, ᙇ ⰼ ࣑ࣝࢫࣥࢱ࣮ࢼࢩࣙࢼࣝ ◊✲㛤Ⓨ㒊 Study on clinical significance of urinary ornithine in citrullinemia patients by GC/MS Zonghai Ruan, Qi Li, Mingji Jin and Chunhua Zhang Department of research & development of MILS International ࠙┠ⓗࠚGC/MS ศᯒࡼࡿᒀ୰࢘ࣛࢩࣝ࢜ࣟࢵࢺ㓟ࡢ␗ᖖ㧗ἥࡀᒀ⣲ᅇ㊰⣔␗ᖖࡢᏛ デ᩿ࡢࣂ࣐࣮࣮࢜࢝ࡋ࡚ྂࡃࡽࢃࢀ࡚࠸ࡿࠋࢃࢀࢃࢀࡣࠊᒀ⣲ᅇ㊰࣓ࣥࣂ࣮࣑ ࣀ㓟ࡢ࢜ࣝࢽࢳࣥࡸࣝࢠࢽࣥ⇕ศゎ⏘≀ࡢྠ᳨ฟࡼࡾࠊ᭦ᒀ⣲ᅇ㊰⣔␗ᖖࡢヲ⣽ デ᩿㈉⊩࡛ࡁࡿ◊✲⤖ᯝࢆ 2000 ᖺࡢᮏᏛ࡛ሗ࿌ࡋࡓࠋᅇᒀ୰ࡢ⎔≧ࢩࢺࣝࣜࣥᡂ ศࡢ᳨ฟ≧ἣࢆຍ࠼ࠊࢩࢺࣝࣜࣥ⾑ᝈ⪅ࡢᒀ୰࢜ࣝࢽࢳ᳨ࣥฟࡢព⩏ࢆ᳨ウࡋࡓࡢ࡛ ሗ࿌ࡍࡿࠋ ࠙᪉ἲࠚඛኳᛶ௦ㅰ␗ᖖࡢࢫࢡ࣮ࣜࢽࣥࢢ࡛ᙜタ౫㢗ࡋ࡚ࡁࡓ୰ᅜேᝈ⪅ 7 ྡ㸦⏨ඣ 2 ࠊዪඣ 5 㸧ࡢᒀℐ⣬⾑ࡘ࠸࡚ศᯒࡋࡓࠋᒀ᳨యࡘ࠸࡚ࠊ᪤ሗࡢ࣮࢘ࣞࢮฎ⌮ ἲࡼࡿ๓ฎ⌮ࡋࡓᚋࠊGC/MS ศᯒࢆ⾜ࡗࡓࠋGC/MS ศᯒࡣࠊJEOL ♫ࡢ JMS-K9 ࡛⾜ࡗࡓࠋ ℐ⣬⾑᳨యࡘ࠸࡚ࠊࢱࣥࢹ࣒࣐ࢫศᯒࡼࡾ⾑୰࣑ࣀ㓟ࢩࣝ࢝ࣝࢽࢳࣥࢆศᯒࡋࡓࠋ ࢱࣥࢹ࣒࣐ࢫࡣᓥὠ♫ࡢ LCMS-8040 ࢆ⏝ࡋࡓࠋᒀℐ⣬⾑ࡢศᯒ⤖ᯝࢆྜࢃࡏ࡚ࠊᙜ タࡢ௦ㅰ␗ᖖゎᯒࣉࣟࢢ࣒࡛ࣛែゎᯒࡋࡓࠋ ࠙⤖ᯝࠚୖグ 7 ࠸ࡎࢀࡶᒀ୰࢘ࣛࢩࣝ࢜ࣟࢵࢺ㓟ࡢ␗ᖖቑຍࢆㄆࡵࡓࠋࡑࡢ࠺ࡕ 6 ᒀ ୰࢜ࣝࢽࢳࣥࡶ᳨ฟࡉࢀࡲࡋࡓࠋྠ࢜ࣝࢽࢳ᳨ࣥฟࡉࢀࡓᝈ⪅ࡢ࠺ࡕࡢ 3 ࡀ⎔≧ ࢩࢺࣝࣜࣥᡂศࡶ᳨ฟࡉࢀࡓࠋణࡋࠊ࠺ࡕ 1 ࡢ᳨ᒀ୰࢜ࣜࢽࢳࣥࡢࣆ࣮ࢡࡀᾘኻ ࡋࠊ௦ࡾ⎔≧ࢩࢺࣝࣜࣥᡂศࢆࡁࡃ᳨ฟࡉࢀࡓወጁ࡞⌧㇟ࡀぢࡽࢀࡓࠋ⾑୰ࡢ࣑ ࣀ㓟ศᯒ࡛ࡣࡍ࡚ࡢࡢࢩࢺࣝࣜࣥࡢୖ᪼ࢆ☜ㄆ࡛ࡁࡓࡢ࡛ࠊᒀ⣲ᅇ㊰⣔␗ᖖࡢࢩࢺ ࣝࣜࣥ⾑Ꮫデ᩿ࡋࡲࡋࡓࠋ ࠙⥲ᣓࠚୖ㏙ࡢ⤖ᯝࡼࡾࠊᒀ୰࢘ࣛࢩࣝ࢜ࣟࢵࢺ㓟ࡢቑຍక࠸ࠊ࢜ࣝࢽࢳࣥࡢ㧗ἥࢆ ㄆࡵࡓ௦ㅰࣉࣟࣇࣝࡣࠊࢩࢺࣝࣜࣥ⾑ࡢᏛデ᩿ࡢ≉ᚩ࡛࠶ࡿࡢࡣ௨๓ࡢሗ࿌୍⮴ ࡋࡓࠋ⎔≧ࢩࢺࣝࣜࣥᡂศࡀࠊ୍㒊ศࡢࢩࢺࣝࣜࣥ⾑ᝈ⪅ࡽ᳨ฟࡉࢀࡓࠋࡇࡢᡂศ ࡢᏛᵓ㐀ࡣࡲࡔ᫂ࡀࠊ࢜ࣜࢽࢳࣥࡢᾘኻฟ⌧ࡍࡿ⌧㇟ࡽࠊ࢜ࣝࢽࢳࣥࡢศゎ⏘≀ ࡛ࡣ࡞࠸᥎ ࡍࡿࠋࡇࢀࡲ࡛⎔≧ࢩࢺࣝࣜࣥᡂศࡀࢩࢺࣝࣜࣥ⾑ࣝࢠࢽࣥࢥ ࣁࢡ㓟⾑ࡢデ᩿࣐࣮࣮࢝ࡋ࡚ሗ࿌ࡉࢀ࡚࠸ࡓࡀࠊ⎔≧ࢩࢺࣝࣜࣥᡂศࡢ᳨ฟࡣᏳ ᐃ࡛࠶ࡾࠊ࢜ࣝࢽࢳࣥࡢ┦㛵ᛶࡀ࠶ࡿࡓࡵࠊᒀ୰࢜ࣝࢽࢳࣥࡢ᳨ฟࡀᒀ⣲ᅇ㊰⣔␗ᖖࡢ ヲ⣽デ᩿ಙ㢗࡛ࡁࡿ࣐࣮࣮࢝ࡋ࡚ㄆ㆑ࡋࡓࠋᚋ⎔≧ࢩࢺࣝࣜࣥᡂศ࢜ࣝࢽࢳ ࣥࡢ┦㛵ᛶࡘ࠸࡚ࡉࡽ◊✲㐍ࡵ࡚ࡺࡁࡓ࠸ࠋ ́́ P-8 GCMS ࡼࡿ⣅౽୰⭉ᩋ⏘≀ࡢ ᐃ ⅲ⹒ཧ, ⚟ཎ⨾௦Ꮚ, ஂ⏣㈗⩏ ᰴᘧ♫ࢸࢡࣀࢫ࣭ࣝ࢞ࣛ࣎ Determination of phenols and indoles in feces using GCMS Olansandan, Miyoko Fukuhara, Takayoshi Hisada TechnoSruga Laboratory Co.,Ltd. ࠙┠ⓗࠚ㏆ᖺࠊ⭠ෆ⣽⳦ࡢᵝࠎ࡞௦ㅰ≀ࡀᐟࡢᗣᙳ㡪ࢆཬࡰࡍࡇࡀሗ࿌ࡉࢀ࡚࠸ࡿࠋ ࡑࢀࡽࡢ㛵ಀࢆヲ⣽᳨ウࡍࡿୖ࡛ࠊ⭠ෆ⣽⳦ྀࡢゎᯒࡀᗈࡃ⾜ࢃࢀ࡚࠸ࡿࠋࡲࡓࠊ⭠ෆ ⣽⳦௦ㅰ≀ࡢ⥲ྜⓗ࡞ゎᯒࡶ㠀ᖖ㔜せ࡛࠶ࡾࠊ௦ㅰ≀ࢆ⢭ᗘࡼࡃࠊࡘ㎿㏿ᐃ㔞࡛ ࡁࡿศᯒἲࡢᵓ⠏ࡀồࡵࡽࢀ࡚࠸ࡿࠋᮏ◊✲࡛ࡣࠊ⭠ෆ⎔ቃᝏࢆホ౯ࡍࡿᣦᶆࡋ࡚▱ ࡽࢀ࡚࠸ࡿ⣅౽୰ࣇ࢙ࣀ࣮ࣝ㢮ࡸࣥࢻ࣮ࣝࠊࢫ࢝ࢺ࣮ࣝ࡞⭉ᩋ⏘≀㛵ࡍࡿ GCMS ࢆ⏝ ࠸ࡓศᯒἲࢆ☜❧ࡍࡿࡇࢆ┠ⓗࡋࡓࠋࢧࣥࣉࣝࡢಖᏑ㛵ࡋ࡚ࡶ᳨ウࡋࡓࡢ࡛ేࡏ࡚ ሗ࿌ࡍࡿࠋ ࠙᪉ἲࠚ᳨యࡢ๓ฎ⌮ࡣࠊΰ⦎ࡋࡓࢧࣥࣉࣝࡼࡾ⣙ 0.2 g ࢆ⛗㔞ࡋࠊෆ㒊ᶆ‽ྵ᭷ࣜࣥ㓟ࣂ ࣇ࣮࡛ᠱ⃮ࡋࠊ85Υ࡚ 15 ศ㛫⇕ฎ⌮ࡋࡓࠋ ෭༷ᚋࢭࢺࢽࢺࣜࣝࢆ⏝࠸࡚ᢳฟࢆ⾜࠸ࠊ PSA-30 ࡼࡾ⢭〇ࡋ࡚ GCMS ౪ࡋࡓࠋᖖே 4 ྡࡢ୍ᅇࡢ⣅౽ࢆࡑࢀࡒࢀ᥇㞟ΰ⦎ࡋ࡚ࠊ 4 ಶᑠศࡋ࡚í30Υ࡛⤖ಖᏑࡋࠊ0 ᪥ࠊ14 ᪥ࠊ28 ᪥(n=3)࠾࠸࡚ ᐃࢆ⾜ࡗࡓࠋ ࠙⤖ᯝࠚᖖே 4 ྡࡢ⣅౽ࡽࣇ࢙ࣀ࣮ࣝ 0.89~2.2 ȝJJࠊp-ࢡࣞࢰ࣮ࣝ 4.2~143 ȝJJࠊࣥࢻ ࣮ࣝ 2.0~56 ȝJJࠊࢫ࢝ࢺ࣮ࣝ 0.16~20 ȝJJ ࠾ࡼࡧ 4-࢚ࢳࣝࣇ࢙ࣀ࣮ࣝ 0.63~4.6 ȝJJ ࡢ⠊ᅖ ᳨࡛ฟࡉࢀࠊಶேᕪࡀࡁࡗࡓࠋᮏἲࡼࡿࣄࢺ⣅౽ࡢΰྜᶆ‽ᾮῧຍᅇ⋡ᐇ㦂࡛ ࡣࠊప⃰ᗘ(0.04 ȝJJ)࡛ 74.1~115%ࠊ㧗⃰ᗘ(1.0 ȝJJ) ࡛ࡣ 86.1~122%࡛࠶ࡗࡓࠋᐇヨᩱ࠾ ࡅࡿ⧞ࡾ㏉ࡋ ᐃ(n=7)ࡋࡓࡢ┦ᑐᶆ‽೫ᕪ(RSDr)ࡣ 0.26~4.3%Ⰻዲ࡞⢭ᗘࡀ☜ㄆࡉࢀ ࡓࠋᮏἲࡢᐃ㔞ୗ㝈ࡣ ȝJJ ࡛࠶ࡗࡓࠋ ࠙⥲ᣓࠚᮏἲࡣࠊࣄࢺࡢ⣅౽ࡔࡅ࡛ࡣ࡞ࡃࣛࢵࢺࠊ࣐࢘ࢫࠊ࣐࢘ࠊࣄࢶࢪࠊࢾ࡞ࡢ⣅౽ ୰⭉ᩋ⏘≀ࡢศᯒἲࡋ࡚ࡢ⏝ࡶᮇᚅ࡛ࡁࡿࠋ ́́ P-9 LC-MS/MS ἲࡼࡿࣄࢺᒀ୰࠾ࡅࡿࣂࢽ࣐ࣜࣝࣥࢹࣝ㓟ࠊ࣍ࣔࣂࢽࣜࣥ㓟ࠊ ࣓ࢱࢿࣇࣜࣥࠊࣀ࣓ࣝࢱࢿࣇࣜࣥ࠾ࡼࡧࢡࣞࢳࢽࣥࡢྠᐃ㔞ἲࡢ᳨ウ ሷᕝுኴ 1, ⣽⏣㤶⧊ 1, ᰘᓮᾈ⨾ 2, ᶓᕝᙲ᭸ 2, ▼ኵ 1 1 ᮥᯘᏛಖᏛ㒊, 2 ᮾி⸆⛉Ꮫ⸆Ꮫ㒊 Simultaneous determination of vanillylmandelic acid, homovanillic metanephrine, normetanephrine and creatinine in human urine acid, Ryota Shiokawa1, Kaori Hosoda1, Hiromi Shibasaki2, Akitomo Yokokawa2, Kazuo Ishii1 1 Kyorin University Faculty of Health Sciences 2 Tokyo University of Pharmacy and Life Sciences School of Pharmacy ࠙┠ⓗࠚ⚄⤒ⱆ⣽⬊⭘ࡣⓑ⾑ḟ࠸࡛ᑠඣከ࠸ࡀࢇ࡛࠶ࡿࠋࡇࡢᝈ࡛ࡣࠊᝈ⪅ࡢᒀ୰ ࢝ࢸࢥ࣮࣑ࣝࣥࡢ᭱⤊௦ㅰ⏘≀࡛࠶ࡿࣂࢽ࣐ࣜࣝࣥࢹࣝ㓟 (VMA) ࣍ࣔࣂࢽࣜࣥ㓟 (HVA) ࡀከࡃἥࡉࢀࡿࠋࡑࡢࡓࡵࠊࢫࢡ࣮ࣜࢽࣥࢢ᳨ᰝࡣࢡࣞࢳࢽࣥ (Cr) ⿵ṇࡋࡓ ᒀ୰ VMAࠊHVA ್ࡀ⏝࠸ࡽࢀ࡚࠸ࡓࡀࠊⰋᛶ⭘⒆ࡢ༊ูࡀᅔ㞴࡛࠶ࡿࡇࡽ⌧ᅾఇ Ṇࡉࢀ࡚࠸ࡿࠋ୍᪉ࠊ〓Ⰽ⣽⬊⭘ࡶ࢝ࢸࢥ࣮࣑ࣝࣥ⏘⏕⭘⒆࡛࠶ࡾࠊࢫࢡ࣮ࣜࢽࣥࢢ᳨ ᰝࡣ Cr ⿵ṇࡋࡓᒀ୰࣓ࢱࢿࣇࣜࣥ (MN) ್ࣀ࣓ࣝࢱࢿࣇࣜࣥ (NMN) ್ࢆ⏝ࡍࡿࠋ VMAࠊHVAࠊCr ࡢࡳ࡞ࡽࡎ MN NMN ࡶྠ ᐃࡍࡿࡇࡼࡾࠊ⚄⤒ⱆ⣽⬊⭘ࢫ ࢡ࣮ࣜࢽࣥࢢࡢデ᩿ࡢ⢭ᗘࡢྥୖࡸࠊヲ⣽࡞〓Ⰽ⣽⬊⭘ࡢ᳨ᰝࡢ୍ຓ࡞ࡿࡇࡀᮇᚅࡉ ࢀࡿࠋࡉࡽࠊ2 ⭘⒆ࡢྜేࡀ࠶ࡿⅬࡽࡶ 5 ✀ࢆྠศᯒࡍࡿࡇࡣ㠀ᖖ᭷⏝࡛ ࠶ࡿࠋᮏ◊✲࡛ࡣࠊᏛⓗᛶ㉁ࡀࡁࡃ␗࡞ࡿ VMAࠊHVAࠊMNࠊNMN Cr ࡢ LC-MS/MS ࡼࡿ▷㛫ྠศᯒἲࢆ᳨ウࡋࡓࠋ ࠙᪉ἲࠚ࣒࢝ࣛࡣ YMC Triart-C18 (150 × 2.0 mm, 3 Pm; YMC)ࠊ⛣ື┦ 10 mM 㓑㓟ࣥࣔࢽ ࣒࢘⁐ᾮࢭࢺࢽࢺࣜࣝ㸦ࢢࣛࢪ࢚ࣥࢺἲ㸧ࢆ⏝࠸ࡓࠋᒀ 10 ml ᑐࡋ 6N ሷ㓟ࢆ 100 Pl ຍ࠼ࡓࡶࡢࢆ 10 ಸᕼ㔘ࡋࠊ㔞ࢆ 100 Pl ㄪ〇ࡋࡓᚋࠊ2 Pl ࢆ ᐃࡋࡓࠋ࡞࠾ࠊෆᶆ‽≀ ㉁ࡣ㔜Ỉ⣲࡛ᶆ㆑ࡉࢀࡓ VMA-d3ࠊHVA-d3ࠊMN-d3ࠊNMN-d3 ࠾ࡼࡧ Cr-d3 ࢆ⏝࠸ࡓࠋ ࠙⤖ᯝ࣭⪃ᐹࠚVMAࠊHVAࠊMNࠊNMNࠊCr ࠾ࡼࡧෆᶆ‽≀㉁ࡣ 7 ศ௨ෆศᯒྍ⬟࡛࠶ ࡗࡓࠋᖖேᒀ࠾ࡅࡿᇶ‽್ࡢ⠊ᅖ࠾࠸᳨࡚㔞⥺ࢆసᡂࡋࡓࡇࢁࠊ┦㛵ಀᩘ 0.9951 㹼0.9997 ࡢⰋዲ࡞┤⥺ᛶࡀᚓࡽࢀࡓࠋ᳨㔞⥺ࡢ⠊ᅖෆ 3 ⃰ᗘ࠾࠸࡚ῧຍᅇヨ㦂ࢆ⾜ࡗ ࡓ⤖ᯝࠊCr ࡣ࠸ࡎࢀࡶ CV 3.6% ௨ୗ࡛࠶ࡗࡓࡀࠊࡢ 4 ✀ࡣ༑ศ࡞⢭ᗘࡀᚓࡽࢀ࡞ࡗࡓ ࡓࡵࠊᘬࡁ⥆ࡁศᯒἲࡢ᳨ウࢆຍ࠼ࡿࠋLC-MS/MS ἲࡼࡿ 5 ✀ࡢྠศᯒࡣࠊ᳨య᳨ᰝ ࡢ▷㛫ࡢほⅬࡽ᭷⏝⪃࠼ࡿࠋ⌧ᅾࠊ⡆౽࡞ᅛ┦ᢳฟἲࡶど㔝ධࢀ᳨ウࢆ㐍ࡵ࡚ ࠾ࡾࠊ⢭ᗘ⌧ᛶࡢ㧗࠸ศᯒἲࢆ☜❧ࡍࡿணᐃ࡛࠶ࡿࠋ ́́ P-10 LC-MS/MS ࡼࡿᒀ୰ࢥࣝࢳࢰ࣮ࣝཬࡧࢥࣝࢳࢰࣥࡢ Į- / ȕ-Ỉ㓟௦ㅰ≀ࡢ ศ㞳ᐃ㔞ἲ ᶓᕝᙲ᭸ 1, ඵ㒓㞞ᘯ 1, ᖹ㔝Ⰻᖹ 1, ⣽⏣㤶⧊ 2, ▼ኵ 2, ྂ⏣ 㝯 1, ᰘᓮᾈ⨾ 1 1 ᮾி⸆⛉Ꮫ⸆Ꮫ㒊, 2 ᮥᯘᏛಖᏛ㒊 Separation and quantitative determination of Į- and ȕ-hydroxylated metabolites of cortisol and cortisone in human urine by LC-MS/MS Akitomo Yokokawa1, Masahiro Hachigo1, Ryohei Hirano1, Kaori Hosoda2, Kazuo Ishii2, Takashi Furuta1, and Hiromi Shibasaki1 1 School of Pharmacy, Tokyo University of Pharmacy and Life Sciences 2 Faculty of Health Sciences, Kyorin University ࠙┠ⓗࠚࢥࣝࢳࢰ࣮ࣝࡣࠊCYP3A ࡼࡾ ȕ-ࣄࢻࣟ࢟ࢩࢥࣝࢳࢰ࣮ࣝ ȕ-OHF) ❧య␗ᛶ య Į-OHF ௦ㅰࡉࢀࡿࠋ₇⪅ࡽࡣࠊ⾑୰ࢥࣝࢳࢰ࣮ࣝ⃰ᗘ-㛫᭤⥺ୗ㠃✚ᒀ୰ ȕ-OHF ἥ㔞ࡽ⟬ฟࡉࢀࡿࢥࣝࢳࢰ࣮ࣝ ȕ-Ỉ㓟௦ㅰࢡࣜࣛࣥࢫ (CLPȕF) ࢆᣦᶆࡋࡓ CYP3A άᛶホ౯ἲࢆ㛤ⓎࡋࡓࠋࡉࡽࠊHPLC-UV ࡛ ȕ-OHF Į-OHF ࢆศ㞳ᐃ㔞ࡋࠊ CLPĮ) ࡀ CLPȕ) ࡢ⣙ 1/10 ࡛࠶ࡿࡇࢆ᫂ࡽࡋࡓࠋ୍᪉ࠊࢥࣝࢳࢰ࣮ࣝࡣ 1ȕ-HSD ࡼࡾࢥࣝࢳࢰࣥ┦ኚࡍࡿࡓࡵࠊCYP3A άᛶホ౯ࡣ ȕ-ࣄࢻࣟ࢟ࢩࢥࣝࢳࢰࣥ ȕ-OHE)ࡶ⪃៖ࡍࡁࡢሗ࿌ࡀ࠶ࡿࡀࠊĮ-OHE ࡢゝཬࡣ࡞࠸ࠋᮏ◊✲࡛ࡣࠊࢥࣝࢳࢰ ࣮ࣝ 6 Ỉ㓟௦ㅰᇶ࡙ࡃ CYP3A άᛶホ౯ࡢྛ 6 Ỉ㓟௦ㅰ≀ࡢᐤࡢ᳨ウࢆ┠ⓗ ࠊLC-MS/MS ࡼࡿᒀ୰ Į-OHF, ȕ-OHF, Į-OHE, ȕ-OHE ࡢศ㞳ศᯒἲࡢ㛤Ⓨࢆ⾜ࡗࡓࠋ ࠙᪉ἲࠚ LC-MS/MS ࡣ TSQ Quantum Ultra (Thermo Fisher Scientific) ࢆ⏝࠸ࡓࠋ ࣒࢝ࣛࡣ Kinetex C8 (phenomenex; 75×3.0 mm I.D., ȝP ࡋࠊෆᶆ‽≀㉁ࡣ ȕ-OHF-2H4 Į-OHF-2H4 ࢆ⏝࠸ࡓࠋ⛣ື┦ࡣ 0.2%ࢠ㓟+10 mM 㓑㓟ࣥࣔࢽ࣒࢘Ỉ⁐ᾮ࣓ࢱࣀ㸫ࣝࢆ⏝࠸ࠊࢢ ࣛࢪ࢚ࣥࢺἲ࡛ ᐃࡋࡓࠋESI (negative-ion mode) ἲ࡛ࡣࠊȕ-OHF Į-OHF ࡢ precursor ion product ion (ࢠ㓟ຍయ) ࡋ࡚ m/z 423 m/z 347 ࢆタᐃࡋࠊȕ-OHE Į-OHE ࡛ ࡣ m/z 421 m/z 345 ࢆタᐃࡋࡓࠋᒀࡢᢳฟࡣ Sep-Pak C18 Plus ࢆ⏝࠸ࡓࠋ ࠙⤖ᯝ࣭⪃ᐹࠚࢢࣛࢪ࢚ࣥࢺἲࡼࡿࢥࢩ࢙࣒ࣝ࢝ࣛ C8 ࡛❧య␗ᛶయࢆศ㞳ࡋࡓࠋȕ-OHF Į-OHF ࡢಖᣢ㛫ࡣ 4.1, 4.7 min (Rs=2.5)ࠊ ȕ-OHE Į-OHE ࡛ࡣ 6.4, 7.1 min (Rs=3.1) ࡛ ࠶ࡗࡓࠋࡇࢀࡲ࡛ᒀ୰ Į-OHE ศᯒࡢሗ࿌ࡣ࡞࠸ࡀࠊ❧య␗ᛶయ ȕ-OHE ࡢ 1/10 ⛬ᗘ┦ ᙜࡍࡿࣆ࣮ࢡࢆ☜ㄆࡋࡓࠋᮏἲࡢ⢭ᗘ࣭⌧ᛶࡣࠊȕ-OHFࠊĮ-OHF ࡛ࡣ┦ᑐㄗᕪࡀ 7.3% ௨ෆࠊኚືಀᩘࡀ 2.0%௨ෆⰋዲ࡛࠶ࡗࡓࠋȕ-OHF-2H4 ࢆෆᶆ‽≀㉁ࡋࡓࠊȕ-OHE Į-OHE ࡢᐃ㔞࡛ࡣ┦ᑐㄗᕪࡀࡁࡃࠊ⌧ᅾࠊᑐᛂࡍࡿᏳᐃྠయᶆ㆑యࢆྜᡂ୰࡛࠶ࡿࠋ ́́ P-11 Dried Blood Spot(DBS)ᒀ୰ࡢከ⢾㢮ࢹ࢟ࢫࢺࣛࣥཬࡧࣄࢻࣟ࢟ࢩ࢚ࢳࣝࢫࢱ ࣮ࢳࡢศᯒ ᑠᓥ㯞ᐇ 1, ᒸ㔝㞞ே 1, ᅵ⫧⨾ᬛᏊ 2, 㝜ᒣಙ 1 1 ᰴᘧ♫ LSI ࣓ࢹ࢚ࣥࢫ ࣥࢳࢻ࣮ࣆࣥࢢࣛ࣎ࣛࢺ࣮ࣜ 2 ᅜ❧ࢫ࣏࣮ࢶ⛉Ꮫࢭࣥࢱ࣮ ࣓ࢹ࢝ࣝࢭࣥࢱ࣮ Analysis of polysaccharides dextran and hydroxyethylstarch in dried blood spot and urine Asami Kojima1, Masato Okano1, Michiko Dohi 2, Shinji Kageyama1 1 Anti-Doping Laboratory, LSI Medience Corporation 2 Medical Centre, Japan Institute of Sports Sciences ࠙┠ⓗࠚ㏆ᖺࠊᣢஂຊྥୖࢆពᅗ࢚ࣜࢫ࣏࢚ࣟࢳࣥࡢ⏝ࡸ㍺⾑ࡼࡾ㉥⾑⌫ࢆቑຍࡉࡏ ࡿࢻ࣮ࣆࣥࢢࡀ➇ᢏࢫ࣏࣮ࢶ࠾࠸࡚ࡁ࡞ၥ㢟࡞ࡗ࡚࠸ࡿࠋࡇࡢࡼ࠺࡞⾑ᾮࢻ࣮ࣆࣥ ࢢᑐࡋ࡚ࠊ➇ᢏ⪅ಶேࡢ࣊ࣔࢢࣟࣅࣥ㔞࡞ࡢ⾑ᾮࣃ࣓࣮ࣛࢱ࣮ࢆ⥅⥆ⓗ ᐃࡋࠊࡑ ࡢኚࡽࢻ࣮ࣆࣥࢢࢆ᳨▱ࡍࡿᡭἲ㸸Athlete Biological Passport (ABP)᳨ᰝࡀᐇࡉࢀ࡚࠸ ࡿࠋࡲࡓࠊ⾑ᅽࡢ⥔ᣢࡸᾋ⭘ࡢ⒪⏝ࡉࢀࡿ⾑₢ቑ㔞࡛࠶ࡿࣄࢻࣟ࢟ࢩ࢚ࢳࣝࢫࢱ ࣮ࢳ (HES)ཬࡧࢹ࢟ࢫࢺࣛࣥ(DEX)ࡣࠊ⾑ᾮࡢᕼ㔘ຠᯝࡀ࠶ࡿࡓࡵࠊ⾑ᾮࢻ࣮ࣆࣥࢢࡢ㞃ⶸ ࡋ࡚⚗Ṇ⸆≀ᣦᐃࡉࢀ࡚࠸ࡿࠋ⌧ᅾࠊࡇࢀࡽࡢ⾑₢ቑ㔞ࡣࠊᒀヨᩱࡼࡿࢻ࣮ࣆ ࣥࢢ᳨ᰝࡼࡾ᳨ฟࡋ࡚࠸ࡿࡀࠊABP ᳨ᰝ࠾࠸࡚ࡣࠊ᥇ᒀࢆకࢃ࡞࠸ࡇࡀከ࠸ࠋࡑࡢ ࡓࡵࠊ⾑ᾮヨᩱࡽࡶ⾑₢ቑ㔞ࡀ᳨ฟ࡛ࡁࡿࡇࡀᮃࡲࢀࡿࠋᖺࠊᡃࠎࡣࠊ⇱⾑ᾮ ࢫ࣏ࢵࢺ㸦Dried Blood Spot: DBS㸧ࡢ⏝ࡀ⯆ዧࡢࢻ࣮ࣆࣥࢢ᳨ᰝ࠾࠸࡚᭷⏝࡛࠶ࡿ ሗ࿌ࡋࡓࠋࡑࡇ࡛ᅇࡣࠊHES ཬࡧ DEX ࠾࠸࡚ࡶ DBS ࢆ⏝ࡋࡓศᯒἲࢆ㐺⏝ࡍࡿ ࢆ᳨ウࡋࡓࠋᮏⓎ⾲࡛ࡣࠊྛ⸆ࡢᢞࡀ ABP ࠼ࡿᙳ㡪ࡘ࠸࡚ࡶሗ࿌ࡍࡿࠋ ࠙᪉ἲࠚDBS㸸⾑ᾮ ȝ/ ࢆ DMPK-C IND ࣮࢝ࢻࢫ࣏ࢵࢺࡋࠊᐊ ᅛᚋࠊ࣐ࢡࣟࣃࣥ ࢳ࡛ᢤࡁྲྀࡾࠊෆ㒊ᶆ‽⁐ᾮ㸦ȕ-cyclodextrin㸧200 ȝ/ ࢆῧຍࡋࠊᨩᢾࡋࡓࠋࡑࡢᚋࠊ㉸㡢Ἴ ᢳฟࢆ⾜ࡗࡓࠋᒀ᳨య㸸ᒀ᳨య 10 ȝ/ ࠊෆ㒊ᶆ‽⁐ᾮ 190 ȝ/ ࢆῧຍࡋࠊᨩᢾࡋࡓࠋ࠸ࡎ ࢀࡢࢧࣥࣉࣝࡶ㉸㐲ᚰศ㞳ࢆ⾜࠸ࠊୖΎ 2 ȝ/ ࢆ UPLC/MS/MS (Waters) ὀධࡋࡓࠋ ࠙⤖ᯝ࣭⪃ᐹࠚDBS ࢆ⏝࠸ࡓ⾑ᾮヨᩱࡼࡿࠊHES ཬࡧ DEX ࡢศᯒ᪉ἲࢆ☜❧ࡋࡓࠋᒀヨ ᩱẚ㍑ࡋ࡚ࡶศᯒ⢭ᗘ᳨࣭ฟឤᗘࡶⰋዲ࡛࠶ࡗࡓࠋᢞヨ㦂࡛᥇ྲྀࡋࡓ⾑ᾮヨᩱࡽࡣ ᢞᚋ 48 㛫ࡲ࡛ࡢ᳨ฟࡀྍ⬟࡛࠶ࡾࠊ⾑ᾮࣃ࣓࣮ࣛࢱ࣮ᙳ㡪ࢆཬࡰࡍ㛫ᖏ࠾࠸࡚ Ⰻዲ᳨ฟࡀྍ⬟࡛࠶ࡗࡓࠋᚋࠊ᥇ᒀࢆᐇࡋ࡞࠸ ABP ᳨ᰝ࠾࠸࡚ࡶࠊ⾑ᾮヨᩱ㸦DBS㸧 ࢆࣃ࣓࣮ࣛࢱ࣮ኚືࡢ㞃ⶸࢆ┠ⓗࡋࡓ⾑₢ቑ㔞ࡢ᳨ฟ㐺⏝ࡍࡿࡇࡀྍ⬟࡞ࡿࠋ ́́ P-12 ℐ⣬⾑ࢆ⏝࠸ࡓ᪂⏕ඣࡢࢡࣞࢳࢽࣥࢫࢡ࣮ࣜࢽࣥࢢ᳨ᰝ◊✲ ୰㔝 ඃ 1, ୖᮧ 2, ୰ᓥⴥᏊ 3, ఀ⸨ဴဢ 3, ᮏ⏣㞞ᩗ 4, 㰻⸨ఙ 1 1 ྡྂᒇᕷ❧Ꮫᑠඣ⛉, 2 ࠶࠸ࡕᑠඣಖ་⒪⥲ྜࢭࣥࢱ࣮⭈⮚⛉, 3 ⸨⏣ಖ⾨⏕Ꮫᑠ ඣ⛉, 4 ᮾி㒔❧ᑠඣಖ་⒪ࢭࣥࢱ࣮ Newborn mass screening using liquid chromatography-tandem mass spectrometry for congenital abnormalies of kidney and urinary tract. Masaru Nakano1, Osamu Uemura 2, Yoko Nakajima3, Tetsuya Ito3, Masataka Honda4, Shinji Saitoh1, 1 Department of Neonatology and Pediatrics, Nagoya City University Graduate School of Medical Sciences 2 Pediatric Nephrology Aichi Children's Health and Medical Center 3 Department of pediatrics, Fujita Health University 4 Tokyo Metropolitan Children's Medical Center ࠙┠ⓗࠚඛኳᛶ⭈ᒀ㊰ᝈ(congenital anomalies of kidney and urinary tract:௨ୗ CAKUT) ࡣዷፎࡢ 0.5%ㄆࡵࡽࢀࠊᑠඣ៏ᛶ⭈ࡢཎᅉࡋ࡚᭱ࡶከ࠸ࠋࡋࡋ CAKUT ࡛ࡣ㏆ ᒀ⣽⟶࠾ࡅࡿ྾㞀ᐖࡼࡿᕼ㔘ᒀࢆ࿊ࡍࡿࡇࡀከࡃࠊ⌧ᅾ⾜ࢃࢀ࡚࠸ࡿࢸ࣮ࣉ ἲ࡛ࡢⓎぢࡣᅔ㞴࡛࠶ࡿࠋᅇᡃࠎࡣࢱࣥࢹ࣒࣐ࢫἲࢆ⏝࠸ࡓ᪂⏕ඣ࣐ࢫࢫࢡ࣮ࣜࢽࣥࢢ ྠࡌᡭἲ࡛ℐ⣬⾑ࡽࢡࣞࢳࢽࣥ㸦Cr㸧ࢆᐃ㔞ࡋࠊ᪂⏕ඣ࠾ࡅࡿℐ⣬⾑ Cr ್ࡢᇶ‽ ್సᡂࢆ⾜࠺ࡇࡋࡓࠋ ࠙᪉ἲࠚࢁ⣬ࡽࡢᢳฟ࡞ ᐃ㛵ࢃࡿᡭᢏࡣ᪂⏕ඣࢱࣥࢹ࣒࣐ࢫࢫࢡ࣮ࣜࢽࣥࢢ‽ࡌ ࡚タᐃࡋࡓࠋℐ⣬⾑ࡽࡢ Cr ್㸦ℐ⣬⾑ Cr ್㸧㏻ᖖࡢ⾑Ύ Cr ್ࡢ┦㛵ࢆぢࡿࡓࡵࠊ ᑠඣ 100 ேࡢ᳨య࡛ℐ⣬⾑ Cr ್⾑Ύ Cr ್ࢆẚ㍑ࡋࡓࠋࡇࡢ┦㛵ࢆ☜ㄆࡋࡓᚋࠊᐇ㝿 ᪂⏕ඣ᳨య 177 ᳨య㸦⏨ඣ 92 ᳨యࠊዪඣ 85 ᳨య㸧࡛ࡢ ᐃࢆ⾜ࡗࡓࠋᮏ◊✲ࡣྡྂᒇ ᕷ❧Ꮫ⌮ጤဨ࡛ᢎㄆࢆཷࡅ࡚࠸ࡿࠋ ࠙⤖ᯝࠚ ᑠඣ 100 ேࡢ᳨య࡛ℐ⣬⾑ Cr ್⾑Ύ Cr ್ࢆẚ㍑ࡋࡓࡇࢁࠊ ℐ⣬⾑ Cr ್=0.56 ⾑Ύ Cr ್㸦R㸰=0.87㸧Ⰻ࠸┦㛵ࡀᚓࡽࢀࡓࠋ᪂⏕ඣℐ⣬⾑ Cr ್ࢆ ᐃࡋࡓࡇࢁ㠀ṇ つศᕸ࡛୰ኸ್ 0.221mg/dL㸦0.191,0.268㸧࡛࠶ࡗࡓࠋ⏨ዪᕪࡣㄆࡵ࡞ࡗࡓࠋ ࠙⪃ᐹࠚℐ⣬⾑ࡢ Cr ࢫࢡ࣮ࣜࢽࣥࢢࡣ᪂⏕ඣᮇ CAKUT ࢆⓎぢࡍࡿࢫࢡ࣮ࣜࢽࣥࢢ᪉ἲ ࡋ࡚⏝ྍ⬟࡛࠶ࡿ⪃࠼ࡓࠋࡉࡽ᳨యᩘࢆ㔜ࡡ⤫ィᏛⓗ᳨ウࢆຍ࠼ࡿ࡛ࠊ⢭ᗘࡢ㧗 ࠸࢝ࢵࢺ࢜ࣇ್ࢆసᡂࡋ࡚ࠊࢫࢡ࣮ࣜࢽࣥࢢᑟධࢆ᳨ウࡋࡓ࠸ࠋ ́́ P-13 ⭠⒴ᝈ⪅∎୰ගᏛ␗ᛶయ௦ㅰ≀ࡢศᯒ すᑿඃử, 㛬 ಇဴ, ㎘ᮌሀ୍㑻, Ỉ㔝 ึ, ㇏ᒸṇ 㟼ᒸ┴❧Ꮫ⸆Ꮫ㒊 Analysis of the chiral metabolites in fingernail of colorectal cancer patients Yuta Nishio, Jun Zhe Min, Kenichiro Todoroki, Hajime Mizuno, Toshimasa Toyo’oka School of pharmaceutical Sciences, University of Shiuoka ࠙┠ⓗࠚ⭠⒴ࡣࠊ᪩ᮇⓎぢࡼࡿ⏕Ꮡ⋡ࡀᴟࡵ࡚㧗ࡃࠊⓎ๓ࡢ᪩ᮇⓎぢཬࡧࡑࡢデ᩿ἲ ࡀᙉࡃồࡵࡽࢀ࡚࠸ࡿࠋࡋࡋࠊᚑ᮶ࡢ⭠⒴ࡢࣂ࣐࣮࣮࢜࢝ࡣ᪩ᮇデ᩿ࡀᅔ㞴࡛࠶ࡿ ࡇࡀၥ㢟どࡉࢀ࡚࠸ࡿࠋ୍᪉ࠊ㏆ᖺࣄࢺ⾑୰࣓ࢱ࣮࣒࣎ࣟゎᯒࡽ⭠⒴᪩ᮇᛂࢆ ♧ࡍ᪂つࣂ࣐࣮࣮࢜࢝ೃ⿵≀ࡋ࡚ 2-Hydroxy butyrate (D-HB)ࠊAspartic acid (Asp)ࠊ Kynurenine (Kyn)ࠊCystamine (Cys)ࡀⓎぢࡉࢀࠊࡑࡢ᭷⏝ᛶࡀ♧၀ࡉࢀࡓ[1]ࠋࡇࢀࡽࡢ᪂つࣂ ࣐࣮࣮࢜࢝ೃ⿵≀ࡣ࢟ࣛࣝ୰ᚰࢆᣢࡘྜ≀ࡶ࠶ࡿࡀࠊࡑࡢගᏛ␗ᛶయࡢ᭷⏝ᛶࡘ࠸ ࡚ࡣࡲࡔ࡛᫂࠶ࡿࠋࡑࡇ࡛ᡃࠎࡣࠊࡇࢀࡽࡢ࢟ࣛࣝ୰ᚰࢆᣢࡘ᪂つࣂ࣐࣮࣮࢜࢝ೃ⿵ ≀╔┠ࡋࡓࠋᅇ⏝࠸ࡿࣄࢺ∎ࡣࠊỗ⏝ࡢ⾑ᾮࡸᒀ␗࡞ࡾࠊ㠀くⓗ᥇ྲྀཬࡧಖᏑ ࡀᐜ࡛᫆࠶ࡾࠊ㛗ᮇ㛫ࡢ⏕యሗࢆᫎࡍࡿࡇࡀ࡛ࡁࠊ៏ᛶᝈデ᩿⏝ࡢ᪂つ⏕యヨᩱ ࡋ࡚ὀ┠ࡉࢀ࡚࠸ࡿ[2]ࠋࡑࡇ࡛ᡃࠎࡣ LC-ESI-MS/MS ࢆ⏝࠸࡚ࠊ⭠⒴ᝈ⪅∎୰ࡢ࢟ࣛࣝ ௦ㅰ≀ࡢ୍ᩧศᯒࢆヨࡳࡓࠋ ࠙᪉ἲࠚㄏᑟయヨ⸆ࡋ࡚ (S)-DBD-Pro-COCl ࢆ⏝࠸ࠊD-HBࠊAspࠊKynࠊCys ࢆᶆ㆑ࡋࠊ LC-ESI-MS/MS ୍࡛ᩧศᯒࢆ⾜ࡗࡓࠋ᥇ྲྀࡋࡓࣄࢺ∎ࡣࠊὙίᚋ⢊○⛗㔞ࡋࠊ௦ㅰ≀ࢆᢳฟ ࡋࠊㄏᑟయ䜢⾜䛳䛯䚹LC ⨨ࡣᓥὠ〇సᡤ〇ࡢ Nexera X2 ࢆ⏝࠸ࠊ࣒࢝ࣛࡣ Imtakt ♫〇 ࡢ Cadenza CD-C18 HT (3 Pm, 150×3 mm I.D.) ࠊ⛣ື┦ࡣ 10 mM HCOONH4 ྵ᭷ H2O ཬࡧ 0.1% HCOOH ྵ᭷ CH3CN ࢆ⏝࠸ࡓࠋ㉁㔞ศᯒィࡣࠊᓥὠ〇సᡤ〇ࡢ LCMS-8040 ࢆ⏝࠸ࠊ ࢜ࣥἲࡣ ESI+࢜ࣥἲ࡛ࠊMRM ࣮ࣔࢻ࡚ ᐃࢆ⾜ࡗࡓࠋ ࠙⤖ᯝ࣭⪃ᐹࠚ㸲✀ࡢ௦ㅰ≀ࢆ(S)-DBD-Pro-COClࢆ⏝࠸ࠊ᭱㐺࡞ㄏᑟయᛂ ᗘࠊᛂ 㛫࡛ㄏᑟయࢆ⾜࠺ࡇ࡛࢟ࣛࣝ୰ᚰࢆ᭷ࡍࡿD-HBࠊAspࠊKyn ࢆࢪࢫࢸ࣐࣮ࣞ࢜యᙧ ᡂࡉࡏࠊC18 ࣒࡛࢝ࣛගᏛ␗ᛶయࢆ 20 min ௨ෆⰋዲ࡞ศ㞳 (Rs>1.57)ࢆ㐩ᡂࡍࡿࡇࡀ࡛ ࡁࡓࠋᢳฟ⁐፹ࡋ࡚࣓ࢱࣀ࣮ࣝࠊࢺ࢚ࣜࢳ࣑ࣝࣥΰྜ⁐ᾮࢆ⏝࠸ࠊ∎୰ࡽึࡵ࡚ Asp D-HB ࡢගᏛ␗ᛶయࢆᢳฟࡍࡿࡇࡀ࡛ࡁࡓࠋ᪥ෆཬࡧ᪥㛫ኚືࡣ 4.54%௨ୗ࡛࠶ࡾࠊῧ ຍᅇ⋡ࡣ 81.12-113.84%࡛࠶ࡗࡓࠋᖖே 20 ேࠊ⭠⒴ᝈ⪅ 23 ேࡢ∎ࢆศᯒࡋࡓࡇࢁࠊ ⭠⒴ᝈ⪅ࡢ AspࠊD-HB ࡢᐃ㔞್ࠊࣆ࣮ࢡ㠃✚ࡢ D/L ẚࡣඹୖ᪼ഴྥࡀ♧ࡉࢀࡓࠋࡑࡢ ᭷ពᕪࡘ࠸࡚ࡶᅇሗ࿌ࡍࡿணᐃ࡛࠶ࡿࠋ ࠙ཧ⪃ᩥ⊩ࠚ -----------------------------------------------------------------------------------------------------------[1] Shin Nishiumi et al., PLoS ONE , (2012) 7, e40459. [2] J.Z. Min et al., J. Chromatogr. B, (2011) 879, 3220-3228. ́́ P-14 UPLC-MS/MS ࡼࡿࣆ࣑ࣜࢪࣥሷᇶ௦ㅰ≀ࡢᐃ㔞ࡼࡿࣆ࣑ࣜࢪࣥ௦ㅰ␗ᖖ ࢫࢡ࣮ࣜࢽࣥࢢ ๓⏣ᗣ༤ 1, ⓙᕝ┿㔛 1, ୰ᓥⴥᏊ 2, ᚋ⸨ెዉ 1, ᇼ⏣♸ᚿ 1, ∦ᒸᬛဢ 3, ᕝฟ⩏ᾈ 1, ఀ⸨ ဴဢ 2, ᮌᮧဴ 1,3 1 ྡྂᒇᕷ❧Ꮫ Ꮫ㝔⸆Ꮫ◊✲⛉, 2 ⸨⏣ಖ⾨⏕Ꮫ ་Ꮫ㒊 ᑠඣ⛉ 3 ྡྂᒇᕷ❧Ꮫ Ꮫ㝔་Ꮫ◊✲⛉ Determination of pyrimidine metabolites for inborn error of pirimidine metabolism by UPLC-MS/MS Yasuhiro Maeda1, Mari Minagawa1, Yoko Nakajima2, Kana Gotoh1, Yuji Hotta1, Tomoya Kataoka3, Yoshihiro Kawade1, Tetsuya Ito2, Kazunori Kimura1,3 1 Graduate School of Pharmaceutical Sciences, Nagoya City University, 2 School of medicine, Fujita Health University, 3 Graduate School of Medical Sciences, Nagoya City University ࠙┠ⓗࠚ᰾㓟ሷᇶ࡛࠶ࡿ uracil ࠾ࡼࡧ thymine ࡣ dihydropyrimidine dehydrogenase (DPDase), dihydropirimidinase (DHPase), ureidopropionase (UPase)ࡢྛ㓝⣲ࡼࡾ㸱ẁ㝵␗௦ㅰࡉࢀ㸪 ȕ-Alanine (BAL) ࠾ࡼࡧ ȕ-Aminoisobutyrate (BAIB)ࢆ⏕ᡂࡍࡿࠋྛ㓝⣲ࡢḞᦆࡢࢫࢡ࣮ࣜ ࢽࣥࢢࡢࡓࡵ㸪ᣦᶆ࡞ࡿ㓝⣲ࡢᇶ㉁ࢆ UPLC-MS/MS ࡛ศᯒࡍࡿᡭἲࢆ☜❧ࡋ㸪ᒀ୰௦ㅰ ≀ࢆศᯒࡋࡓࠋ ࠙᪉ἲࠚࢥࣥࢺ࣮ࣟࣝ࠾ࡼࡧ UPase Ḟᦆᝈ⪅ࡢᒀࢆ㸪ෆ㒊ᶆ‽≀㉁ࢆྵࡴỈ࡛ 50%ᕼ㔘 ᚋ 㸪 UPLC-MS/MS (Waters) ᑟ ධ ࡋ 㸪 uracil ࡑ ࡢ ௦ ㅰ ≀ ࡛ ࠶ ࡿ dihydrouracil (DHU), ȕ-ureidopropionate (UP), BAL ࠾ࡼࡧ thymine ࡑࡢ௦ㅰ≀࡛࠶ࡿ dihydrothymine (DHT), ȕ-ureidoisobutyrate (UIB), BAIB ࢆ୍ᩧᐃ㔞ࡋࡓࠋࡉࡽ㸪ᒀ୰௦ㅰ⏘≀⃰ᗘࡢᇶ‽࡞ࡿ creatinine (cre)ࢆྠ ᐃࡋࡓࠋUPLC ࣒࢝ࣛ Acquity UPLC HSS T3㸦2.0 × 150 mm, Waters㸧ࢆ⏝࠸㸪⛣ື┦ࢆ 0.1%ࢠ㓟Ỉ⁐ᾮ 100% ࡽࢭࢺࢽࢺ࡛ࣜࣝ gradient ศᯒࡋࡓࠋ ࠙⤖ᯝࠚ ࢥࣥࢺ࣮ࣟࣝ (n = 50) ࠾࠸࡚ࡣ uracil, DHU, UP, BAL ࡣ 4.8-8.5 ± 5.5-7.1 (ave, ± SD) μmol/mmol·cre, thymine, DHT, UIB ࡣ 1.1-1.3 ± 1.3-2.7 μmol/mmol·cre ࡛࠶ࡗࡓࡀ㸪BAIB 418 ± 620 μmol/mmol·cre,ಶேᕪࡀ㠀ᖖࡁࡗࡓࠋUPase Ḟᦆᝈ⪅ (n= 3)ࡢᒀࡽࡣ㸪 UPase ࡢᇶ㉁࡛࠶ࡿ UP UIB ࡀࢥࣥࢺ࣮ࣟࣝࡢ 200 ಸ௨ୖ᳨ฟࡉࢀࡓࠋ୍᪉ UPase ࡢ௦ㅰ ≀ ࡛ ࠶ ࡿ BAL ࡣ ࢥ ࣥ ࢺ ࣟ ࣮ ࣝ ᕪ ࡣ ぢ ࡽ ࢀ ࡞ ࡗ ࡓ ࠋ BAIB ࡘ ࠸ ࡚ ࡣ 1.0-3.0 μmol/mmol·cre పୗഴྥ࡛࠶ࡗࡓࠋ ࠙⪃ᐹࠚUPLC-MS/MS ࡼࡿࣆ࣑ࣜࢪࣥ௦ㅰ␗ᖖࡢࢫࢡ࣮ࣜࢽࣥࢢࡣ㸪᳨యࡢᒀࢆ↹㞧࡞ ๓ฎ⌮ࢆࡏࡎ㸪ᐜ᫆⾜࠺ࡇࡀྍ⬟࡛࠶ࡿࠋUPase Ḟᦆ࡛ࡣᇶ㉁࡛࠶ࡿ UP, UIB ࡀ㧗⃰ ᗘ᳨࡛ฟࡉࢀデ᩿᭷⏝࡛࠶ࡗࡓࠋࡲࡓ㸪⏕ᡂ≀ࡢ BAIB ࡀపୗഴྥ࡛࠶ࡿࡇࡀ⚄⤒ ≧ࢆ࿊ࡍࡿ୍ᅉ࡛࠶ࡿྍ⬟ᛶࡀ♧၀ࡉࢀࡓࠋ ́́ P-15 ࣥࢻ࢟ࢩࣝ◲㓟ࡣṧᏑ⭈ᶵ⬟ࡢపୗࡶ⾑୰✚ࡋ࣑࢘ࣞࢵࢡࢧࣝࢥ ࣌ࢽ㛵ಀࡍࡿ బ⸨ᜨ⨾Ꮚ 1,2, ᳃ ᘓᩥ 1, 㕥ᮌள㔛Ἃ 1, Ⳣཎ┿ᜨ 1, ⃝ዉ✑ 1, ୕ᯞ㍜ 3, ሙ㑳Ꮚ 1, Ọ⤮⌮ 1, బ⸨ ༤ 1,2, ⩚ 4, ఀ⸨㈆ 1 1 ᮾᏛᏛ㝔 ་Ꮫ⣔◊✲⛉, 2 ᮾᏛᏛ㝔 ⸆Ꮫ◊✲⛉, 3 ᮾ࣓ࢹ࣭࣓࢝ࣝ࢞ࣂ ࣥࢡᶵᵓ, 4 ಟᩥᏛᗣᰤ㣴Ꮫ㒊 Indoxyl sulfate accumulates in blood as residual renal function decreases, and is related to uremic sarcopenia Emiko Sato1,2, Takefumi Mori1, Arisa Suzuki1, Sanae Sugawara1, Nao Kurasawa1, Daisuke Saigusa3, Ikuko Oba1, Eri Naganuma1, Hiroshi Sato1,2, Toshimitsu Niwa4, Sadayoshi Ito1 1 Division of Clinical Pharmacology and Therapeutics, Graduate School of Pharmaceutical Science, Tohoku University, 2Division of Nephrology, endocrinology and Vascular Medicine, Graduate School of Medicine, Tohoku University, 3Tohoku Medical Megabank Organization, Tohoku University, 4Faculty of Health and Nutrition, Shubun University ࠙┠ⓗࠚ៏ᛶ⭈⮚࠾࠸࡚(chronic kidney disease; CKD)࠾࠸࡚ࠊ⭈ᶵ⬟ࡢపୗక࠸యෆ ✚ࡋࡓᒀẘ≀㉁ࡀཎᅉ࡞ࡾࠊ➽ῶᙅ㸦ࢧࣝࢥ࣌ࢽ㸧ࢆⓎࡍࡿ࣑࢘ࣞࢵࢡࢧ ࣝࢥ࣌ࢽࡀ╔┠ࡉࢀ࡚࠸ࡿࠋCKD ࠾࠸࡚ࢧࣝࢥ࣌ࢽࡣ⏕Ꮡ⋡ᙉ࠸ᙳ㡪ࢆ࠼ࡿࡇ ࡽண㜵ࡀ㔜せ࡛࠶ࡾࠊࡑࡢⓎᶵᗎࢆゎ᫂ࡍࡿࡇࡀᚲ㡲࡛࠶ࡿࠋᮏ◊✲ࡣ MS ࢆ⏝࠸ ࡚࣑࢘ࣞࢵࢡࢧࣝࢥ࣌ࢽⓎᶵᗎࢆゎ᫂ࡍࡿࡇࢆ┠ⓗࡋ࡚࠸ࡿࠋ ࠙᪉ἲࠚ⭡⭷㏱ᯒᝈ⪅ࢆᑐ㇟ࡋ⭡⭷ᖹ⾮ヨ㦂ࡢ⾑₢⭡⭷㏱ᯒᾮࢆᅇࡋࠊ16 ✀㢮ࡢ ᒀẘ≀㉁ࡢࢱ࣮ࢤࢵࢺ࣓ࢱ࣑࣎ࣟࢡࢫࢆ⾜࠸ࠊ⮫ᗋࣃ࣓࣮ࣛࢱ࣭యᡂศศᯒ⨨ࢹ࣮ࢱ ࡢ㛵㐃࠾ࡼࡧᒀẘ≀㉁ࡢ⭡⭷㏱㐣ᛶࡢ᳨ウࢆ⾜ࡗࡓࠋࡉࡽ➽ⱆ⣽⬊ᰴ C2C12 ࢆ⏝࠸ࠊ ᒀẘ≀㉁ࡢ㦵᱁➽ᑐࡍࡿᙳ㡪ࢆ࣓ࢱ࣑࣎ࣟࢡࢫࡢどⅬࡽ᳨ウࢆ⾜ࡗࡓࠋ ࠙⤖ᯝࠚࢱ࣮ࢵࢤࢵࢺࡋࡓᒀẘ≀㉁ࡢ࠺ࡕࠊ4 ✀㢮ࡢᒀẘ≀㉁ࡀ᭷ព⾑ᾮ୰࡛ቑຍ ࡋ࡚࠸ࡓࠋࡇࢀࡽࡢ≀㉁ࡢ࠺ࡕࣥࢻ࢟ࢩࣝ◲㓟ࠊ࣓ࢳࣝࢢࢽࢪࣥࠊࢢࢽࢪࣀࢥࣁࢡ 㓟ࡀṧᏑᶵ⬟ࡢపୗక࠸యෆ✚ࡋ࡚࠸ࡓࠋࡇࡢ࠺ࡕ⾑୰ࣥࢻ࢟ࢩࣝ◲㓟࠾ࡼࡧ࣓ ࢳࣝࢢࢽࢪࣥ⃰ᗘయෆࡢ㦵᱁➽㔞ࡢ㛵㐃ࡀ࠶ࡿࡇࡀㄆࡵࡽࢀࡓࠋC2C12 ࢆ⏝࠸ࡓ ⣽⬊ቑṪヨ㦂ࡢ⤖ᯝࡽࠊࣥࢻ࢟ࢩࣝ◲㓟ࡢࡳቑṪᢚไస⏝ࡀㄆࡵࡽࢀࡓࠋࡉࡽࣥ ࢻ࢟ࢩࣝ◲㓟Ꮡᅾୗ࠾ࡅࡿ C2C12 ࡢ࣓ࢱ࣑࣎ࣟࢡࢫࢆ⾜ࡗࡓ⤖ᯝࠊࣥࢻ࢟ࢩࣝ◲㓟ࡢ C2C12 ෆࡢྲྀࡾ㎸ࡳࡀ☜ㄆࡉࢀࠊࡉࡽ࢚ࢿࣝࢠ࣮⏘⏕㛵㐃ࡍࡿ࣑ࣀ㓟ࡢ᭷ព࡞ῶ ᑡࡀㄆࡵࡽࢀࡓࠋ ࠙⪃ᐹࠚᮏ◊✲ࡣ MS ࢆ⏝࠸ࡓ࣓ࢱ࣑࣎ࣟࢡࢫ࡛ࠊࣥࢻ࢟ࢩࣝ◲㓟ࡀ㦵᱁➽࠾ࡅࡿ࢚ࢿ ࣝࢠ࣮⏘⏕ᙳ㡪ࢆ࠼࣑࢘ࣞࢵࢡࢧࣝࢥ࣌ࢽࢆᘬࡁ㉳ࡇࡍࡇࢆ♧၀ࡋࠊࣥࢻ࢟ࢩ ࣝ◲㓟ࡢ᪂ࡓ࡞୍㠃ࢆぢฟࡋࡓࠋ ́́ P-16 ➽ࢪࢫࢺࣟࣇ࣮ᝈ⪅ࡢᒀ୰ࣉࣟࢫࢱࢢࣛࣥࢪࣥ D2 ࠾ࡼࡧ E2 ௦ㅰ≀ࡢኚື ➉ෆᩔᏊ 1, ฟⰋ༤ 2, ᯇᑿ㞞ᩥ 3 1 ⚄ᡞ⸆⛉Ꮫ, 2 ⟃ἼᏛᅜ㝿⤫ྜ╧╀་⛉Ꮫ◊✲ᶵᵓ, 3 ⚄ᡞᏛ㝔Ꮫ⥲ྜࣜࣁࣅࣜࢸ࣮ ࢩࣙࣥᏛ㒊 Fluctuations of urinary prostaglandin D2 and E2 metabolites in Duchenne muscular dystrophy patients Atsuko Takeuchi1, Yoshihiro Urade2, Masafumi Matsuo3 1 Kobe Pharmaceutical University 2 Tsukuba University, International Institute for Integrative Sleep Medicine 3 Kobe Gakuin University, The Faculty of Rehabilitation ࠙┠ⓗࠚDuchenne ᆺ➽ࢪࢫࢺࣟࣇ࣮(Duchennne muscular dystrophy : DMD)ࡣ㐍⾜ᛶࡢ➽ ⴎ⦰ࢆ࿊ࡋ㸪ᴟࡵ࡚㔜⠜࡞㑇ఏᛶᝈ࡛࠶ࡿࠋᮏᝈࡣ㸪ཎᅉ㑇ఏᏊ࡛࠶ࡿࢪࢫࢺࣟࣇ ࣥ㑇ఏᏊࡢ࢚ࢡࢯࣥḞኻ࠾ࡼࡧ㔜」➼ࡢኚ␗ࡼࡾ㸪➽ࡢ⣽⬊⭷ᙧᡂ㛵ࡍࡿࢪࢫࢺࣟ ࣇࣥࢱࣥࣃࢡ㉁ࡀḞᦆࡍࡿ㑇ఏᛶ➽ᝈ࡛࠶ࡿࠋே✀㛵ಀ࡞ࡃฟ⏕⏨Ꮚ⣙ 3,500 ே 1 ேࡢྜ࡛Ⓨࡍࡿࠋᡃࠎࡣ௨๓ࠊDMD ᝈ⪅ࡢ➽⫗࡛ࡣ⅖ࡸࣞࣝࢠ࣮࡞㛵ࡍࡿ ࣉࣟࢫࢱࢢࣛࣥࢪࣥ D2 ྜᡂ㓝⣲ࡢⓎ⌧ࡀஹ㐍ࡋ࡚࠾ࡾࠊDMD ࡢ≧デ᩿ PGD2 ࡢᒀ୰௦ㅰ ≀㸦PGDM㸧⃰ᗘࡀ᭷ຠ࡛࠶ࡿࡇࢆሗ࿌ࡋࡓࠋᅇࡣࠊPGD2 ྠᵝࡢ COX ࡢస⏝࠾ࡼࡧ PGE2 ྜᡂ㓝⣲ࡼࡾ⏕ᡂࡍࡿ PGE㸰ὀ┠ࡋࠊDMD ᝈ⪅ࡢᒀ୰ PGDM ඹ PGE2 ௦ㅰ≀㸦PGEM㸧 ࢆᐃ㔞ࡋࠊኚືࢆㄪࡓࠋ ࠙᪉ἲࠚDMD ᝈ⪅࠾ࡼࡧᖖ⪅ࡢᒀ 0.4ml PGDM-d6ࠊPGEM-d6 ࢆຍ࠼ࠊᅛ┦ᢳฟ࣒࢝ࣛ ࢆ⏝࠸࡚ PG ௦ㅰ≀ࢆᢳฟࡋࠊᢳฟᾮࢆ⃰⦰ᅛ࣭⁐ゎࡋ࡚ ᐃ⏝ヨᩱࡋࡓࠋᶆ‽ヨᩱ࣭ ᐃ⏝ヨᩱࢆ API3000 LC-MS/MS system 㐺⏝ࡋࠊ᭱㐺᮲௳ࡢࣉ࣮ࣜ࢝ࢧ࣮࠾ࡼࡧࣉࣟࢲ ࢡࢺ࢜ࣥࢆ㑅ࡧࠊSRM㸦Selected Reaction Monitoring㸧ἲ࡛ ᐃࡋࡓࠋPGDM ࡲࡓࡣ PGEM ࡑࢀࡒࢀࡢෆᶆ‽≀㉁ࡢࣆ࣮ࢡ㠃✚ẚࢆ⏝࠸࡚ᐃ㔞್ࢆ⟬ฟࡋࡓࠋࡲࡓࠊࢡࣞࢳࢽ ࣥࢆᐃ㔞ࡋࠊ⿵ṇࡋࡓࠋ ࠙⤖ᯝ/⪃ᐹࠚLC-MS/MS ࡼࡾࠊPGDM ࠾ࡼࡧ PGEM ࡣྠศ㞳ᐃ㔞ࡀྍ⬟࡛࠶ࡗࡓࠋ᳨ 㔞⥺ࡶⰋዲ࡞┤⥺ᛶࢆ♧ࡋࠊಙ㢗ᛶࡢ㧗࠸ᐃ㔞ࡀ࡛ࡁࡓ⪃࠼ࡽࢀࡓࠋᒀ୰ PGDM ⃰ᗘ࠾ ࡼࡧᒀ୰ PGEM ⃰ᗘࢆ DMD ᝈ⪅ᖖ⪅࡛ẚ㍑ࡋࡓࡁࠊDMD ᝈ⪅ࡢ᪉ࡀࡶᩘ್ࡀ 㧗ࡗࡓࠋࡋࡋ࡞ࡀࡽࠊᒀ୰ PGDM ⃰ᗘࡣ␗࡞ࡾࠊᒀ୰ PGEM ⃰ᗘࡣ DMD ࡢデ᩿ ᭷ຠ࡛࠶ࡿ᩿ᐃࡍࡿࡇࡣ㞴ࡋࡃࠊᚋࡶ᳨ウࡋ࡚࠸ࡃᚲせࡀ࠶ࡿ⪃࠼ࡽࢀࡓࠋ ́́ P-17 ᥈㔪࢚ࣞࢡࢺࣟࢫࣉ࣮ࣞ/ࢱࣥࢹ࣒㉁㔞ศᯒ(PESI/MS/MS)ࡼࡿ࣐࢘ࢫ⫢⮚ෆ ࡢ࣓ࢱ࣮࣒࣎ࣟ┤᥋ศᯒἲ㸦ࣥࢱࢡࢺ࣭࣓ࢱ࣮࣒࣎ࣟศᯒἲ㸧ࡢᵓ⠏ ᯘ ⏤⨾ 1,2, ㈈ὠ ᱇ 1,2, ᮧ⏣ 3, ཎ⨾ 1, ୰ษኴ 1, ⲡ㔝㯞⾰Ꮚ 1, 㑣㡲ẸỤ 4, ୰ᓥᏹᶞ 3, ▼ᕝဴஓ 1, ᅵᶫ ᆒ 1, ▼ 1 1 ྡྂᒇᏛᏛ㝔་Ꮫ⣔◊✲⛉, 2 ྡྂᒇᏛ㧗➼◊✲㝔, 3 ᓥὠ〇సᡤ, 4 ୰㒊Ꮫ⏕ ᗣ⛉Ꮫ㒊 Development of an intact metabolome analytical method of mouse hepatic tissue by probe electrospray ionization-tandem mass spectrometry (PESI/MS/MS) Yumi Hayashi1,2, Kei Zaitsu1,2, Tasuku Murata3, Tomomi Ohara1, Kenta Nakagiri1, Maiko Kusano1, Tamie Nakajima4, Hiroki Nakajima3, Tetsuya Ishikawa1, Hitoshi Tsuchihashi1, Akira Ishii1 1 Nagoya University Graduate School of Medicine, 2Institute for Advanced Research, Nagoya University, 3Shimadzu Corporation, 4College of Life and Health Sciences, Chubu University ࠙┠ⓗࠚෆᅉᛶ௦ㅰ≀㸦࣓ࢱ࣮࣒࣎ࣟ㸧ゎᯒ࠾࠸࡚ࡣࠊ๓ฎ⌮ࡸࢧࣥࣉࣜࣥࢢ࠾ࡅࡿ ࣂࢫࢆ㝖እࡍࡿࡇࡣ㞴ࡋࡃࠊ⏕యෆࡢ࣓ࢱ࣮࣒࣎ࣟࡢኚືࢆṇ☜⿵㊊ࡍࡿ ࡓࡵࡣࠊ࣓ࢱ࣮࣒࣎ࣟࡢ┤᥋ศᯒἲࡢᵓ⠏ࡀྍḞ࡛࠶ࡿࠋ᪂つ࢜ࣥἲ࡛࠶ࡿ᥈㔪 ࢚ࣞࢡࢺࣟࢫࣉ࣮ࣞ࢜ࣥἲ(PESI)ࡣࠊࢧࣥࣉࣝࡢ๓ฎ⌮ࡀࠕせ࡛ࠖ࠶ࡾࠊ⏕యヨᩱ୰ ࡢ࣓ࢱ࣮࣒࣎ࣟࡢ┤᥋ศᯒࡀྍ⬟࡛࠶ࡿࠋࡑࡇ࡛ᮏ◊✲࡛ࡣࠊPESI/MS/MS ࡼࡿ⏕య⤌⧊ ୰࣓ࢱ࣮࣒࣎ࣟࡢ┤᥋ศᯒἲ㸦ࣥࢱࢡࢺ࣭࣓ࢱ࣮࣒࣎ࣟศᯒἲ㸧ࢆᵓ⠏ࡋࡓࠋࡉࡽᮏ ἲࢆࠕCCl4 ㄏᑟᛶᛴᛶ⫢㞀ᐖࣔࢹ࣐ࣝ࢘ࢫࠖࡢ࣓ࢱ࣮࣒࣎ࣟゎᯒᛂ⏝ࡋࠊ᭷⏝ᛶࢆ᳨ド ࡋࡓࠋ ࠙᪉ἲࠚື≀ᐇ㦂: 6 㐌㱋 C57/BL6J ࣐࢘ࢫ CCl4 ࣮࢜ࣜࣈ࢜ࣝ⁐ᾮ(0.5 ml/kg)ࡲࡓࡣ࢜ࣜ ࣮ࣈ࢜ࣝࢆ⭡⭍ෆᢞࡋࡓ(n=5)ࠋ24 㛫ࡢ⤯㣗ᚋࠊ⫢⮚ࢆ᥇ྲྀࡋࠊᛴ㏿⤖ࡋࡓࠋ⨨㸸 ᓥὠ〇సᡤ〇 PESI ࢜ࣥ※࠾ࡼࡧ LCMS-8040 ࢱࣥࢹ࣒ᆺ㉁㔞ศᯒィࢆ⏝࠸ࡓࠋヨᩱㄪ〇㸸 ⣙ 3 mm ゅࡢ⫢⮚ษ∦ 50% EtOH Ỉ⁐ᾮࢆ㐺㔞ῧຍࡋࠊࢧࣥࣉࣝࣉ࣮ࣞࢺࢭࢵࢺࡋࡓࠋ ศᯒ᮲௳: ࣉࣟࢲࢡࢺ࢜ࣥࢫ࢟ࣕࣥ࠾ࡼࡧ SRM ࣮ࣔࢻ࡛ ᐃࢆ⾜ࡗࡓࠋᚓࡽࢀࡓ⤖ᯝࡣ SIMCA-P+ࡼࡿከኚ㔞ゎᯒ࠾ࡼࡧ R ࡼࡿ᭷ពᕪ᳨ᐃࢆ⾜ࡗࡓࠋ ᐃἲࡢ᳨ド: GC/MS/MS 㸦⨨:ᓥὠ〇సᡤ〇 GCMS-TQ8040㸧ࢆ⏝࠸࡚࣓ࢱ࣮࣒࣎ࣟゎᯒࢆ⾜࠸ࠊ⤖ᯝࢆ᳨ドࡋࡓࠋ ࠙⤖ᯝ࠾ࡼࡧ⪃ᐹࠚPESI/MS/MS ࡼࡾ 27 ✀ࡢ௦ㅰ≀ࢆྠᐃࡋࡓࠋSRM ࢺࣛࣥࢪࢩࣙࣥ࠾ ࡼࡧ ᐃ㛫➼ࢆ᭱㐺ࡋࡓᚋࠊ⫢㞀ᐖࣔࢹࣝ࠾ࡼࡧࢥࣥࢺ࣮ࣟࣝ⩌ࡘ࠸࡚⫢⮚ヨᩱࡢ ࣥࢱࢡࢺ࣭࣓ࢱ࣮࣒࣎ࣟゎᯒࢆ⾜ࡗࡓࠋPCA ࢫࢥࣉࣟࢵࢺ࠾࠸࡚ 2 ⩌ࡣⰋዲศ㞳 ࡋࠊ≉ᐃࡢᡂศ࠾࠸࡚᭷ព࡞ኚືࡀㄆࡵࡽࢀࡓࠋGC/MS/MS ࢆ⏝࠸࡚ᮏ⤖ᯝࢆ᳨ドࡋࡓ ࡇࢁࠊPESI/MS/MS ࡛ᚓࡽࢀࡓ⤖ᯝ᭷ព࡞┦㛵ࡀㄆࡵࡽࢀࡓࠋ௨ୖࡢ⤖ᯝࠊᮏἲࡣࣥ ࢱࢡࢺ࣭࣓ࢱ࣮࣒࣎ࣟゎᯒࢆྍ⬟ࡍࡿ᪂つศᯒἲࡋ࡚᭷⏝࡛࠶ࡿࡇࡀ♧ࡉࢀࡓࠋ ́́ P-18 㧗⬡⫫㣗ᦤྲྀࡀᘬࡁ㉳ࡇࡍ⭠ෆ⎔ቃࡢኚᑐࡍࡿ࣓ࢱ࣮࣒࣎ࣟゎᯒࡼࡿホ౯ すᾏ ಙ 1, ྜྷ⏣ ඃ 1,2 1 ⚄ᡞᏛᏛ㝔་Ꮫ◊✲⛉, 2 ᅜ❧◊✲㛤Ⓨἲே᪥ᮏ་⒪◊✲㛤Ⓨᶵᵓ, AMED-CREST Evaluation of high-fat diet-induced alterations in the intestinal environment by metabolome analysis Shin Nishiumi1, Masaru Yoshida1, 2 1 Kobe University Graduate School of Medicine 2 AMED-CREST, Japan Agency for Medical Research and Development ࠙┠ⓗࠚ⭠⟶ᝈ࡛࠶ࡿ⭠ࡀࢇࡣࠊࡑࡢⓎせᅉࡢࡦࡘࡀ⎔ቃᅉᏊࡢኚࡉࢀ࡚࠸ࡿࠋ ᪥ᮏ࡛ࡶࠊ㏆ᖺࠊ㧗⬡⫫㣗ࡸ㧗࣮࢝ࣟࣜ㣗࠸ࡗࡓ㣗⏕άࡢḢ⡿ࡀ㐍ࢇ࡛࠾ࡾࠊࡑࡢ⤖ ᯝࡋ࡚ࠊ⭠ࡀࢇࡢᝈ⪅ᩘࡀቑຍࡋ࡚ࡁࡓྍ⬟ᛶࡀࢃࢀ࡚࠸ࡿࠋࡲࡓࠊ᭱㏆࡛ࡣࠊ⬡ ⫫ྵ㔞ࡢከ࠸㣗ࡢᦤྲྀࡀࠊ⭠ෆ⣽⳦ྀᙳ㡪ࢆ࠼ࡿࡇࢆ♧ࡍሗ࿌ࡀ࡞ࡉࢀ࡚࠸ࡿࠋ ᮏ◊✲࡛ࡣࠊ⭠ࡀࢇ࣐࢘ࢫࣔࢹࣝࢆ⏝࠸࡚ࠊ࣓ࢱ࣮࣒࣎ࣟゎᯒࡼࡾࠊ㧗⬡⫫㣗ᦤྲྀ ࡼࡿ⭠ෆ⎔ቃࡢኚࢆࠊపศᏊ௦ㅰ≀࡛ࣞ࣋ࣝホ౯ࡋࡓࠋ ࠙᪉ἲࠚᮏ◊✲ࡣࠊ⭠ࡀࢇࣔࢹࣝࡋ࡚ᗈࡃ⏝ࡉࢀ࡚࠸ࡿ APCmin/+࣐࢘ࢫࢆ⏝࠸࡚ᐇ㦂 ࢆᐇࡋࡓࠋAPCmin/+࣐࢘ࢫࠊ㧗⬡⫫㣗ࠊ࠶ࡿ࠸ࡣࠊᑐ↷㏻ᖖ㣗ࢆᦤྲྀࡉࡏࠊ⥆ࡅ࡚ࠊ⭠ ⟶࣏࣮ࣜࣉⓎ⏕ᩘࢆィ ࡋࡓࠋࡲࡓࠊ⭠ෆᐜ≀୰ࡢపศᏊ௦ㅰ≀ࢆࠊ࢞ࢫࢡ࣐ࣟࢺࢢࣛ ࣇ㉁㔞ศᯒィࢆ⏝࠸࡚ศᯒࡋࡓࠋ ࠙⤖ᯝࠚAPCmin/+࣐࢘ࢫ㧗⬡⫫㣗ࢆᦤྲྀࡉࡏࡿࡇ࡛ࠊ㏻ᖖ㣗ᦤྲྀẚ㍑ࡋ࡚ࠊ⭠⟶࣏ࣜ ࣮ࣉࡀከࡃⓎ⏕ࡍࡿࡇࡀ☜ㄆ࡛ࡁࡓࠋࡲࡓࠊ㧗⬡⫫㣗ᦤྲྀࡼࡾࠊ⭠ෆ࠾ࡅࡿపศ Ꮚ௦ㅰ≀ࣉࣟࣇࣝࡀ␗࡞ࡿࠊࡍ࡞ࢃࡕࠊపศᏊ௦ㅰ≀ᇶ࡙࠸ࡓ⭠ෆ⎔ቃࡀኚࡍࡿ ࡇࡀ᫂ࡽ࡞ࡗࡓࠋ ࠙⪃ᐹࠚᮏ◊✲ࢆᐇࡍࡿࡇ࡛ࠊ㧗⬡⫫㣗ᦤྲྀࢆ⥅⥆ⓗᦤྲྀࡍࡿࡇࡀࠊపศᏊ௦ㅰ≀ ᇶ࡙࠸ࡓ⭠ෆ⎔ቃࡢኚࡘ࡞ࡀࡿ࠸࠺ࡇࢆ☜ㄆ࡛ࡁࡓࠋ㧗⬡⫫㣗ᦤྲྀࡼࡾࠊ⭠ ⟶࣏࣮ࣜࣉᩘࡢቑຍࡶ☜ㄆ࡛ࡁࡓࡇࡽࠊ㧗⬡⫫ᦤྲྀᇶ࡙ࡃ⭠ෆ⎔ቃࡢኚࡀࠊ⭠⟶ ࣏࣮ࣜࣉᩘቑຍ㉳ᅉࡍࡿྍ⬟ᛶࡀ♧၀ࡉࢀࡓࠋᚋࠊࡢࡼ࠺࡞⭠ෆ⎔ቃࡀࠊࡍ࡞ࢃࡕࠊ ࡢࡼ࠺࡞௦ㅰ≀ࡀࠊ⭠⟶࣏࣮ࣜࣉࠊࡉࡽࡣࠊ⭠ࡀࢇࡢⓎ⏕㛵ಀࡋ࡚࠸ࡿࡢࢆ᫂ ࡽࡋ࡚࠸ࡃᚲせࡀ࠶ࡿ⪃࠼ࡽࢀࡿࠋ ́́ P-19 ⺯ග࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࡼࡿ࣐࢘ࢫ⫢⮚⅖㒊࠾ࡅࡿ GC-MS/MS ௦ㅰ ࣉࣟࣇࣜࣥࢢゎᯒ ᕤ⸨ᜤᙪ, ୰す , ᕝྡಟ୍, ᆏᮁ, ᒣཱྀ ு, ➉ෆ ྖ, ᑿᓥ⾜ ᰴᘧ♫ᓥὠ〇సᡤ GC-MS/MS metabolic profiling analysis of the inflamed mouse liver by dosing fluorescent imaging probe Yukihiko Kudo, Takeshi Nakanishi, Shuichi Kawana, Takero Sakai, Ryo Yamaguchi, Tsukasa Takeuchi, Noriyuki Ojima Shimadzu Corporation ࠙┠ⓗࠚ⮬ᐙ⺯ගࡢᙳ㡪ࡸගᩓࡀᑡ࡞ࡃ㧗⢭⣽ᗘࡢ⏬ീࡀᚓࡽࢀࡿࡇࡽࠊᚑ᮶⏝࠸ࡽ ࢀ࡚࠸ࡿ㏆㉥እ⺯ගἼ㛗ࡼࡾࡶ᭦㛗࠸ NIR-ϩ(1000nm ௨ୖ)㡿ᇦࡢἼ㛗ࢆ⏝࠸ࡓ in vivo ㏆ ㉥እ⺯ග࣓࣮ࢪࣥࢢࢩࢫࢸ࣒ࢆ㛤Ⓨࡋ࡚࠸ࡿࠋᮏ࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࡣࠊ㧗⢭⣽࡞⏬ ീࡀᚓࡽࢀࡿ㠃ࠊ⫢⮚ࡢ㢧ⴭ࡞㞟✚⅖ࡀぢࡽࢀࡿࡓࡵࠊࡇࡢⅬࢆᨵၿࡋ࡚࠸ࡃᚲ せࡀ࠶ࡿࠋᮏ◊✲࡛ࡣࠊ⺯ග࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࡢ⫢⮚ࡢ㞟✚ࡀ࣐࢘ࢫࡢࡼ࠺࡞ ᙳ㡪ࢆཬࡰࡋ࡚࠸ࡿࢆ☜ㄆࡍࡿࡓࡵࠊ⫢⮚࠾ࡅࡿ௦ㅰ≀ኚືࢆ㧗ศ㞳ࠊ㧗ឤᗘ࡞ศ ᯒࡀྍ⬟࡞ GC-MS/MS ࢆ⏝࠸࡚ Scan ศᯒࠊMRM ศᯒࡼࡾホ౯ࡋࡓࠋ ࠙᪉ἲࠚScan ཬࡧ MRM ࡣ GCMS-TQ8040(ओᓥὠ〇సᡤ)ࠊศ㞳࣒࢝ࣛࡣ BPX-5 30m × 0.25mm I.D. df=0.25ȣm(SGE)࡛⾜ࡗࡓࠋSmart Metabolites Database (ओᓥὠ〇సᡤ)ᦚ㍕ࡉ ࢀࡓศᯒ࣓ࢯࢵࢻࢆ⏝ࡋࠊศᯒ㛫 23 ศ࡛ 475TMS ㄏᑟయ௦ㅰ≀ࢆᑐ㇟ ᐃࢆ⾜ࡗ ࡓࠋࢥࣥࢺ࣮࣐ࣟࣝ࢘ࢫࠊ࠾ࡼࡧ⺯ග࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈ 100ȣL(100mg/mL)ࢆᑿ㟼⬦ᢞ ࡋ࡚ 48 㛫ᚋ῝㯞㓉ୗ࡛ᏳᴦṚࡉࡏࡓ࣐࢘ࢫࡢ⫢⮚ࢆ⤖⢊○ࡋࠊ㝖ࢱࣥࣃࢡฎ⌮ᚋ ࡢୖΎࢆ┿✵⇱࣭⁐ゎᚋ࣓ࢺ࢟ࢩ࣒-TMS ㄏᑟయࢆ⾜࠸ศᯒヨᩱࡋࡓࠋ ࠙⤖ᯝࠚࢥࣥࢺ࣮ࣟࣝཬࡧࣉ࣮ࣟࣈᢞࡋࡓ࣐࢘ࢫ⫢⮚ࡽᚓࡽࢀࡓヨᩱࢆ Scan ཬࡧ MRM ࡛ ᐃࡋࡓ⤖ᯝࠊScan ࡛ࡣࢥࣥࢺ࣮ࣟࣝ:101 ᡂศࠊᢞ᭷:113 ᡂศࠊMRM ࡛ࡣࢥࣥࢺ࣮ࣟ ࣝ:198 ᡂศࠊᢞ᭷:230 ᡂศࡢ௦ㅰ≀ࡀ᳨ฟ࡛ࡁࡓࠋࣉ࣮ࣟࣈᢞࡢ᭷↓ࡼࡿ⫢⮚ࡢ௦ ㅰ≀ࢆ OPLS-DA ゎᯒࡋࡓ⤖ᯝࠊScan ࡛ࡣࣉ࣮ࣟࣈᢞࡼࡿ⅖ࢆᫎࡍࡿ᥎ᐃࡉࢀࡿ ࣂ࣐࣮࣮࢜࢝ೃ⿵ 47 ᡂศࠊMRM ࡛ࡣ 94 ᡂศࢆᢳฟࡋࡓࠋMRM ࡛ᢳฟࡉࢀࡓᡂศࡣ TCA ࢧࢡࣝ(Citric acidࠊcis-Aconitic acid ➼)ࠊࣆ࣑ࣜࢪࣥࢾࢡࣞ࢜ࢳࢻศゎ(Uridineࠊ Dihydrouracil ➼)➼ࡢ௦ㅰ⤒㊰㛵㐃ࡍࡿᡂศࡀྵࡲࢀࡿࠋ ࠙⪃ᐹࠚMRM ࢆ⏝࠸࡚࣐࢘ࢫ⫢⮚ࡢ௦ㅰ≀ࢆ ᐃࡍࡿࡇࡼࡾࠊጉᐖᡂศࡀ㝖ཤࡉࢀᐇ ㉁ⓗ࡞ឤᗘࡀྥୖࡋࡓ⤖ᯝࠊScan ࡼࡾከࡃࡢ௦ㅰ≀ࡀ᳨ฟ࡛ࡁࡓࠋࡇࡢࡇࡣࠊMRM ࡣ Scan ࡼࡾከࡃࡢࣂ࣐࣮࣮࢜࢝ೃ⿵ࡀ᳨ฟ࡛ࡁࡿࡇࢆ♧၀ࡋࠊ࣐࣮࣮࢝᥈⣴࠾࠸࡚᭷ ⏝࡛࠶ࡿࡇࢆ⾲ࡋ࡚࠸ࡿࠋࡲࡓࠊࣂ࣐࣮࣮࢜࢝ೃ⿵ࡢከࡃࡀ⅖ࡼࡾቑຍࡋࡓࡇ ࡽࠊᗈ⠊࡞௦ㅰ⤒㊰ᑐࡋ࡚㐣࡞௦ㅰᛂ࡞ࡢ␗ᖖࡀ⏕ࡌ࡚࠸ࡿࡇࡀ♧၀ࡉࢀࡿࠋ ́́ P-20 UPLC/MS/MS ࡼࡿ᪥ᮏேࣉࣟࣆ࢜ࣥ㓟⾑ᝈ⪅ࡢࣉࣟࣆ࢜ࢽࣝ-CoA ࢝ࣝ࣎࢟ࢩ ࣮ࣛࢮάᛶ ᐃ ᚋ⸨ెዉ 1, ๓⏣ᗣ༤ 1, ୰ᓥⴥᏊ 2, ఀ⸨ဴဢ 2, ๓⏣㝧Ꮚ 1, ᇼ⏣♸ᚿ 1, ∦ᒸᬛဢ 3, ᕝฟ ⩏ᾈ 1, ᮡᒣᡂྖ 4, ᮌᮧဴ 1,3 1 ྡྂᒇᕷ❧ᏛᏛ㝔⸆Ꮫ◊✲⛉ , 2 ⸨⏣ಖ⾨⏕Ꮫᑠඣ⛉, 3 ྡྂᒇᕷ❧ᏛᏛ㝔་ Ꮫ◊✲⛉, 4 ឡ▱Ꮫ㝔Ꮫ⸆Ꮫ㒊 An assay of propionyl-CoA carboxylase activity by UPLC/MS/MS in patients with propionic acidemia in Japan Kana Gotoh1, Yasuhiro Maeda1, Yoko Nakajima2, Tetsuya Ito2, Yoko Maeda1, Yuji Hotta1, Tomoya Kataoka3, Yoshihiro Kawade1, Naruji Sugiyama4, Kazunori Kimura1,3 1 Graduate School of Pharmaceutical Sciences, Nagoya City University, 2Department of Pediatrics, Fujita Health University, 3Graduate School of Medical Sciences, Nagoya City University, 4School of Pharmacy, Aichi-Gakuin University ࠙┠ⓗࠚࣉࣟࣆ࢜ࣥ㓟⾑(PA)ࡣࠊࣉࣟࣆ࢜ࢽࣝ-CoA ࢝ࣝ࣎࢟ࢩ࣮ࣛࢮ(PCC)Ḟᦆࢆཎᅉ ࡍࡿ㑇ఏᛶ௦ㅰᝈ࡛࠶ࡿࠋࡑࡢ⮫ᗋ≧ࡣࠊ᪂⏕ඣᮇⓎࡍࡿ㔜⠜࡞ࡶࡢࡽࠊ᪂⏕ ඣࢫࢡ࣮ࣜࢽࣥࢢ᳨࡛ฟࡉࢀࡿ↓≧ࡢࡶࡢࡲ࡛ᵝࠎ࡛࠶ࡿࠋPCC άᛶࢆ▱ࡿࡇࡣ㸪 ᝈࡢ⛬ᗘࢆண ࡍࡿୖ࡛㔜せ࡞ᡭࡀࡾ࡞ࡿࠋᡃࠎࡣࠊPA ᝈ⪅ࡢࣜࣥࣃ⌫ࢆ⏝࠸ࡓ㓝⣲ ᛂࢆ⾜࠸ࠊUPLC/MS/MS ࡼࡾ PCC άᛶࢆ ᐃࡍࡿ᪉ἲࢆ㛤Ⓨࡋࡓࠋ ࠙᪉ἲࠚPA ᝈ⪅ࡲࡓࡣᖖேࡢࣜࣥࣃ⌫ࢆ㉸㡢Ἴ࡛◚ቯࡋᠱ⃮ᾮࡋࡓࠋࡇࢀࣉࣟࣆ࢜ࢽ ࣝ-CoAࠊATPࠊMgCl2 ࢆຍ࠼ࠊࡇࡢΰྜᠱ⃮ᾮࢆ 37 Υ࡛ 30 ศ࣮ࣥ࢟ࣗ࣋ࢺࡋࡓࠋࡇࡢ ᛂ࡛⏕ᡂࡋࡓ࣓ࢳ࣐ࣝࣟࢽࣝ-CoA ࢆ UPLC/MS/MS ࢆ⏝࠸࡚ᐃ㔞ࡋࡓࠋUPLC/MS/MS ࡼࡿ ᐃࡣࠊAcquity UPLC BEH C18 culumn (2.0x150 mm)ࢆ⏝࠸ࠊ⛣ື┦ 400 mmol/L HCOONH4 (pH 7.4)ࢭࢺࢽࢺࣜࣝࢆ⏝ࡋࡓࠋ ࠙⤖ᯝࠚ㔜ࡢ PA ᝈ⪅࡛ࡣ࣓ࢳ࣐ࣝࣟࢽࣝ-CoA ࡣ⏕ᡂࡏࡎ PCC άᛶࡣࢮ࡛ࣟ࠶ࡗࡓࠋ୍ ᪉ࠊ㍍ࡲࡓࡣ↓≧ࡢ PA ᝈ⪅࡛ࡣᖖேẚ㍑ࡋ࡚ 2-20%ࡢ࣓ࢳ࣐ࣝࣟࢽࣝ-CoA ࡀ⏕ ᡂࡋࡓࠋ ࠙⪃ᐹࠚᡃࠎࡢ㓝⣲άᛶ ᐃἲ࡛ࡣࠊ㍍࣭↓≧ PA ᝈ⪅࡛ࡢ PCC ṧᏑάᛶࢆṇ☜ ᐃ ࡍࡿࡇࡀ࡛ࡁࠊPA ᝈ⪅࠾ࡅࡿᝈࡢ⛬ᗘࢆุ᩿ࡍࡿࡇࡀྍ⬟࡞ࡗࡓࠋ㍍ PA ᝈ ⪅ࡢከࡃࡣ PCCB 㑇ఏᏊ Y435C ኚ␗ࢆᣢࡗ࡚࠾ࡾࠊ᪥ᮏ࡛ࡣࢥࣔࣥኚ␗ࡋ࡚▱ࡽࢀ࡚ ࠸ࡿࠋᮏ◊✲࡛ࡣࠊY435C ኚ␗ࢆᣢࡘ PA ᝈ⪅ࡢ PCC άᛶࡣᖖேࡢ⣙ 10%࡛࠶ࡗࡓࠋ Phenotype 㓝⣲άᛶࡢ㛵ಀࢆ᫂ࡽࡍࡿࡓࡵࠊ᭦࡞ࡿ◊✲ࡀᚲせࡔ⪃࠼ࡽࢀࡿࠋ ́́ P-21 ᐇ ᇶ࡙ࡃ MS/MS ࢫ࣌ࢡࢺࣝࣛࣈ࣮ࣛࣜࢆ⏝࠸ࡓ㓟ࣜࣥ⬡㉁ࡢໟᣓⓗ ࣓ࢱ࣮࣒࣎ࣟゎᯒࢩࢫࢸ࣒ࡢ☜❧ 㟷ᰗⰋᖹ 1,2, ụ⏣㈗ 1,2, ᭷⏣ ㄔ 1,2 1 ⌮Ꮫ◊✲ᡤ⤫ྜ⏕་⛉Ꮫࢭࣥࢱ࣮࣓ࢱ࣮࣒࣎ࣟ◊✲ࢳ࣮࣒ 2 ᶓᕷ❧Ꮫ⏕་⛉Ꮫ◊✲⛉ศᏊ࢚ࣆࢤࣀ࣒⛉Ꮫ◊✲ᐊ Comprehensive metabolomics of oxidized phospholipids using a measured MS/MS spectra library Ryohei Aoyagi1,2, Kazutaka Ikeda1,2, Makoto Arita1,2 1 Laboratory for Metabolomics, RIKEN Center for Integrative Medical Sciences (IMS) 2 Cellular and Molecular Epigenetics Laboratory, Graduate School of Medical Life Science, Yokohama City University ࠙┠ⓗࠚ㓟ࣜࣥ⬡㉁ࡣࠊࣜࣥ⬡㉁ࡢ⬡⫫㓟㙐ࡀάᛶ㓟⣲✀ࡸ௦ㅰ㓝⣲࡛㓟ࡉࢀࡿࡇ࡞ ࡼࡾ⏕ᡂࡍࡿࠋࡇࢀࡽ㓟ࣜࣥ⬡㉁ࡣࠊື⬦◳ࢆࡣࡌࡵࡍࡿᵝࠎ࡞ᝈࡢⓎࡸ 㐍⾜㛵ࢃࡗ࡚࠸ࡿྍ⬟ᛶࡀᣦࡉࢀ࡚࠸ࡿࡀࠊ⏕యෆ࠾ࡅࡿศᕸࡸືែࠊ௦ㅰไᚚࠊ ࠾ࡼࡧ⏕⌮ᶵ⬟ࡘ࠸࡚ࡣᮍࡔ᫂࡞Ⅼࡀከ࠸ࠋࡑࡢ⌮⏤ࡢ୍ࡘࡋ࡚ࠊධᡭྍ⬟࡞ᶆ‽ ≀㉁ࡀ㝈ࡽࢀ࡚࠾ࡾࠊໟᣓⓗ࡞࣓ࢱ࣮࣒࣎ࣟゎᯒࢩࢫࢸ࣒ࡀ☜❧ฟ᮶࡚࠸࡞࠸ࡇࡀᣲࡆ ࡽࢀࡿࠋࡑࡇ࡛ᮏ◊✲࡛ࡣࠊᇵ㣴⣽⬊㓟⬡⫫㓟ࢆῧຍࡍࡿࡇࡼࡾ⏕ᡂࡍࡿ㓟ࣜ ࣥ⬡㉁ࢆ⏝࠸ࡿࡇ࡛ᐇ ᇶ࡙ࡃ MS/MS ࢫ࣌ࢡࢺࣝࡢ㞟ࢆ⾜࠸ࠊࡇࡢሗࢆ⏝࠸ࡓ㓟 ࣜࣥ⬡㉁ࡢໟᣓⓗ࣓ࢱ࣮࣒࣎ࣟゎᯒࢩࢫࢸ࣒ࡢᵓ⠏ࢆ┠ᣦࡋࡓࠋ ࠙᪉ἲࠚHEK293 ⣽⬊㓟⬡⫫㓟ࢆῧຍࡋࠊࡑࡢ⤖ᯝ⏕ᡂࡋࡓ㓟ࣜࣥ⬡㉁ࢆᅛ┦ᢳฟ 㸦Monospin C18: GL science)࡛ㄪ〇ࡋࡓࠋḟ UPLC/Triple TOF-MS (Waters/SCIEX)ࢆ⏝࠸࡚ Information dependent acquisition (IDA) ࣮ࣔࢻ࡛ࣀࣥࢱ࣮ࢤࢵࢺゎᯒࢆ⾜࠸ࠊMS/MS ࢫ࣌ࢡ ࢺࣝࡼࡿ㓟ࣜࣥ⬡㉁ࡢໟᣓⓗ࡞ྠᐃ࠾ࡼࡧᵓ㐀ゎᯒࢆ⾜ࡗࡓࠋ ࠙⤖ᯝ⪃ᐹࠚ㓟⬡⫫㓟ࡢῧຍࡼࡾ⏕ᡂࡋࡓ㓟ࣜࣥ⬡㉁ࡢᵓ㐀ゎᯒࡼࡾࠊࡇࢀࡲ࡛ ⣙ 300 ✀㢮ࡢ㓟ࣜࣥ⬡㉁ศᏊ✀ࡢ MS/MS ࢫ࣌ࢡࢺࣝࢆ㞟ࡍࡿࡇࡀ࡛ࡁࡓࠋࡇࢀࡽ ࡢሗࢆࡶࠊ୕㐃ᅄ㔜ᴟᆺ MS ࢆ⏝࠸ࡓࢱ࣮ࢤࢵࢺゎᯒࡽ㧗ឤᗘࡘᐃ㔞ⓗ࡞ ᐃ⣔ ࢆᵓ⠏ࡋࡓࠋ⏕యヨᩱࢆ⏝࠸ࡓ㓟ࣜࣥ⬡㉁ࡢ᳨ฟ࠾ࡼࡧᐃ㔞ศᯒᛂ⏝ࡋࡓࡘ࠸࡚ ࡶ⤂ࡋࡓ࠸ࠋ ́́ P-22 ࢫࢸࣟࢻ᳨ᰝヨᩱࡋ࡚ࡢ∎ࡢホ౯㸸ᕥྑࡢᡭࡢ∎୰ࢫࢸࣟࢻࡢྵ㔞ᕪ ᑠᕝ⚈㑻 1, ຍ⸨⏤㑣 1, 㧗㔝 㤶 1, ୰␁ຬኴ㑻 1, ᒣᙧ᠇୍㑻 1, 㛬 ಇဴ 2, ᮾ 㐩ஓ 1 ᮾி⌮⛉Ꮫ⸆Ꮫ㒊, 2㟼ᒸ┴❧Ꮫ⸆Ꮫ㒊 1 Evaluation of the utility of fingernail clipping as sample for steroid test: Differences in fingernail steroid contents between right and left hands Shoujiro Ogawa 1, Yuina Kato 1, Kaori Takano 1, Yutaro Nakaaze 1, Kenichiro Yamagata 1,Jun Zhe Min 2, Tatsuya Higashi 1 1 Faculty of Pharmaceutical Sciences, Tokyo University of Science 2 School of Pharmaceutical Sciences, University of Shizuoka 䛆┠ⓗ䛇 ∎ࡣ↓③ࠊ↓くⓗ᥇ྲྀྍ⬟࡛࠶ࡿࡇຍ࠼ࠊ୰㛗ᮇ㛫ࡢ⏕యሗࢆಖᏑࡋ࡚ ࠸ࡿࡇࡽࠊ៏ᛶᝈࡢ᪂ࡋ࠸᳨ᰝヨᩱࡋ࡚ᮇᚅࡉࢀ࡚࠸ࡿࠋࡋࡋࠊ⌧Ⅼ࡛ࡣࢫ ࢸࣟࢻࢆᣦᶆࡍࡿෆศἪ᳨ᰝᑐࡋࠊヨᩱࡋ࡚ࡢ∎㛵ࡍࡿሗࡣᴟࡵ࡚ஈࡋ࠸ࠋ ࠼ࡤᕥྑࡢᡭࡢ∎୰ࢫࢸࣟࢻࡢྵ㔞ᕪ࡞ࡣ࡛᫂࠶ࡿࠋࡑࡇ࡛ᮏ◊✲࡛ࡣ LC/ESI-MS/MSࡼࡿ∎୰testosterone (T) cortisol (F) ࡢྠᐃ㔞ἲࠊglycochenodeoxycholic acid (GCDCA) taurochenodeoxycholic acid (TCDCA) ࡢ ྠ ᐃ 㔞 ἲ ࠊ ཬ ࡧ dehydroepiandrosterone sulfate (DHEAS) ᐃ㔞ἲࢆ㛤Ⓨࡋࠊ᳨ᰝヨᩱࡋ࡚ࡢ∎ࡢホ౯ࡢ୍ࡘ ࡋ࡚ࠊࡇࢀࡽ5✀ࡢࢫࢸࣟࢻࡢᕥྑࡢᡭࡢ∎୰ྵ㔞ᕪࢆゎᯒࡋࡓࠋ 䛆ᐇ㦂䛇 ᖖ࣎ࣛࣥࢸ (⏨ዪྛn = 10) ࡽ᥇ྲྀࡋࡓ∎ (➨1ᣦཬࡧ➨2ᣦ) ࢆ1 mmゅ௨ ୗ⣽᩿ࡋࠊ⇱ (45oCࠊ3 h) ࡋ࡚ಖᏑࡋࡓࠋ∎ヨᩱ (10 mg) ࡣෆᶆ‽≀㉁ (ྛࢫࢸࣟࢻ ࡢ2Hᶆ㆑య) ࢆྵࡴ50% EtOH࠶ࡿ࠸ࡣ70% MeOH (300 ȝL) ୰ᨺ⨨ (60oCࠊ2 h) ᚋࠊ㉸㡢 Ἴฎ⌮ (15 min) ࡋࡓࠋୖΎࢆᅛ┦ᢳฟ࣮࢝ࢺࣜࢵࢪ࡛⢭〇ࡋࠊLC/ESI-MS/MSࡋࡓࠋ 䛆⤖ᯝ䛇 ྛ䝇䝔䝻䜲䝗䛻䛴䛔䛶ᕥྑ䛾ᡭࡢ∎୰ࢫࢸࣟࢻྵ㔞 (LཬࡧR) ࡢẚ (L/R) ࢆ⟬ฟࡋ ࡓࡇࢁࠊGCDCA࡛0.40㸫2.03ࠊTCDCA࡛0.82㸫2.10ࠊDHEAS࡛0.44㸫2.13࡞ࡾࠊࡇࢀࡽ ࡢࢫࢸࣟࢻ࡛ࡣRLࡢࡕࡽࡢ⤖ᯝࢆ⏝࠸ࡿࡼࡗ࡚ࠊ⏘⏕࣭ศἪ≧ែࡢホ౯ࡀࡁ ࡃ␗࡞ࡿࡇࡀ♧၀ࡉࢀࡓࠋ୍᪉ࠊTཬࡧF࡛ࡣL/Rࡀࡑࢀࡒࢀ0.84㸫1.24ཬࡧ0.83㸫1.27࡛࠶ ࡗࡓࠋྜ≀ࡢlogDࢣࣛࢳࣥᑐࡍࡿぶᛶࡣṇࡢ┦㛵ࡀ࠶ࡿࡇࡀሗ࿌ࡉࢀ࡚࠾ࡾࠊ TࡸF࡞ࡢỈᛶࡢ㧗࠸ࢫࢸࣟࢻࡣ∎࣐ࢺࣜࢡࢫྲྀࡾ㎸ࡲࢀࡓᚋࠊ᪥ᖖάື (ᡭὙ࠸㸪 ධᾎ࡞) ࠾ࡅࡿ⁐ኻࡀᑡ࡞ࡃࠊLRᕪࡀ⏕ࡌࡃ࠸ࡶࡢ᥎ᐹࡉࢀࡓࠋࡲࡓࠊ∎୰T ྵ㔞᫂ࡽ࡞ᛶᕪ (⏨ᛶ㸸2.07 ± 0.64 ng/g㸪ዪᛶ㸸0.58 ± 0.33 ng/g) ࡀほᐹࡉࢀࡿ୍᪉࡛ࠊ Fྵ㔞 (⏨ᛶ㸸5.23 ± 1.62 ng/g㸪ዪᛶ㸸4.49 ± 1.38 ng/g) ࡣࡑࢀࡀㄆࡵࡽࢀ࡞ࡗࡓ㸬௨ୖ ࢆ⥲ྜࡍࡿࠊ∎ࢆ⏝࠸࡚ྛಶேࡢTࡸFࡢ⏘⏕࣭ศἪ≧ែࡀホ౯࡛ࡁࡿࡶࡢ⪃࠼ࡽࢀࡓࠋ ́́ P-23 ⬡⫫⣽⬊ࡢ⬡⫫࠾ࡅࡿ㐣㓟ࢺࣜࢢࣜࢭࣜࢻࡢศᯒ ῄⴍ 1, ⦾ᐩ㸦ᰩᯘ㸧㤶⧊ 1, ᑠᯘ ᝆ 1, ༓ⴥோᚿ 1 1 ᾏ㐨Ꮫ Ꮫ㝔ಖ⛉Ꮫ◊✲㝔 Analysis of triglyceride hydroperoxides in lipid droplets from adipocyte Shu-Ping Hui1, Kaori Kuribayashi-Shigetomi1, Yu kobayashi1, Hitoshi Chiba1, 1 Faculty of heath science, Hokkaido University ࠙⫼ᬒ࣭┠ⓗࠚ⫧‶࣭⢾ᒀ࣭㧗⾑ᅽ࣭ື⬦◳ࢆࡣࡌࡵࡋࡓ⏕ά⩦័ࡢⓎࡣࠊෆ⮚ ⬡⫫ࡢ㐣✚ࡀせᅉࡔゝࢃࢀ࡚࠸ࡿࠋࡋࡋ࡞ࡀࡽࠊࡢࡼ࠺࡞࣓࢝ࢽࢬ࣒࡛ෆ⮚ ⬡⫫✚ࢆᘬࡁ㉳ࡇࡍࡢࠊࡲࡓࠊ✚ࡉࢀࡓ⬡⫫ࡣࡢࡼ࠺࡞ᡂศ࡞ࡢ࡞ᮍࡔ ᫂࡞Ⅼࡀከ࠸ࠋ㏆ᖺࠊ࢞ࣛࢫ࢟ࣕࣆ࣮ࣛࣜࢆ⏝࠸࡚⏕య⤌⧊ࡸ⣽⬊ෆࡢపศᏊ㛵ࡍࡿ㉁ 㔞ศᯒἲࡢ◊✲ࡀሗ࿌ࡉࢀࡓ㸦Nakajima K., et al Analy Sci. 2003; Mizuno H., et al, J Mass Spectrom, 2008㸹 Tsuyama N., et al, Anal Sci, 2008㸧. ᮏ◊✲ᐊ࡛☜❧ࡉࢀ ࡓ୍⣽⬊ෆ⬡⫫ࡢ㓟ホ౯⣔㸦㉁㔞ศᯒἲ㸧ࢆ⏝࠸࡚ࠊ⬡⫫⣽⬊࠼ࡽࢀ࡚࠸ࡿ⬡⫫ ࡢࡳࢆ㑅ᢥⓗ᥇ྲྀࡋࠊࢺࣜࢢࣜࢭࣜࢻ (TG) ཬࡧ㐣㓟ࢺࣜࢢࣜࢭࣜࢻ (TG-OOH) ࢆ ศᯒࡋࡓࠋ ࠙᪉ἲࠚ⣽⬊ࡣࠊேࡢෆⶶ⬡⫫⤌⧊୍␒㏆࠸ゝࢃࢀ࡚࠸ࡿࣛࢵࢺࡢ⭠㛫⭷⬡⫫⣽⬊ࡼࡾ ᥇ྲྀࡋࡓ stromal-vascular cells (SVCs)ࢆ⏝ࡋࡓ (Visceral Adipocyte Culture Kit V-1; Cosmo Bio Co.Ltd., Japan)ࠋᮏ⣽⬊ࡣࠊ୍㐣ᛶࡢㄏᑟ่⃭ࡢ㝿୍⯡ⓗ⏝࠸ࡽࢀ ࡿࢹ࢟ࢧ࣓ࢱࢰࣥཬࡧࢯࣈࢳ࣓ࣝࢳࣝ࢟ࢧࣥࢳࣥࢆ⏝ࡍࡿࡇ࡞ࡃࠊ୍㐌㛫࡛ ⬡⫫⣽⬊ศࡍࡿࡇࡀྍ⬟࡛࠶ࡿ㸦Shimizu, Cell Biol Int, 2006㸧 ࠋ⬡⫫⣽⬊ࡽ ⬡⫫ࢆ᥇ྲྀࡍࡿ๓ࠊᇵᆅࢆ྾ᘬࡋࠊࣜࣥ㓟⦆⾪⏕⌮㣗ሷỈ(PBS)࡛ࡍࡍࡄࠋ⬡⫫⣽⬊ ࠾ࡅࡿ⬡⫫ࡣࠊ㢧ᚤ㙾(IX71, ࢜ࣜࣥࣃࢫ)ࡢୗ࡛ࠊ㔠࡛ࢥ࣮ࢸࣥࢢࡉࢀࡓ⮬ᐙ〇࢟ࣕ ࣆ࣮ࣛࣜ㸦㔪㸧࠾ࡼࡧ࣐ࢡࣟࣥࢪ࢙ࢡࢱ࣮ (IM- 11-2 ࠊࢼࣜࢩࢤ)ࢆ⏝࠸࡚྾ᘬࡋࡓࠋ ḟ࠸࡛ࠊ㔪᭷ᶵ⁐፹ࢆῧຍࡋࠊࡑࡢࡲࡲ ESI-Orbitrap ㉁㔞ศᯒィᑟධࡋࠊᐃᛶศᯒ ࢆ⾜ࡗࡓࠋ࡞࠾ࠊᐃᛶศᯒᚲせ࡞ࢺࣜ࢜ࣞࣥ(TG 18:1/18:1/18:1)ཬࡧ㐣㓟ࢺࣜࢢࣜ ࢭࣜࢻ(TG-OOH 16:0/18:2/16:0)ࡣ ᶆရࡋ࡚Ꮫྜᡂࡉࢀࡓࠋ(Hui SP, et al. Lipids 2003, 38; Hui SP, et al. Anal Bioanal Chem 2013, 405) ࠙⤖ᯝ࣭⪃ᐹࠚྜᡂࡉࢀࡓ TG 18:1/18:1/18:1 ཬࡧ TG-OOH 16:0/18:2/16:0 ࡣ୧᪉ࡶ MS ࢫ࣌ࢡࢺ࡛ࣝࡣ[M+Na]+ࡋ࡚ほᐹࡉࢀࡓࠋࡲࡓࠊࡑࢀࡽࡢ MS2 ࢫ࣌ࢡࢺࣝࡀᚓࡽࢀࡓࠋ⏕ ࡁ ࡓ ⬡ ⫫ ⣽ ⬊ ࡽ ᥇ ྲྀ ࡋ ࡓ ⬡ ⫫ ࡽ ࡶ ྠ ࡌ ࡃ TG 18:1/18:1/18:1 ཬ ࡧ TG-OOH 16:0/18:2/16:0 ࡀ[M+Na]+ࡋ࡚ほᐹࡉࢀࠊMS2 ࢫ࣌ࢡࢺࣝࡶᚓࡽࢀࡓࠋࡼࡗ࡚ࠊ⬡⫫ TG 18:1/18:1/18:1 ཬࡧ TG-OOH 16:0/18:2/16:0 ࡀᏑᅾࡋࡓࡇࢆ☜ㄆࡋࡓࠋᮏ◊✲࡛ࡣࠊ TG 18:1/18:1/18:1 ཬࡧ TG-OOH 16:0/18:2/16:0 ࢆྵࡵࠊ20 ✀㢮ࡢ TG ཬࡧ 15 ✀㢮ࡢ TG-OOH ࢆ᳨ฟࡋࡓࠋ⬡⫫⣽⬊ෆࡢ⬡⫫ࡣࠊ㓟ࡉࢀ࡚࠸ࡿࡇࡀ᫂ࡽ࡞ࡗࡓࠋ ́́ P-24 LC/MS/MS ࡢ⮫ᗋ᳨ᰝᛂ⏝ ̿ࣅࢱ࣑ࣥ D ௦ㅰ≀ ᐃࢆᇶ┙̿ బ⸨ Ᏺ 1, ▼ẟᓫஅ 2, ᑠᕝ⚈㑻 3, すᮧ ᇶ 2,4, ᯇୗ୍அ 2,4, ᮾ 㐩ஓ 3, 㔝ᮧᩥኵ 1 1 ༓ⴥᏛ་Ꮫ㒊㝃ᒓ㝔࣐ࢫࢫ࣌ࢡࢺ࣓ࣟࢺ᳨࣮ࣜᰝデ᩿Ꮫ, 2 ༓ⴥᏛ་Ꮫ㒊㝃ᒓ㝔᳨ᰝ 㒊, 3 ᮾி⌮⛉Ꮫ⸆Ꮫ㒊⮫ᗋศᯒ⛉Ꮫ◊✲ᐊ, 4 ༓ⴥᏛᏛ㝔་Ꮫ◊✲㝔ศᏊែゎᯒᏛ Clinical application of LC/MS/MS -focusing on vitamin D metabolites testingMamoru Satoh1, Takayuki Ishige2, Shoujiro Ogawa3, Motoi Nishimura2,4, Kazuyuki Matsushita2,4, Tatsuya Higashi3, Fumio Nomura1 1 Division of Clinical Mass Spectrometry, Chiba University Hospital 2 Clinical Laboratory, Chiba University Hospital 3 Faculty of Pharmaceutical Sciences, Tokyo University of Science 4 Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University ࠙⫼ᬒ┠ⓗࠚ⌧ᅾࡢ⮫ᗋ᳨ᰝᐊ࡛ࡣࠊྛ✀ࢫࢸࣟࢻ࣭࣍ࣝࣔࣥࣅࢱ࣑ࣥ D ௦ㅰ≀࡞ࡢప ศᏊྜ≀ࡢศᯒࡣᢠయࡼࡿචᏛⓗ ᐃἲࡀ⏝࠸ࡽࢀ࡚࠸ࡿࠋචᏛⓗ ᐃἲࡣ ᳨యฎ⌮⬟ຊࡀ㧗ࡃࠊ⮫ᗋ᳨ᰝ࠾࠸࡚ᚲ㡲࡛࠶ࡿ୍᪉ࠊᕪᛂࡢᏑᅾࡸ࢟ࢵࢺ㛫ᕪ࣭ タ㛫ᕪࡢၥ㢟ࡀᣦࡉࢀ࡚࠸ࡿࠋపศᏊྜ≀ࡣഃ㙐ᵓ㐀࡞ࡢᚤᑠ࡞㐪࠸ࡼࡾ⏕≀Ꮫⓗ άᛶࡀࡁࡃ␗࡞ࡿࡓࡵࠊ⢭ᐦ࡞௦ㅰືែࡢホ౯ࡣࠊᚤᑠᵓ㐀ᕪࢆᘚูࡍࡿࡇࡢ࡛ࡁࡿ LC/MS/MS ࡛ࡢ ᐃࡀ㠀ᖖ᭷⏝࡛࠶ࡿࠋᮏⓎ⾲࡛ࡣࠊLC/MS/MS ࡢ⮫ᗋ᳨ᰝᐊᑟධࡢ㸯 ࡋ࡚ࠊࣅࢱ࣑ࣥ D ௦ㅰ≀ࡢศᯒࢆ⤂ࡍࡿࠋࣅࢱ࣑ࣥ D ࡣ࢝ࣝࢩ࣒࢘ࡢ௦ㅰㄪ⠇ᚲせ࡞ ⬡⁐ᛶࣅࢱ࣑ࣥࡋ࡚▱ࡽࢀ࡚࠾ࡾࠊ㏆ᖺ࡛ࡣࣅࢱ࣑ࣥ D ࡢ㊊ࡀከࡃࡢᝈࡢⓎࣜࢫࢡ ࢆ㧗ࡵࡿࡇࡀሗ࿌ࡉࢀὀ┠ࡉࢀ࡚࠸ࡿࠋ⾑୰ࡢࡓࡿࣅࢱ࣑ࣥ D ௦ㅰ≀ࡢ㸯ࡘ࡛࠶ࡿ 25(OH)ࣅࢱ࣑ࣥ D ࡣࣅࢱ࣑ࣥ D ࡢᰤ㣴≧ែࡢホ౯ࢆࡋࡓ┠ⓗ࡛ ᐃࡉࢀ࡚࠸ࡿࠋࡲࡓ᭱ ㏆ࠊ᪂⏕ඣ࠾࠸࡚ 25(OH)D ࡢ␗ᛶయ࡛࠶ࡿ 3-epi-25(OH)D3 ࡀ 25(OH)D ࡢ 8㹼60㸣ẚ㍑ ⓗ㧗⃰ᗘ࡛Ꮡᅾࡍࡿࡇࡶሗ࿌ࡉࢀ࡚࠸ࡿࠋ3-epi-25(OH)D3 ࡣ⏕⌮άᛶࢆᣢࡓ࡞࠸ࡀࠊࡇ ࢀࡀ᪂⏕ඣࡢ 25(OH)D ᐃ್ࢆㄗࡗ࡚㧗್ࡋ࡚࠸ࡿྍ⬟ᛶࡀ࠶ࡾࠊಶࠎࡢࣅࢱ࣑ࣥ D ௦ㅰ ≀ࢆṇ☜ᐃ㔞࡛ࡁࡿࡇࡀồࡵࡽࢀ࡚࠸ࡿࠋࡑࡇ࡛ᅇᡃࠎࡣࠊάᛶᆺࣅࢱ࣑ࣥ D ᐦ᥋ ࡞㛵ಀ࠶ࡿάᛶᆺࣅࢱ࣑ࣥ D㸦24,25(OH)2D3㸧ࡶྵࡵࡓ 4 ✀ࡢࣅࢱ࣑ࣥ D ௦ㅰ≀ࡘ࠸ ᳨࡚ᰝᛂ⏝ࢆ┠ⓗࡋ࡚ࠊ⮫ᗋ᳨ᰝࢆ⾜࠺㝿⤯ᑐồࡵࡽࢀࡿṇ☜ᗘ࣭⌧ᛶ࣭Ᏻᐃᛶ࣭ ᭱ᑠᐃ㔞ឤᗘ࣭࣐ࢺࣜࢡࢫࡢᖸ΅࣭᥇⾑⟶✀ࡢᙳ㡪࣭ᚑ᮶ἲࡢ┦㛵ࡘ࠸࡚ヲ⣽᳨ウࢆ ⾜ࡗࡓࠋ ࠙᪉ἲࠚࣥࣇ࢛࣮࣒ࢻࢥࣥࢭࣥࢺࡢᚓࡽࢀࡓᖖே⾑Ύ᳨యࢆ⏝࠸ࡓࠋ⾑Ύ 20PL IS ࢆࢫ ࣃࢡࡋࡓᢳฟᾮ 280PL ࢆΰࡋࠊSLE (Supported Liquid extraction)ࢆ⾜ࡗࡓࠋᢳฟ⁐ᾮࢆ ᅛᚋ DAPTAD ㄏᑟయࢆᐊ ࡛ 1 㛫⾜࠸ SRM ᐃࢆ⾜ࡗࡓࠋHPLC ࡣ NanoSpace SI-2 ࢆ⏝࠸ࠊ࢜ࣥἲࡣ ESIࠊ㉁㔞ศᯒィࡣ୕㐃ᅄ㔜ᴟ㉁㔞ศᯒィ TSQ vantage ࢆ⏝࠸ࡓࠋ 0.0202 ng/mLࠊ ࠙⤖ᯝ࣭⪃ᐹࠚ LOQ ࡣᕼ㔘┤⥺ᛶ CV10%௨ୗࡢࢡࣛࢸࣜࡽ 0.0905 ng/mLࠊ 0.0241 ng/mLࠊ0.0127 ng/mL㸦ྛ 25(OH)D3ࠊ3-epi-25(OH)D3ࠊ24,25(OH)2D3ࠊ25(OH)D2㸧࡛࠶ ࡗࡓࠋᖖே⾑Ύࢆ⏝࠸ࡓ⢭ᗘࡣྠ⌧ᛶࡀࡑࢀࡒࢀ CV 0.9%ࠊCV 3.0%ࠊCV 3.8%ࠊCV 4.4% ࡛ 20 ᪥㛫ࡢ᪥ᕪ⌧ᛶࡀ CV 2.2%ࠊ CV 3.4%ࠊ CV 7.8%ࠊ CV 4.4% 㸦ྛ 25(OH)D3ࠊ 3-epi-25(OH)D3ࠊ 24,25(OH)2D3ࠊ 25(OH)D2㸧 ࡛࠶ࡗࡓࠋ NIST SRM972a ࢆ⏝ࡋࡓṇ☜ᗘࡣ Level2 ⾑Ύ࡛ 100.5%ࠊ 96.1%ࠊ99.3%㸦ྛ 25(OH)D3ࠊ3-epi-25(OH)D3ࠊ25(OH)D2㸧࡛࠶ࡾࠊNIST ࡢᣦᐃࡋࡓ⠊ᅖ ࡲࡗ࡚࠾ࡾࠊ᪥ᖖ᳨ᰝࡋ࡚༑ศ⏝࡛ࡁࡿ⪃࠼࡚࠸ࡿࠋ ́́ P-25 ࣓ࢱ࣮࣒࣎ࣟゎᯒࡼࡿዷፎ㧗⾑ᅽ⭈⒪ᶆⓗศᏊࡢ᥈⣴ ὠᅧ⏤ెᏊ 1, బ⸨ᜨ⨾Ꮚ 1,2, అ㛫ᬛྐ 1, బ⸨ ༤ 1,2, 㧗ᶫಙ⾜ 1,2, ୕ᯞ㍜ 2,3 1 ᮾᏛᏛ㝔⸆Ꮫ◊✲⛉, 2 ᮾᏛᏛ㝔་Ꮫ⣔◊✲⛉, 3 ᮾᏛᮾ࣓ࢹ࣭࢝ࣝ ࣓࢞ࣂࣥࢡᶵᵓ Metabolomic screening for biomarkers of preeclampsia Yukako Tsunokuni1, Emiko Sato1, 2, Tomofumi Fushima1, 2, Hiroshi Sato1,2, Nobuyuki Takahashi1,2, Daisuke Saigusa2,3 1 Graduate School of Pharmaceutical Science, Tohoku University 2 School of Medicine, Tohoku University 3 Tohoku Medical Megabank Organization, Tohoku University ࠙┠ⓗࠚዷፎ㧗⾑ᅽ⭈ (Preeclampsia : PE) ࡣࠊዷፎ 20 㐌௨㝆㧗⾑ᅽ⺮ⓑᒀࢆ࿊ࡍࡿ ែ࡛࠶ࡾࠊ㔜ࡍࡿࡇ࡛ẕయⱝࡋࡃࡣᏊᙳ㡪ࢆ࠼ࡿᜍࢀࡀ࠶ࡿᝈ࡛࠶ࡿࠋ⌧ᅾ ࡲ࡛ࠊPE ࡢデ᩿ࡣ⾑ᅽཬࡧࢱࣥࣃࢡᒀࡀ⏝࠸ࡽࢀ࡚࠸ࡿࡀࠊ᫂☜࡞ែࡢኚࡼࡿ デ᩿ᇶ‽ࡀᐃ⩏ࡉࢀ࡚࠸࡞࠸ࠋᚑࡗ࡚ࠊPE ࡢែࢆゎ᫂ࡋࠊ᪩ᮇⓎぢࢆྍ⬟ࡍࡿ᪂つデ ᩿࣐࣮࣮࢝ศᏊࡢྠᐃࡀồࡵࡽࢀ࡚࠸ࡿࠋᮏ◊✲࡛ࡣࠊPE ࡢែゎ᫂ࢆࡍࡿࡇࢆ┠ⓗ ࡋࠊࣔࢹ࣐ࣝ࢘ࢫࢆ⏝࠸ࡿ⒪ࢱ࣮ࢤࢵࢺศᏊཬࡧデ᩿࣐࣮࣮࢝ࡢ᥈⣴ࢆᐇࡋࡓࠋ ࠙᪉ἲࠚึࡵࠊICR ࣐࢘ࢫ (ዷፎ 8 㐌㱋) ࠊྍ⁐ᆺ VEGF ཷᐜయ 1 (sFlt-1)ࢆ㐣Ⓨ⌧ࡉ ࡏࡿࢹࣀ࢘ࣝࢫࢆᢞࡋࠊPE ࣔࢹ࣐ࣝ࢘ࢫࢆసᡂࡋࡓ (1) ࠋḟࠊࣔࢹ࣐ࣝ࢘ࢫࡽ⾑ ₢ࢆ᥇ྲྀࡋࠊglobal metabolomics (GMet) ゎᯒࢆᐇࡋࡓࠋศᯒᇶ┙ࡣࠊLC ᅄ㔜ᴟ-ࣇ࣮ࣜ ࢚ኚᆺ㉁㔞ศᯒィࢆ᥋⥆ࡋࡓ LC-Q-FT/MS ࢆ⏝࠸ࠊpositive (pos) ཬࡧ negative (neg) ୧࣮࢜ࣥࣔࢻ࡚ ᐃࢆᐇࡋࡓࠋࡲࡓࠊศᯒ࣒࢝ࣛ ZIC-pHILIC ࢆ㑅ᢥࡋࠊ10 mmol/L 㔜Ⅳ㓟ࣥࣔࢽ࣒࢘⁐ᾮ (pH 9.2) ཬࡧࢭࢺࢽࢺࣜࣝࢆ⏝࠸ࡿࢢࣛࢪ࢚ࣥࢺ⁐ฟ࡚ྜ ≀ࢆ⁐ฟࡋࡓࠋᚓࡽࢀࡓࢹ࣮ࢱࡣࠊProgenesis QI ཬࡧ SIMCA-P ࢆ⏝࠸ࡿࡇࡼࡿྜ≀ ྠᐃཬࡧከኚ㔞ゎᯒࢆᐇࡋࠊࣔࢹ࣐ࣝ࢘ࢫ࠾࠸࡚≉␗ⓗኚືࡍࡿྜ≀ࢆᢳฟࡋࡓࠋ ࡲࡓࠊྜ≀ࡣ LC-MS/MS ࢆ⏝࠸ࡿ targeted metabolomics (TMet) ࡼࡾࠊᐃ㔞ホ౯ࡋࡓࠋ ࠙⤖ᯝཬࡧ⪃ᐹࠚGMet ࡼࡾᚓࡽࢀࡓ 1011 ✀ (pos) ཬࡧ 986 ✀ (neg) ࡢྜ≀ࢆ⏝࠸ࡿ OPLS-DA ゎᯒࡢ⤖ᯝࠊPE ⩌࠾࠸࡚ࠊ⾑₢୰ࡢࢭࢳࣝ࢝ࣝࢽࢳࣥཬࡧ㛗㙐ࢩࣝ࢝ࣝࢽ ࢳࣥࡀ sFlt-1 㠀ᢞ࣐࢘ࢫẚ㍑ࡋ࡚᭷ពప್࡞ࡗࡓ (P < 0.05)ࠋࡲࡓࠊྛྜ≀ࡣࠊ TMet ࡢ⤖ᯝ࠾࠸࡚ࡶྠᵝప್࡛࠶ࡿࡇࡀ♧ࡉࢀࡓࠋࢭࢳࣝ࢝ࣝࢽࢳࣥࡣࠊ࣑ࢺࢥ ࣥࢻࣜࡢ⬡⫫㓟㓟㛵ࢃࡿࡇࡽࠊᚋ PE ࠾ࡅࡿࢭࢳࣝ࢝ࣝࢽࢳࣥࡢືែ⬡ ⫫㓟㓟ࡢ㛵㐃ࢆゎ᫂ࡋࠊࢱ࣮ࢤࢵࢺศᏊࡢ᭷⏝ᛶࢆホ౯ࡍࡿணᐃ࡛࠶ࡿࠋ (1) Lu F et al. Am J Obstet Gynecol. 2007 Apr;196(4):396. ́́ P-26 ⺯ග࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈᢞ࣐࢘ࢫ⫢⤌⧊ᑐࡍࡿ LC/MS ࢆ⏝࠸ࡓ௦ㅰ≀ ୍ᩧศᯒ ୰す 1, ᕤ⸨ᜤᙪ 1, ᕝྡಟ୍ 1, ᒣཱྀ ு 1, ➉ෆ ྖ 1, ᑿᓥ⾜ 1 1 ᓥὠ〇సᡤ Simultaneous of primary metabolites by LC/MS for liver tissue from a mouse dosed with fluorescent probes Tsuyoshi Nakanishi1, Yukihiko Kudo1, Shuichi Kawana1, Ryo Yamaguchi1, Tsukasa Takeuchi1, Noriyuki Ojima1 1 Shimadzu Corporation ࠙┠ⓗࠚ㏆㉥እ⺯ගἼ㛗ࡼࡾࡶ㛗࠸ NIR-ϩ㸦>1000 nm㸧㡿ᇦࡢἼ㛗ࢆ⏝࠸ࡓ in vivo ㏆㉥እ ⺯ග࣓࣮ࢪࣥࢢࢩࢫࢸ࣒ࢆᓥὠ〇సᡤ࡛ࡣ㛤Ⓨࡋ࡚࠸ࡿࡀࠊᮏᢏ⾡ࡼࡿ㧗⢭⣽࡞࣓ ࣮ࢪࣥࢢ⏬ീࡀᚓࡽࢀࡿ㠃ࠊ⌧≧ࡢࣉ࣮ࣟࣈࡣ⫢⮚ࡢ㢧ⴭ࡞㞟✚ࡀㄆࡵࡽࢀࡿࡓࡵࠊ ࡇࡢⅬࢆᨵၿࡋ࡚࠸ࡃᚲせࡀ࠶ࡿࠋࡇࡇ࡛ࡣࠊ⺯ග࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࡢ⫢⮚ࡢ㞟✚ ࡀ࣐࢘ࢫࡢࡼ࠺࡞ᙳ㡪ࢆཬࡰࡋ࡚࠸ࡿࢆ☜ㄆࡍࡿࡓࡵࠊ⫢⮚࠾ࡅࡿ௦ㅰ≀ኚື ࢆࢺࣜࣉࣝᅄ㔜ᴟᆺ LC/MS ࢆࡗ࡚ホ౯ࡋࡓࠋ ࠙᪉ἲࠚ⺯ග࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࢆ 100 ȣ㹪(100 mg/ml㸧ࢆᑿ㟼⬦ᢞࡋࡓ BALB/c-nu ࣐ ࢘ࢫࢆᢞ 48 㛫ᚋࠊ῝㯞㓉ୗ࡛ᏳᴦṚࡉࡏ⫢⤌⧊ࢆฟࡋࡓࠋฟࡋࡓ⫢⤌⧊ࡣ㏿ࡸ ⤖ᚋࠊ࣓ࢱࣀ࣮ࣝ୰࡛◚○ࡋࡓࠋࢡ࣒࣭࣓ࣟࣟ࣍ࣝࢱࣀ࣮ࣝᢳฟἲࡼࡿ⬡㉁࣭ࢱ ࣥࣃࢡ㉁ࡢ㝖ཤࠊ5kDa cutoff ࣇࣝࢱ࣮ࡼࡿℐ㐣ࢆ⾜ࡗࡓࠋḟ㐲ᚰ࢚ࣂ࣏࣮ࣞࢱࡼ ࡿ⃰⦰ᚋࠊ㉸⣧Ỉ࡛⁐ゎࡋ࡚㐺ᐅᕼ㔘ࡋࡓᚋࠊLC/MS ࡼࡿ௦ㅰ≀ࡢ୍ᩧศᯒࢆ⾜ࡗࡓࠋ LC/MS ศᯒ࡛ࡣࠊ࢜ࣥ࣌ヨ⸆ࡋ࡚ࢺࣜࣈࢳ࣑ࣝࣥࢆ⛣ື┦ຍ࠼ࡓ࢜ࣥ࣌ἲ ࡼࡿ୍ᩧศᯒࠊPFPP ࣒࢝ࣛࢆ⏝࠸ࡓ㏻ᖖࡢ㏫┦⣔࡛ࡢศᯒࢆ⾜ࡗࡓࠋྛ௦ㅰ≀ࡢࣆ࣮ ࢡ㠃✚ࢆෆ㒊ᶆ‽≀㉁ࡢ㠃✚್ࢆᇶ‽ࡋࡓ㠃✚ẚࢆẚ㍑ࡍࡿࡇ࡛ࠊ⺯ග࣓࣮ࢪࣥࢢ ࣉ࣮ࣟࣈᢞࡼࡿ௦ㅰ≀ࡢኚືࢆẚ㍑ࡋࡓࠋ ࠙⤖ᯝࠚ࢜ࣥ࣌ἲࡼࡿ୍ᩧศᯒ⤖ᯝࡽࡣゎ⢾⣔ࢆ୰ᚰࡋࡓ⢾ࣜࣥ㓟ࡸࢾࢡࣞ࢜ࢳ ࢻ௦⾲ࡉࢀࡿ௦ㅰ≀ࢆ᳨ฟࡍࡿࡇࡀ࡛ࡁࡓࠋࡲࡓ PFPP ࣒࢝ࣛࢆ⏝࠸ࡓ㠀࢜ࣥ࣌ἲ ࡛ࡣࠊTCA ᅇ㊰࠾ࡅࡿ᭷ᶵ㓟ࡸ Transsulfuration ⤒㊰௦ㅰ≀ࠊ࣑ࣀ㓟ࠊࢾࢡࣞ࢜ࢩࢻ࡞ ࢆ᳨ฟࡋࡓࠋ⺯ග࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࡢᮍᢞ㸭ᢞ㛫࠾ࡅࡿ௦ㅰ≀ኚືࡋ࡚ࡣࠊ ᢞ⩌࠾࠸࡚ TCA ᅇ㊰ࡢ᭷ᶵ㓟࣭࣑ࣀ㓟ࢆࡣࡌࡵࡍࡿ௦ㅰ≀࠾࠸࡚ⴭࡋ࠸ቑࠊ ⫹Ồ㓟࣭ATP ࡢపୗࡀㄆࡵࡽࢀࡓࠋ ࠙⪃ᐹࠚᢞࡉࢀࡓ⺯ග࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࡀ⫢⤌⧊✚ࡍࡿࡇ࡛⏕ࡌࡿ⫢㞀ᐖࠊ࣑ ࢺࢥࣥࢻࣜࡢᶵ⬟㞀ᐖࡸ⫹Ồ㓟ྜᡂ⬟ࡢపୗ⏤᮶ࡍࡿ௦ㅰ≀ኚືࡀࠊࢺࣜࣉࣝᅄ㔜ᴟ ᆺ㉁㔞ศᯒ⨨㸦LC/MS㸧ࢆ⏝࠸ࡓ୍ᩧศᯒࡼࡗ࡚♧၀ࡉࢀࡓࠋ ́́ P-27 ࣐ࢡࣟࣇ࣮ࣟLC/MS/MS ࡼࡿᒀ୰పศᏊ࣌ࣉࢳࢻ୍ᩧศᯒἲ ⏣ṇつ, బ⸨ᙪ, 㝜ᒣಙ, ᒸ㔝㞞ே ᰴᘧ♫ LSI ࣓ࢹ࢚ࣥࢫ ࣥࢳࢻ࣮ࣆࣥࢢࣛ࣎ࣛࢺ࣮ࣜ Doping control analysis of small peptides in human urine by microfluidic chromatography/tandem mass spectrometry Masanori Ohta, Mitsuhiko Sato, Shinji Kageyama, Masato Okano, Anti-Doping Laboratory, LSI Medience Corporation ࠙┠ⓗࠚ㏆ᖺࠊ➇ᢏࢫ࣏࣮ࢶ࠾࠸࡚ᡂ㛗࣍ࣝࣔࣥศἪ่⃭≀㉁㸦GHS㸧ࢆࡣࡌࡵࡍࡿప ศᏊ࣌ࣉࢳࢻࢆ⏝࠸ࡓࢻ࣮ࣆࣥࢢࡀࡁ࡞ၥ㢟࡞ࡗ࡚࠸ࡿࠋࡇࢀࡽపศᏊ࣌ࣉࢳࢻࡢศ ᯒ࡛ࡣࠊᒀ୰⃰ᗘ࡛ᩘ༑ pg/mL ࡽᩘⓒ pg/mL ప⃰ᗘ࡛ࡢ᳨ฟࡀྍ⬟࡞㧗ឤᗘศᯒࡀᚲ せ࡛࠶ࡿࠋ㏻ࠊప⃰ᗘ≀㉁ࡢ㧗ឤᗘศᯒࡣࢼࣀࣇ࣮࡛ࣟࡢ ESI ࢜ࣥࡼࡿ㧗ឤᗘ LC/MS/MS ἲࡀ⏝࠸ࡽࢀࡿࡀࠊࢼࣀࣇ࣮ࣟศᯒࡣࢫࣉ࣮࣮ࣞࣖࡢㄪᩚ࡞ྲྀᢅ࠸ࡀ㞴ࡋࡃࠊ ࡲࡓศᯒ㛫ࡶ㛗ࡃࢫ࣮ࣝࣉࢵࢺࡀప࠸ࡇࡀ㞴Ⅼ࡛࠶ࡿࠋWaters ♫ࡢ IonKey ࣔࢪ࣮ࣗࣝ ࢆ⏝࠸ࡓ࣐ࢡࣟࣇ࣮࡛ࣟ࢜ࣥࡣࠊࢼࣀࣇ࣮ࣟẚὶ㏿ࡀ㏿ࡃࠊࡲࡓศᯒ࣒࢝ࣛ ࢫࣉ࣮࣮ࣞࣖࡀ୍య࡞ࡗ࡚࠾ࡾࢫࣉ࣮࣮ࣞࣖࡢㄪᩚࡀせ࡛࠶ࡿࡓࡵࠊࢫ࣮ࣝࣉࢵࢺ࠾ ࡼࡧỗ⏝ᛶࡢ㧗࠸㧗ឤᗘศᯒࡀྍ⬟࡛࠶ࡿࠋࡑࡇ࡛ࠊᡃࠎࡣࡇࡢ࣐ࢡࣟࣇ࣮ࣟLC/MS/MS ࡼࡾᒀ୰ࡢపศᏊ࣌ࣉࢳࢻࡢ㧗ឤᗘ㎿㏿୍ᩧศᯒἲࡢ㛤Ⓨࢆ⾜ࡗࡓࠋ ࠙᪉ἲࠚᒀ 1mL ෆ㒊ᶆ‽⁐ᾮ࠾ࡼࡧ 0.8 M ࣜࣥ㓟⦆⾪ᾮ (pH 7.4) ࢆῧຍࡋࠊ㏫┦࣑ࢵࢡ ࢫ࣮ࣔࢻᙅ㝧࢜ࣥᆺ࣒࢝ࣛ (Oasis WCXࠊWaters) ࡼࡿᅛ┦ᢳฟࢆ⾜ࡗࡓࠋᢳฟᾮ ࢆ 45Υࠊῶᅽୗ࡛㐲ᚰ⃰⦰ࡋࠊṧࡉࢆ 0.1% HCOOH ࡛⁐ゎࡋࠊࢧࣥࣉࣝ⁐ᾮࡋࡓࠋࡇ ࡢࢧࣥࣉࣝ⁐ᾮࢆ࣐ࢡࣟࣇ࣮ࣟLC/MS/MS ࢆ⏝࠸࡚ศᯒ࣭ ᐃࡋࡓࠋ ⨨ࡣ nanoACQUITY UPLC/Xevo TQ-S/ion Key (Waters)ࠊࢺࣛࢵࣉ࣒࢝ࣛࡣ M-Class Trap Symmetry C18 100ύ (5 ȝm 300 ȝm×50 mmࠊWaters)ࠊศᯒ࣒࢝ࣛࡣ BEH C18 130ύ iKey (1.7 ȝm 150 ȝm×100 mmࠊ Waters)ࢆ⏝ࡋࡓࠋ⛣ື┦ࡣ 0.1% HCOOH ࠾ࡼࡧ 0.1% HCOOH in CH3CN ࢆ⏝࠸ࠊࢢࣛ ࢪ࢚ࣥࢺ⁐ฟࡋࡓࠋ࢜ࣥࡣ ESI (+)ࡋࠊ1 ᡂศ࠶ࡓࡾ 2 ࡘࡢ mass transition ࡼࡿ MRM ᐃࢆ⾜ࡗࡓࠋ ࠙⤖ᯝ࣭⪃ᐹࠚ࣐ࢡࣟࣇ࣮ࣟLC/MS/MS ࡼࡿᒀ୰పศᏊ࣌ࣉࢳࢻࡢ 31 ᡂศ୍ᩧศᯒἲࢆ ☜❧ࡋࡓࠋ᳨ฟឤᗘࡣࢼࣀࣇ࣮ࣟศᯒᴫࡡྠ⛬ᗘࡢ㧗ឤᗘศᯒࡀྍ⬟࡛࠶ࡾࠊศᯒ㛫 ࡶ 1 ᳨య 15 ศ㧗࠸ࢫ࣮ࣝࣉࢵࢺศᯒࢆྍ⬟ࡋࡓࠋᮏἲࡢࢻ࣮ࣆࣥࢢ᳨ᰝࡢ㐺⏝ᛶࢆ ☜ㄆࡍࡿࡓࡵࠊGHS 〇ࡢ୍ࡘ࡛࠶ࡿ GHRP-2 ࡢ᭹⏝⪅ࡢᒀヨᩱࢆᮏἲࡼࡾศᯒࡋࡓ ࡇࢁⰋዲ࡞᳨ฟࡀྍ⬟࡛࠶ࡗࡓࠋᮏἲࡣࠊࢻ࣮ࣆࣥࢢ᳨ᰝ࡛ࡶヨᩱࡋ࡚ࢃࢀጞࡵࡓ⾑ Ύヨᩱ୰ࡢపศᏊ࣌ࣉࢳࢻศᯒࡢ㐺⏝ࡶྍ⬟࡞ࡿࡇࡀᮇᚅ࡛ࡉࢀࡿࠋ ́́ P-28 nano LC/MS/MS ࢆ⏝࠸ࡓࣛࢵࢺ⫢⮚୰⫹Ồ㓟୍ᩧศᯒἲࡢᵓ⠏ ὸ㔝⨾ 1,2, ㈈ὠ ᱇ 1, ℧ኴᮁ 1, ⲡ㔝㯞⾰Ꮚ 1, ᳃୍ဢ 2, ෆ⸨ஂ㞝 3, 㑣㡲ẸỤ 4, ᅵᶫ ᆒ 1, ▼ 1 1 ྡྂᒇᏛᏛ㝔་Ꮫ⣔◊✲⛉, 2 㔠ᇛᏛ㝔Ꮫ⏕ά⎔ቃᏛ㒊, 3 ⸨⏣ಖ⾨⏕Ꮫ་Ꮫ㒊, 4 ୰㒊Ꮫ⏕ᗣ⛉Ꮫ㒊 Development of a simultaneous analytical method of bile acids in rat liver by nano LC/MS/MS Tomomi Asano1,2, Kei Zaitsu1, Kentaro Taki1, Maiko Kusano1, Kazuya Kitamori2, Hisao Naito3, Tamie Nasu4, Hitoshi Tsuchihashi1, Akira Ishii1 1 Nagoya University Graduate School of Medicine, 2College of Human Life and Environment, Kinjo Gakuin University, 3Fujita Health University School of Medicine, 4College of Life and Health Sciences, Chubu University ࠙┠ⓗࠚ⫹Ồ㓟㸦BA㸧ࡣ့ங㢮ࡢ⫹ỒᏑᅾࡍࡿࢫࢸࣟࢻㄏᑟయࡢ⥲⛠࡛࠶ࡿࠋᡃࠎࡣࡇ ࢀࡲ࡛⏕యヨᩱ୰ BA ࡢ୍ᩧศᯒἲࡋ࡚ࠊUPLC/MS/MS ࢆ⏝࠸ࡓᡭἲࢆᵓ⠏ࡋ࡚ࡁࡓࠋᮏ ἲࡣከ᳨యࢆࣁࢫ࣮ࣝࣉࢵࢺ࡛ฎ⌮ࡍࡿࡇࢆ┠ⓗࡋࡓศᯒἲ࡛࠶ࡿࡀࠊ୍⯡ BA ࡣከࡃࡢ␗ᛶయࡀᏑᅾࡍࡿࡓࡵࠊࡼࡾศ㞳ᛶ⬟ࡢ㧗࠸ศᯒἲࡶྍḞ࡛࠶ࡿࠋࡑࡇ࡛ᮏ◊ ✲࡛ࡣࠊnano LC ࢆ⏝࠸ࡓ⫹Ồ㓟୍ᩧศᯒἲࡢᵓ⠏ࢆヨࡳࡓࠋࡉࡽࠊࣛࢵࢺ⫢⮚ࡽࡢ BA ᢳฟ᮲௳ࡘ࠸࡚ࡶ᳨ウࡋࠊࣛࢵࢺ⫢⮚ヨᩱࡽࡢ⫹Ồ㓟୍ᩧศᯒἲࢆ᳨ウࡋࡓࠋ ࠙᪉ἲࠚBA㸦28 ✀㸧ࡣᕷ㈍ᶆ‽ရࢆ㉎ධࡋࡓࠋࡲࡓࠊෆ㒊ᶆ‽ࡋ࡚ 4 ✀㢮ࡢ BA Ᏻᐃྠ యᶆ㆑ྜ≀ࢆ⏝ࡋࡓࠋ⨨ࡣ nano LC ࢩࢫࢸ࣒ DiNa-2A㸦KYA Tech㸧࠾ࡼࡧ 4000 QTRAP 㸦AB Sciex㸧ࢆ⏝ࡋࡓࠋศᯒ᮲௳ࡢ᳨ウ㸸0.1 ng/mL ࡲࡓࡣ 1 ng/mL ㄪᩚࡋࡓ BA ᶆ‽ရ ΰྜᾮศ㞳᮲௳ࢆ⏝࠸࡚ࠊSRM ᮲௳ࡢ᭱㐺࠾ࡼࡧ⨨ឤᗘࡢ☜ㄆࢆ⾜ࡗࡓࠋࡲࡓࠊ⛣ື┦ 㓑㓟ࣥࣔࢽ࣒࢘Ỉ⁐ᾮࠊ࣓ࢱࣀ࣮ࣝ㸦MeOH㸧࠶ࡿ࠸ࡣࢭࢺࢽࢺࣜࣝ㸦ACN㸧ࢆ⏝࠸࡚ ศ㞳᮲௳ࢆ᳨ウࡋࡓࠋ࣍ࣔࢪࢼࢬ᮲௳ࡢ᳨ウ㸸50% MeOHࠊMeOHࠊACN ࠶ࡿ࠸ࡣ MeOH࣭ACN ΰᾮ㸦1:1, v/v㸧࡛ࣛࢵࢺ⫢ヨᩱࢆࡑࢀࡒࢀ࣍ࣔࢪࢼࢬࡋࡓࠋ㐲ᚰศ㞳ᚋࡢୖΎࢆ⃰⦰ ᅛࡋࠊ⛣ື┦⁐ゎࡋࡓࡶࡢࢆศᯒヨᩱࡋࡓࠋ ࠙⤖ᯝ࠾ࡼࡧ⪃ᐹࠚ⛣ື┦ ACN ࢆ⏝࠸ࡓሙྜࠊ୍㒊ࡢࣆ࣮ࢡࡀඹ⁐ฟࡋࠊศ㞳ࡀᅔ㞴࡛࠶ ࡗࡓࡀࠊMeOH ࢆ⏝࠸ࡓሙྜࡣྛࣆ࣮ࢡࢆⰋዲศ㞳࡛ࡁࡓࠋᶆ‽ရࢆ⏝࠸ࡓ⨨ឤᗘࡋ ࡚ࠊ ᴫࡡ 0.1 ng/mL(SRM ࣮ࣔࢻ)ࡢ᳨ฟࡀྍ⬟࡛࠶ࡗࡓࠋ ࡲࡓࠊ ᪤ሗᚑࡗ࡚⫢ヨᩱࢆ 50% MeOH ࡛࣍ࣔࢪࢼࢬࡋࡓሙྜࠊࡑࡢᚋࡢ⬺ሷ࠾ࡼࡧ㝖ࢱࣥࣃࢡ᧯సࡀ↹㞧࡛࠶ࡿࡇࡽࠊ᭷ ᶵ⁐፹ࢆ⏝࠸ࡓ࣍ࣔࢪࢼࢬἲࡘ࠸᳨࡚ウࡋࡓࠋࡑࡢ⤖ᯝࠊMeOH࣭ACN ΰᾮࢆ⏝࠸ࡓ࣍ࣔ ࢪࢼࢬἲ࡛ࡣࠊẚ㍑ⓗⰋዲ࡞ᅇ⋡ࡀᚓࡽࢀࠊ⫢ヨᩱ୰ࡢ⡆᫆ BA ᢳฟࡀྍ⬟࡞ࡗࡓࠋ ́́ P-29 LC-MS/MS ἲࡼࡿ㇋ࢯࣇࣛ࣎ࣥ࠾ࡼࡧ࢚ࢡ࣮࢜ࣝࡑࡢᢪྜ௦ㅰ≀ࡢ ୍ᩧศᯒἲࡢ᳨ウ ᮌୗ⍞㈗ 1, ⣽⏣㤶⧊ 1, ᰘᓮᾈ⨾ 2, ᶓᕝᙲ᭸ 2, ▼ኵ 1 1 ᮥᯘᏛಖᏛ㒊, 2 ᮾி⸆⛉Ꮫ⸆Ꮫ㒊 Simultaneous analysis of daidzein, genistein, equol and their metabolites in humans by liquid chromatography tandem mass spectrometry Mizuki Kinoshita1, Kaori Hosoda1, Hiromi Shibasaki2, Akitomo Yokokawa2, Kazuo Ishii1 1 Kyorin University Faculty of Health Sciences 2 Tokyo University of Pharmacy and Life Sciences School of Pharmacy ࠙┠ⓗࠚࢲࢮࣥࡸࢤࢽࢫࢸࣥ௦⾲ࡉࢀࡿ㇋ࢯࣇࣛ࣎ࣥࡣࠊ࢚ࢫࢺࣟࢤࣥస⏝ࢆ ᭷ࡍࡿࡓࡵࠊ࣍ࣝࣔࣥ౫Ꮡᛶᝈࡢண㜵᭷ຠ࡛࠶ࡿࠋ୍᪉ࠊ࢚ࢡ࣮࢜ࣝࡣࠊ⭠ෆ⣽⳦ ࡼࡾࢲࢮࣥࡽ⏕ᡂࡉࢀࠊࡼࡾᙉຊ࡞࢚ࢫࢺࣟࢤࣥస⏝ࢆᣢࡘࡓࡵ᭦ᖺᮇ≧ࡢ⦆ ࢆᮇᚅࡋࡓ㣗ရᡂศࡋ࡚ࡶὀ┠ࢆ㞟ࡵ࡚࠸ࡿࠋ࢚ࢫࢺࣟࢤࣥస⏝ࢆࡣࡌࡵࡍࡿ㇋ ࢯࣇࣛ࣎ࣥࡢ⏕యస⏝ࢆṇ☜ホ౯ࡍࡿࡓࡵࡣࠊ⾑୰࠾ࡼࡧᒀ୰ࡢࢲࢮࣥࡸࢤࢽ ࢫࢸࣥࡢࡳ࡞ࡽࡎ࢚ࢡ࣮࢜ࣝࡢ௦ㅰ࣭యෆືែࡢ⥙⨶ⓗ࡞ᢕᥱࡀᚲせ࡛࠶ࡿࠋᡃࠎࡣ᪤ HPLC ࢆ⏝࠸ࡓࢲࢮࣥࢤࢽࢫࢸࣥࡢᢪྜ௦ㅰ≀୍ᩧศᯒἲࢆሗ࿌ࡋࡓࠋ ࡋࡋࠊ ࢚ࢡ࣮࢜ࣝ㛵ࡋ࡚ࡣࠊᢪྜ௦ㅰ≀ࢆྵࡴ୍ᩧศᯒἲࡀ࡞࠸ࠋࡑࡇ࡛ LC-MS/MS ἲࢆ⏝࠸ ࡿࢲࢮࣥࠊࢤࢽࢫࢸࣥ࠾ࡼࡧ࢚ࢡ࣮࢜ࣝࡑࡢᢪྜ௦ㅰ≀ࡢ୍ᩧศᯒἲࢆ᳨ウࡋࡓࠋ ࠙᪉ἲࠚLC-MS/MS ࡣ TSQ Quantum Ultra (Thermo Fisher Scientific) ࢆ⏝࠸ࡓࠋࢲࢮࣥࠊ ࢤࢽࢫࢸࣥࠊ࢚ࢡ࣮࢜ࣝࡑࢀࡽࡢᢪྜ௦ㅰ≀ 24 ✀ࢆศᯒᑐ㇟ࡋࡓࠋྛᢪྜయࡢᶆ ရࡣᏛྜᡂࡋࠊLC-MS NMR ࡚ᵓ㐀ࢆỴᐃࡋࡓࠋ࣒࢝ࣛ YMC-Triart C18 (100×2.0 mm I.D., 3 Pm; YMC)ࠊ⛣ື┦㓑㓟ࣥࣔࢽ࣒࢘⁐ᾮࢭࢺࢽࢺࣜࣝ㸦ࢢࣛࢪ࢚ࣥࢺἲ㸧 ࢆ⏝࠸࡚ LC ศ㞳ࡋࡓᚋࠊᶆရࢆ⏝࠸࡚᭱㐺ࡋࡓ SRM ᳨ฟ᮲௳ୗ࡚ 24 ✀ࢆศᯒࡋࡓࠋ ࠙⤖ᯝ࣭⪃ᐹࠚࡍ࡛☜❧ࡋ࡚࠸ࡿ HPLC ࡼࡿࢲࢮࣥࢤࢽࢫࢸࣥࡢᢪྜ௦ㅰ≀ࡢ ୍ᩧศᯒ᮲௳ࢆ㐺⏝ࡋࡓࡇࢁࠊ24 ✀ࡣ 35 ศ௨ෆ࡚⁐㞳ࡉࢀࡓࠋࢲࢮࣥࢤࢽࢫ ࢸࣥࡑࡢᢪྜ௦ㅰ≀ 14 ✀࠾ࡼࡧ࢚ࢡ࣮࢜ࣝࡑࡢ㔜ᢪྜయ 3 ✀ࡘ࠸࡚ࡣⰋዲࣆ ࣮ࢡศ㞳ࡋࡓࠋࡋࡋࠊ࢚ࢡ࣮࢜ࣝࡢࢢࣝࢡࣟࣥ㓟࠾ࡼࡧ◲㓟ࡢᢪྜ⨨␗ᛶయ 4 ✀ࡣ ศ㞳࡛ࡁࡎࠊLC ศ㞳᮲௳ࡢ᳨ウࢆ㐍ࡵ࡚࠸ࡿࠋศ㞳᮲௳ࡢ☜❧ᚋࡣࠊࡁ࡞⢊ (10 g) ࢆ ᦤྲྀࡋࡓ⿕㦂⪅࠾ࡅࡿ⾑₢୰ࢲࢮࣥࠊࢤࢽࢫࢸࣥ࠾ࡼࡧ࢚ࢡ࣮࢜ࣝࡑࡢᢪྜ௦ ㅰ≀ࡢ ᐃࢆ⾜࠺ணᐃ࡛࠶ࡿࠋ㇋ࢯࣇࣛ࣎ࣥࡑࡢᢪྜ௦ㅰ≀ࡢ௦ㅰ࣭యෆືែ◊✲ ࡣࠊ㇋ࢯࣇࣛ࣎ࣥࡢ⏕యస⏝ࡢṇ☜࡞ホ౯᭷⏝࡞ሗࢆᥦ౪ࡍࡿࡶࡢ⪃࠼ࡿࠋ ́́ P-30 ⮫ᗋ᳨ᰝࢆ┠ⓗࡋࡓ LC-MS/MS ࡼࡿ⾑Ύ୰ࢩࣝ࢝ࣝࢽࢳࣥࡢᐃ㔞ศᯒἲࡢ 㛤Ⓨ ᑠᯘᘯ 1, ᒣ⏣ 1, ᆓ ு㍜ 1, 㛗㇂ᕝ᭷⣖ 1, ᒣཱྀΎḟ 1, ᇛୗ⩏ 2, ఀ⸨ᑗ 2, ᡭ㔝 2, ཎᡂ 2 1 ᓥ᰿Ꮫ་Ꮫ㒊ᑠඣ⛉, 2 ✚Ỉ࣓ࢹ࢝ࣝᰴᘧ♫ Development of method for acylcarnitines in serum using LC-MS/MS Hironori Kobayashi1, Kenji Yamada1, Ryousuke Bo1, Yuki Hasegawa1, Seiji Yamaguchi1, Tomoyoshi Shiroshita2, Toshimasa Ito2, Akira Ideno2, Toshinari Oh-hara2 1 Department of pediatrics, Shimane University Faculty of Medicine 2 SEKISUI MEDICAL Co., LTD. ࠙┠ⓗࠚLC-MS/MS ࢆ⏝࠸ࡿ᪂⏕ඣ࣐ࢫࢫࢡ࣮ࣜࢽࣥࢢ㸦NBS㸧ࡢᬑཬక࠸ࠊ୍⯡⮫ᗋ࠾ ࡅࡿ⾑Ύ୰ࢩࣝ࢝ࣝࢽࢳࣥ㸦AC㸧ศᯒࡢ㟂せࡀ㧗ࡲࡗ࡚ࡁࡓࠋNBS ࡛⾜ࢃࢀࡿศᯒࡣ⾑ᾮ ࢁ⣬ࢆ⏝࠸ࠊ᪤▱⃰ᗘࡢෆ㒊ᶆ‽┠ⓗ≀㉁ࠊ୧⪅ࡢ࢜ࣥᙉᗘࢆẚ㍑ࡋࠊᐃ㔞ࡉࢀ࡚࠸ࡿࠋ ࡇࡢ᪉ἲࡣపࢥࢫࢺ࡛㔞ศᯒࢆ⾜࠺ࡣඃࢀ࡚࠸ࡿࡀࠊศᯒᶵჾ㛫࡛ᐃ㔞್ࡢᕪ㐪ࡀ⏕ࡌ ࡿࠊᐃ㔞ᛶࡀ༑ศ࡛࡞࠸࡞ࠊ⮫ᗋ᳨ᰝࡋ࡚⏝ࡣㄢ㢟ࡶ࠶ࡿࠋࡑࡇ࡛ᡃࠎࡣ⮫ᗋ᳨ᰝ ࡛ࡢ⏝ࢆᛕ㢌ࠊ⾑Ύ୰ࡢ AC ᐃ㔞ἲࢆᵓ⠏ࡋࠊࣂࣜࢹ࣮ࢩࣙࣥヨ㦂ࢆᐇࡋࡓࠋ ࠙᪉ἲࠚ㏱ᯒฎ⌮ࡋࡓࣄࢺ⾑Ύࠊᐃࡉࢀࡿ AC ⃰ᗘࢆ࢝ࣂ࣮ࡍࡿࡼ࠺ 5 ⃰ᗘㄪ〇ࡋࡓ 15 ✀ࡢ AC ࢆྵࡴΰྜᶆ‽⁐ᾮ㸦1%ࢠ㓟ࢆྵࡴ࢚ࢱࣀ࣮ࣝ⁐ᾮ㸧ࢆῧຍࡋࠊ⢭ᗘ⟶⌮⏝㏵㸦QC ⾑Ύ㸧ࢆවࡡࡓ᳨㔞⥺సᡂ⏝ࡢᶆ‽⾑Ύ 5 ✀㢮ࢆㄪ〇ࡋࡓࠋㄪ〇ࡋࡓ QC ⾑Ύཬࡧᶆ‽⾑Ύ 㸦ྜィ 7 ⃰ᗘ㸧ࠊྛ AC ࡢᏳᐃྠయࢆྵࡴෆ㒊ᶆ‽⁐ᾮࢆῧຍᚋࠊ࢚ࢱࣀ࣮ࣝࢆຍ࠼࡚⁐ ᾮ㒊ศࢆᅇࡋࡓࠋᚓࡽࢀࡓ⁐ᾮࢆ❅⣲Ẽὶୗ࡛ᅛࡋࠊᅛࡋࡓヨᩱ⁐ゎ⁐፹ࢆຍ࠼ ࡚⁐ゎࡋࠊ㐲ᚰศ㞳ᚋࡢୖΎࢆ ᐃ⏝ࢧࣥࣉࣝࡋࡓࠋ ࡞࠾ࠊศᯒࡣ LC-MS/MS㸦LC-20A㸸ᓥὠ〇సᡤཬࡧ API2000㸸AB Sciex㸧ࢆ⏝࠸࡚ HILIC ࣮ࣔࢻࡢศᯒ࣒࡛࢝ࣛ ᐃࢆ⾜ࡗࡓࠋᵓ⠏ࡋࡓྛ AC ࡢᐃ㔞ศᯒἲࡘ࠸࡚ࠊ᳨㔞⥺ࡢ┤⥺ᛶࠊ ୪ࡧࠊQC ⾑Ύ ᐃࡢ᪥ෆཬࡧ᪥㛫࡛ࡢ⌧ᛶཬࡧṇ☜ᛶࡘ࠸࡚ࠊࡑࢀࡒࢀホ౯ࡋࡓࠋ ࠙⤖ᯝ࠾ࡼࡧ⪃ᐹࠚᵓ⠏ࡋࡓࣄࢺ⾑Ύ୰ AC ࡢ⃰ᗘ ᐃἲࡣࠊࡑࢀࡒࢀࠊC0㸦2.0㹼200 ȝPRO/㸧 ࠊ C2㸦1.0㹼100 ȝPRO/ࠊ௨ୗ༢┬␎㸧 ࠊC3㸦0.24㹼24㸧 ࠊC4㸦0.1㹼10㸧 ࠊC5㸦0.06㹼6㸧 ࠊC5-OH ࠊC6㸦0.05㹼5㸧 ࠊC8㸦0.05㹼5㸧 ࠊC10㸦0.05㹼5㸧 ࠊC12㸦0.05㹼5㸧 ࠊ 㸦0.1㹼10㸧 ࠊC5-DC㸦0.05㹼5㸧 C14㸦0.06㹼6㸧 ࠊC14:1㸦0.06㹼6㸧 ࠊC16㸦0.24㹼2.4㸧ཬࡧ C18㸦0.1㹼10㸧ࡢᐃ㔞⠊ᅖ࡛Ⰻዲ࡞ ┤⥺ᛶࡀᚓࡽࢀࠊࡑࢀࡽࡢ᳨㔞⥺ࡢ┦㛵ಀᩘ㸦㹰㸧ࡣ 0.9942㹼0.9998 ࡛࠶ࡗࡓࠋ ࡲࡓࠊᶆ‽⾑Ύྠ ᐃࡋࡓ QC ⾑Ύࡢ᪥ෆ࡛ࡢ⌧ᛶ㸦CV%㸧ཬࡧṇ☜ᛶ㸦RE%㸧 ࡣࠊ࡚ࡢ AC 㛵ࡋ࡚ࠊCV% = 1.0㹼12.3%ཬࡧ RE% = -13.6㹼10.0%ࡢ⠊ᅖ࡛࠶ࡾࠊⰋዲ࡞ ⤖ᯝࡀᚓࡽࢀࡓࠋࡲࡓࠊ 3 ᪥㛫ࡢ⌧ᛶཬࡧṇ☜ᛶࢆホ౯ࡋࡓࡇࢁࠊࡑࢀࡒࢀ CV% = 2.4 㹼10.2%ཬࡧ RE% = -11.5㹼8.1%Ⰻዲ࡛࠶ࡗࡓࠋᅇ☜❧ࡋࡓศᯒ᪉ἲ࡛ࡣ⢭ᗘ⟶⌮⏝᳨య ࢆ᳨㔞⥺సᡂ⏝᳨యࡋ࡚⏝࡛ࡁࡿ⢭ᗘ࠶ࡆࡿ࡛ᚑ᮶ࡣูࠎ⾜ࢃࢀ࡚࠸ࡓᕤ⛬ࢆ༢ ⣧ࡋࡓࠋࡇࡢศᯒἲࡼࡾ LC-MS/MS ࡼࡿ⾑Ύ AC ศᯒἲࡢᶆ‽ࡀྍ⬟࡛࠶ࡾࠊ⢭ᐦ ᳨ᰝࡸࣇ࢛࣮ࣟࢵࣉࡢศᯒ㈉⊩ࡍࡿࡀᮇᚅࡉࢀࡿࠋᮏⓎ⾲࡛ࡣࠊᮏ ᐃἲࡼࡾ୍ ⯡᳨యࢆ ᐃࡋࡓ⤖ᯝࡘ࠸࡚ࡶሗ࿌ࢆ⾜࠺ணᐃ࡛࠶ࡿࠋ ́́ P-31 LC/ESI-MS/MSࡼࡿ⾑₢୰25-hydroxyvitamin D3ཬࡧࡑࡢ◲㓟ᢪྜయࡢྠ ᐃ㔞ἲࡢ㛤Ⓨ ᚋ⸨ᙬె1, ᶓ⏣㯞⾰1, ᑠᕝ⚈㑻1, ᑠᯇ㈼ྖ2, ᮡᾆᓫᾈ2, ᮾ 㐩ஓ1 1 ᮾி⌮⛉Ꮫ⸆Ꮫ㒊, 2㟼ᒸ῭⏕⥲ྜ㝔 Development of a method for simultaneous determination 25-hydroxyvitamin D3 and its 3-sulfate by LC/ESI-MS/MS of plasma Ayaka Goto1㸪Mai Yokota1㸪Shoujiro Ogawa1㸪Kenji Komatsu2㸪Takahiro Sugiura2㸪Tatsuya Higashi1 1 Faculty of Pharmaceutical Sciences, Tokyo University of Science 2 Shizuoka Saiseikai General Hospital 䛆┠ⓗ䛇 ᭱㏆ࠊᑠඣ࠾ࡅࡿࣅࢱ࣑ࣥ D ㊊ࡀࡃࡿ࡞ࡢ㦵ᝈࡢࡳ࡞ࡽࡎࠊᑗ᮶ࡢ⢾ᒀ ࡸከⓎᛶ◳࡞ࡢ༴㝤ᅉᏊࡶ࡞ࡿࡇࡀሗ࿌ࡉࢀࠊὀ┠ࡉࢀ࡚࠸ࡿࠋ⌧ᅾࠊࣅࢱ ࣑ࣥ D ࡢ౪⤥≧ែࡣ⾑୰ 25-hydroxyvitamin D3 [25(OH)D3] ⃰ᗘᇶ࡙࠸࡚ホ౯ࡉࢀ࡚࠸ࡿ ࡀࠊඛᡃࠎࡣ⾑₢୰ 25(OH)D3 3-sulfate [25(OH)D3S] ࡢ LC/ESI-MS/MS ᐃ㔞ἲࢆ㛤Ⓨࡍࡿ ࡶࠊஙඣ࡛ࡣ 25(OH)D3S ࡀ 25(OH)D3 ࡼࡾࡶ㧗⃰ᗘ࡛Ꮡᅾࡍࡿࡇࠊࡲࡓࠊࡑࡢࣞ࣋ ࣝࡣṇᮇ⏘ඣࡼࡾࡶ᪩⏘ඣ࡛ప࠸ࡇࢆ᫂ࡽࡋࡓ 1) ࠋ25(OH)D3S ࡣ㈓ⶶᆺࣅࢱ࣑ࣥ D ࡋ࡚ാ࠸࡚࠸ࡿࡶ⪃࠼ࡽࢀࠊஙඣࡢࣅࢱ࣑ࣥ D ౪⤥≧ែࢆࡼࡾṇ☜ホ౯ࡍࡿࡣࠊ ⾑୰ 25(OH)D3 ࡶ 25(OH)D3S ࢆྠᐃ㔞ࡍࡿࡇࡀ㔜せ⪃࠼ࡽࢀࡿࠋᚑ᮶ࡢ᪉ἲࡣ 25(OH)D3 䛸 25(OH)D3S 䜢ู䚻䛻ᐃ㔞 (䛭䜜䛮䜜ṇ䜲䜸䞁ཬ䜃㈇䜲䜸䞁᳨ฟ) 䛩䜛䜒䛾䛷䛒䛳䛯䛜䚸 ᅇ䚸䝇䝹䞊䝥䝑䝖䛾ྥୖ䜢┠ᣦ䛧䚸୧䝡䝍䝭䞁 D ௦ㅰ≀䛾ྠᐃ㔞ἲ䛾㛤Ⓨ䜢ヨ䜏䛯䚹 䛆ᐇ㦂䛇 ⾑₢ ȝ/ ࢆ 2H3-25(OH)D3 ཬࡧ 2H6-25(OH)D3S (ෆᶆ‽≀㉁) ࢆྵࡴ MeCN ࡛㝖 ⺮ⓑᚋࠊOasis HLB ࣮࢝ࢺࣜࢵࢪ࡚⢭〇ࡋࠊDAPTAD ࡼࡿㄏᑟయᛂࡋࡓࠋࡇࢀ ࢆ௨ୗࡢ᮲௳ࡢ LC/ESI-MS/MS ࡋࡓ [⨨㸸Waters LC-2695 ࢆ Waters Quattro Premier XE ᥋⥆㸹࣒࢝ࣛ㸸YMC-3DFN3UR&56ȝP㸪150 × 2.0 mm i.d.)㸹⛣ື┦㸸ࢢࣛࢪ࢚ࣥࢺ⁐ ฟ㸪MeOH-0.05% HCOOH ྵ᭷ 10 mM HCOONH4 (4:1ࠊv/v) Ѝ MeCN-0.05% HCOOH ྵ᭷ 10 mM HCOONH4 (9:1ࠊv/v)㸹ὶ㏿㸸0.2 mL/min㸹᳨ฟ㸸SRM]ࠋ 䛆⤖ᯝ䛇 DAPTAD ㄏᑟయࡼࡾࠊṇ࢜ࣥ ESI-MS/MS ࡼࡿ 25(OH)D3 25(OH)D3S ࡢ ྠᐃ㔞ࡀྍ⬟࡞ࡿࡶࠊ25(OH)D3 3-epi-25(OH)D3 (άᛶ௦ㅰ≀) ࡢศ㞳ࡶ㐩ᡂ ࡉࢀࡓࠋ᳨㔞⥺ࡣ 25(OH)D3 ࡛ࡣ 1.0–50 ng/mLࠊ25(OH)D3S ࡛ࡣ 2.5–50 ng/mL ࡢ⠊ᅖ࡛ r2 Ӎ 0.994 ࡢ┤⥺ᛶࡀᚓࡽࢀࠊஙඣࣉ࣮ࣝ⾑₢ࢆ⏝࠸ࡓ⌧ᛶヨ㦂 (RSD㸸4.5%௨ୗ) ࡢ⤖ᯝࡶ Ⰻዲ࡛࠶ࡗࡓࠋ⌧ᅾࠊ᪩⏘ඣࢆྵࡴஙඣ (⏕ᚋ 10 ᪥௨ෆ) ࡢ⾑₢୰୧௦ㅰ≀ࡢᐃ㔞ࢆ㐍ࡵ ࡚࠾ࡾࠊࡇࡢ⤖ᯝࡘ࠸࡚ࡶⓎ⾲ࡍࡿணᐃ࡛࠶ࡿࠋ 䛆ཧ⪃ᩥ⊩䛇-------------------------------------------------------------------------------------------------------------J. Chromatogr. B, 969, 230–234 (2014). ́́ P-32 LC-MS/MS ࡼࡿ⾑Ύ࢚ࢫࢺࣟࢤࣥ࠾ࡼࡧࣉࣟࢤࢫࢸࣟࣥࡢྠᐃ㔞 ᐑᯘభ⾰ 1, బ⸨ Ᏺ 2, ⬥ṇ㈗ 2, すᮧ ᇶ 1, ᯇୗ୍அ 1, 㔝ᮧᩥኵ 2 1 ༓ⴥᏛᏛ㝔 ་Ꮫ◊✲㝔 ศᏊែゎᯒᏛ 2 ༓ⴥᏛ་Ꮫ㒊㝃ᒓ㝔࣐ࢫࢫ࣌ࢡࢺ࣓ࣟࢺ᳨࣮ࣜᰝデ᩿Ꮫ Simultaneous measurement of estrogens and progesterone in serum by LC-MS/MS Yui Miyabayashi1, Mamoru Satoh2, Masaki Takiwaki2, Motoi Nishimura1, Kazuyuki Matsushita1, Fumio Nomura2 1 Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University 2 Division of Clinical Mass Spectrometry, Chiba University Hospital ࠙┠ⓗࠚ⌧ᅾ⮫ᗋ᳨ᰝᐊ࡛ࡣ⾑୰ࡢ 17ș࢚ࢫࢺࣛࢪ࣮࢜ࣝ(E2)࣭ࣉࣟࢤࢫࢸࣟࣥ(P)ࡢ ᐃ චᏛⓗ ᐃἲࢆ⏝࠸࡚࠸ࡿࠋචᏛⓗ ᐃἲࡣࣁࢫ࣮ࣝࣉࢵࢺ࡛࠶ࡾ᳨య᳨ᰝ࠾࠸ ࡚ᚲ㡲ࡢᢏ⾡࡛࠶ࡿࡀࠊ⏝ᢠయࡢᕪᛂࡼࡾᵓ㐀␗ᛶయࡸ௦ㅰ⏘≀ࡢ ࡾ㎸ࡳࡀᣦ ࡉࢀ࡚࠸ࡿࠋࡲࡓࠊE2 ࡣ㛢⤒ᚋࡢዪᛶࡸᑠඣࡢ᳨య࡛ࡣ ᐃឤᗘ௨ୗ࡞ࡾࠊែᢕᥱ ᚲせ࡞ ᐃ್ࡀᚓࡽࢀ࡚࠸࡞࠸ࡢࡀ⌧≧࡛࠶ࡿࠋLC/MS/MS ࢆ⏝࠸ࡓ ᐃ࡛ࡣᚤ⣽࡞ᵓ㐀 ኚࢆᘚูࡋ࡚ ᐃ࡛ࡁࡿࡇຍ࠼ࠊྠከ㡯┠ࡢ ᐃࡀྍ⬟࡞ࡿࠋᐇ㝿⮫ᗋࢧ ࢻࡽ᳨ᰝᐊ࣮࢜ࢲ࣮ࡉࢀࡿ㡯┠ࡋ࡚ E2 P ࡣࢭࢵࢺ࡛ฟࡉࢀࡿࡇࡀከ࠸ࠋࡑࡇ࡛ ᅇࠊࡼࡾ㧗ឤᗘ࡛ࢫ࣮ࣝࣉࢵࢺࡢ㧗࠸࢚ࢫࢺࣟࢤࣥࣉࣟࢤࢫࢸࣟࣥࡢྠ ᐃἲࡢᵓ ⠏ࢆ┠ᣦࡋ᳨ウࢆ⾜ࡗࡓࠋ ࠙᪉ἲࠚ⾑Ύࡣࣥࣇ࢛࣮࣒ࢻࢥࣥࢭࣥࢺࡢᚓࡽࢀࡓᖖேዪᛶࢆ⏝ࠋ⣧ရࡲࡓࡣ⾑Ύ ȝO ࢆ␃Ỉ࡛ಸᕼ㔘ࡋࠊ,6ȝO ࢆῧຍ࣭ΰᚋ SLE (Supported Liquid extraction)ࢆ⾜ࡗ ࡓࠋSLE ࡣ 96well ࣇ࢛࣮࣐ࢵࢺࡢ ISOLUTE SLE+ࢆ⏝ࡋࡓࠋᢳฟᾮࡣ⇱ᚋ Dansyl Chloride ࡼࡿㄏᑟయࢆ 60Υ࡛ 5 ศ㛫⾜࠸ SRM ᐃࢆ⾜ࡗࡓࠋศ㞳ࡣ UPLC(Bruker) ࢆ⏝࠸ࠊ࢜ࣥἲࡣ ESI ἲࠊ㉁㔞ศᯒィࡣ୕㐃ᅄ㔜ᴟ㉁㔞ศᯒィ EVOQ Elite (Bruker)⏝࠸ ࡓࠋ ࠙⤖ᯝࠚ⣧ရࢆ⏝ࡋࡓྠ⌧ᛶ%CV(n=5)ࡣ E1 5.84%ࠊE2 6.42%ࠊP 5.6%࡛࠶ࡗࡓࠋࡲࡓ ⣧ရ࡛ࡢ LOQ(SN=10)ࡣ E1 5pg/mlࠊE2 5pg/mlࠊP 50pg/ml ࡛࠶ࡗࡓࠋSLE ࢆ⏝࠸ࡓ๓ฎ⌮࡛ ࡢᅇ⋡(n=5)ࡣ E1 92.7%ࠊE2 91.2%ࠊP 83.8%Ⰻዲ࡞⤖ᯝ࡛࠶ࡗࡓࠋ ࠙⪃ᐹࠚ᳨ウ᳨యᩘࡀ༑ศ࡛ࡣ࡞࠸ࡀࠊᚑ᮶㝔᳨ᰝᐊ࡛ࢃࢀ࡚࠸ࡿ᪉ἲྠ➼ࡢᐃ㔞ឤ ᗘࢆᚓࡿࡇࡀ࡛ࡁࡓࠋᚋࠊNISTࠊBCR ࢆ⏝࠸ࡓṇ☜ᗘࠊ⢭ᗘࡢ᳨ウࢆ㐍ࡵࡿࠋࡲࡓࠊ ⌧ᅾ༓ⴥᏛ㝔࡛ࡣデᐹ๓᳨ᰝࢆ⾜ࡗ࡚࠾ࡾࠊ᳨యࢆཷ⌮ࡋ࡚ࡽ ᐃ⤖ᯝࢆ⮫ᗋሗ ࿌ࡍࡿࡲ࡛ࡢ㛫ࡣ㸯㛫௨ෆ࡛࠶ࡿࠋᅇࡢ ᐃ᪉ἲ࡛ࡣ๓ฎ⌮ࢆ⡆౽࡞ SLE ࢆ⏝ࡍ ࡿࡇ࡛ ᐃ⤖ᯝࡀฟࡿࡲ࡛ࡢ㛫ࡣ 30 ศ࡛࠶ࡿࠋᚋ๓ฎ⌮ࡢ⮬ືࢆ⾜࠺ࡇ࡛ࡉࡽ ࡞ࡿ㧗㏿ࠊᏳᐃࢆᅗࡾࡓ࠸⪃࠼࡚࠸ࡿࠋ ́́ P-33 㔜Ỉ⣲ࣀࣅࣞࢳࣥࡢྜᡂ LC/MS/MS ࡼࡿࣀࣅࣞࢳࣥᐃ㔞ࡢᛂ⏝ ᖹ㔝ṇᝅ 1, ⡿⃝㈗அ 2, ㌴ Ⅸඔ 2, ⚷ ῭Ὀ 1,2,3, ሐෆ せ 1 1 ୰㒊Ꮫᛂ⏝⏕≀Ꮫ㒊, 㸰୰㒊Ꮫ⏕≀ᶵ⬟㛤Ⓨ◊✲ᡤ, 3 ᰴᘧ♫ Ἀ⦖ࣜࢧ࣮ࢳࢭࣥࢱ࣮ Synthesis and application of deuterated nobiletin for determination of nobiletin by LC/MS/MS Shogo Hirano1, Takayuki Yonezawa2, Byung-Yoon cha2, Je-Tae Woo 1,2,3, Kaname Tsutsumiuchi1 1 College of Bioscience and Biotechnology, Chubu University 2 Research Institute for Biological Function, Chubu University 3 Okinawa research center Co., Ltd ࠙┠ⓗࠚᒱ㜧⸆⛉Ꮫࡢబᮌࡽࡣࠊⓑ㔠Ⅳ⣲(Pt/C)ཬࡧࣃࣛࢪ࣒࢘Ⅳ⣲(Pd/C)ࢆ㔜Ỉ୰Ỉ⣲ 㞺ᅖẼୗ࡛⏝࠸ࡿࡇࡼࡾⰾ㤶⎔࠶ࡿ࠸ࡣࣝ࢟ࣝᇶୖ࡛ H-D ᛂࡀ㐍⾜ࡍࡿࡇ ᙜ◊✲ᐊ࡛ࡣ LC/MS/MS ᐃ࡞ࡼࡿᏳᐃྠయヨᩱࡢ᭷⏝ᛶ╔┠ࡋࠊ ࢆぢฟࡋࡓ 1)ࠋ ࡇࡢ H-D ᛂࢆ⏝࠸࡚⏕⌮άᛶ≀㉁ࡢࢧࣟࢤ࣮ࢺ≀㉁ࢆྜᡂࡋࠊ⏕యヨᩱ୰ࡢ㧗ឤᗘ ศᯒ⏝ࡋ࡚ࡁࡓ 2)ࠋᮏ◊✲࡛ࡣࠊࡇࡢᛂࡼࡿ㔜Ỉ⣲≀ࡢྜᡂࡑࡢ⏝ࡢ୍ ࡋ࡚ࠊ㏆ᖺᢠ⫧‶స⏝ࡸࣥࢫࣜࣥᢠᛶࡢᨵၿ࡞ᵝࠎ࡞ຠ⬟ࡀⓎぢࡉࢀὀ┠ࡉࢀࡿࣀ ࣅࣞࢳࣥ(NOB)3)ࡢ㔜Ỉ⣲ࡑࢀࢆෆ㒊ᶆ‽⏝࠸ࡓ LC/MS/MS ศᯒࡢ᳨ウࢆ⾜ࡗࡓࠋ ࠙᪉ἲࠚ NOB ࡢ㔜Ỉ⣲ᛂࡣ࣑ࢽࣂ࣮࣒࢟ࣗࢳ࣮ࣗࣈ NOB 10 mg (25 mmol) ࠊ5%Pt/C 2.5 mgࠊD2O 2.0 mL ࢆຍ࠼ࠊỈ⣲㞺ᅖẼୗ 180Υ࡛ 24 㛫ᛂࢆ⾜ࡗࡓࠋᚓࡽࢀࡓ㔜Ỉ⣲ࣀ ࣅࣞࢳࣥ(NOB-d)ࡢᵓ㐀ࡣ NMR ཬࡧ LC/MS ࡛ホ౯ࡋࡓࠋ㔜Ỉ⣲ᛂࡼࡾᚓࡽࢀࡓ NOB-d ࢆ࣐࢘ࢫ⾑Ύ 10 ȝ/ ୍ᐃ㔞ῧຍࡋࡓᚋࠊ࣓ࢱࣀ࣮ࣝ+ࢡ࣒ࣟࣟ࣍ࣝΰྜ⁐፹[1:1 (v/v)]ࢆ 0.50 mL ຍ࠼࡚᧠ᢾࠊ㐲ᚰศ㞳ࡋୖࡳࢆ⇱ࡉࡏࡓࠋࡑࡢᚋ 10 mmol/L ࢠ㓟Ỉ⁐ ᾮ+ࢭࢺࢽࢺࣜࣝ[1:1 (v:v)]ΰྜ⁐፹ 200 ȝ/ ࡛⁐ゎࡋࠊLC/MS/MS ࢆ⏝࠸ࡓῧຍᅇᐇ 㦂ࢆ⾜ࡗࡓࠋࢡ࣐ࣟࢺࢢ࣒ࣛ࠾ࡅࡿ NOB NOB-d ࡢࣆ࣮ࢡ㠃✚ẚࢆẚ㍑ࡍࡿࡇ ࡼࡗ࡚࣐࢘ࢫ⾑Ύྵࡲࢀ࡚࠸ࡿ NOB ࡢᐃ㔞ࢆ⾜ࡗࡓࠋ ࠙⤖ᯝ⪃ᐹࠚH-D ᛂ࡛ࡣ㔜Ỉ⣲ࡀ 3 ಶ⨨ࡋࡓ NOB-d (m/z 406)ࢆᚓࡓࠋࡲࡓࠊ㔜Ỉ ⣲ᛂࡢ㐣⛬࠾࠸࡚ 24 㛫ࡢᛂᚋࠊD2O Pt/C ࢆධࢀ᭰࠼ᗘᛂࡉࡏࡿࡇࡼ ࡗ࡚ᮍᛂࡢ NOB ⏤᮶ࡍࡿ m/z 403 ࡢࣆ࣮ࢡࡀᖜῶᑡࡍࡿࡇࢆぢฟࡋࡓࠋ⾑Ύࢧ ࣥࣉࣝࢆ⏝࠸࡚ࠊῧຍᅇᐇ㦂ࢆ⾜ࡗࡓ⤖ᯝࠊNOB (m/z 403Ѝ373)ࡢࣆ࣮ࢡ㠃✚್࡛⤯ᑐ᳨ 㔞⥺ࢆసᡂࡋࡓሙྜ NOB-d (m/z 406Ѝ376)ࡢࣆ࣮ࢡ㠃✚ẚ᳨࡛㔞⥺ࢆసᡂࡋࡓሙྜࡢ ᅇ⋡ࢆẚ㍑ࡋࡓࡇࢁࠊࣆ࣮ࢡ㠃✚್࡛ồࡵࡓሙྜࡢᅇ⋡ࡣ 90%ࡔࡗࡓࡀ㠃✚ẚ࡛ồ ࡵࡓሙྜࡣ 95%࡛࠶ࡾࠊ5%ࡢᨵၿࡀぢࡽࢀࡓࠋ 1) H. Sajiki et al., Bull. Chem. Soc. Jpn, 81, 278-286 (2008). 2) S. Hirano et al., JSBMS letters, 39, 110 (2014). 3) B.-Y. Cha et al., J. Nutr. Biochem., 24, 156–162 (2013). ́́ P-34 ࣄࢺ㠌ᖏ࠾ࡅࡿࢢࣜࢥࢧ࣑ࣀࢢࣜ࢝ࣥࡢゎᯒ 㛗Ꮚᬕ⨾ 1, ཎ ఙṇ 1, ᪥ྜྷᓠ㯇 1, Ἑ㔝㏻ᛌ 2, ෆᑿ♸ྖ 2, ᅵᒇ⨾ຍᏊ 1 ᓥ᰿Ꮫ ་Ꮫ㒊 1 ⏕Ꮫㅮᗙ, 2 ᩚᙧእ⛉Ꮫㅮᗙ Analysis of GAG in human ligament Harumi Osago1, Nobumasa Hara1, Mineyoshi Hiyoshi1, Michihaya Kono2, Yuji Uchio2, Mikako Tsuchiya1 1 Department of Biochemistry, Shimane University, Faculty of Medicine 2 Department of Orthopedic Surgery, Shimane University, Faculty of Medicine ࠙┠ⓗࠚࢢࣜࢥࢧ࣑ࣀࢢࣜ࢝ࣥ (GAG) ࡣ⢾ࡀ⧞ࡾ㏉ࡍᇶᮏ㦵᱁✀ࠎ࡞⛬ᗘࡢ◲㓟ࡀ ㉳ࡇࡗ࡚࠸ࡿ⢾㙐࡛࠶ࡾࠊࢥࣥࢻࣟࢳࣥ/ࢹ࣐ࣝࢱࣥ◲㓟ࠊࣄࣝࣟࣥ㓟ࠊ࣊ࣃࣛࣥ◲㓟 ࠾ࡼࡧࢣࣛࢱࣥ◲㓟ࡢ㸲ࢡࣛࢫศ㢮ࡉࢀࡿࠋGAG ࡣ㛵⠇㌾㦵ࠊ㠌ᖏࠊ⓶࡞ࡢ⣽⬊እ ᇶ㉁ከࡃྵࡲࢀࡿࡀࠊࡑࡢ⤌ᡂࡢ㐪࠸ࡀࡑࢀࡒࢀࡢ⤌⧊ࡢᶵ⬟㛵ಀࡋ࡚࠸ࡿ⪃࠼ࡽ ࢀ࡚࠸ࡿࠋGAG ࡢヲ⣽࡞ゎᯒࢆ⾜࠺ࡓࡵࠊࢃࢀࢃࢀࡣ㉁㔞ศᯒࡼࡿ㧗ឤᗘࠊ≉␗ⓗ ࡘ⥙⨶ⓗゎᯒἲࢆ㛤Ⓨࡋࠊࣈࢱࡢ㌾㦵㠌ᖏ࠾ࡅࡿ GAG ⤌ᡂࡢ㐪࠸ࢆ᫂ࡽࡋࡓࠋ ࣄࢺ࡛ࡣ㠌ᖏࡢኚᛶ࣭⫧ཌ㌾㦵⤌⧊ࡢቑ⏕㸦㌾㦵ᡂ㸧ࡀక࠺ࡇࡀሗ࿌ࡉࢀ࡚࠾ࡾࠊ GAG ࡢ㉁ⓗ࣭㔞ⓗኚࡀணࡉࢀࡿࠋࡇࢀࢆᐇドࡍࡿࡓࡵࡣᚤ㔞ࡢࣄࢺ㠌ᖏࡽࡢ GAG ゎᯒࡀᚲせ࡞ࡿࠋᅇࢃࢀࢃࢀࡢ㛤Ⓨࡋࡓ᪉ἲ࡛ṇᖖࣄࢺ㠌ᖏࡽࡢ GAG ゎᯒࡀྍ⬟࡛ ࠶ࡿࢆ᳨ウࡋࡓࠋ ࠙᪉ἲࠚṇᖖࣄࢺ㠌ᖏࡽᢳฟࠊ⢾ࡋࡓ GAG ࢆࠊከᏍᛶࢢࣛࣇࢺ࣮࣒࢝࣎ࣥ࢝ࣛ 㸦Hypercarb, Thermo Scientific ♫㸧ୖ࡛ศ㞳ࡋࡓᚋࠊESI-QqQ㸦Shimadzu, 8030㸧ࡼࡗ࡚ࠊ ㈇࣮࢜ࣥࣔࢻ࡛ ᐃࡍࡿࠋ ࠙⤖ᯝࠚ㔜㔞 4㹼8 mg ࡢࣄࢺ㠌ᖏ⤌⧊ࡼࡾࠊ2㹼5 Pg ࡢ GAG ࡀᚓࡽࢀࡓࠋ40㹼80 ng ࡢ GAG ࢆ⏝࠸࡚㉁㔞ศᯒࡼࡿゎᯒࢆ⾜ࡗࡓ⤖ᯝࠊࣄࣝࣟࣥ㓟ࡣࢥࣥࢻࣟࢳࣥ◲㓟ࡢ࠾ࡼࡑ 5 ศࡢ㸯ࡶ㐩ࡋࠊࢥࣥࢻࣟࢳࣥ◲㓟ࡢ୰࡛ࡣ㸯◲㓟యࡀ 8 ࢆ༨ࡵࠊ㠀◲㓟యࡼࡾ㸰◲ 㓟యࡢ᪉ࡀከ࠸ࡇࡀ᫂ࡽ࡞ࡗࡓࠋ ࠙⪃ᐹࠚ㉁㔞ศᯒࡼࡾ mg ༢ࡢࣄࢺṇᖖ㠌ᖏࢆ⏝࠸࡚ GAG ࡢヲ⣽ゎᯒࡀྍ⬟࡛࠶ࡿࡇ ࠊࣄࢺࡢ㠌ᖏࡣࣈࢱࡢࡑࢀఝࡓ⤌ᡂࢆ♧ࡍࡇࡀࢃࡗࡓࠋᚋࡇࡢ᪉ἲࢆ⏝࠸࡚ࣄ ࢺࡢኚᛶ࣭⫧ཌࡋࡓ㠌ᖏ⤌⧊ࢆྠᵝゎᯒࡋࠊGAG ࡢ㉁ⓗ࣭㔞ⓗ࡞ኚࢆ᫂ࡽࡍࡿࡇ ࡣࠊែࡢゎ᫂ࡸ⒪ἲࡢ㛤Ⓨᐤࡍࡿ⪃࠼ࡽࢀࡿࠋ ́́ P-35 㸰✀㢮ࡢᏳᐃྠయᶆ㆑ἲࢆ⏝࠸ࡓ⭤⬔⒴ࡢ⾑୰ࣂ࣐࣮࣮࢜࢝ࢱࣥࣃࢡ㉁ࡢ ᥈⣴ ᖹ⏣ెஓ 1, 㐲⸨ඞஓ 1, ᩪ⸨㐩ஓ 1,2, ᕝᓥ♸ 2, ༡⏣ ㄽ 3, ᯇᮏᑗ 3, ᒾᮧṇႹ 3, ᑠᑎ⩏⏨ 1,2 1 㔛Ꮫ⌮Ꮫ㒊⏕≀≀⌮Ꮫ◊✲ᐊ, 2 㔛Ꮫ⌮Ꮫ㒊㝃ᒓᝈࣉࣟࢸ࣑࢜ࢡࢫࢭࣥࢱ࣮, 3 㔛Ꮫ་Ꮫ㒊Ἢᒀჾ⛉ Discovery of biomarker proteins in plasma of bladder cancer patients using two types of stable-isotope labeling methods Yoshiya Hirata1, Katsuya Endo1,Tatsuya Saito1, 2 , Yusuke Kawashima2,Satoru Minamida3, Kazumasa Matsumoto3,Masatsugu Iwamura3,Yoshio Kodera1, 2 1 Laboratory of Biophysics, Department of Physics, Kitasato University School of Science 2 Center for Disease Proteomics, Kitasato University School of Science 3 Department of Urology, Kitasato University School of Medicine ࠙┠ⓗࠚ⾑ᾮࡣᝈࡸᗣ≧ែࢆᫎࡍࡿሗࢆྵࡳࠊ᥇ྲྀࡶᐜ᫆࡞ࡓࡵࠊ㔜せ࡞⮫ᗋ᳨య ࡛࠶ࡿࠋࡋࡋࠊヲ⣽࡞ࣉࣟࢸ࣮࣒࢜ゎᯒࡣࠊ⤌⧊ࡸ⣽⬊ẚ࡚ᅔ㞴࡞Ⅼࡀከࡃࠊ⮫ᗋ ᛂ⏝ྍ⬟࡞ࣂ࣐࣮࣮࢜࢝ࡢ᥈⣴ࡣᴟࡵ࡚ᑡ࡞࠸ࠋࡑࡇ࡛ᮏ◊✲࡛ࡣࠊ2 ✀㢮ࡢᏳᐃྠ యᶆ㆑ἲࢆ⏝࠸ࡿࡇ࡛ࠊ⭤⬔⒴デ᩿࣐࣮࣮࢝ೃ⿵ࢱࣥࣃࢡ㉁ࡢ᥈⣴ཬࡧ᳨ドࢆ⾜ࡗࡓࠋ ࠙᪉ἲࠚヨᩱㄪ〇ࡣࠊ⊂⮬ࡢ⾑Ύ࣭⾑₢ࢱࣥࣃࢡ㉁ศ⏬ἲ Serum/plasma fraction ἲ(SF ἲ) 㧗Ꮡᅾ㔞ࢱࣥࣃࢡ㉁ 12 ✀㢮㝖ཤ࣒࢝ࣛࢆ⤌ࡳྜࢃࡏ࡚⾜ࡗࡓࠋ᥈⣴ࡢࡓࡵࡢẚ㍑ศᯒࡣࠊ MS/MS ศᯒࡼࡗ࡚ᮍྠᐃᡂศࢆࡶẚ㍑ศᯒ࡛ࡁࡿ Tandem Mass Tag ヨ⸆ ( TMT 6 plex, Thermo Fisher Scientific)ࢆ⏝࠸ࡓࠋࡲࡓࠊࡇ࠺ࡋ࡚᥈⣴ࡋࡓ࣐࣮࣮࢝ೃ⿵ࢱࣥࣃࢡ㉁ࡢ᳨ド ࡣࢪ࣓ࢳࣝᶆ㆑ἲࢆ⏝࠸࡚⾜ࡗࡓࠋ ᐃࡣపὶ㏿ nano flow LC Easy-nLC 1000 (Thermo Fisher Scientific)࣋ࣥࢳࢺࢵࣉᆺࣇ࣮࢚ࣜኚ㉁㔞ศᯒィ LC-MS/MS Q-Exactive (Thermo Fisher Scientific) ⤌ࡳྜࢃࡏࡓ LC-MS ࢆ⏝ࡋࡓࠋ ᐃࢹ࣮ࢱࡢゎᯒࡣྠᐃゎᯒ⏝ࢯࣇ ࢺ࢙࢘ Proteome Discoverer 1.4 (Thermo Fisher Scientific)ࢆ⏝࠸ࡓࠋ ࠙⤖ᯝ࣭⪃ᐹࠚ⭤⬔⒴ᝈ⪅⾑₢ 4 ᳨యࡎࡘࡢΰྜ⾑₢ 6 ヨᩱ (ᡭ⾡๓ 3 ヨᩱࠊᡭ⾡ᚋ 3 ヨᩱ) ࢆᑐ㇟ࡋࡓ᥈⣴ᐇ㦂࠾࠸࡚ࠊ269 ✀㢮ࡢࢱࣥࣃࢡ㉁⏤᮶ࡍࡿ㓝⣲ᾘ࣌ࣉࢳࢻ 2,046 ✀㢮ࢆྵࡴ⣙ 20,000 ✀㢮ࡢ㓝⣲ᾘ࣌ࣉࢳࢻ㸦ᮍྠᐃ࣌ࣉࢳࢻࢆྵࡴ㸧ࡢ㧗⢭ᗘ࡞ẚ㍑ศ ᯒࢆᐇ⌧ࡋࡓࠋࡑࡢ⤖ᯝࠊ⣙ 30 ✀㢮ࡢࢱࣥࣃࢡ㉁⏤᮶ࡍࡿ⣙ 80 ࣌ࣉࢳࢻ࠾࠸࡚ᡭ⾡ క࠺᭷ព࡞ቑῶࡀ☜ㄆࡉࢀࡓࠋࡉࡽࠊᮍྠᐃ࣌ࣉࢳࢻ࠾࠸࡚ࡶᡭ⾡๓ᚋࡢࡕࡽ ୍᪉ࡋほ ࡉࢀ࡞࠸࣌ࣉࢳࢻࢆྵࡴ⣙ 80 ✀㢮ࡢ࣐࣮࣮࢝ೃ⿵࣌ࣉࢳࢻࡢ᳨ฟᡂຌࡋ ࡓࠋⓎ⾲࡛ࡣࠊ᳨ドᐇ㦂ࡢ⤖ᯝࡶሗ࿌ࡍࡿࠋ ́́ P-36 Abcd1 ࣀࢵࢡ࢘ࢺ࣐࢘ࢫࡢ⬻ࡢࣜࣥ⬡㉁ゎᯒ ℈ᘯኴ㑻 1, ⸨ཎඃᏊ 1, Ᏺ⏣㞞ᚿ 2, ୰ᖖ㞝 2, ୗ⃝ఙ⾜ 3, ᶓᒣ᫂ 1 1 ᖇி࣭⸆, 2 ᐩᒣ࣭⸆, 3 ᒱ㜧࣭⏕⛉Ꮫ⥲ྜ◊✲ᨭࢭࣥࢱ࣮ Phospholipid profile of Abcd1 knockout mouse brain Kotaro Hama1, Yuko Fujiwara1,, Masashi Morita2,, Tsuneo Imanaka2, Nobuyuki Shimozawa3, Kazuaki Yokoyama1 1 Teikyo University Faculty of Pharmaceutical Sciences 2 University of Toyama Graduate School of Medicine & Pharmaceutical Sciences 3 Gifu University Life Science Research Center ࠙┠ⓗࠚ⭈ⓑ㉁ࢪࢫࢺࣟࣇ࣮ (X-ALD) ࡣࠊⅣ⣲ᩘ 24 ௨ୖࡢᴟ㛗㙐⬡⫫㓟ࢆ࣌ࣝ࢜ ࢟ࢩࢯ࣮࣒ෆ㍺㏦ࡍࡿ ABCD1 ⺮ⓑ㉁ࡢ␗ᖖࢆཎᅉࡍࡿ㐍⾜ᛶࡢ⬺㧊ᝈ࡛࠶ࡿࠋ X-ALD ᝈ⪅యෆ࡛ࡣᴟ㛗㙐⬡⫫㓟ࡢ✚ࡀ㢧ⴭ࡛࠶ࡿࡀࠊᴟ㛗㙐⬡⫫㓟ࡀయෆ࡛ࡢࡼ࠺ ࡞⬡㉁ࡋ࡚Ꮡᅾࡍࡿࡣ᫂ࡽ࡛࡞࠸ࠋࡲࡓ⌧ᅾࡲ࡛⾑₢࠶ࡿ࠸ࡣᇵ㣴⥺⥔ⱆ⣽⬊ ࠾ࡅࡿ⬡㉁ゎᯒࡀ⾜ࢃࢀ࡚࠸ࡿࡀࠊ⮚ჾ࡛ࣞ࣋ࣝࡢᴟ㛗㙐⬡⫫㓟ྵ᭷⬡㉁ࣉࣟࣇࣝࡣ ࡛᫂࠶ࡿࠋࡋࡋ࡞ࡀࡽᴟ㛗㙐⬡⫫㓟ྵ᭷⬡㉁ࡣඖࠎ⏕యᚤ㔞ࡋ࡞࠸ࡓࡵࠊ⥙⨶ⓗ ࡞ゎᯒࡣࡇࢀࡲ࡛ᅔ㞴࡛࠶ࡗࡓࠋࡑࡇ࡛ᮏ◊✲࡛ࡣࠊABCD1 ࡢᶵ⬟␗ᖖࡶ࡞࠺ከ✀ࡢ ᴟ㛗㙐⬡⫫㓟ྵ᭷ࣜࣥ⬡㉁ࡢኚືࢆᢕᥱࡍࡿࡇࢆ┠ⓗࡋ࡚ࠊX-ALD ࣔࢹࣝື≀࡛࠶ࡿ Abcd1 KO ࣐࢘ࢫࡢ⬻୰ࡢࣜࣥ⬡㉁ࡘ࠸࡚ࠊከẁ㝵 MRM ࣮ࣔࢻࢆ⏝࠸ࡓ㧗ឤᗘᐃ㔞ศᯒ ࡼࡾኚື⬡㉁ࢆຠ⋡Ⰻࡃぢฟࡋࠊࡑࢀࡽࡢᵓ㐀ࢆᐃᛶศᯒࡼࡾ᫂ࡽࡋࡓࠋ ࠙᪉ἲࠚ࣐࢘ࢫ⬻ࡽ Bligh & Dyer ἲ࡚⬡㉁⏬ศࢆᢳฟࡋࠊ㏫┦࣒࢝ࣛࢆ⏝࠸࡚ LC/ESI-MS ࡼࡾ⬡㉁ࢆ ᐃࡋࡓࠋࢩࣝ㙐 2 ᮏศࡢⅣ⣲ᩘࡀ 32 ࡽ 54ࠊ㣬ᗘࡀ 0 ࡽ 12 ࡲ࡛ࡢྛ✀ࣜࣥ⬡㉁ࡘ࠸࡚ MRM ࣮ࣔࢻ࡚ᐃ㔞 ᐃࡋࠊ㔝⏕ᆺ࣐࢘ࢫ Abcd1 KO ࣐࢘ࢫ㛫࡛᭷ពᕪࡢぢࡽࢀࡓ⬡㉁ศᏊ✀ࡘ࠸࡚ࠊࣇࣛࢢ࣓ࣥࢺゎᯒࡼࡾศᏊᵓ㐀ࢆỴ ᐃࡋࡓࠋ ࠙⤖ᯝࠚⅣ⣲ᩘ 24 ௨ୖࡢᴟ㛗㙐⬡⫫㓟ࡣ࣍ࢫࣇࢳࢪࣝࢥࣜࣥࠊ ࣍ࢫࣇࢳࢪ࢚ࣝࢱࣀ࣮ ࣑ࣝࣥ࠾ࡼࡧࢫࣇࣥࢦ᳨࣑࢚ࣜࣥฟࡉࢀࡓࠋ᭱㙐㛗ࡣ 34ࠊ㣬ᗘࡣ 0 ࡽ 6 ࡛ ࠶ࡗࡓࠋࣇࣛࢢ࣓ࣥࢺ࢜ࣥゎᯒ࠾࠸࡚ࠊࣜࣥ⬡㉁ࡢࣜࢰయ┦ᙜࡍࡿࣇࣛࢢ࣓ࣥࢺ ࢜ࣥࡣ㣬ᗘࡀ 0 ࠶ࡿ࠸ࡣ 1 ࡛࠶ࡗࡓࡇࡽࠊ㣬ᗘࡀ 0 ࠶ࡿ࠸ࡣ 1 ࡢᴟ㛗㙐⬡⫫ 㓟ࡣࣜࣥ⬡㉁ࡢࢢࣜࢭ࣮ࣟࣝ㦵᱁ࡢ sn-1 ⤖ྜࡍࡿ᥎ᐃࡉࢀࡓࠋࡲࡓⅣ⣲ᩘ 16 ࡽ 22 ࡲ࡛ࡢ㛗㙐⬡⫫㓟ࡽᵓᡂࡉࢀࡿ࣍ࢫࣇࢳࢪࣝࢭࣜࣥࠊ࣍ࢫࣇࢳࢪࣝࣀࢩࢺ࣮ࣝ࠾ ࡼࡧ࣍ࢫࣇࢳࢪࣝࢢࣜࢭ࣮ࣟࣝࡢྛศᏊ✀ࡢ࠺ࡕࠊ୍㒊ࡢศᏊ✀ࡘ࠸࡚ࠊ㔝⏕ᆺẚ ࡚ Abcd1 KO ࣐࢘ࢫ࡛ῶᑡࡍࡿഴྥࡀぢࡽࢀࡓࠋ ࠙⪃ᐹࠚᮏ◊✲ࡼࡾࢢࣜࢭ࣮ࣟࣝ㦵᱁ࡢ sn-1 ࢆㄆ㆑ࡍࡿᶵᵓࡀᏑᅾࡍࡿࡇࠊ࠾ࡼࡧ Abcd1 ⺮ⓑ㉁ࡢ␗ᖖࡼࡾࠊᴟ㛗㙐⬡⫫㓟ࡢࡳ࡞ࡽࡎ㛗㙐⬡⫫㓟௦ㅰࡶᙳ㡪ࢆཷࡅࡿࡇࡀ ♧၀ࡉࢀࡓࠋ ́́ P-37 Ᏻᐃྠయᶆ㆑ἲࢆ⏝࠸ࡓࢫࢺࣞࢫ㞀ᐖࣔࢹ࣐ࣝ࢘ࢫᾏ㤿ࡢࣉࣟࢸ࣮࣒࢜ኚື ࡢゎᯒ ᑠ㧗㡴Ꮚ 1, ᑠᯘ༓ 1, ຍ⸨ె 1,2, 㧗ᶫᯞ㔛 1, ᩧ⸨㐩ஓ 1,2, ᕝᓥ♸ 2, ᯈ ㄔ 3, ᒣ᳃᪩⧊ 3, Ọᒣ༤㏻ 3, 㣤⏣ㅍᐅ 4, ᐑᒸ ➼ 4, 㧗ᶫṇ㌟ 3, ᑠᑎ⩏⏨ 1,2 1 㔛Ꮫ⌮Ꮫ㒊≀⌮Ꮫ⛉⏕≀≀⌮Ꮫ◊✲ᐊ, 2 㔛Ꮫ⌮Ꮫ㒊㝃ᒓᝈࣉࣟࢸ࣑࢜ࢡࢫࢭ ࣥࢱ࣮, 3 㔛Ꮫ་Ꮫ㒊⏕Ꮫ◊✲ᐊ, 4 㔛Ꮫ་Ꮫ㒊⢭⚄⛉ Hippocampus proteome analysis of stress disorder model mouse using stable isotope labeling method Shoko Odaka1, Chiharu Kobayashi1, Rika Kato1,2, Eri Takahashi1, Tatsuya Saito1,2, Yusuke Kawashima2, Makoto Itakura3, Saori Yamamori3, Hiromichi Nagayama3, Yuuki Iida4, Hitoshi Miyaoka4, Masami Takahashi3, Yoshio Kodera1,2 1 Laboratory of Biophysics, Department of Physics, Kitasato University School of Science 2 Center for Disease Proteomics, Kitasato University School of Science 3 Department of Biochemistry, Kitasato University School of Medicine 4 Department of Psychiatry, Kitasato University School of Medicine ࠙┠ⓗࠚࢫࢺࣞࢫ♫ゝࢃࢀࡿ⌧௦࠾࠸࡚ࠊᵝࠎ࡞ࢫࢺࣞࢫ㛵㐃㞀ᐖࡀሗ࿌ࡉࢀ࡚࠸ࡿࠋ ࡋࡋࠊࡑࡢⓎᶵᗎ࡞ࡽࡧᐈほⓗ࡞デ᩿ἲࡣ☜❧ࡉࢀ࡚࠸࡞࠸ࠋࡑࡇ࡛ᡃࠎࡣࠊࣄࢺ ࡢࢫࢺࣞࢫ㛵㐃㞀ᐖࡢែࢆ⾑ᾮᡂศࡽ᥎ ࡍࡿࡇࢆ┠ⓗࡋ࡚ࠊྛ✀ࢫࢺࣞࢫ㞀ᐖ ࣔࢹ࣐ࣝ࢘ࢫࢆᑐ㇟⬻⤌⧊⾑ᾮࡢ୧㠃ࡽ◊✲ࢆ㐍ࡵ࡚࠸ࡿࠋᮏ◊✲࡛ࡣࡑࡢ୍⎔ ࡋ࡚ࠊࣆࣟ࢝ࣝࣆࣥᢞࡼࡗ࡚ྍ㏫ⓗ࡞Ᏻᵝ⾜ືࢆ♧ࡍࣔࢹ࣐ࣝ࢘ࢫᾏ㤿ࡢࣉࣟࢸ࢜ ࣮࣒ኚືࡢゎᯒࢆ⾜ࡗࡓࠋ ࠙᪉ἲࠚࢥࣥࢺ࣮࣐ࣟࣝ࢘ࢫ㸦3 ༉㸧ࠊࣆࣟ࢝ࣝࣆࣥࢆᢞࡋྍ㏫ⓗ࡞Ᏻᵝ⾜ືࢆ㉳ࡇ ࡉࡏࡓ࣐࢘ࢫ㸦8 ༉㸧ࡢᾏ㤿ࢆᑐ㇟ࡋࠊྍ⁐ᛶᡂศ㞴⁐ᛶᡂศࢆᢳฟࡋࡓࠋࡇࢀࡽࡢ㓝 ⣲ᾘ≀Ᏻᐃྠయᶆ㆑ヨ⸆㸦Isobaric Tag ヨ⸆㸹TMT 6plex,Thermo Fisher Scientific㸧ࢆ ᶆ㆑ࡋࠊnano-LC ᅄ㔜ᴟࣇ࣮࢚ࣜኚࣁࣈࣜࢵࢻ㉁㔞ศᯒィ㸦Q-Exactive,Thermo Fisher Scientific㸧ࢆ⤌ࡳྜࢃࡏࡓ LC-MS/MS ࢆ⏝࠸࡚⥙⨶ᛶࡢ㧗࠸㧗⢭ᗘẚ㍑ศᯒἲࢆ☜❧ࡋࠊ ᛂ⏝ࡋࡓࠋ ࠙⤖ᯝ⪃ᐹࠚ11 ༉ࡢࣔࢹ࣐ࣝ࢘ࢫᾏ㤿୰ࡢࢱࣥࣃࢡ㉁ࢆศᯒࡋࡓ⤖ᯝࠊࢩࢼࣉࢫ㛵㐃ࢱࣥ ࣃࢡ㉁ࡸཷᐜయࠊࢳࣕࣥࢿࣝࢱࣥࣃࢡ㉁ࠊࢢࣜ⣽⬊ࡢ࣐࣮࣮࢝➼ࢆྵࡴ⣙ 4,000 ✀㢮ࡢࢱ ࣥࣃࢡ㉁ࡀྠᐃࡉࢀࡓࠋึṌⓗ࡞ゎᯒࡋ࡚⣙ 1,600 ✀㢮ࡢࢱࣥࣃࢡ㉁⏤᮶ࡍࡿ⣙ 8,600 ✀㢮ࡢ㓝⣲ᾘ࣌ࣉࢳࢻࢆᑐ㇟ẚ㍑ゎᯒࢆ⾜ࡗࡓࠋࡑࡢ⤖ᯝࠊHeat shock protein ࡸ DNA damage-binding proteinࠊSynaptotagmin-1 ➼ࡢࢱࣥࣃࢡ㉁ࡀᏳᵝ⾜ືࡢᣦᶆ㸦⛣ື㊥㞳ࡸ᫂ ᡤᏑᅾẚ⋡㸧┦㛵ࡋ࡚ኚືࡋ࡚࠸ࡓࠋ ́́ P-38 Effects of preanalytical variables on serum peptidome profiling for long-term storage using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry ᅵ⏣⚈ኸ1, బ⸨ Ᏺ1, ᱵᮧၨྐ2, ᭮ᕝ୍ᖾ3, ⬥ṇ㈗1, ูᗓ⨾ዉᏊ4, すᮧ ᇶ4, ᑠᑎ⩏⏨5, ᯇୗ୍அ4, 㔝ᮧᩥኵ1 1 ༓ⴥᏛ་Ꮫ㒊ᒓ㝔࣐ࢫࢫ࣌ࢡࢺ࣓ࣟࢺ᳨࣮ࣜᰝデ᩿Ꮫ, 2ᒸᒣᏛᏛ㝔་ṑᏛ⥲ྜ ◊✲⛉, 3㯞ᕸᏛ⏕⎔ቃ⛉Ꮫ㒊⮫ᗋ᳨ᰝᢏᖌᏛ⛉, 4༓ⴥᏛ་Ꮫ㒊་Ꮫ◊✲㝔ศᏊែ ゎᯒᏛ, 5㔛Ꮫ⌮Ꮫ㒊≀⌮Ꮫ⛉ Sachio Tsuchida1, Mamoru Satoh1, Hiroshi Umemura2, Kazuyuki Sogawa3, Masaki Takiwaki1, Minako Beppu4, Motoi Nishimura4, Yoshio Kodera5, Kazuyuki Matsushita4, Fumio Nomura1 1 Division of Clinical Mass Spectrometry, Chiba University Hospital 2 Departments of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences 3 Department of Biochemistry, School of Life and Environmental Science, Azabu University 4 Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University 5 Laboratory of Biomolecular Dynamics, Department of physics, School of Science, Kitasato University The peptidome profiling of human serum is a promising tool for identifying novel disease-associated biomarkers. However, care must be taken while collecting samples and handling procedures that could have a profound impact on serum peptidome patterns. The effects of preanalytical variables on serum peptidome profiles for long-term storage have not yet been fully clarified. In the present study, we tested the effects of preanalytical variables, including different freezing temperatures and methods to thaw specimens, on MALDI-TOF MS-based serum peptidome patterns for long-term storage. We applied automation and robotics to the ClinProtTM system (Bruker Daltonics, Bremen, Germany) and evaluated the effects of selected parameters on the MS patterns of serum peptides for long-term storage (12 months). We evaluated the effects of different freezing temperatures; that is, ZHIUR]HVHUXPVDPSOHVIURPVXEMHFWVDWHLWKHUíqC RUí& in freezers for long-term storage (12 months). The same experimental protocols as described above were also applied to serum proteome analysis using SDS-PAGE with densitometry. Our results showed that tKHLQWHQVLWLHVRIP]P]DQGP]SHDNVZHUHGHFUHDVHG On the other hand, the intensity of P]SHDNZDVLQFUHDVHG'LIIHUHQWIUHH]LQJWHPSHUDWXUHV dramatically affected the serum peptidome profiling. However, gel-based protein profiling was not apparently altered by the two different freezing temperatures. The effects of preanalytical variables on both gel-based and gel-free serum proteome and peptidome patterns as evaluated in detail in the present study will enable us to standardize blood sampling and long-term storage conditions for interlaboratory and multicenter studies for the validation of biomarker candidates. ́́ P-39 H-D ᛂࢆ⏝࠸ࡓࣁ࣑ࣝࣥࡢࢧࣟࢤ࣮ࢺ≀㉁ྜᡂ ᶓᒣ⿱ኈ 1, ᖹ㔝ṇᝅ 1, ⡿⃝㈗அ 2, ㌴ Ⅸඔ 2, ⚷ ῭Ὀ 1,2,3, ሐෆ せ 1 1 ୰㒊Ꮫᛂ⏝⏕≀Ꮫ㒊, 㸰୰㒊Ꮫ⏕≀ᶵ⬟㛤Ⓨ◊✲ᡤ, 3 ᰴᘧ♫Ἀ⦖ࣜࢧ࣮ࢳࢭࣥࢱ࣮ Synthesis of Surrogate Compounds of Harmine by H-D Exchange Reaction Yuji Yokoyama1, Shogo Hirano1, Takayuki Yonezawa2, Byung-Yoon cha2, Je-Tae Woo 1,2,3, Kaname Tsutsumiuchi1 1 College of Bioscience and Biotechnology, Chubu University 2 Research Institute for Biological Function, Chubu University 3 Okinawa research center Co., Ltd ࠙┠ⓗࠚᙜ◊✲ᐊ࡛ࡣࡇࢀࡲ࡛ࠊLC/MS/MS ࡞ࢆ⏝࠸ࡓᐃ㔞ศᯒ࠾࠸࡚ෆ㒊ᶆ‽≀㉁ ࡋ࡚ࡢᏳᐃྠయヨᩱ(ࢧࣟࢤ࣮ࢺ≀㉁)ࡢ㔜せᛶ╔┠ࡋࠊᒱ㜧⸆⛉Ꮫࡢబ෬ᮌࡽࡀ㛤 Ⓨࡋࡓᆒ୍⣔ⓑ㔠᪘ゐ፹ࡼࡿ㔜Ỉ⣲ᶆ㆑ᛂ 1)ࢆ⏝࠸ࡓ⏕⌮άᛶ≀㉁ࡢ H-D ᛂ ࡑࢀࡽࢆ⏝࠸ࡓ⏕యヨᩱ୰ࡢᐃ㔞ศᯒࢆሗ࿌ࡋ࡚ࡁࡓ 2)ࠋ㏆ᖺࠊᡃࠎࡣィⲡࡽᢳฟࡉ ࢀࡿࣁ࣑ࣝࣥὀ┠ࡋࠊࡇࡢྜ≀ࡀ㦵ⱆ⣽⬊ศᚲせ࡞㌿ᅉᏊࡢቑຍࢆక࠸࡞ࡀࡽ 㦵ⱆ⣽⬊ศ࣑ࢿࣛࣝࢆಁ㐍ࡍࡿࡇࢆⓎぢࠊ㦵⢒㧼ࡸṑ࿘⒪ࡢᛂ⏝ࢆ᳨ウ ࡋ࡚࠸ࡿ 3)ࠋࡺ࠼ᮏ◊✲࡛ࡣ H-D ᛂࢆ⏝࠸ࡓࣁ࣑ࣝࣥࡢ㔜Ỉ⣲ࢆ᳨ウࡋࡓࠋ ࠙᪉ἲࠚ࣑ࢽࣂ࣮࣒࢟ࣗࢳ࣮ࣗࣈࣁ࣑ࣝࣥ㸦ᮾிᡂᕤᴗ♫〇㸧ࢆ 5.0 mg (24 Pmol)ࠊ 5% Pt/C ࢆ 2.0 mg 㔞ࡾ᥇ࡾࠊ㔜Ỉ 2.0 mL ࢆຍ࠼࡚ศᩓࡉࡏࡓࠋᐜჾෆࢆỈ⣲࢞ࢫ⨨ࡋࠊ 120Υ࡛ 24 㛫ᛂࡉࡏࡓᚋࠊᛂᾮ⣙ 10 mL ࡢࢭࢺࢽࢺࣜࣝࢆຍ࠼࡚ࢁ㐣ࡋࠊPt/C ࢆ㝖ཤࠊࢁᾮࢆ⃰⦰⇱ࡋ࡚ⓑⰍ⢊ᮎ≧ࡢ㔜Ỉ⣲ࣁ࣑ࣝࣥࢆᚓࡓࠋ ࠙⤖ᯝ⪃ᐹࠚᚓࡽࢀࡓ㔜Ỉ⣲ࣁ࣑ࣝࣥࢆ LC/MS ࡛☜ㄆࡋࡓࡇࢁࠊཎᩱࡢࣁ࣑ࣝࣥ ࡰྠࡌ UV ࠾ࡼࡧ࢜ࣥࢡ࣐ࣟࢺࢢ࣒ࣛࢆ♧ࡋࡓࠋࡲࡓࠊ⁐ฟࣆ࣮ࢡࡢ MS ࢫ࣌ࢡࢺࣝ ࡛ࡣཎᩱࡢࣁ࣑࡛ࣝࣥࡣࣉࣟࢺࣥຍయࡢ m/z 213 ࡢࣆ࣮ࢡࡢࡳࡀࡁࡃほ ࡉࢀࡓࡀࠊ㔜 Ỉ⣲ࣁ࣑࡛ࣝࣥࡣ m/z 220 ࢆ᭱ᙉᗘࡍࡿ」ᩘࡢࣆ࣮ࢡࡀ m/z 213-221 ࢃࡓࡾほ ࡉ ࢀࡓࠋPt/C ゐ፹ࡣⰾ㤶⎔࠾ࡅࡿ C-H ࢆ C-D ኚࡉࡏࡿࡇࡀሗ࿌ࡉࢀ࡚࠸ࡿࡓࡵࣁ ࣑࡛ࣝࣥࡣ㍍Ỉ⣲ࡀ㔜Ỉ⣲⨨ࡉࢀࡿࡣ᭱ 5 ࡘࡲ࡛ணࡉࢀ࡚࠸ࡓࠋࡋࡋࠊᐇ㝿 ࡣ᭱ 8 ಶࡢ㔜Ỉ⣲⨨ࡀ㉳ࡇࡗ࡚࠸ࡓࡓࡵࠊ㔜⤖ྜࡢ㑏ඖᛂࡸⅣ⣲̿Ⅳ⣲⤖ྜࡢ ษ᩿࡞ࡀᠱᛕࡉࢀࡓࡀࠊ1H-NMR ࡛ゎᯒࡋࡓ⤖ᯝࠊⓑ㔠Ⅳ⣲ࡀゐ፹ࡍࡿ࣋ࣥࢮࣥ⎔ࡢỈ⣲ ௨እ࣓ࢳࣝᇶ࠾࠸࡚ࡶ㔜Ỉ⣲ᛂࡀ㐍⾜ࡋ࡚࠸ࡿࡇࡀุ᫂ࡋࡓࠋ 1) H. Sajiki et al., Bull. Chem. Soc. Jpn, 81, 278-286 (2008). 2) S. Hirano et al., JSBMS letters, 39, 110 (2014). 3) T. Yonezawa et al., Biochem. Biophys. Res. Commun., 409, 260–265 (2011). ́́ P-40 MALDI-TOF MS ࠾ࡅࡿ Neisseria meningitidis ࡢㄗྠᐃ୍ 㔝ᬛᏊ ឡ▱་⛉Ꮫ㝔ឤᰁไᚚ㒊 Example of misidentification of Neisseria meningitidis in MALDI-TOF MS Tomoko Ohno Aichi Medical University Hospital Infection Control Team ࠙ࡣࡌࡵࠚMALDI-TOF MS ࢆ⏝࠸ࡓᚤ⏕≀ྠᐃࡀ⏝ࡉࢀࡿࡼ࠺࡞ࡾࠊ㎿㏿ྠᐃࢆ⾜࠺ࡇ ࡀ࡛ࡁࡿࡼ࠺࡞ࡗࡓࠋ ᙜ㝔ࡢ⾑ᾮᇵ㣴ࡣ MALDI-TOF MS ࢆ⏝ࡋ㎿㏿ྠᐃࢆ⾜ࡗ࡚࠸ࡿࠋ ࡑࡇ࡛⾑ᾮᇵ㣴ࡽ Neisseria meningitidis MALDI-TOF MS ࡛ྠᐃࠊ5 㢮ឤᰁࡢく ᛶ㧊⭷⅖⳦ឤᰁ࡛ᒆࡅฟࡀᚲせ࡛࠶ࡿ⤖ᯝ࡞ࡗࡓࡀࠊ᭱⤊ⓗ Neisseria cinerea ྠᐃࡉࢀࡓ୍ࢆሗ࿌ࡍࡿࠋ ࠙ࠚ30 ṓ௦⏨ᛶࠊBurkitt ࣜࣥࣃ⭘デ᩿࡛ධ㝔 4 ᪥┠ࡼࡾᏛ⒪ἲᐇ୰ࠊ⾑ᾮᇵ㣴 2 ࢭࢵࢺࡀ㝧ᛶ࡞ࡾࠊMALDI-TOF MS㸦Burker Daltnics ♫㸧࠾࠸࡚ࠊN. meningitidis (best match:Score Value 2.024, second best math:Score Value 1.966)ྠᐃࡉࢀࡓࠋࡑࡇ࡛ ⾑ᾮᇵ㣴ᾮỿ´ࢆ⏝࠸ PASTREX ࣓ࢽࣥࢪࣕࢸࢫࢆ⾜ࡗࡓࡇࢁࠊ㠀≉␗ⓗᛂࡼࡿ จ㞟ࢆㄆࡵࡓࠋࡉࡽᖹᯈᇵᆅࡢࢥࣟࢽ࣮࡛ ID ࢸࢫࢺ HN-20 ࣛࣆࢵࢻ ࢽࢵࢫ(᪥Ỉ〇 ⸆ᰴᘧ♫)ࢆ⾜ࡗࡓࡇࢁࠊNeisseria 2 㸦60㸣㸧,N. gonorrhoeae 㸦30㸣㸧,Neisseria 3 㸦7㸣㸧ྠᐃࡉࢀࡓࠋࢥࣟࢽ࣮ᙧ≧ࡣ N. meningitidis ࡣ␗࡞ࡾ⢓ᛶ࡛ࢥࣟࢽ࣮ࡶᑠ ࡉࡃࠊឤཷᛶ᳨ᰝࡣ⪏ᛶഴྥࢆ♧ࡋࡓࠋNeisseria 2 ヱᙜࡍࡿ⳦✀ࡣ N. cinerea, N. flavescens ࡀྵࡲࢀ࡚࠸ࡿࠋ᭱⤊ⓗࡣ 16S rRNA 㡿ᇦ㑇ఏᏊ BLAST ゎᯒ࡛ࡣ N㸬cinerea 㸦100㸣㸧ྠᐃࡉࢀࡓࠋ ࠙⪃ᐹࠚ ᅇᡃࠎࡣ MALDI-TOF MS ࡛ N. meningitidis ྠᐃࡉࢀࡓ N. cinerea ࢆ⤒㦂ࡋࡓࠋ ᳨ฟ㢖ᗘࡢ㧗ࡃ࡞࠸⳦ྡࡀྠᐃࡉࢀࡓሙྜࠊScore Value ᩘ್ࡢ☜ㄆࠊࢥࣟࢽ࣮ࡢ⏕Ꮫⓗ ᛶ≧࡞ࡶ㋃ࡲ࠼ྠᐃࢆ⾜ࢃ࡞ࡅࢀࡤ࡞ࡽ࡞࠸࡛࠶ࡗࡓࠋ Ꮫእ༠ຊ⪅㸸ᮎᯇᐶஅ ᒣᓊ⏤ె ୕㬞ᘅ⦾ ́́ P-41 MALDI-TOF MS ࡼࡿ⾑ᾮᇵ㣴㝧ᛶ࣎ࢺࣝᇵ㣴ᾮࢆ⏝࠸ࡓ┤᥋ྠᐃࡘ࠸࡚ ụࣨ㇂ెᑑᏊ, ᅵᒇ ᠇ 㟼ᒸᕷ❧ΎỈ㝔 ᳨ᰝᢏ⾡⛉ Direct identification of bacteria in positive blood culture bottles by MALDI-TOF MS Kazuko Ikegaya, Ken Tsuchiya Department of Clinical Laboratory,Shizuoka City Shimizu Hospital ࠙┠ⓗࠚMALDI-TOF MS ࡣᚤ⏕≀ྠᐃࡢ་⒪ᶵჾࡋ࡚ᅜෆ࡛ࡢ⏝ࡀᣑࡋ࡚࠸ࡿࠋᚑ᮶ࡢ ᚤ⏕≀ྠᐃࡣࠊᵝࠎ࡞ᡭἲࢆ⏝࠸࡚ᩘ᪥ࡅ࡚≉ᚩࢆᑟࡁฟࡋࠊࢹ࣮ࢱ࣮࣋ࢫ↷ྜࡋ࡚ ⳦ྡࢆỴᐃࡋ࡚࠸ࡓࠋࡋࡋࠊMALDI-TOF MS ࢆ⏝࠸ࡓᚤ⏕≀ྠᐃ࡛ࡣᩘ༑ศ࡛⤖ᯝࡀᚓࡽ ࢀࡿࠋᅇࠊ⮫ᗋⓗ㔜せ࡞⾑ᾮᇵ㣴↔Ⅼࢆ࠶࡚ࠊMALDI-TOF MS ࡼࡿ⾑ᾮᇵ㣴㝧ᛶ࣎ ࢺࣝᇵ㣴ᾮࢆ⏝࠸ࡓ┤᥋ྠᐃࡢ᭷⏝ᛶࡘ࠸᳨࡚ウࡋࡓࠋ ࠙᪉ἲࠚ 2013 ᖺ 9 ᭶㹼2014 ᖺ 12 ᭶ࡲ࡛ᥦฟࡉࢀࠊ 㝧ᛶ࡞ࡗࡓ⾑ᾮᇵ㣴 466 ᳨యࡢ࠺ࡕࠊ ༢⊂⳦ࡀ᳨ฟࡉࢀࡓ 407 ᳨యࢆᑐ㇟ࡋࡓࠋ⾑ᾮᇵ㣴⨨࡛㝧ᛶࢩࢢࢼࣝࡀฟࡓ࣎ࢺࣝᇵ 㣴ᾮࢆᢤࡁྲྀࡾࠊ⣽⳦ᅇࡢ๓ฎ⌮ࢆ⾜ࡗࡓฎ⌮῭ࡳ᳨యࢆ MALDI-TOF MS ࡛ ᐃࡋࡓ㸦┤ ᥋ྠᐃ㸧 ࠋྠࢢ࣒ࣛᰁⰍ࠾ࡼࡧᖹᯈᇵᆅࢧࣈ࢝ࣝࢳ࣮ࣕࢆᐇࡋࠊ⩣᪥Ⓨ⫱ࢥࣟࢽ࣮ ࢆ MALDI-TOF MS ࡛ ᐃࡋࡓ㸦ࢥࣟࢽ࣮ྠᐃ㸧ࠋࢥࣟࢽ࣮ྠᐃࢆṇࡋ࡚ࠊࡑࢀࡒࢀࡢ⤖ᯝ ࢆẚ㍑ࡋࡓࠋ࡞࠾ࠊ㉁㔞ศᯒィࡣ VITEK MS v2㸦ࢩࢫ࣓ࢵࢡࢫ㸧ࢆ⏝ࡋࡓࠋ ࠙⤖ᯝࠚ༢⊂⳦ࡀ᳨ฟࡉࢀࡓ 407 ᳨యࡢ࠺ࡕࠊ┤᥋ྠᐃ࡛⳦ྡࡀᚓࡽࢀࡓࡢࡣ 351 ᳨య 㸦86.2%㸧࡛࠶ࡾࠊ┤᥋ྠᐃ⳦ྡࢥࣟࢽ࣮ྠᐃࡀ୍⮴ࡋࡓࡢࡣ 343 ᳨య㸦97.7%㸧࡛࠶ࡗࡓࠋ ┤᥋ྠᐃࡼࡾ⳦ྡࡀᚓࡽࢀࠊࡘࢥࣟࢽ࣮ྠᐃ୍⮴ࡍࡿྜࡣ 84.3%࡛࠶ࡗࡓࠋ⳦ྡ ୍⮴ࡢ 8 ᳨యࡢ࠺ࡕࠊ6 ᳨యࡣ࣎ࢺࣝᇵ㣴ᾮࡢࢢ࣒ࣛᰁⰍᙧែ┤᥋ྠᐃ࡛ᚓࡽࢀࡓ⳦ྡࡢ ⳦ᙧែࡀ୍⮴࡛࠶ࡗࡓࠋ ࠙⪃ᐹࠚMALDI-TOF MS ࡼࡿ┤᥋ྠᐃࡣࠊ⤖ᯝᙳ㡪ࢆ࠼ࡿᛮࢃࢀࡿᇵ㣴ᾮෆࡢ⳦௨እ ࡢᡂศࢆዴఱࡋ࡚㝖ཤࡋࠊ⳦ᾮ㏆࠸≧ែ๓ฎ⌮࡛ࡁࡿࡀ࣏ࣥࢺ࡛࠶ࡿࠋࡲࡓࠊ ┤᥋ྠᐃࢆ⮫ᗋάࡍࡓࡵࡣࢥࣟࢽ࣮ྠᐃࡢ㧗࠸୍⮴⋡ࡀồࡵࡽࢀࡿࠋ⌧⾜ࡢ๓ฎ ⌮᪉ἲࡣࠊ࣎ࢺࣝྲྀࡾฟࡋࡽ 45 ศ௨ෆ࡛ 86%⛬ᗘࡢྠᐃ⋡ࡀᚓࡽࢀ࡚࠸ࡿࠋ┤᥋ྠᐃ࡛ ⳦ྡࢆᚓࡿࡇࡀ࡛ࡁࢀࡤࠊࢥࣟࢽ࣮ྠᐃࡢ୍⮴⋡ࡣ 97.7%㧗࠸ࠋ࣎ࢺࣝᇵ㣴ᾮࡢࢢࣛ ࣒ᰁⰍ⤖ᯝేࡏࡿࡇ࡛ࠊࡉࡽ⢭ᗘ㧗ࡃ⮫ᗋሗ࿌ࡍࡿࡇࡀྍ⬟࡛࠶ࡿࠋ⾑ᾮᇵ㣴 ࡢ┤᥋ྠᐃࢆ⾜࠺ࡇࡣ᪩ᮇࠊࡼࡾ㐺ษ࡞ᢠ⳦⸆ࡢ㑅ᢥ⧅ࡀࡿࡶࡢ⪃࠼ࡿࠋ ́́ P-42 MALDI mass spectrometry imaging ࡼࡿ⤖⤌⧊ࣞໟᇙஙࡀࢇ⤌⧊ࡢ పศᏊ௦ㅰ⏘≀ࣉࣟࣇࣜࣥࢢ ᐥ⏣ಙ༤ 1, ஂಖ ┿ 1, ୕ᾆ 3, ෆ⏣◊ᐂ 1, ᐑᓮဴஅ 2, ⸨ᮧ⏤⣖ 3, ᪩ᕝⱥ 3, ሯ㝯⏕ 1, ᐑᆏ⩏ᾈ 1, ┿㘠㐩ஓ 1, ᑠ⏣⩏┤ 2, Ỉඖ୍༤ 4, ୰ᮧ㞞ྐ 1 1 ᕞᏛ⮫ᗋ࣭⭘⒆እ⛉, 2 ᕞᏛᙧែᶵ⬟⌮, 3 ᕞᏛඛ➃⼥ྜ་⒪ࣞࢻࢵࢡࢫࢼ ࣅ◊✲ᣐⅬ, 4 ᕞᏛ㝔 ࡀࢇࢭࣥࢱ࣮ MALDI mass spectrometry imaging profiling of low molecular metabolites with frozen tissue microarray embedded breast cancer tissues. N.Torata1, M.Kubo1, D.Miura3, K. Ohuchida1, T.Miyazaki2, Y.Fujimura3, E.Hayakawa1, T.Otsuka1, Y.Miyasaka1, T Manabe1, Y.Oda2, K.Mizumoto4, M.Nakamura1 1 Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Departments of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, 3 Innovation Center for Medical Redox Navigation, Kyushu University, 4Kyushu University Hospital Cancer Center 2 ࠙┠ⓗࠚࣄࢺ⏤᮶⤌⧊ࢆ⏝࠸ࡓ㉁㔞ศᯒἲ࡛ࡣࠊࣃࣛࣇࣥࣈࣟࢵࢡࡸᢳฟࡢᙳ㡪ࡼࡾࠊ ᦆ࡞ࢃࢀ࡚ࡋࡲ࠺ሗࡀ࠶ࡿࠋࡑࡇ࡛⊂⮬ᢏ⾡ࢆ⏝࠸࡚ࠊங⒴⤌⧊ࡢ⤖⤌⧊ࣞ (fTMA)ࢆᵓ⠏ࡋࠊMALDI mass spectrometry imaging (MALDI-MSI)ࡼࡿపศᏊ௦ㅰ⏘≀ࡢ ࣐ࢵࣆࣥࢢࢆ⾜ࡗࡓࠋࡇࡢ᪉ἲࡼࡾࠊ」ᩘࢧࣥࣉࣝࡢ⒴㛵㐃௦ㅰ⏘≀ࢆຠ⋡ࡼࡃศᯒࡍ ࡿࡇࡀ࡛ࡁࡓࡢ࡛⭘⒆ࠊṇᖖ㒊࠾ࡅࡿࣉࣟࣇࣝ⤖ᯝࡢẚ㍑ࡶሗ࿌ࡍࡿࠋ ࠙᪉ἲࠚ99 ࡽ᥇ྲྀࡋࡓங⭢⤌⧊ 119 ࢧࣥࣉࣝ㸦⭘⒆ 84ࠊṇᖖ 35㸧ࢆ⏝࠸࡚ࠊfTMA ࣈࣟࢵࢡࢆస〇ࡋࠊ9̺࣑ࣀࢡࣜࢪࣥ࠾ࡼࡧ AXIMA Confidence㸦ᓥὠ〇సᡤ㸧ࢆ⏝࠸ࡓ MADLI-MSI ࢆ⾜ࡗࡓ(m/z range㸸50㹼1000ࠊ㝜࣮࢜ࣥࣔࢻ)ࠋศᯒᚋࡢࣉࣞࣃ࣮ࣛࢺ࡚ࠊ ⭘⒆࣭㠀⭘⒆㒊ࢆ☜ㄆࡋࠊ୧㒊ࡢ m/z ࢩࢢࢼࣝศᕸࢆ BioMap ࡚ᢳฟ࣭ẚ㍑ࢆ⾜ࡗࡓࠋ ࠙⤖ᯝࠚ᳨ฟ࡛ࡁࡓ 1915 ಶࡢࣆ࣮ࢡࡢ࠺ࡕࠊ60㸣௨ୖࡢࢧࣥࣉ࡛ࣝඹ㏻᳨ฟࡉࢀࠊ㧗࠸ ࢩࢢࢼࣝࢆ♧ࡍ 185 ࣆ࣮ࢡࢆゎᯒᑐ㇟ࡋࡓࠋᑐᛂࡍࡿ௦ㅰ≀ࡀ᥎ᐃ࡛ࡁࡓ m/z ✀ࡣ 18 ࡛ࠊ ከࡃࡣ ATP ࡞࢚ࢿࣝࢠ࣮௦ㅰ㛵ࡍࡿࡶࡢ࡛࠶ࡗࡓࠋ⭘⒆ࠊṇᖖࡢ Energy Charge(EC)࠾ ࡼࡧ ATP+ADP+AMP ⥲㔞(AXP)ࡢẚ㍑࡛ࠊ࠸ࡎࢀࡶ⭘⒆㒊࠾࠸࡚᭷ព㧗್ࢆ♧ࡋࡓ ࠊ㸯ಶ௨ୖࡢࣜࣥࣃ⠇㌿⛣᭷↓࠾ࡼ ࡀ㸦EC; T : N = 0.56 : 0.35ࠊAXP; 17453 : 2066, p<0.0001㸧 ࡧ⤌⧊ᆺࠊ⭘⒆ᚄࡣ᫂ࡽ࡞┦㛵ࡣ↓ࡗࡓࠋ ࠙⪃ᐹࠚfTMA MADLI-MSI ࢆ⤌ࡳྜࢃࡏࡿࡇࡼࡾࠊ࣓ࢱ࣎ࣜࢵࢡ࣐ࢵࣆࣥࢢࢆຠ⋡ ࡼࡃ⾜࠸ࡇࡀ࡛ࡁࠊங⭢⤌⧊⭘⒆㒊࡛ࠊṇᖖࡼࡾࡶ㧗࠸ EC ್ࢆㄆࡵࡓࠋ⌧Ⅼࡢ᳨ウ࡛ ࡣ᪂つࡢࣂ࣐࣮࣮࢜࢝ೃ⿵࡞ࡿ௦ㅰ≀ࡣྠᐃ࡛ࡁ࡞ࡗࡓࡀࠊࢧࣥࣉࣝ୰ࡢྜ≀ࡢ ࡼࡾヲ⣽࡞ᵓ㐀ゎᯒࢆ㐍ࡵࡿࡇ࡛ࠊࡼࡾከࡃࡢሗࡀᚓࡽࢀࡿࡇࡀᮇᚅࡉࢀࡿࠋ ́́ P-43 ᚠ⎔ჾ㛵㐃⤌⧊࠾ࡅࡿ㹊㹇㹋ࢻ࣓ࣥࢱࣥࣃࢡ㉁」ྜయゎᯒ ᒣ୰ᐶ᫂ 1, ᑎ⏣ ᜨ 1, ⳥ᆅἋ⪨Ꮚ 1, ᔱ⏣ᓫྐ 2, ᳜⏣ึỤ 3, 㣤ཎᘯ 4, ụᕝ㞞ဢ 1 1 ྠᚿ♫Ꮫ⏕་⛉Ꮫ㒊་⏕ࢩࢫࢸ࣒Ꮫ⛉, 2 ᓥὠ〇సᡤᇶ┙ᢏ⾡◊✲ᡤ, 㸱ᅜ❧ᚠ⎔ჾ ◊✲ࢭࣥࢱ࣮⌮㒊, 4 ᕞᏛᏛ㝔་Ꮫ◊✲㝔⬻⚄⤒እ⛉ Multiple protein complex analysis of LIM domain proteins in the cardiovascular systems Hiroaki Yamanaka1, Megumi Terada2, Sayako Kikuchi2, Takashi Shimada1, Hatsue Ueda2, Koji Iihara1, Masaya Ikegawa3 1 Department of Life and Medical Systems, Faculty of Life and Medical Sciences, Doshisha University 2 Life Science Research Center, Shimadzu Corporation 3 Department of Pathology, National Cerebral and Cardiovascular Center 4 Department of Neurosurgery, Postgraduate school of Medicine, Kyushu University ㏆ᖺࠊᚰ⮚ࠊ⾑⟶ࠊ⫵࠸ࡗࡓᚠ⎔ჾ㛵㐃⤌⧊ࡢࣉࣟࢸ࣮࣒࢜ゎᯒὀ┠ࡀ㞟ࡲࡗ࡚ ࠸ࡿࠋࢃࢀࢃࢀࡣࠊࡇࢀࡲ࡛ᚠ⎔ჾ㛵㐃⤌⧊ࢆᑐ㇟ Blue Native PAGE ἲࢆ⏝࠸ࡓࢱࣥ ࣃࢡ㉁」ྜయゎᯒࢆ⾜ࡗ࡚ࡁࡓࠋᮏ◊✲࡛ࡣࠊࡑࡢ࡞ࡽ LIM ࢻ࣓ࣥࢆᣢࡘࢱࣥࣃࢡ ㉁ࣇ࣑࣮ࣜὀ┠ࡋࡓࠋLIM ࢻ࣓ࣥࡣࠊ㑇ఏᏊⓎ⌧ࠊ⣽⬊᥋╔ࠊ⣽⬊㐠ືࠊ࠾ࡼࡧࢩ ࢢࢼࣝఏ㐩ࡢㄪ⠇ᅉᏊࡋ࡚ࠊᶵ⬟ⓗከᵝ࡞ᙺࢆᣢࡘࠋ࡞࡛ࡶࠊfour and a half LIM (FHL)ࣇ࣑࣮ࣜศ㢮ࡉࢀᚰ⮚⾑⟶⣔࡛ࡢⓎ⌧ࡢㄆࡵࡽࢀࡿ FHL-1 (Kyo-T㸯)ࡣࠊ skeletal muscle LIM 1 (SLIM1)ࡋ࡚ࡶ▱ࡽࢀࠊ࣐࢘ࢫᝈࣔࢹࣝࡸࣄࢺࢤࣀ࣒ゎᯒࡢ⤖ᯝ ࡽ⫧ᆺᚰ➽ࡸ⫵㧗⾑ᅽ࡞ࡢᚠ⎔ჾࡢ㛵㐃ࡀ♧၀ࡉࢀ࡚࠸ࡿࠋᅇࡢゎᯒࡢ⤖ ᯝࠊFHL-1 ࡣ࣐࢘ࢫ⫵࠾࠸࡚㢧ⴭ࡞ࢱࣥࣃࢡ㉁Ⓨ⌧ࡢ࠶ࡿࡇࠊẚ㍑ᑐ㇟ࡋ࡚ᚰᐊࠊᚰ ᡣࠊື⬦ྛ㒊࠾ࡅࡿ⤌⧊ࣉࣟࢸ࣮࣒࢜ẚ㍑ࡍࡿࡇࡼࡾ」ྜయᙧᡂࡢ␗࡞ࡿࡇ ࡀ♧၀ࡉࢀࡓࠋᮏ◊✲࡛ࡣࠊᚠ⎔ჾ㛵㐃⤌⧊ࡢࣉࣟࢸ࣮࣒࢜ゎᯒࡢᡭἲࡋ࡚ࠊBlue Native PAGE ἲຍ࠼ࠊᢠయࢆ⏝࠸ࡓ affinity purification ࡢᚋࡢ⥙⨶ⓗ」ྜయゎᯒࢆᑟ ධࡍࡿࡇ࡛⤌⧊ࡢ௦ㅰࡸᶵ⬟ࠊࡑࡢ◚⥢ࡋ࡚ࡢᝈࡢ㛵㐃ࡅࢆ᥈⣴࡛ࡁࡿࠊⱝ ᖸࡢ⪃ᐹࢆ⾜ࡗࡓࠋ ́́ P-44 ࣄࢺ⫾┙࠾ࡅࡿ⤊ᮎ⤧ẟᖿ⤧ẟ࠾ࡅࡿࣜࣥ⬡㉁ศᕸࣃࢱ࣮ࣥࡢ≉ᚩ⫾ ┙⌮ᡤぢࡢ┦㛵ࡘ࠸࡚ ᒣ㷂㤶⧊ 1, ṇᮌ⣖㝯㸰, ᖾᮧᏘᏊ 1, ᪩ᆏᏕᏹ 3, ఀᮾᏹ 1, 㔠ᒣᑦ⿱ 1, ℩⸨ග㸰 1 ᯇ་⛉Ꮫ⏘፬ே⛉Ꮫㅮᗙ, 2 ᯇ་⛉Ꮫゎ๗Ꮫㅮᗙ⣽⬊⏕≀Ꮫศ㔝, 3 ᾏ㐨Ꮫ Ꮫ㝔ಖ⛉Ꮫ◊✲㝔 Imaging Mass Spectrometry Analysis of Differential Expression Patterns of Phospholipid Molecular Species in Terminal and Stem Villi associated with Pathological Findings in the Human Term Placentas Kaori Yamazaki1, Noritaka Masaki, 2, Yukiko Kohmura-Kobayashi1, Takahiro Hayasaka3, Hiroaki Itoh1, Naohiro Kanayama1, Mitsutoshi Setou2 1 Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine 2 Department of Cell Biology and Anatomy, Hamamatsu University School of Medicine 3 Department of Health Science, School of Medicine, Hokkaido University ࠙┠ⓗࠚᡃࠎࡣࠊࡇࢀࡲ࡛ࠊ࣓࣮ࢪࣥࢢ㉁㔞ศᯒ(IMS)ࢆ⏝࠸࡚⫾┙⤧ẟ⤌⧊ࢆホ౯ࡋࠊ⤊ ᮎ⤧ẟ࡛ࡣ phosphatidylcholine (PC)(16:0/20:4)ࡀࠊᖿ⤧ẟ࡛ࡣ sphingomyelin (SM) (d18:1/16:0)ࡢⓎ⌧ࡀஹ㐍ࡋ࡚࠸ࡿࡇࢆ᫂ࡽࡋࡓࠋ ⌮ᡤぢࡢ㛵㐃ᛶࢆㄪࡿࡓࡵࠊ ᅇࠊዷፎ㧗⾑ᅽೃ⩌(PIH)ࡲࡓࡣ⫾ඣⓎ⫱(FGR)ྜేዷፎࡢ⫾┙ࢆゎᯒࡋࡓࠋ ࠙᪉ἲࠚ⌮ጤဨࡢᢎࡢୗࠊዷፎᮎᮇࡢ FGR ࢆకࢃ࡞࠸ PIH 4 (PIH ⩌)ࠊPIH ࢆ కࢃ࡞࠸ FGR 5 (FGR ⩌)ࡢ⫾┙ࡽ⤖ษ∦ࢆసᡂࡋࡓࠋ࣐ࢺࣜࢵࢡࢫᨭ࣮ࣞࢨ࣮ ⬺㞳࢜ࣥ㉁㔞ศᯒ࣓࣮ࢪࣥࢢἲ(MALDI-IMS)ࡼࡾࠊษ∦ୖ 25 μm ᅄ᪉ࡢ㡿ᇦࢆゎᯒ ࡋࡓࠋ㐃⥆ษ∦ࡢ HE ᰁⰍീࡢẚ㍑ࡼࡾ⤧ẟ⤌⧊࠾ࡅࡿࣜࣥ⬡㉁Ⓨ⌧ࣃࢱ࣮ࣥࢆホ౯ ࡋࠊ⫾┙ࡢ⌮⤌⧊Ꮫⓗᡤぢ㸦villitis of unknown etiology, thrombus, atherosis,chorioammnionitis immature terminal villi, multiply branched terminal villi㸧ࡢⓎ⌧ࡢ㛵ಀࢆㄪࡓࠋ ࠙⤖ᯝࠚ6 ಶࡢ⫾┙⌮ᡤぢࡢ࠺ࡕ 3 ಶ௨ୖࡢᡤぢࡀ࠶ࡗࡓ 2 ࡛ࡣࠊ⤊ᮎ⤧ẟ࠾ࡅࡿ PC (16:0/20:4)ࡢⓎ⌧ࠊᖿ⤧ẟ࠾ࡅࡿ SM (d18:1/16:0)ࡢⓎ⌧ࡀࡶపୗࡋ࡚࠸ࡓࠋ⌮ ᡤぢࡀ 2 ಶ௨ୗࡢࡶࡢࡘ࠸࡚ࡣࠊ⤊ᮎ⤧ẟ࠾࠸࡚ PC (16:0/20:4)ࡢࡳࡀⓎ⌧ࡋ࡚࠸ࡓ ࡶࡢࡀ 4 ࠊ⤊ᮎ⤧ẟ࠾ࡅࡿ PC (16:0/20:4)ࡢⓎ⌧ࠊᖿ⤧ẟ࠾ࡅࡿ SM (d18:1/16:0) ࡢⓎ⌧ࡀࡶࡳࡽࢀࡓࡶࡢࡀ 3 ࡛࠶ࡗࡓࠋ ࠙⪃ᐹࠚྜేዷፎ࡛ࡣࠊ⫾┙ࡢ⌮ᡤぢᚑ࠸⤧ẟ⤌⧊࠾ࡅࡿࣜࣥ⬡㉁⤌ᡂኚࡀࡳ ࡽࢀࡓࠋ≉⌮ᡤぢࡢⓎ⌧ᩘࡀከ࠸ࡶࡢࠊ⤧ẟ⤌⧊≉᭷ࡢࣜࣥ⬡㉁ࡢⓎ⌧ࡀపୗࡍ ࡿࡇࡀࢃࡗࡓࠋ ́́ P-45 ⫵⥺⥔㛵㐃ࡋࡓ⬡㉁ࡢ⥙⨶ゎᯒ ᒣྜྷᖾ 1,2, ṇᮌ⣖㝯 2, Ἑ㔝㞞ே 1, ᴮᮏ⣖அ 1, ୰ᮧ♸ኴ㑻 1, ⸨⃝᭸ᖾ 1, ┤㍤ 1, 㡲⏣㝯ᩥ 1, ℩⸨ග 2 1 ᯇ་⛉Ꮫ ෆ⛉Ꮫ➨ㅮᗙ, 2 ྠ ゎ๗Ꮫㅮᗙ⣽⬊⏕≀Ꮫศ㔝 Comprehensive analysis of lipids related with pulmonary fibrosis Yoshiyuki Oyama1,2, Noritaka Masaki2, Masato Kono1, Noriyuki Enomoto1, Yutaro Nakamura1, Tomoyuki Fujisawa1, Naoki Inui1, Takafumi Suda1, Mitsutoshi Setou2 1 Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine 2 Department of Cell Biology and Anatomy, Hamamatsu University School of Medicine, ࠙⫼ᬒࠚ⫵ࡢ⥺⥔࠾࠸࡚ࠊ⫵ࢧ࣮ࣇࢡࢱࣥࢺࡢせᡂศ࡛࠶ࡿࣜࣥ⬡㉁ࡢ⤌ᡂࡀኚ ࡍࡿࡇࡀẼ⟶ᨭ⫵⬊Ὑίᾮ㸦BALF㸧ࢆ⏝࠸ࡓ᳨ウ࡛♧၀ࡉࢀ࡚࠸ࡿࡀࠊᐇ㝿⥺⥔ࡋ ࡓ㒊࠾ࡅࡿࣜࣥ⬡㉁⤌ᡂࢆㄪࡓሗ࿌ࡣᮍࡔ࡞࠸ࠋ ㉁㔞㢧ᚤ㙾ἲ㸦MALDI-IMS㸧ࡣࠊ⤌⧊ෆᒁᅾᚑ࠺ศᏊ⤌ᡂཬࡧࡑࡢⓎ⌧㔞ࡢྍどࢆ ྍ⬟ࡍࡿࠋᵝࠎ࡞ศᏊ✀ࢆゎᯒࡍࡿࡇࡀྍ⬟࡛࠶ࡾࠊ≉⬡⫫㓟⤌ᡂࡢ␗࡞ࡿ⬡㉁ࡢ ༊ูࡀྍ⬟࡛࠶ࡿࡇࡽ⬡㉁ゎᯒࡑࡢጾຊࢆⓎࡋࠊデ᩿࣐࣮࣮࢝ࡢ᳨ฟ࠾ࡼࡧ ࡑࡢែゎᯒᐤࡋ࡚᮶ࡓࠋ ࠙┠ⓗࠚ㉁㔞㢧ᚤ㙾ἲࢆ⏝࠸࡚ື≀ࣔࢹࣝࡢ⫵ᒁᡤ࠾ࡅࡿ⫵⥺⥔㛵㐃ࡋࡓ⬡㉁ࡢኚ ࢆ᫂ࡽࡍࡿࠋ ࠙᪉ἲࠚ⬚㒌ࡽྲྀࡾฟࡋࡓ⫵ࡣࡑࡢࡲࡲ࡛ࡣ⬺ࡋ࡚࠸ࡿࡓࡵ⫵⬊㡿ᇦࡢᵓ㐀ࡀኻࢃࢀ࡚ ࡋ ࡲ ࠺ ࠋ ࡑ ࡢ ࡓ ࡵ ㉁ 㔞 㢧 ᚤ 㙾 ἲ ࡢ ㉁ 㔞 ศ ᯒ ࢫ ࣌ ࢡ ࢺ ࣝ ࠼ ࡿ ᙳ 㡪 ࡀ ᑡ ࡞ ࠸ 2% carboxymethyl cellulose ࢆẼ⟶ෆࡼࡾὀධࡋࠊ⫵ࢆ inflation ࡋࡓᚋ⤖ࡋࠊษ∦ࢆసᡂࡋࡓࠋ ヨᩱࡋ࡚ṇᖖ࣐࢘ࢫࣈ࣐ࣞ࢜ࢩࣥ㸦BLM㸧⫵⥺⥔ࣔࢹ࣐ࣝ࢘ࢫࡢ㐃⥆ษ∦ࢆస ᡂࡋࠊ㉁㔞㢧ᚤ㙾ἲࡼࡾゎᯒࡋࡓࠋࡲࡓ㐃⥆ษ∦ᑐࡋ࡚࣐࣊ࢺ࢟ࢩ࣭࢚ࣜࣥ࢜ࢪࣥ㸦HE㸧 ᰁⰍࡼࡿᙧែほᐹࢆ⾜ࡗࡓࠋ ࠙⤖ᯝࠚṇᖖ࣐࢘ࢫࠊBLM ࣔࢹ࣐ࣝ࢘ࢫࡢṇᖖ㒊ཬࡧ⥺⥔㒊ࢆẚ㍑ࡍࡿࠊ⥺⥔ࡀ 㐍⾜ࡍࡿࡘࢀࠊ⫵ࢧ࣮ࣇࢡࢱࣥࢺࡢせᵓᡂᡂศ࡛࠶ࡿ PC(16:0/16:0)ࡀῶᑡࡋ࡚࠸ࡓࠋ ࠙⤖ㄒࠚBALF ゎᯒ࡛ࡣయⓗ࡞ኚࡋ࡚ࡋᤊ࠼ࡽࢀ࡚࠸࡞ࡗࡓ PC(16:0/16:0)ࡢῶᑡ ࡀࠊ㉁㔞㢧ᚤ㙾ࢆ⏝࠸ࡓ┤᥋ほᐹࡼࡾṇᖖ㒊࠾ࡅࡿῶᑡࠊ⥺⥔㒊࠾ࡅࡿࡼ ࡾⴭࡋ࠸ῶᑡࡢ✀㢮ࡢኚࡼࡿࡶࡢ࡛࠶ࡿࡇࡀ♧ࡉࢀࡓࠋ ́́ P-46 ࢺࣜࣉࣝࢿ࢞ࢸࣈங⒴ࡢⓎண ᅉᏊࡢ㉁㔞㢧ᚤ㙾ࢆ⏝࠸ࡓ᥈ồ ⣽ᕝඃᏊ 1, ṇᮌ⣖㝯 2, ᯇୗ⚈Ꮚ 2, ᮡᒣᰤ 2, ᑠ༤அ 1, ᳝㇂⣖ᙪ 1, ℩⸨ග 2 1 ᯇ་⛉Ꮫ➨୍እ⛉, 2 ᯇ་⛉Ꮫゎ๗Ꮫㅮᗙ ⣽⬊⏕≀Ꮫศ㔝 Investigation of predictive factor of recurrence in triple negative breast cancer using mass microscope Yuko Hosokawa1, Noritaka Masaki2, Shoko Matsushita2, Eiji Sugiyama2, Hiroyuki Ogura1, Norihiko Shiiya1, Mitsutoshi Setou2 1 Hamamatsu University School of Medicine Department of 1st Surgery 2 Hamamatsu University School of Medicine Department of Cell Biology and Anatomy ࠙┠ⓗࠚங⒴ࡣୡ⏺ⓗዪᛶࡢ⒴ࡼࡿṚஸࡢ࡞せᅉ࡛࠶ࡿࠋங⒴ࡣ࣍ࣝࣔࣥཷᐜయࡸ HER2 ཷᐜయࡢ᭷↓, Ki67 ࡢ㧗ప࡛ 5 ࡘࡢࢧࣈࢱࣉศ㢮ࡉࢀࡿࠋ୰࡛ࡶ࣍ࣝࣔࣥཷᐜ య࡛࠶ࡿ࢚ࢫࢺࣟࢤࣥཷᐜయࣉࣟࢤࢫࢸࣟࣥཷᐜయ㝜ᛶ, HER2 ཷᐜయ㝜ᛶࡢࢺࣜࣉࣝࢿ ࢞ࢸࣈங⒴ࡣయࡢ 10-15㸣ࢆ༨ࡵ, ᪩ᮇⓎࡋணᚋࡀᝏ࠸ࡇࡀ▱ࡽࢀ࡚࠸ࡿࠋ ୍᪉࡛ࢺࣜࣉࣝࢿ࢞ࢸࣈங⒴ࡢ୰ࡶணᚋࡢⰋ࠸ࡶᏑᅾࡍࡿࡀ, ᮇࡢࡼ࠺᫂ ☜࡞ணᚋᅉᏊࡣࢃࡗ࡚࠸࡞࠸ࠋࡲࡓங⒴⤌⧊୰࡛ࡣṇᖖ⤌⧊ẚ㍑ࡋ࡚⬡㉁⤌ᡂࡀ␗࡞ ࡿࡇࡀ▱ࡽࢀ࡚࠾ࡾ, ⬡㉁௦ㅰࡀ⭘⒆ࡢ㐍ᒎ㛵ಀࡋ࡚࠸ࡿࡢሗ࿌ࡶ࠶ࡿࡇࡽ, Ⓨࡶᙳ㡪ࡋ࡚࠸ࡿ⪃࠼ࡽࢀࡿࠋᮏ◊✲࡛ࡣ㉁㔞㢧ᚤ㙾ࢆ⏝࠸࡚ࢺࣜࣉࣝࢿ࢞ࢸࣈ ங⒴࠾ࡅࡿ⬡㉁⤌ᡂࢆゎᯒࡋ, Ⓨ㛵ಀࡍࡿᅉᏊࢆ᥈ồࡍࡿࠋ ࠙᪉ἲࠚᡭ⾡᥇ྲྀᚋ⤖ಖᏑࡉࢀࡓࢺࣜࣉࣝࢿ࢞ࢸࣈங⒴ࡢ᳨య 9 ࢆ⏝࠸࡚㉁㔞㢧 ᚤ㙾㸦mass microscope, ᓥὠ〇సᡤ㸧࡛⥙⨶ⓗゎᯒࢆ⾜ࡗࡓࠋほᐹᮇ㛫ࡢ୰ኸ್ࡣ 34 ᭶࡛, Ⓨࡣ 3 ࡛࠶ࡗࡓࠋ࣐ࢺࣜࢵࢡࢫࡣ 125㹫M ࡢ◲㓟ࣥࣔࢽ࣒࢘ࢆຍ࠼ࡓ 2,5ࢪࣄࢻࣟ࢟ࢩࢭࢺࣇ࢙ࣀࣥࢆ⏝ࡋࡓࠋ ㉁㔞⠊ᅖࡀ m/z700 ࡽ 900 ࡢ㝧࢜ࣥ m/z650 ࡽ 950 ࡢ㝜࢜ࣥࢆࡑࢀࡒࢀゎᯒࡋࡓࠋࢹ࣮ࢱࡢゎᯒࡣᑓ⏝ࢯࣇࢺ(Imaging MS Solution, ᓥὠ〇సᡤ)࡛⾜ࡗࡓࠋࡲࡓィ ⤖ᯝࡼࡾᚓࡽࢀࡓࢩࢢࢼࣝᑐᛂࡍࡿ⬡㉁ྜ≀ ࡢ᳨⣴ࡣ HMDB(http://www.hmdb.ca/spectra/ms/search)ࢆ⏝࠸ࡓࠋ ࠙⤖ᯝࠚ㠀Ⓨ⩌Ⓨ⩌ࢆẚ㍑ࡋࡓࡇࢁ, 㝧࣮࢜ࣥࣔࢻࡢゎᯒ࡛ࡣ m/z706.5 ࡢࢩࢢࢼ ࣝࡀⓎ⩌࡛᭷ពቑຍࡋ࡚࠸ࡓࠋHMDB ࡢẚ㍑ࡽࡇࡢࢩࢢࢼࣝࡣࣜࣥ⬡㉁ࡢ୍ࡘ࡛ ࠶ࡿࣇ࢛ࢫࣇࢳࢪࣝࢥࣜࣥ(phosphatidylcholine, PC) (30:0)᥎ᐃࡉࢀࡓࠋ㝜࣮࢜ࣥࣔ ࢻࡢゎᯒ࡛ࡣ⩌㛫᭷ព࡞ᕪࡣㄆࡵࡽࢀ࡞ࡗࡓࠋ ࠙⪃ᐹࠚᚑ᮶ࢺࣜࣉࣝࢿ࢞ࢸࣈࡋ࡚ศ㢮ࡉࢀࡓங⒴ヨᩱࢆ㉁㔞㢧ᚤ㙾ゎᯒࡍࡿࡇࡼ ࡾ, Ⓨ⩌㠀Ⓨ⩌࡛ࡣ⣽⬊⭷ࡢせ࡞ᵓᡂᡂศ࡛࠶ࡿ PC ࡢ⤌ᡂࡀ␗࡞ࡿࡇࡀ♧ࡉࢀ ࡓࠋᮏ◊✲ࡼࡗ࡚ PC(30:0)ࡣࢺࣜࣉࣝࢿ࢞ࢸࣈங⒴ࡢⓎண ᅉᏊࡋ࡚ぢ࠸ࡔࡉࢀ, ⭘⒆ࡢ㐍ᒎࢃࡗ࡚࠸ࡿ⪃࠼ࡽࢀࡓࠋ ́́ P-47 ⏕య࣑ࣥྜ≀ࢆᑐ㇟ࡋࡓ᪂つㄏᑟయἲࡼࡿ࣐࢘ࢫ⬻ࡢ㉁㔞ศᯒ࣓ ࣮ࢪࣥࢢ ῝㔝 ⳹ 1, ⬥ ⣖ᙪ 1, Ṋྐ㑻 1,2, ℩⸨ග 2, ▮ᑿ⫱Ꮚ 1 1 ᯇ་⛉Ꮫ࣓ࢹ࢝ࣝࣇ࢛ࢺࢽࢡࢫ◊✲ࢭࣥࢱ࣮, 2 ᯇ་⛉Ꮫゎ๗Ꮫㅮᗙ⣽⬊⏕≀ Ꮫศ㔝 Imaging mass spectrometry of mouse brain tissues using a new derivatization method targeting biogenic amines Hana Fukano1, Michihiko Waki 1,, Shiro Takei1, 2, Mitsutoshi Setou2, Ikuko Yao1 1 Medical Photonics Center, Hamamatsu University School of Medicine 2 Department of Cell Biology and Anatomy, Hamamatsu University School of Medicine ࠙┠ⓗࠚ㉁㔞ศᯒ࣓࣮ࢪࣥࢢ (IMS) ࡣࠊ⤌⧊ษ∦୰ࡢ⏕యศᏊࡢᒁᅾࢆほᐹࡍࡿᡭἲ ࡋ࡚ὀ┠ࢆ㞟ࡵ࡚࠸ࡿࠋࡇࢀࡲ࡛⬡㉁ࡸ⺮ⓑ㉁➼ࡀྍどࡉࢀࠊ ᐃᑐ㇟࡞ࡿศᏊ ✀ࡣቑ࠼⥆ࡅ࡚࠸ࡿࠋᅇᡃࠎࡣࠊ࣑ࣀ㓟ࡸࣔࣀ࣑ࣥ⣔⚄⤒ఏ㐩≀㉁ࢆྵࡴ⏕య ࣑ࣥྜ≀ࡢຠ⋡ⓗ࡞᳨ฟࢆ┠ᣦࡋࠊ㉁㔞ศᯒ࣓࣮ࢪࣥࢢࡢࡓࡵࡢ࣑ࣀᇶࡢᏛⓗ ㄏᑟయἲࡢ☜❧ࢆヨࡳࡓࠋ ࠙᪉ἲࠚㄏᑟయヨ⸆ࡋ࡚ࠊsuccinimidyl 4- [3,5-Dimethyl-4- (4-nitrobenzyloxy) phenyl] -4-oxobutyrate (S0808) ࢆ⏝ࡋࡓࠋ࣐࢘ࢫ⬻ษ∦ࢆ ȝm ࡢཌࡉࢫࣛࢫࡋࠊᑟ㟁ᛶࢫ ࣛࢻ࢞ࣛࢫ᥋╔ࡋࡓࠋసᡂࡋࡓヨᩱୖࠊࢭࢺࢽࢺࣜࣝࢆ⁐፹ࡋࡓ 5.5mM ࡢ S0808 ࢆࢫࣉ࣮ࣞࢆ⏝࠸࡚ᆒ୍ᄇ㟝ࡋࡓࠋ ᐃࡣᓥὠ〇సᡤࡢ iMScope prototype ࢆ ⏝ࡋࠊゎᯒࡣ Imaging MS SolutionTM ࢆ⏝ࡋࡓࠋ ࠙⤖ᯝࠚㄏᑟయฎ⌮ࢆࡋࡓ࣐࢘ࢫ⬻ษ∦ࡢ ᐃࡽࠊࣛࢽࣥࠊGABAࠊࢭࣜࣥࠊࢩ ࢫࢸࣥࠊࢱ࢘ࣜࣥࠊࢢࣝࢱ࣑ࣥ㓟ࠊࢻ࣮ࣃ࣑ࣥࠊࢭࣟࢺࢽࣥࡢ 8 ࡘࡢ≉␗ⓗ࡞ࣆ࣮ࢡ ࡀほ ࡉࢀࡓࠋ୍᪉ࠊㄏᑟయヨ⸆ࢆࢫࣛࢻ࢞ࣛࢫᄇ㟝ࡋ࡞ࡗࡓ࣐࢘ࢫ⬻ษ∦࡛ ࡣࠊࣆ࣮ࢡࡀほ ࡉࢀ࡞ࡗࡓࠋࡇࢀࡽࡢࣆ࣮ࢡࡢ㉁㔞㟁Ⲵẚ (m/z) ࡣࠊ࣑ࣀ㓟ࡸࣔ ࣀ࣑ࣥ⣔⚄⤒ఏ㐩≀㉁ࡢศᏊ㔞ࡽィ⟬ࡋࡓㄏᑟయ≀ࡢ m/z ୍⮴ࡋࡓࠋࡉࡽࡇ ࢀࡽࡢࣆ࣮ࢡ୰࡛ࢩࢢࢼࣝᙉᗘࡢᙉࡗࡓࢢࣝࢱ࣑ࣥ㓟ࠊࢱ࢘ࣜࣥࠊࢭࣟࢺࢽࣥ㛵ࡋ ࡚ࠊㄏᑟయ≀ࡢ࣐࢘ࢫ⬻ษ∦࠾ࡅࡿศᕸࢆྍどࡋࠊ␗࡞ࡿศᕸࢆ♧ࡍࡇࢆ᫂ࡽ ࡋࡓࠋ ࠙⪃ᐹࠚᅇࠊ࣐࢘ࢫ⬻ษ∦࠾࠸࡚ㄏᑟయฎ⌮ࢆ⾜࠸ࠊ⏕య࣑ࣥྜ≀ࢆ IMS ࡛ྠ ᳨ฟࡋࠊྍどࡍࡿࡇࡀ࡛ࡁࡓࠋ⏕య࣑ࣥྜ≀ࢆ IMS ࡛ほ ࡍࡿᡭἲࡣࠊ⚄ ⤒⢭⚄ᝈࡢែゎᯒᛂ⏝࡛ࡁࡿᮇᚅࡉࢀࡿࠋ ́́ P-48 ⺯ග࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈᢞ࣐࢘ࢫ⫢⤌⧊ᑐࡍࡿྛ✀࣓࣮ࢪࣥࢢᢏ⾡ࡢ 㐺⏝ ᒣཱྀ ு 1, ᒣᮏ༟ᚿ 1, ୰ᕝ ⸅ 1, Ώ㒊┤ᶞ 2, ➉ෆ ྖ 1, ᑿᓥ⾜ 1 1 ᰴᘧ♫ ᓥὠ〇సᡤ, 2 ࣞࢽࢩ࣮ࣙᰴᘧ♫ Multiple Imaging analysis using MSI and Raman technique in inflamed mouse liver dozed with fluorescent imaging probe Ryo Yamaguchi1, Takushi Yamamoto1, Kaoru Nakagawa1, Naoki Watabe2, Tsukasa Takeuchi1, Noriyuki Ojima1 1 Shimadzu Corporation 2 Renishaw ࠙┠ⓗࠚᓥὠ〇సᡤ࡛ࡣᚑ᮶⏝࠸ࡽࢀ࡚࠸ࡿ㏆㉥እ⺯ගἼ㛗ࡼࡾࡶ᭦㛗࠸ NIR-ϩ㸦1000nm ௨ୖ㸧㡿ᇦࡢἼ㛗ࢆ⏝࠸ࡓ in vivo ㏆㉥እ⺯ග࣓࣮ࢪࣥࢢࢩࢫࢸ࣒ࢆ㛤Ⓨࡋ࡚࠸ࡿࠋ⺯ ග࣓࣮ࢪࣥࢢᚲせ࡞࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࢆඹྠ◊✲⪅㛤Ⓨࡋ࡚࠸ࡿࡀ㸪㧗⢭⣽࡞ ⏬ീࡀᚓࡽࢀࡿ㠃㸪⌧≧ࡢࣉ࣮ࣟࣈࡣ⫢⮚ࡢ㢧ⴭ࡞㞟✚ࡀぢࡽࢀࡿࡓࡵ㸪ࡇࢀࢆᨵၿ ࡋ࡚࠸ࡃᚲせࡀ࠶ࡿࠋᮏ᳨ウ࡛ࡣ㸪⺯ග࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࡢ⫢⮚ࡢ㞟✚ࡀ࣓࣮ࢪ ࣥࢢ౪ࡍࡿ࣐࢘ࢫࡢࡼ࠺࡞ᙳ㡪ࢆཬࡰࡋ࡚࠸ࡿࠊᵝࠎ࡞ゅᗘࡽ᳨ウࢆ⾜ࡗࡓࠋ ᅇࡣ㸪㉁㔞ศᯒ࣓࣮ࢪࣥࢢ࡛ࡢゎᯒຍ࠼㸪⺯ග࣓࣮ࢪࣥࢢ୪ࡧ࣐ࣛࣥศගἲ ࡼࡿ࣓࣮ࢪࣥࢢࢹ࣮ࢱࡶ࠶ࢃࡏ࡚ሗ࿌ࡍࡿࠋ ࠙᪉ἲࠚ⺯ග࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࢆ 100ȣ㹪(100mg/ml㸧ࢆᑿ㟼⬦ᢞࡋࡓ BALB/c-nu ࣐ ࢘ࢫࢆᢞ 48 㛫ᚋ㸪῝㯞㓉ୗ࡛ᏳᴦṚࡉࡏ⫢⤌⧊ࢆฟࡋࡓࠋฟࡋࡓ⫢⤌⧊ࢆ 10um ཌⷧษࡋ㸪ᑟ㟁ᛶࢫࣛࢻࢢࣛࢫᦚ㍕ࡋࡓࠋ࣐ࢺࣜࢡࢫࡋ࡚ࡣ 9-AA ࢆ⏝ࡋࡓࡢࡕ㸪 ࣓࣮ࢪࣥࢢ㉁㔞ศᯒࢆᐇࡋࡓࠋࡲࡓ㸪㐃⥆ษ∦ࢆ⏝ࡋ࡚࣐ࣛࣥศගἲ࡛ࡢゎᯒࢆᐇ ࡋࡓࠋ ࠙⤖ᯝࠚపศᏊ௦ㅰ≀ࡋ࡚ࡢ ATP࣭ADP࣭AMP ຍ࠼㸪⫹Ồ㓟ࡢศᕸ⏬ീࡀྲྀᚓࡉࢀࡓࠋ ྛ✀࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࡢᢞ࠶ࡾ/࡞ࡋ࡚㸪㢧ⴭ࡞ศᕸኚࡣぢ࠸ࡔࡏ࡞ࡗࡓࡶࡢ ࡢ㸪ྛ ᐃࢹ࣮ࢱᑐࡋ࡚ࡢ┦ᑐᙉᗘẚ㍑ࡼࡾᏑᅾ㔞ࡢቑῶࢆ᳨ฟ࡛ࡁࡓࠋ୍᪉㸪࣐ࣛ ࣥศගἲࡼࡿྍど࡛ࡣ⸆ࡑࡢࡶࡢࡢྍどࡶᡂຌࡋ࡚࠾ࡾ㸪ู㏵ྲྀᚓࡋࡓᰁⰍ⏬ ീẚ㍑ࡍࡿࡇ࡛㸪⫢㞀ᐖࡢ㛵㐃ᛶࡀ♧၀ࡉࢀࡓࠋ ࠙⪃ᐹࠚᮏ࡛ࡣ㸪ྠ୍ࢧࣥࣉࣝᑐࡋ࡚␗࡞ࡗࡓཎ⌮ࡢ࣓࣮ࢪࣥࢢᢏ⾡ࢆ⏝ࡍࡿࡇ ࡛㸪௦ㅰ≀ࡢศᕸྍど㸪⸆ࡑࡢࡶࡢࡢྍどᡂຌࡋࡓࠋࡇࡢࡼ࠺⺯ග࣓࣮ࢪ ࣥࢢ㸪㉁㔞ศᯒ࣓࣮ࢪࣥࢢ㸪࣐࣓࣮ࣛࣥࢪࣥࢢࡢే⏝ࡣ㸪⸆ࡢస⏝ᶵᗎゎ࣭᫂ẘᛶ ࣓࢝ࢽࢬ࣒ゎ᫂᭷ຠ࡛࠶ࡿ⪃࠼ࡽࢀࡿࠋ ́́ P-49 ㉁㔞ศᯒ࣓࣮ࢪࣥࢢࢹ࣮ࢱࢆ⏝࠸ࡓ⤌⧊ษ∦ࡢ࢚ࣥࢺࣟࣆ࣮࣓࣮ࢪࣥࢢゎᯒ బ⸨㥴ᖹ, బ⸨ᬛோ, ṇᮌ⣖㝯, ℩⸨ග ᯇ་⛉Ꮫ ゎ๗Ꮫㅮᗙ ⣽⬊⏕≀Ꮫศ㔝 Entropy Imaging of Tissue Sections from Mass Spectrometry Imaging Data. Shumpei Sato, Tomohito Sato, Noritaka Masaki, Mitsutoshi Setou Department of Cell Biology and Anatomy, Hamamatsu University School of Medicin ࠙┠ⓗࠚ㉁㔞ศᯒ࣓࣮ࢪࣥࢢἲࡣ⤌⧊ษ∦ᑐࡋ࡚࣮ࣞࢨ࣮ࢆ㉮ᰝࡍࡿࡇ࡛✵㛫ሗࢆ ྵࡵࡓ㉁㔞ศᯒࢆ⾜࠺᪉ἲ࡛࠶ࡿࠋ୍⯡ⓗ࡞ゎᯒ࡛ࡣࠊ┠ⓗࡢศᏊࡢ m/z ࡔࡅὀ┠ࡋࠊࡑ ࡢศᕸࢆゎᯒࡍࡿࠋ୍᪉ࠊ⏕≀ࡣከᵝ࡞ศᏊࢆෆໟࡋࠊ⪁ࡸᝈ࡞ࡼࡿศᏊࡢᙳ 㡪ࡣ㠀ᖖከᒱΏࡿࠋࡇࡢࡼ࠺࡞⭾࡞ศᏊࡢኚືࢆಠ▔ࡋ࡚ᤊ࠼ࡿࡓࡵࠊᡃࠎࡣ㉁ 㔞ศᯒࢹ࣮ࢱࢆ⏝࠸࡚ࢩࣕࣀ࢚ࣥࣥࢺࣟࣆ࣮ࢆ⟬ฟࡋࠊ㉁㔞ศᯒ࣓࣮ࢪࣥࢢࡢྛⅬẖࡢ ࢩࣕࣀ࢚ࣥࣥࢺࣟࣆ࣮ࢆ⤌⧊ୖᥥฟࡍࡿࡇࢆヨࡳࡓࠋࡇࢀࡼࡾ⭾࡞ศᏊࡽ࡞ࡿ ྛⅬࡢ㉁㔞ศᯒࢫ࣌ࢡࢺࣝࡢ≉ᚩࢆ⤌⧊ୖ࡛ẚ㍑ࡍࡿࡇࢆ┠ⓗࡋࡓࠋ ࠙᪉ἲࠚ⏕≀ヨᩱ࠾࠸࡚ࢩࣕࣀ࢚ࣥࣥࢺࣟࣆ࣮ࢆ࣓࣮ࢪࣥࢢࡍࡿヨࡳࡣᮏ◊✲ࡀึࡵ࡚ ࡛࠶ࡿࡓࡵࠊࡲࡎࡣ࣐࢘ࢫ⫢⮚ࢆ⏝࠸࡚㐺ษ࡞᮲௳ࢆ᳨ウࡋࡓࠋ࣐࢘ࢫ⮚ჾࡣ㢁᳝⬺⮻ᚋࠊ ⣲᪩ࡃྲྀࡾฟࡉࢀ࡚ࢻࣛࢫࡼࡾ⤖ࡉࢀࡓࠋ⫢⮚ࡣࢡࣛ࢜ࢫࢱࢵࢺ࡛ 10 ȝm ཌ ⷧษࡉࢀࠊITO ࢥ࣮ࢺࢫࣛࢻ㈞ࡾࡅࡽࢀࡓࠋࡇࡢࢫࣛࢻࡣ࣐ࢺࣜࢡࢫ(9AA)ࢆ ╔ࡉࢀࠊ㉁㔞ศᯒ࣓࣮ࢪࣥࢢ⨨(ultraflexII, Bruker Daltonics)ࡼࡾ ᐃࡉࢀࡓࠋ ᐃࡉ ࢀࡓࢹ࣮ࢱࡣ SIMentorpy (ᓥὠ〇సᡤ)ࢯࣇࢺ࢙࢘ࡼࡗ࡚ኚࡉࢀࠊࢩࣕࣀ࢚ࣥࣥࢺࣟ ࣆ࣮ീࡋ࡚⤌⧊ୖᥥฟࡉࢀࡓࠋ᮲௳᳨ウ࡛ࡣ ᐃࣃ࣓࣮ࣛࢱ࣮ࢆኚ᭦ࡋࠊࢩࣕࣀ࢚ࣥ ࣥࢺࣟࣆ࣮ീ࠾ࡅࡿ್ࡢᖹᆒࡸศᩓ࡞ࢆᇶ㐺ษ࡞᮲௳ࢆỴᐃࡋࡓࠋ ᐃ᮲௳ࡢỴᐃ ᚋࠊ࣐࢘ࢫࡢ⫢⮚ࠊ⬻ࠊ⭈⮚ࡢࢩࣕࣀ࢚ࣥࣥࢺࣟࣆ࣮ീࢆ㐌㱋ẖẚ㍑ࡋࠊ⏕≀ヨᩱ࠾ ࠸࡚ࢩࣕࣀ࢚ࣥࣥࢺࣟࣆ࣮ࡀຍ㱋ࡼࡾ࠺ኚࡍࡿࡢࢆㄪࡓࠋ ࠙⤖ᯝࠚ ᐃ᮲௳᳨ウࡋ࡚ࠊ ᐃ m/z ⠊ᅖ, ᐃ࣮࢜ࣥࣔࢻ, ࣮ࣞࢨ࣮↷ᑕᅇᩘ, ࣮ࣞࢨ ࣮ᙉᗘ, ᐃⅬ㛫㝸, ࣛࣥࢲ࣒࢛࣮࢘ࢡࡢ᭷↓ࡘ࠸᳨࡚ウࡋࡓࠋྛ᮲௳ࢆኚࡉࡏࡓࡁ ࡢࢩࣕࣀ࢚ࣥࣥࢺࣟࣆ࣮ࡢᖹᆒཬࡧศᩓᑐࡋ࡚ ᐃ㛫ࡢࡤࡽࡘࡁࡀᑡ࡞࠸᮲௳ࢆỴᐃࡋ ࡓࠋỴᐃࡉࢀࡓ᮲௳ࢆ⏝࠸࡚࣐࢘ࢫࡢ⬻, ⫢⮚, ⭈⮚ࢆ 1, 2, 4, 8, 16 㐌㱋࡛ẚ㍑ࡋࡓ⤖ᯝࠊ ࢩࣕࣀ࢚ࣥࣥࢺࣟࣆ࣮ࡢᙉᗘศᕸࡢኚࡀ㐌㱋㛵ಀࡋ࡚࠸ࡿࡇࡀ᫂ࡽ࡞ࡗࡓࠋ ࡲࡓࠊ࣐࢘ࢫ⬻ࡢᵓ㐀ࡀࢩࣕࣀ࢚ࣥࣥࢺࣟࣆ࣮ࡢኚ࡛ᤊ࠼ࡽࢀࡿࡇࡀศࡗࡓࠋ ࠙⪃ᐹࠚᅇࡢ᮲௳᳨ウࡼࡾࠊ㉁㔞ศᯒ࣓࣮ࢪࣥࢢࡢࢹ࣮ࢱࡽࢩࣕࣀ࢚ࣥࣥࢺࣟࣆ࣮ࢆ ⤌⧊ୖ࡛࣓࣮ࢪࣥࢢ࡛ࡁࡿࡼ࠺࡞ࡗࡓࠋᮏᡭἲࡣࢩࣕࣀ࢚ࣥࣥࢺࣟࣆ࣮ࡼࡾ⬻ࡢ⤌⧊ ᵓ㐀ࢆᫎࡍࡿ࡛ࣞ࣋ࣝ㉁㔞ศᯒࢫ࣌ࢡࢺࣝࡢ≉ᚩࢆẚ㍑ࡍࡿࡇࡀ࡛ࡁࡿࠋࡲࡓࠊ⤌⧊ࡢ 㐌㱋కࡗࡓኚࡶᤊ࠼ࡿࡇࡀ࡛ࡁࡓࡓࡵࠊᚋࠊࡢゎᯒᛂ⏝ࡋ࡚⾜ࡁࡓ࠸ࠋ ́́ P-50 ࣥࢺࢩࢽࣥࡢయෆືែゎᯒ ㈈‶ಙᏹ 1, ✄ⴥᰭ㔛 1, ⸨᳃㝯㐨 1, Ⲯཝဴဢ 2, ᑠᯘἋ⧊ 2, ᳃ᒣ㐩ဢ 1 1 ㏆␥Ꮫ㎰Ꮫ㒊 2 ᰴᘧ♫࣡࢝ࢧ⏕ά Pharmacokinetic analysis of anthocyanins in mouse Nobuhiro Zaima1, Shiori Inaba1, Takamichi Fujimori1, Tetsuya Sogon2, Saori Kobayashi2, Tatsuya Moriyama 1 1 Kinki University 2 Wakasa Seikatsu Corporation ࠙┠ⓗࠚࣥࢺࢩࢽࣥࡣ᳜≀࠾࠸࡚ᗈࡃᏑᅾࡍࡿⰍ⣲࡛࠶ࡿࠋᢠ㓟ᛶࢆ᭷ࡍࡿࡇ ࡽࠊᶵ⬟ᛶ㣗ရ⣲ᮦ࡞ࡋ࡚ࡶ╔┠ࡉࢀࠊࡑࡢ⏕⌮άᛶ㛵ࡍࡿ◊✲ࡀከࡃ⾜ࢃࢀ࡚࠸ ࡿࠋࣥࢺࢩࢽࣥࡢ⏕⌮άᛶࢆ⌮ゎࡍࡿୖ࡛ࠊࣥࢺࢩࢽࣥࡢయෆືែࢆゎᯒࡍࡿࡇ ࡀ㔜せ࡛࠶ࡿࡀࠊࡇࢀ㛵ࡋ࡚ࡣ᫂࡞Ⅼࡀከ࠸ࠋᮏ◊✲࡛ࡣࠊ㉁㔞ศᯒ࣓࣮ࢪࣥࢢ ἲ㸦matrix-assisted laser desorption/ionization (MALDI)–Imaging mass spectrometry (IMS)ࢆ⏝࠸ ࡚ࠊࣥࢺࢩࢽࣥࢆྍどࡍࡿࡇࡼࡗ࡚ࠊయෆືែࢆ᫂ࡽࡍࡿࡇࢆ┠ⓗࡋ ࡓࠋ ࠙᪉ἲࠚື≀ᐇ㦂ࡣ㏆␥Ꮫື≀ᐇ㦂つ⛬ᚑࡗ࡚⾜ࡗࡓࠋddy ࣐࢘ࢫ㸦࢜ࢫࠊ6 㐌㱋㸧ࡣ 22±2Υࠊ12 㛫ࡢ᫂ᬯࢧࢡࣝࡢ⎔ቃୗ࡛㣫⫱ࡋࡓࠋ㥆ᚋࠊࣅ࣮ࣝ࣋ࣜࡼࡾᢳฟࡋࡓ ࣥࢺࢩࢽࣥΰྜ≀ࢆ⤒ཱྀཬࡧ⭡⭍ෆᢞࡋࡓࠋ₤ὶᚋ║ࢆ᥇ྲྀࡋࠊᾮయ❅⣲࡛⤖ࡋ ࡓᚋࠊࢡࣛ࢜ࢫࢱࢵࢺ㸦Leica Microsystems㸧࡛ ȝP ࡢษ∦ࡋࡓࠋసᡂࡋࡓษ∦࣐ࢺ ࣜࢵࢡࢫࡋ࡚ DHB㸦2,5-Dihydroxybenzonic acid㸧⁐ᾮࢆሬᕸࡋࠊ㉁㔞ศᯒ⨨㸦MALDI LTQ-XL (ThermoFisher Scientific)㸧 ౪ࡋࡓࠋࣉ࢚ࣛࣜࣥࡢື ែࡢྍどࡣࠊ Image Quest(ThermoFisher Scientific)ࢆ⏝࠸ࡓࠋ ࠙⤖ᯝࠚࣅ࣮ࣝ࣋ࣜᏑᅾࡍࡿ࡞ࣥࢺࢩࢽࣥศᏊ✀ࡢ୍ࡘ࡛࠶ࡿ Cyanidin 3-glucoside 㸦m/z 449 ĺP] 287㸧ࢆ ᐃࡋࡓ⤖ᯝࠊ⤒ཱྀᢞ⩌࡛ࡣ᫂░࡞ࣆ࣮ࢡࡣ᳨ฟࡉࢀ࡞ࡗࡓࠋ ⭡⭍ෆᢞ⩌࠾࠸࡚ࡣࠊ⥙⭷እᒙࡢ➽ᒙ࿘㎶ࣆ࣮ࢡࡀほᐹࡉࢀࡓࠋᮏ◊✲ࡢ⤖ᯝࡽࠊ ⭡⭍ෆᢞࡉࢀࡓࣥࢺࢩࢽࣥࡣ║⤌⧊ࡲ࡛⛣⾜ࡍࡿࡇࡀ♧ࡉࢀࡓࠋ⤒ཱྀᢞࡉࢀࡓ ࣥࢺࢩࢽࣥࡣࠊᮏ◊✲᮲௳࡛ࡣほᐹࡉࢀ࡞ࡗࡓࡓࡵࠊᚋࡉࡽ᳨ウࢆ㐍ࡵࡿணᐃ ࡛࠶ࡿࠋ ́́ P-51 ◲㓟ࣥࣔࢽ࣒࢘ࡣ࣐ࢺࣜࢵࢡࢫῧຍࡋ࡚ MALDI-IMS ࠾ࡅࡿ⬻ෆ࢝ࣝ ࢽࢳࣥࠊࢭࢳࣝ࢝ࣝࢽࢳࣥࠊࢢࣜࢭࣟ࣍ࢫ࣍ࢥࣜࣥ⏤᮶ࡢࢩࢢࢼࣝࢆ 10 ಸ௨ ୖቑᙉࡍࡿ ᮡᒣᰤ, ṇᮌ⣖㝯, ᯇୗ⚈Ꮚ, ℩⸨ග ᯇ་⛉Ꮫ་Ꮫ⣔◊✲⛉ゎ๗Ꮫㅮᗙ⣽⬊⏕≀Ꮫศ㔝 Ammonium sulfate improves signal intensities of carnitine, acetylcarnitine, and glycerophocholine more than ten times higher in matrix-assisted laser desorption/ionization imaging mass spectrometry as a matrix additive Eiji Sugiyama, Noritaka Masaki, Shoko Matsushita, Mitsutoshi Setou Department of Cell Biology and Anatomy, Hamamatsu University School of Medicine ࠙┠ⓗࠚ࣐ࢺࣜࢵࢡࢫᨭ࣮ࣞࢨ࣮⬺㞳࣓࣮࢜ࣥࢪࣥࢢ㉁㔞ศᯒἲࡣ」ᩘࡢศᏊࡢศ ᕸࢆ୍ᩧゎᯒ࡛ࡁࡿᡭἲ࡛࠶ࡾࠊࡉࡽከࡃࡢศᏊࢆ᳨ฟࡍࡿࡓࡵᡭἲࡢ㛤ⓎࠊᨵⰋ ࡀ┒ࢇ⾜ࢃࢀ࡚࠸ࡿࠋ◲㓟ࣥࣔࢽ࣒࢘(AmS)ࡣ࣐ࢺࣜࢵࢡࢫῧຍࡢ୍ࡘ࡛࠶ࡾࠊࣝ ࢝ࣜ㔠ᒓ࢜ࣥࡢᖸ΅ࢆጉࡆࡿ㧗࠸ሷᯒຠᯝ➼ࢆࡶࡓࡽࡍࡇ࡛࣌ࣉࢳࢻࡸ⢾⬡㉁ࡢ ࢜ࣥࢆ㢧ⴭಁ㐍ࡍࡿࡇࡀሗ࿌ࡉࢀ࡚࠸ࡿࠋࡋࡋࠊAmS ࡢ࢜ࣥಁ㐍ຠᯝࡘ ࠸࡚ࡢᇶ♏ⓗ࡞᳨ウࡣ༑ศ⾜ࢃࢀ࡚࠾ࡽࡎࠊࡑࡢ⏝ᑐ㇟ࡣ㝈ࡽࢀ࡚࠸ࡿࠋࡑࡇ࡛ᮏ◊✲ ࡛ࡣࠊAmS ࡼࡾ࢜ࣥࡀᨵၿࡍࡿపศᏊࢆ᥈⣴ࡋࠊ࣓࣮ࢪࣥࢢࡢᛂ⏝ࢆヨࡳࡓࠋ ࠙᪉ἲࠚ8 㐌㱋ࡢ C57BL/6J ࣐࢘ࢫ⬻ࢆ᥇ྲྀࡋゎᯒࡋࡓࠋࡲࡎࠊ࣍ࣔࢪࢿ࣮ࢺ(100 mg tissue/mL) ࢆ AmS(0, 16, 31, 63, 125, and 250 mM)ࢆྵࡴ࣐ࢺࣜࢵࢡࢫ⁐ᾮ(DHB 50 mg/mL in 50% methanol)➼㔞ΰྜࡋࡓᚋࠊᑟ㟁ᛶࢫࣛࢻ࢞ࣛࢫୖୗࡋ ᐃࡋࡓࠋ╔┠ࡋࡓࣆ࣮ࢡ ࡣከẁ㝵㉁㔞ศᯒ(MS/MS)ࡼࡾྠᐃࡋࡓࠋ⥆࠸࡚ࠊí20°C ࡢᗜෆ࡛ཌࡉ 10 μm ࡋࡓ▮ ≧ษ∦ࢆᑟ㟁ᛶࢫࣛࢻ࢞ࣛࢫ㈞ࡋࡓᚋࠊ࣐ࢺࣜࢵࢡࢫ⁐ᾮ(DHB 50 mg/mL in 50% methanol with/without 250 mM AmS)ࢆᡭືࢫࣉ࣮ࣞἲ࡚ሬᕸࡋ ᐃࡋࡓࠋ ࠙⤖ᯝࠚAmS 250 mM ࡢῧຍࡼࡾࠊ⬻࣍ࣔࢪࢿ࣮ࢺ୰ࡢ࢝ࣝࢽࢳࣥ(Car)ࠊࢭࢳࣝ࢝ࣝࢽ ࢳࣥ(AcCar)࠾ࡼࡧࢢࣜࢭࣟ࣍ࢫ࣍ࢥࣜࣥ(GPC)⏤᮶ࡢᖹᆒࢩࢢࢼࣝᙉᗘࡀࡑࢀࡒࢀ⣙ 300, 700, 2500 ಸቑᙉࡋࡓࠋ ࡇࡢ࢜ࣥಁ㐍ຠᯝࡣ 63 mM ௨ୖࡢ⃰ᗘ࡛㢧ⴭ⌧ࢀࡓࠋ ࡉࡽࠊ AmS 250 mM ࡢῧຍࡼࡾ⤌⧊ษ∦୰ࡢ Car, AcCar, GPC ⏤᮶ࡢᖹᆒࢩࢢࢼࣝᙉᗘࡣࡑࢀࡒ ࢀ⣙ 10, 20, 40 ಸቑᙉࡋࠊ࠸ࡎࢀࡢ⤌⧊ෆศᕸࡶ᫂░ྍどࡉࢀࡓࠋ ࠙⪃ᐹࠚCar, AcCar, GPC ࡣ࠸ࡎࢀࡶศᏊෆᏳᐃࡋࡓṇ㟁Ⲵࢆᣢࡘ➨ᅄ⣭ࣥࣔࢽ࣒࢘ྜ ≀࡛࠶ࡾ࢜ࣥࡉࢀࡸࡍ࠸ࡓࡵࠊAmS ῧຍࡢᜠᜨࢆࡁࡃཷࡅࡓ⪃࠼ࡽࢀࡿࠋAmS ࡣ ࡢ࣐ࢺࣜࢵࢡࢫࡸ㧗ឤᗘᡭἲᐜ᫆⤌ࡳྜࢃࡏࡿࡇࡀྍ⬟࡛࠶ࡾࠊAmS ࢆᵝࠎ࡞ ศᯒ᮲௳ᛂ⏝ࡍࡿࡇ࡛ࡼࡾከࡃࡢศᏊࡢゎᯒࡀྍ⬟࡞ࡿࡇࡀᮇᚅࡉࢀࡿࠋ ́́ P-52 ⾪✺᩿㠃✚ᇶ࡙ࡃ MALDI ࣓࣮ࢪࣥࢢཬࡧ MS/MS ࣇࣛࢢ࣓ࣥࢺࢹ࣮ࢱࡢ㛵㐃 ࡅࡼࡿ⬡㉁ࡢྠᐃᒁᅾゎᯒ ᑎᓮ┿ᶞ 1, Mark Towers 2, Emmanuelle Claude 2 Johannes PC Vissers 1 ᪥ᮏ࢛࣮࢘ࢱ࣮ࢬᰴᘧ♫, 2 ࢛࣮࢘ࢱ࣮ࢬ࣭ࢥ࣮࣏࣮ࣞࢩࣙࣥ 2 LIPID VISUALISATION AND IDENTIFICATION THROUGH COLLISION CROSS SECTION AIDED CORRELATION OF MALDI IMAGING AND MS/MS FRAGMENTATION DATA SETS Maki Terasaki1, Mark Towers2, Emmanuelle Claude2, Johannes PC Vissers2 1 Nihon Waters K.K., 2Waters Corporation [INTRODUCTION] Mass spectrometry imaging (MSI) is rapidly becoming an established technique within lipidomics research. Using MSI, a broad range and number of species can be visualised within a tissue section. However, subsequent identification can be challenging due to the large number of isobaric or near isobaric species. Lipids can be identified by subsequently extracting them from the same, or a consecutive, tissue section and performing MS/MS. However, when correlating the datasets, identifications can become obfuscated due to lack of certainty that the lipids extracted and identified, relate to the m/z peaks seen in the imaging data, especially when relying on accurate mass alone as the identification is not being performed in-situ. Here, we demonstrate the use of ion mobility to differentiate ions and calculate collision cross sections (CCS). This is utilised along with accurate mass to add confidence to the correlation between the MALDI imaging and extracted lipids datasets and the subsequent identifications by MS/MS. [Methods] A thin section of a rat brain section was produced using a cryotome. 9-Aminoacridine (9-AA) matrix was applied evenly to the sample in several coats using a Suncollect™ sprayer. Lipids were extracted from consecutive tissue sections. Droplets were placed on to the tissue section using a pipette then drawn off and pooled prior to spotting on a target plate. The same 9-AA matrix solution was mixed on target with the extract samples. Data were acquired using a SYNAPT HDMS G2-Si mass spectrometer in HDMS mode. [Results] After peak picking the imaging data set with an ion intensity cut off of 50, 7,598 peaks were detected in the range of m/z 400-1150. Matching the peaks using accurate mass against a subset of the lipid maps structural database, resulted in 195 matching peaks (+/-3ppm). Plotting the matching peaks as m/z vs CCS area, a general lipid trend line can be observed as well as several CCS outliers. By estimating the CCS area trend line, a broad based filter can be applied to remove the outliers. After CCS filtering, 165 lipid candidates remained. ́́ P-53 ๓㢌ഃ㢌ⴥኚᛶᝈ⪅⬻ෆ࠾ࡅࡿࢱ࢘ࣜࣥࡢ⃰ᗘ࠾ࡼࡧศᕸゎᯒ ᯇୗ⚈Ꮚ 1, ṇᮌ⣖㝯 1, ㏆⸨ 1, Ṋྐ㑻 1, ㉥ὠ⿱ᗣ 2,3, ⛅⏣ኳᖹ 4, ᮡᒣᰤ 1, ⚟⏣ᩔኵ 4, ▮ᑿ⫱Ꮚ 5, ℩⸨ග 1 1 ᯇ་⛉Ꮫゎ๗Ꮫㅮᗙ⣽⬊⏕≀Ꮫศ㔝, 2 ⚟♴ᮧ㝔㛗ᑑ་Ꮫ◊✲ᡤ, 3 ྡྂᒇᕷ❧Ꮫ Ꮫ㝔་Ꮫ◊✲⛉ᆅᇦ་⒪ᩍ⫱Ꮫ, 4 ᯇ་⛉Ꮫ⚄⤒⏕⌮Ꮫㅮᗙ, 5 ᯇ་⛉Ꮫ࣓ࢹ࢝ ࣝࣇ࢛ࢺࢽࢡࢫࢭࣥࢱ࣮ග࣓࣮ࢪࣥࢢ◊✲ᐊ Taurine concentration and distribution in brain of frontaltemporal lobar degeneration patients Shoko Matsushita1, Noritaka Masaki1, Takeshi Kondo1, Shiro Takei1, Hiroyasu Akatsu2,3, Tenpei Akita4, Eiji Sugiyama1, Atsuo Fukuda4, Ikuko Yao5, Mitsutoshi Setou1 1 Department of Cell Biology and Anatomy, Hamamatsu University School of Medicine, 2Choju Medical Institute, Fukushimura Hospital, 3Department of Medicine for Aging in Place and Community-Based Medical Education, Nagoya City University Graduate School of Medical Sciences, 4Department of Neurophysiology, Hamamatsu University School of Medicine, 5 Department of Optical Imaging, Medical Photonics Research Center, Hamamatsu University School of Medicine ࠙┠ⓗࠚ๓㢌ഃ㢌ⴥኚᛶ(FTLD)ࡣ๓㢌ⴥ࣭ഃ㢌ⴥࡀ㢧ⴭⴎ⦰ࡍࡿ⚄⤒ኚᛶᝈ࡛࠶ࡾࠊ 㓟ࢫࢺࣞࢫ➼ࡼࡾ␗ᖖࣜࣥ㓟ࡉࢀࡓࢱ࢘ࡸ TDP-43 ࡞ࡢࢱࣥࣃࢡ㉁ࡢ✚ࡀぢࡽࢀ ࡿࠋᢠ㓟స⏝ࢆᣢࡘࢱ࢘ࣜࣥࡣ㓟ࢫࢺࣞࢫࢆῶࡽࡍࡇ࡛⚄⤒ಖㆤస⏝ࢆ♧ࡍࡇࡀ ▱ࡽࢀ࡚࠸ࡿࡀࠊFTLD ࡢ㛵ಀᛶࡣ࡛᫂࠶ࡿࠋࡑࡇ࡛ࠊLC-ESI-MS ࡼࡿᐃ㔞ゎᯒࠊ MALDI-IMS ࡼࡿศᕸゎᯒࢆ⾜࠸ࠊFTLD ࠾ࡅࡿࢱ࢘ࣜࣥࡢኚὀ┠ࡋࠊゎᯒࡋࡓࠋ ࠙᪉ἲࠚFTLD ࠾ࡼࡧᑐ↷⩌ࡢࣄࢺṚᚋ⬻ 9 ࢆ⏝࠸ࠊྛࡢ๓㢌ⴥ࣭ᚋ㢌ⴥࢆゎᯒࡋ ࡓࠋLC-ESI-MS ࡛ࡣ⤖◚○ᚋࠊ࣓ࢱࣀ࣮ࣝᢳฟࡋࡓヨᩱࢆ ᐃࡋࡓࠋMALDI-IMS ࡛ࡣ 10 Pm ࡢཌࡉ⬻⤌⧊ࢆⷧษࡋࠊ9-࣑ࣀࢡࣜࢪࣥࢆࢫࣉ࣮ࣞἲ࡚ሬᕸᚋࠊ ᐃࡋࡓࠋ ࠙⤖ᯝࠚ⬻ෆࡢࢱ࢘ࣜࣥ⃰ᗘࡣࠊFTLD ⩌ࡢ๓㢌ⴥ࡛ 1.7±1.1 Pmol/g±SDࠊᚋ㢌ⴥ࡛ 1.4±0.6 Pmol/g±SD ࡛࠶ࡾࠊᑐ↷⩌ࡢ๓㢌ⴥ࡛ 1.5±0.5 Pmol/g±SDࠊᚋ㢌ⴥ࡛ 1.5±0.6 Pmol/g±SD ࡛࠶ ࡗࡓࠋࢱ࢘ࣜࣥࡣⓑ㉁ẚ㍑ⓗከࡃศᕸࡋ࡚࠸ࡿ࠸࠺▱ぢࡀᚓࡽࢀࡓࠋFTLD ⩌ࡢ๓㢌ⴥ ࠾࠸࡚ࠊࢱ࢘ࣜࣥ⃰ᗘࡀ 3.1Pmol/g ࠾ࡼࡧ 4.0Pmol/g ࡼࡾ᭷ព㧗್ࢆ♧ࡋࡓࢆ ㄆࡵࠊ࠸ࡎࢀࡶࣜࣥ㓟 TDP-43 ࡀ㝧ᛶ࡛࠶ࡗࡓࠋ ࠙⪃ᐹࠚⓑ㉁ࡣ⾑ᾮ⬻㛵㛛ࢆᙧᡂࡍࡿ⥺⥔ᛶࢫࢺࣟࢧࢺࡀከࡃᏑᅾࡍࡿࡇࡀ▱ࡽࢀ ࡚࠾ࡾࠊࢱ࢘ࣜࣥࡢὶධ㛵ࢃࡿࢺࣛࣥࢫ࣏࣮ࢱ࣮ࡢ㛵ࡀணࡉࢀࡓࠋࢱ࢘ࣜࣥࡢ⃰ᗘ ୖ᪼ࡀࡳࡽࢀࡓࡢࡣ㢧ⴭ࡞⬻ࡢⴎ⦰ࡀࡳࡽࢀࡿ๓㢌ⴥ࡛࠶ࡾࠊࣜࣥ㓟 TDP-43 ࡢ㛵㐃ᛶ ࡀ♧၀ࡉࢀࡓࠋ ́́ P-54 ㉁㔞ศᯒ࣓࣮ࢪࣥࢢἲࢆ⏝࠸ࡓ࢜ࣜࢦࢹࣥࢻࣟࢧࢺศ㐣⛬ࡢྍど ᖹཎᖾᜨ㸯, ⱝᯘẎಇ㸯, ᳃ ᚭ⮬㸯,㸰, ▮ᑿ⫱Ꮚ 3, ὠ⏣㞞அ 4, ᮏᐙᏕ୍㸳, ᑠụኴ㑻㸯, ᚋ⸨ோᚿ 6, ᑠ㔝ᙪ 6, ᒣ⏣ஂኵ㸯 1 㛵す་࣭་࣭ゎ๗Ꮫ➨୍, 2 㫽ྲྀᏛ࣭་࣭ಖᏛ⛉, 3 ᯇ་࣭࣓ࢹ࢝ࣝࣇ࢛ࢺ ࢽࢡࢫ◊✲ࢭࣥࢱ࣮, 4 㧘▱Ꮫ࣭⥲◊, 5 㧘▱Ꮫ࣭་࣭⏕Ꮫ, 6 ி㒔ᗓ་࣭⏕≀Ꮫ Visualization of oligodendrocyte differentiation processes by using imaging mass spectrometry Yukie HIRAHARA1, Taketoshi WAKABAYAHSHI1, Tetuji MORI 1, 2, Ikuko Yao3, Masayuki TSUDA4, Koichi HONKE5, Taro KOIKE1, Hitoshi Gotoh6, Katsuhiko ONO6, Hisao YAMADA1 1 Department of Anatomy and Cell Science, Kansai Medical University, 2 Faculty of Medicine, Tottori Universitye, 3Medical Photonics Research Center, Hamamatsu University School of Medicine, 4 Science Research Center, 5 Department of Biochemistry, Kochi University Medical School, 6 Department of Biology, Kyoto Prefectural University of Medicine ࣑࢚ࣜࣥᙧᡂ⣽⬊࢜ࣜࢦࢹࣥࢻࣟࢧࢺ㸦OL㸧ࡣࠊ⬡㉁ᐩࡴ⣽⬊࡛࠶ࡾࠊศ࣐࣮࢝ ࣮⢾⬡㉁ࡀࢃࢀ࡚࠸ࡿࠋO4 ࣔࣀࢡ࣮ࣟࢼࣝᢠయࡣࠊ⫾⏕ᮇ OL ๓㥑య⣽⬊ࡽ⏕ᚋࡢ㧊 㠧ᙧᡂ⮳ࡿࡲ࡛ࡢ OL ศ࣭ᡂ⇍㐣⛬ࢆㄆ㆑ࡍࡿศ࣐࣮࣮࢝ࡋ࡚ࠊୡ⏺୰࡛ࢃࢀ࡚ ࠸ࡿࠋO4 ᢠయࡢㄆ㆑㒊㛵ࡋ࡚ࡣࠊ◲㓟⢾⬡㉁ࠊࢫࣝࣇࢳࢻ࡛࠶ࡿỴᐃࡉࢀ࡚࠸ ࡿࡀࠊ⫾⏕ᮇࡢ⬨㧊⭡ഃ㒊ࡽⓎ⏕ࡍࡿ OL ⣔㆕Ỵᐃ⮫⏺Ⅼࢆ♧ࡍ O4 㝧ᛶ๓㥑⣽⬊࡛ࡣࠊ ࢫࣝࣇࢳࢻྜᡂࡀ☜ㄆࡉࢀ࡚࠸࡞ࡗࡓࠋᚑࡗ࡚ࠊ⫾⏕ᮇ O4 ㄆ㆑ᢠཎࡣࠊࢫࣝࣇࢳࢻ ௨እࡢࡶࡢ࡛࠶ࡿྍ⬟ᛶࡀ⪃࠼ࡽࢀ࡚ࡁࡓࠋࡑࡇ࡛ࠊ⤌⧊ᶆᮏ୰ࡢ⬡㉁ศᕸᐦᗘࢆ㧗࠸ゎ ീᗘ᳨࡛ฟ࡛ࡁࡿ㉁㔞ศᯒ࣓࣮ࢪࣥࢢἲࢆ࠸ࠊࡇࡢ⫾⏕ᮇฟ⌧ࡍࡿ O4 ㄆ㆑࢚ࣆࢺ࣮ ࣉࡢᐇែࢆ᳨ドࡋࡓࠋ࢘ࢩ⬻⏤᮶ࡢᵝࠎ࡞⬡⫫㓟ࢆࡶࡗࡓ 12 ✀㢮ࡢࢫࣝࣇࢳࢻࡢࢫ࣌ࢡ ࢺࣝࢆྠᐃࡋࡓᚋࠊO4 㝧ᛶ OL ๓㥑⣽⬊Ⓨ⌧㡿ᇦࡋ࡚ሗ࿌ࡉࢀ࡚࠸ࡿࢽ࣡ࢺࣜ⬇ 8 ᪥┠⬨ 㧊⤌⧊ᑐࡋ࡚ࠊ࣐ࢺࣜࢵࢡࢫᨭ࣮ࣞࢨ࣮⬺㞳࢜ࣥἲࡼࡿ㉁㔞ศᯒࢆ࠾ࡇ࡞ࡗࡓࠋ ᐃࢹ࣮ࢱࡽྵ᭷ศᏊࡢ࢜ࣥศᕸࢆ⏬ീࡋࠊࢫࣝࣇࢳࢻศᕸࡢẚ㍑ࢆ⾜ࡗࡓ⤖ᯝࠊ ⬨㧊⤌⧊యᗈࡀࡗ࡚ศᕸࡍࡿ࣍ࢫࣇࢳࢪࣝࣀࢩࢺ࣮ࣝᑐࡋ࡚ࠊ⬨㧊⭡ഃ㒊≉␗ ⓗ⬡⫫㓟ࡢ▷࠸ C16 ࢫࣝࣇࢳࢻ C18 ࢫࣝࣇࢳࢻࡢࢩࢢࢼࣝࢆㄆࡵࡓࠋࡇࢀࡽࡣࠊ ࣑࢚ࣜࣥ㠧㇏ᐩᏑᅾࡍࡿ C24 ࢫࣝࣇࢳࢻࡣ␗࡞ࡿࡶࡢ࡛࠶ࡗࡓࠋ୍᪉࡛ࠊ㉁㔞ศ ᯒ࣓࣮ࢪࣥࢢἲ࠾࠸࡚ࠊᡂ⋇࣑࢚ࣜࣥ㠧࡛ࡣࠊᵝࠎ࡞㛗ࡉࡢ⬡⫫㓟ࢆࡶࡗࡓࢫࣝࣇ ࢳࢻࡀ᳨ฟྍ⬟࡛࠶ࡿࡀࠊࢫࣝࣇࢳࢻࢆྜᡂࡍࡿ㓝⣲ࠊࢭࣞࣈࣟࢩࢻ◲㓟ᇶ㌿⛣㓝⣲ (CST)ࢆḞᦆࡍࡿ࣐࢘ࢫ⬻࡛ࡣࠊ㧊㠧ྵࡲࢀࡿࡍ࡚ࡢࢫࣝࣇࢳࢻࡣᾘ⁛ࡋ࡚࠸ࡓࠋCST Ḟᦆ࣐࢘ࢫࡣࠊ⏕Ꮫⓗゎᯒ࠾࠸࡚ࡶࢫࣝࣇࢳࢻࡣྜᡂࡉࢀ࡞࠸ඹ O4 㝧ᛶ⣽⬊ࡶ ฟ⌧ࡋ࡞࠸ࠋᚑࡗ࡚ࠊ㉁㔞ศᯒ࣓࣮ࢪࣥࢢἲ࡛♧ࡍࢫࣝࣇࢳࢻࡢ್ࡀಙ㢗ᛶࡢ㧗࠸ࡶ ࡢ࡛࠶ࡿ࠸࠼ࡿࠋࡉࡽࠊ࣐࢘ࢫ⫾⏕ᮇࡢ OL ๓㥑య⣽⬊Ⓨ⏕ẕᆅ࡛ࡣࠊC18-OH ࡀඃ ᳨ฟࡉࢀࠊࡇࢀࡽࡣࠊ⬨㧊୰ᚰ⟶㏆ഐࡽᘏ㧊ࠊᶫ OL Ⓨ⏕కࡗ࡚ᒁᅾࡍࡿᵝᏊࡀ ᤊ࠼ࡽࢀࡓࠋࢫࣝࣇࢳࢻࡣࠊ⫾⏕ᮇࡢ OL ⣔㆕Ỵᐃ⮫⏺Ⅼࡽ࣑࢚ࣜࣥ㠧ᵓ⠏⮳ࡿࡲ࡛ ࡢ OL ศ㐣⛬ࢆ㏻ࡌ࡚ྜᡂࡉࢀ࡚࠸ࡿࡇࡀ᫂ࡽ࡞ࡗࡓࠋ ́́ P-55 ⫢ษ㝖㔞╔┠ࡋࡓ࣐࢘ࢫ⫢ษ㝖ᚋ⫢⏕ࡢ࣓࣮ࢪࣥࢢ㉁㔞ศᯒ ཱྀබኴ 1, ㎷ 㞝 2, ୰ᕝ♸㍤ 2, ୰㑦ᬛஅ 3, Ἴከ㔝ᝋᮁ 1, ୖᮏఙ 1, ụᕝ㞞ဢ 2 1 ி㒔Ꮫ་Ꮫ◊✲⛉⫢⫹⮅⛣᳜እ⛉, 2 ྠᚿ♫Ꮫ⏕་⛉Ꮫ㒊་⏕ࢩࢫࢸ࣒Ꮫ⛉, 3 㛵す་⛉Ꮫ⸆⌮Ꮫㅮᗙ Imaging mass spectrometry of liver regeneration after partial hepatectomy in mice, focusing on the resected liver volume Kohta Iguchi1, Yudai Tsuji 2, Yuki Nakagawa2, Tomoyuki Nakamura3, Etsuro Hatano1, Shinji Uemoto1, Masaya Ikegawa2 1 Department of Surgery, Graduate School of Medicine, Kyoto University 2 Department of Life and Medical Systems, Faculty of Life and Medical Sciences, Doshisha University 3 Department of Pharmacology, Kansai Medical University ⫢ษ㝖⾡ࡣࠊ⫢⣽⬊⒴ࠊ㌿⛣ᛶ⫢⒴ᑐࡋ࡚᰿ࡢᮇᚅฟ᮶ࡿ୰ᚰⓗ⒪ἲ࡛࠶ࡿࠋ୍ ᪉ࠊ⾡ᚋ⫢(Posthepatectomy liver failure; PHLF)ࡣ㔞⫢ษ㝖క࠺㐣ᑠṧ⫢ ࡢ⏕༑ศ㉳ᅉࡍࡿ⮴Ṛⓗྜే࡛࠶ࡾࠊᝈ⪅ಶࠎࡢ⫢ᶵ⬟ᛂࡌࡓ⫢ษ㝖㔞ࡀ PHLF Ⓨ῝ࡃ㛵㐃ࡍࡿࠋࡋࡋࠊᐇ㝿⮫ᗋᛂ⏝ྍ⬟࡞ PHLF Ⓨࢆࣔࢽࢱ࣮ࡍࡿ㗦ᩄ࡞࣐࣮ ࣮࢝ࡸ⒪⸆ࡣᏑᅾࡏࡎࠊᚋࡢ☜❧ࡀᮇᚅࡉࢀࡿࠋ⫢⏕㛵ࡍࡿ◊✲ࡣ⸆≀ㄏᑟᛶ ⫢യᐖࣔࢹࣝࡸ 70%㒊ศ⫢ษ㝖㸦70%PHx㸧ࣔࢹࣝࡀ▱ࡽࢀ࡚࠸ࡿࠋᡃࠎࡣ㐣ཤࠊ࣐࢘ࢫᅄ ሷⅣ⣲⫢യᐖࣔࢹࣝ࠾࠸࡚ࠊ⾑Ύ⫹Ồ㓟ࡢࣂ࣐࣮࣮࢜࢝ࡋ࡚ࡢ᭷⏝ᛶࢆࠊᐃ㔞ᛶࠊ ⫢⤌⧊ୖࡢศᕸࡢഃ㠃ࡽሗ࿌ࡋࡓ㸦Shimada, J Proteome Res, 2010㸧ࠋᅇࠊ࣐࢘ࢫ PHx ࣔࢹࣝࢆ⏝ࡋࠊ࣓࣮ࢪࣥࢢ㉁㔞ศᯒࡼࡿṧᏑ⫢ෆࡢ௦ㅰ≀ࡢ㛫࣭✵㛫ⓗኚࢆゎ ᯒࡋࡓࠋᮏᐇ㦂࡛ࡣࠊࢹ࣮ࢱ ᐃࠊゎᯒࡣ MALDI ᆺ㉁㔞㢧ᚤ㙾㸦iMScope, ᓥὠ〇సᡤ㸧ࢆ ⏝ࡋࠊ9-࣑ࣀࢡࣜࢪࣥࢆ࣐ࢺࣜࢵࢡࢫࡋࡓ㝜࣮࢜ࣥࣔࢻ࡚ 300-900m/z ࡢศᏊ ࢆ ᐃࡋࡓࠋ㏻ᖖࡢ⫢⏕㐣⛬ࢆ᳨ウࡍࡿࡢ㢖⏝ࡉࢀࡿ 70%PHx ࣔࢹࣝ࠾࠸࡚ࡣࠊ⫢⣽ ⬊ෆࡢ୍ḟ⫹Ồ㓟࡞ࡽࡧ⬦⟶ෆ ATP㸦ࢹࣀࢩࣥ 3 ࣜࣥ㓟㸧≉ᚩⓗ࡞ᙉᗘ࣭ศᕸኚࡢ ࠶ࡿࡇࡀ᫂ࡽ࡞ࡗࡓࠋ୍᪉ࠊ⫢ษ㝖㔞ࢆቑῶࡋࡓࣔࢹࣝࠊ༶ࡕ 30%PHx ࡣ⫢⣽⬊ࡢศ ࢆకࢃ࡞࠸⫢⫧ࣔࢹࣝࠊ90%PHx ࡣ㏻ᖖ⫢⏕ࡽ㐓⬺ࡋࡓ⮴Ṛⓗ PHLF ࣔࢹࣝ⪃࠼ࡽ ࢀ࡚࠸ࡿࠋᡃࠎࡣ࣐࢘ࢫ 30%ࠊ90%PHx ࣔࢹࣝࠊ70%PHx ࣔࢹࣝࡢẚ㍑᳨ウࢆ⾜࠺ࡇࡼ ࡗ࡚ࠊ୍ḟ⫹Ồ㓟ࠊ⬦⟶ෆ ATP ࢆྵࡵࡓࠊ⫢⏕࣭PHLF ࡢ࣐࣮࣮࢝࡞ࡾᚓࡿศᏊࢆ㛫࣭ ✵㛫ⓗ᳨ウࡋࠊሗ࿌ࡍࡿࠋ ́́ P-56 ㉁㔞㢧ᚤ㙾ࡼࡿࢸࢫࢺࢫࢸࣟࣥ◲㓟࢚ࢫࢸࣝࡢ࣐࢘ࢫ⢭ᕢ࠾ࡅࡿྍど ⇃⏣ࣥࣜ࢜ࣂࢹ㸯, ㇂ཱྀஂဴ㸰, ▮ᑿ⫱Ꮚ㸱, ྂ⏣ாྐ㸲, ᯇ⏣බᚿ㸰, ఀ⸨ㄔ㸯 㸯 㛵す་⛉Ꮫ་Ꮫㅮᗙ, 㸰⭈Ἢᒀჾእ⛉Ꮫㅮᗙ, 㸱ᯇ་⛉Ꮫ࣓ࢹ࢝ࣝࣇ࢛ࢺࢽࢡࢫ ◊✲ࢭࣥࢱ࣮, 㸲ᒱ㜧Ꮫ་Ꮫ⣔◊✲⛉ Visualization of testosterone sulfate ester on mouse testis with imaging mass spectrometry Henri-Obadja Kumada1, Hisanori Taniguchi2, Ikuko Yao3, Kyoji Furuta4, Tadashi Matsuda2, Seiji Ito1 1 Departments of Medical Chemistry and 2Urology and Andrology of Kansai Medical University, 3 Medical Photonics Research Center, Hamamatsu University School of Medicine, 4Gifu University Graduate School of Medicine ࠙┠ⓗࠚࢸࢫࢺࢫࢸࣟࣥ(௨ୗࠊTs)ࡣ⢭ᕢࡢ Leydig ⣽⬊࡚ࢥࣞࢫࢸ࣮ࣟࣝࢆฟⓎ≀㉁ࡋ ࡚ྜᡂࡉࢀࡿ⏨ᛶ࣍ࣝࣔࣥࡢࡦࡘ࡛࠶ࡿࠋ⏕ᡂࡉࢀࡿ㏿ࡸ⾑୰ᨺฟࡉࢀࠊᶆⓗ ⮚ჾస⏝ࡍࡿࠋTs ࡣ⾑୰⃰ᗘࢆ ELISA ࡼࡗ࡚ ᐃ࡛ࡁࡿࡀࠊ⢭ᕢࡽᨺฟࡉࢀࡿࡇ ࡽࠊ⢭ᕢ࡛ࡢ᳨ฟࡣᅔ㞴ࡉࢀ࡚࠸ࡓࠋࡑࡇ࡛ࠊᮏ◊✲࡛ࡣ㉁㔞㢧ᚤ㙾ࢆ࠸࣐࢘ࢫ⢭ ᕢษ∦ୖ࡚ Ts ࢆྍどࡍࡿࡇࢆ┠ⓗࡋࡓࠋ ࠙᪉ἲࠚTs ࡣ༢య࡛ࡣ࢜ࣥࡉࢀࡃ࠸ࡀࠊỈ㓟ᇶࢆࡶࡘࡓࡵࠊ୕㓟◲㯤ࣆࣜࢪࣥ㘒య (௨ୗࠊSO3Py)ࢆຍ࠼࡚ 55Υ 2 㛫ຍ ࡋ࡚ࢸࢫࢺࢫࢸࣟࣥ◲㓟࢚ࢫࢸࣝ(௨ୗࠊTsS)ㄏ ᑟయࡋࡓࠋࡇࢀ matrix ࡋ࡚ ǂ-ࢩࣀ-4-ࣄࢻࣟ࢟ࢩࢣ⓶㓟(௨ୗࠊCHCA)ࢆຍ࠼ࠊ ㉁㔞㢧ᚤ㙾ࡣࣉࣟࢺࢱࣉᶵ(ᓥὠ〇సᡤ)ࢆ⏝࠸ࡓࠋ࣐࢘ࢫ⢭ᕢࡣ↓ฎ⌮ࡢࡶࡢࢦࢼࢺࣟ ࣆࣥ(hCG)2000 ༢/20Pl ࢆ࣐࢘ࢫ⓶ୗὀᑕࡋ࡚ Ts ࡢ⏕ᡂࢆㄏᑟࡋ 1 㛫ᚋฟࡋࡓ ⢭ᕢࡢ୧⪅ࢆ౪ࡋࡓࠋ⤖⤌⧊ໟᇙࡣ㉁㔞ศᯒᖸ΅ࡋ࡞࠸࢝ࣝ࣎࢟ࢩ࣓ࢳࣝࢭ࣮ࣝࣟ ࢫࢼࢺ࣒ࣜ࢘(CMC)ࢆ⏝࠸ࡓࠋࡇࢀࡽࡢ࣐࢘ࢫ⢭ᕢࡢ⤌⧊ษ∦ࡶ SO3Py ࢆᄇᑕࡋࠊ55Υ 2 㛫ຍ ࡢࡢࡕ CHCA ࢆᄇᑕࡋ࡚㉁㔞㢧ᚤ㙾࡛ ᐃࡋࡓࠋ ᐃ᮲௳ࡣ㈇࢜ࣥࠊ᳨ฟჾ㟁 ᅽ 2.1kV ࠊ㢧ᚤ㙾ಸ⋡ 20 ಸ࡛ࠊMS ࡢሙྜࡣ↷ᑕᚄ 0ࠊ࣮ࣞࢨ࣮ᙉᗘ 80%(100%ࡢࡢࣞ ࣮ࢨ࣮࢚ࢿࣝࢠ࣮㸸0.010PJ)ࠊMS/MS ࡛ࡣ↷ᑕᚄ 4ࠊ࣮ࣞࢨ࣮ᙉᗘ 80%࡛࠶ࡗࡓࠋ⏬ീ ࡣ Imaging Mass Solution (Ver.1.01.02)ࡢ࣓࣮ࢪᶵ⬟ࢆ⏝࠸ࡓࠋ ࠙⤖ᯝࠚTsS ᶆ‽ရ࡛ࡣ MS (m/z=367.15, TsS C19H27O5S), MS/MS (m/z=96.96, fragment HSO4-)୧᪉ࣆ࣮ࢡࢆㄆࡵࡓࠋ↓ฎ⌮ࡢ࣐࢘ࢫ⢭ᕢ࡛ࡣࡇࢀࡽࡢࣆ࣮ࢡࡀㄆࡵࡽࢀ࡞ࡗ ࡓࡀࠊhCG ࡛ฎ⌮ࡋࡓ⢭ᕢ࡛ࡣ࠸ࡎࢀࡢࣆ࣮ࢡࡶ᳨ฟࡉࢀࠊ⤌⧊ษ∦ୖ࡛ࡣ MS ࡢࣆ࣮ࢡ ࢆ♧ࡍ㯤ⰍࡢᩬⅬࡀ୍㠃ㄆࡵࡽࢀࡓࠋࡲࡓ MS/MS ࡶ⤌⧊ษ∦ୖࣆ࣮ࢡࢆ♧ࡍ㯤Ⰽࡢᩬ Ⅼࡀ MS ୍⮴ࡋ࡚ᗈ࠸⠊ᅖ࡛ㄆࡵࡽࢀࡓࠋ ࠙⪃ᐹࠚMS ࡢ MS/MS ࡛ࡶࣆ࣮ࢡࡀ᳨ฟࡉࢀࡓ㒊ࡢ⏬ീࢆᥥฟ࡛ࡁࡓࡢ࡛ࠊ ◲㓟࢚ࢫࢸࣝࡉࢀࡓ Ts ࡢ⢭ᕢ࡛ࡢ᳨ฟࡀ㉁㔞ศᯒ࡛ࡣࡌࡵ࡚ྍ⬟࡞ࡗࡓࠋ ́́ P-57 㹑㹂㹒ࣛࢵࢺࡢ⮅⮚ࢆᑐ㇟ࡋࡓࣉࣟࢸ࣑࢜ࢵࢡ㉁㔞࣓࣮ࢪࣥࢢ ┈ᒣ 1, ᒾᓮᩍ 2, ⴱཎ⏤㈗ 3, ⱝᅬ ༤ 1, 㡞⃝ ᓫ 2, ⸨ࣨ㇂ᾈᩥ 1, ᮾᒣ┿ 1, ᪥ẚ 1, ᰗᾈ⏤⣖ 1, ᐟ㇂┿⏤ 3, ụᕝ㞞ဢ 3 1 ᑠ㔝⸆ရᕤᴗ, 2 ࣈ࣮ࣝ࢝ࢲࣝࢺࢽࢡࢫ, 3 ྠᚿ♫Ꮫ⏕་⛉Ꮫ㒊་⏕ࢩࢫࢸ࣒Ꮫ⛉ Proteomic Mass Imaging of Pancreas from SDT Rat Model Kei Masuyama1, Noriyuki Iwasaki2, Yuki Kuzuhara 2, Hiroshi Wakazono1, Takashi Nirasawa2, Hirofumi Fujigaya1, Masumi Higashiyama1, Daisuke Hibi1, Hiroyuki Yanagi1, Mayu Shukutani3, Masaya Ikegawa3 1 Ono Pharmaceutical Co., Ltd. 2 Bruker Daltonics K.K. 3 Department of Life and Medical Systems, Faculty of Life and Medical Sciences, Doshisha University ⌧ᅾࠊ⢾ᒀᝈ⪅ᩘࡣᡃࡀᅜࡢࡳ࡞ࡽࡎୡ⏺࡛ᖺࠎቑຍࡋ࡚࠸ࡿࠋ⢾ᒀࡣ㌟࡛࠶ ࡾࠊẼࡢ㐍⾜ࡶࣥࢫࣜࣥឤཷᛶࡸ⪏⢾⬟ኚࡀ⾲ࢀࠊࡸࡀ࡚㧗⾑⢾ࠊ㧗⬡㉁ ⾑ࠊࡦ࠸࡚ࡣ⮅⮚ࡢș⣽⬊ࡢࣥࢫࣜࣥศἪపୗࡼࡾࣥࢫࣜࣥ㊊ࡀᘬࡁ㉳ࡇࡉࢀ ࡿࠋ⢾ᒀࡢⓎᶵᗎࡸẼࡢ㐍⾜ࢆゎᯒࡍࡿୖ࡛⮅⮚ࣛࣥࢤࣝࣁࣥࢫᓥࡢ⌮Ꮫⓗኚ ࡸࡑࡢศᏊᇶ┙ࡘ࠸࡚ゎᯒࡍࡿࡇࡣ᭱ࡶ㔜せ࡛࠶ࡿࠋᮏ◊✲࡛ࡣࠊ᪥ᮏேከࡃぢࡽ ࢀࡿ⫧‶ࢆకࢃ࡞࠸㸰ᆺ⢾ᒀࡢࣔࢹࣝື≀ࡋ࡚ Spontaneously Diabetic Torii (SDT)ࣛࢵ ࢺࢆ⏝࠸ࡓࠋᑐ↷⩌㸦SD ࣛࢵࢺ 9 㐌㱋㸧ཬࡧ 9ࠊ16ࠊ20 㐌㱋ࡢ SDT ࣛࢵࢺࡢ⮅⮚ษ∦ࢆ⏝ ࠸࡚ࢱࣥࣃࢡ㉁ࣞ࣋ࣝࡢ࣓࣮ࢪࣥࢢ࣐ࢫࢫ࣌ࢡࢺ࣓ࣟࢺ࣮ࣜ㸦Imaging Mass Spectrometry : IMS㸧ࢆᐇࡋࡓࠋIMS ࡣ MALDI-TOF MS㸸ultraflextreme㸦Bruker Daltonics㸧ࢆ⏝࠸ࠊ50 ȣm ࡢ✵㛫ศゎ⬟࡛ ᐃࢆ⾜ࡗࡓࠋ⤌⧊ࡣࠊon tissue ࡛ࢺࣜࣉࢩࣥฎ⌮ࢆ⾜࠸ࠊࡉࡽ LC-MALDI-MS ཬࡧ LC-ESI-MS ࡢࡘࡢᡭἲ࡛⥙⨶ⓗࢱࣥࣃࢡྠᐃࢆᐇࡋࡓࠋ ࡑࡢ⤖ᯝࠊ ⤌⧊ࡈ⣙ 200 ಶࡢࢱࣥࣃࢡ㉁ࡀྠᐃࡉࢀࡓࠋᮏࣔࢹࣝ࠾ࡅࡿ⮅ᓥࡢึᮇኚࡋ࡚ ⾑⟶ᣑᙇࡸฟ⾑ࡀㄆࡵࡽࢀ࡚࠸ࡿࡀࠊ⢾ᒀࡢ㐍⾜క࠸ࠊࣥࢫࣜࣥࠊࢢࣝ࢝ࢦࣥࡢศ ᕸࢆᣦᶆ⮅ᓥ࠾ࡼࡧ⮅ᓥ࿘㎶ศᕸࡍࡿࢱࣥࣃࢡ㉁ࢆ᥈⣴ࡋࡓࠋ≉ᚩⓗ࡞ศᕸࡋ࡚ࠊ ⢾ᒀࡢึᮇ≧ែ࡛࠶ࡿ 9 㐌㱋ࡢ SDT ࣛࢵࢺࡢኚ㒊ࡢࡳ࡛ᙉࡃⓎ⌧ࡍࡿࢱࣥࣃࢡ㉁ࡀ☜ ㄆࡉࢀࡓࠋࡲࡓࠊᑐ↷⩌ࡢࡳ࡛Ⓨ⌧ࡋ࡚࠸ࡿࢱࣥࣃࢡ㉁ࡸࠊ⢾ᒀࡢ㐍⾜క࠸ࢩࢢࢼࣝ ࡀቑᙉࡋࡓࢱࣥࣃࢡ㉁ࡶᢳฟࡉࢀࡓࠋᮏ◊✲ࡼࡾᚓࡽࢀࡓ⮅ᓥࣉࣟࢸ࣮࣒࢜ࡢᐇ㦂ⓗࠊ ⮫ᗋⓗ᳨ドࡢᚲせᛶࡀ♧၀ࡉࢀࡓࠋ ́́ P-58 ⚄⤒㞀ᐖᛶ⑊③ࣔࢹ࣐ࣝ࢘ࢫ࠾ࡅࡿ⬨㧊ᚋゅࡢ⬡㉁ኚ ᆏ㔝ၨ 1, ṇᮌ⣖㝯㸯, ᮧጾኵ㸯, ୕ཎ၏ᬦ㸯, ᚎ㛼㸯, ᯇᒣᖾᘯ 1, ℩⸨ග㸯 1 ᯇ་⛉Ꮫ་Ꮫ⣔◊✲⛉ Analysis of lipid distribution in dorsal horn using matrix-assisted laser desorption/ionization imaging mass spectrometry in neuropathic pain model mice Tomohiro Banno1, Noritaka Masaki1, Takao Omura1, Yuuki Mihara1, Dongmin Xu 1, Yukihiro Matsuyama1, Mitsutoshi Setou1 1 Hamamatsu University School of Medicine ࠙┠ⓗࠚ㏆ᖺࠊ⚄⤒㞀ᐖᛶ⑊③࠾࠸࡚⬡㉁ࡢᯝࡓࡍᙺࡀὀ┠ࢆ㞟ࡵ࡚࠸ࡿࠋ࣓࣮ࢪࣥ ࢢ㉁㔞ศᯒἲ㸦MALDI-IMS㸧ࡣ⤌⧊ෆ࠾ࡅࡿ⬡㉁ࡢᒁᅾࢆ⬡⫫㓟⤌ᡂ࡛ࣞ࣋ࣝ༊ูࡋࠊ ྠᐃࡍࡿࡇࡀྍ⬟࡞ᡭἲ࡛࠶ࡿࠋᮏ◊✲ࡢ┠ⓗࡣࠊMALDI-IMS ࢆ⏝࠸࡚⚄⤒㞀ᐖᛶࣔࢹ ࣐ࣝ࢘ࢫࡢ⬨㧊ᚋゅ࠾ࡅࡿࣜࣥ⬡㉁ศᕸࡢኚࢆゎᯒࡍࡿࡇ࡛ࠊ⚄⤒㞀ᐖᛶ⑊③ᑐ ࡍࡿ⬡㉁ࡢᙺࢆゎ᫂ࡍࡿࡇ࡛࠶ࡿࠋ ࠙᪉ἲࠚC57BL6J 㞝 8 㐌㱋࣐࢘ࢫࢆ⏝࠸ࡓࠋᮎᲈ⚄⤒㞀ᐖᛶ⑊③ࣔࢹࣝࡋ࡚ spared nerve injury (SNI) model ࢆసᡂࡋࠊẚ㍑ᑐ㇟ࡋ࡚ sham model ࢆ⏝࠸ࡓࠋ⑊③ホ౯ࡋ࡚ von Frey test ࢆ⾜ࡗࡓࠋ⾡ᚋ 3ࠊ7ࠊ21 ᪥ L5 ࣞ࣋ࣝࡢ⬨㧊ࢆฟࡋࠊ᪂㩭⤖ษ∦ࢆసᡂࡋࡓࠋ࣐ ࢺࣜࢡࢫࡋ࡚ DHB ࢆ⏝࠸ࠊ㝧࣮࢜ࣥࣔࢻࡢ MALDI-IMS ࡛ࣜࣥ⬡㉁ࡢ 1 ࡘ࡛࠶ࡿࣇ࢛ ࢫࣇࢳࢪࣝࢥࣜࣥ㸦PC㸧ࡢ⬨㧊ෆ࠾ࡅࡿศᕸࢆゎᯒࡋࡓࠋࡲࡓࠊࢫࢺࣟࢧࢺࡸ࣐ ࢡࣟࢢࣜࡢᒁᅾẚ㍑ࡍࡿࡓࡵ GFAPࠊIba1 ࡼࡿ㐃⥆ษ∦ࡢචᰁⰍࡶ⾜ࡗࡓࠋ ࠙⤖ᯝࠚvon Frey test ࡛ࡣ SNI ⩌࠾࠸࡚ᦆയ┤ᚋࡽ᭷ព⑊③㜈್ࡀపୗࡋ 21 ᪥ࡲ࡛ᣢ ⥆ࡋ࡚࠸ࡓࠋMALDI-IMS ࡼࡿ PC ࡢゎᯒ࡛ࡣᦆയᚋ 7 ᪥ࡢⅬ࡛ SNI ⩌࠾࠸࡚ࣛ࢟ ࢻࣥ㓟ྵ᭷ࣜࣥ⬡㉁ (AA-PC)ࡢ 1 ࡘ࡛࠶ࡿ PC(diacyl-16:0/20:4)ࡀ⬨㧊ᚋゅ࡛ቑຍࡋ࡚࠸ࡓࠋ ୍᪉࡛ࠊᦆയᚋ 3 ᪥ࠊ21 ᪥ࡢⅬ࡛ࡣྛ✀ PC ᭷ព࡞ኚࡣࡳࡽࢀ࡞ࡗࡓࠋචᰁⰍീ ࡛ ࡶ SNI ⩌ ࠾ ࠸ ࡚ ほ ᐹ ᮇ 㛫 ࡛ ࣐ ࢡ ࣟ ࢢ ࣜ ࡢ ቑ ຍ ࡀ ⬨ 㧊 ᚋ ゅ ࡛ ࡳ ࡽ ࢀ ࠊ PC(diacyl-16:0/20:4)ྠᵝᦆയᚋ 7 ᪥ࡢⅬ࡛᭱ࡶ㞟✚ࡀከࡗࡓࠋ ࠙⪃ᐹࠚ⚄⤒㞀ᐖᛶ⑊③ࣔࢹ࣐ࣝ࢘ࢫ࠾࠸࡚ᦆയᚋ 7 ᪥࡛⬨㧊ᚋゅ࠾࠸࡚ AA-PC ࡀୖ ᪼ࡋ࡚࠸ࡓࠋⓎ⌧ࡢศᕸࡣ࣐ࢡࣟࢢࣜࡢ㞟✚㢮ఝࡋ࡚࠸ࡓࡓࡵࠊPC(diacyl-16:0/20:4) ࡢኚࡣ࣐ࢡࣟࢢࣜࡢ㞟✚ࡑࢀక࠺⅖㛵ࡋ࡚࠸ࡿ⪃࠼ࡽࢀࡿࠋ ́́ P-59 ࡆࡗṑ㢮⢭ᕢ࠾ࡅࡿࢾࢡࣞ࢜ࢳࢻࡢ࣓࣮ࢪࣥࢢ㉁㔞ศᯒ ୰すஅ 1, ㎷ 㞝 1, ୰ᕝ♸㍤ 1, ཱྀබኴ 1, ゅ⏣ఙே 1, ୰㑦ᬛஅ 2, ᯇ႐அ 3, ᕷᒸ ኴ㑻 4, ᑠᕝ ಟ 3, ụᕝ㞞ဢ 1 1 ྠᚿ♫Ꮫ⏕་⛉Ꮫ㒊་⏕ࢩࢫࢸ࣒Ꮫ⛉, 2 㛵す་⛉Ꮫ⸆⌮Ꮫㅮᗙ, 3 ி㒔ᏛᏛ㝔 Ἢᒀჾ⛉Ꮫ, 4 ࠸ࡕ࠾Ἢᒀჾ⛉ࢡࣜࢽࢵࢡ Imaging Mass Spectrometry of rodent testis focusing on nucleotides Katsuyuki Nakanishi1, Yudai Tsuji2, Yuki Nakagawa2, Kohta Iguchi1, Nobuto Kakuda1, Tomoyuki Nakamura2, Yoshiyuki Matsui1, Kentaro Ichioka4, Osamu Ogawa3, Masaya Ikegawa1 1 Department of Life and Medical Systems, Faculty of Life and Medical Sciences, Doshisha University 2 Department of Pharmacology, Kansai Medical University 3 Department of Urology, Graduate School of Medicine, Kyoto University 4 Ichioka Urological Clinic ⏨ᛶዷࡢデ᩿⢭ᕢ⤌⧊ࡢ⏕᳨ࡣ㠀ᖖ㔜せ࡛࠶ࡿࠋᮏ◊✲࡛ࡣࠊᑗ᮶ⓗ⢭ᕢ⤌ ⧊ࡢ⌮デ᩿౪ࡍࡿࡓࡵࠊẼᅽ MALDI 㢧ᚤ㉁㔞ィࢆ⏝࠸࡚ࠊ࣐࢘ࢫ࠾ࡼࡧࣛࢵࢺ⢭ᕢ ࠾ࡅࡿࢾࢡࣞ࢜ࢳࢻࡢ࣓࣮ࢪࣥࢢࢆヨࡳࡓࠋゎᯒࡣ 5 㐌㱋 ICR ࣐࢘ࢫ࠾ࡼࡧ 5 㐌㱋 Wistar ࣛࢵࢺ⢭ᕢࢆ⏝࠸ࡓࠋ㢁᳝⬺⮻ᚋࠊ30 ⛊௨ෆࡍࡤࡸࡃ⢭ᕢࢆྲྀࡾฟࡋࠊᾮయ❅⣲ ࡛ᛴ㏿෭ࡋࡓࠋ⤖⤌⧊ࡽࢡࣜ࢜ࢫࢱࢵࢺ࡛ཌࡉ 10ȣm ࡢⷧษ∦ࢆసࡾࠊ㏱᫂ᑟ㟁ᛶ ࢫࣛࢻࢢࣛࢫ(ITO)⼥ゎ᥋╔ࡋࡓࠋ࣐ࢺࣜࢵࢡࢫࡣ㸷㸫࣑ࣀࢡࣜࢪࣥࢆ⏝࠸ negative mode ࡚ゎᯒࢆ⾜ࡗࡓࠋ୧ഃ⢭ᕢࡢෆࠊ୍᪉ࡣṚᚋኚࢆᢚไࡍࡿ┠ⓗ࡛⇕ฎ ⌮ࢆຍ࠼ࠊࡑࡢຠᯝࢆẚ㍑᳨ウࡋࡓࠋ㢧ᚤ㉁㔞ィࡣࠊiMScope(ᓥὠ〇సᡤ)ࢆ⏝࠸ DHB(2, 5-dihydroxybenzoic acid)࡛࢟ࣕࣜࣈ࣮ࣞࢩࣙࣥࢆ࠾ࡇ࡞ࡗࡓࠋࢹ࣮ࢱࡣࠊImaging MS Solution (ᓥὠ〇సᡤ)ࢆ⏝࠸࡚ゎᯒࡋࡓࠋm/z ࡢ್ࡽ௦ㅰ≀ࡢ≉ᐃࡣࠊMETLIN ࢆཧ↷ ࡋࡓࠋࡑࡢ⤖ᯝࠊࡇࢀࡲ࡛ሗ࿌ࡢ࠶ࡗࡓ Seminolipids ࡢศᕸࡃࢃ࠼ ATP, ADP, AMP ࡞ ࡢࢾࢡࣞ࢜ࢳࢻࡢศᕸࢆほᐹࡍࡿࡇࡀ࡛ࡁࡓࠋᚋࡣࠊ⢭Ꮚᙧᡂࡸዷࡢ㛵㐃࠾ ࠸࡚⢭ᕢࡢࢾࢡࣞ࢜ࢳࢻࢆᑐ㇟ࡋࡓ࣓࣮ࢪࣥࢢࢆ⾜࠸ࠊ᳨ドࢆ⾜࠺ࠋ ́́ P-60 ㉁㔞࣓࣮ࢪࣥࢢἲࢆ⏝࠸ࡓࣁࣟ࣌ࣜࢻ࣮ࣝ⏤᮶ࣆࣜࢪࢽ࣒࢘௦ㅰ≀ࡢ⬻ෆศ ᕸ㛵ࡍࡿྍどࡢ᳨ウ ྜྷ⏣ཎつ 1, ୰す㇏ᩥ 2, ᮡᮏ㤶ዉ 3, ᕴ ಙ 1, ༑ᔒ୍㞝 4 1 ㏆␥Ꮫ་Ꮫ㒊ἲ་Ꮫ, 2 㜰་⛉Ꮫ⮫ᗋ᳨ᰝ་Ꮫ, 3 㜰ᏛᏛ㝔་Ꮫ⣔◊✲⛉ἲ་Ꮫ, 4 ୍⯡♫ᅋἲே་⸆ศᯒ༠ MALDI mass spectrometry imaging for direct measurement of the neurotoxic pyridinium metabolite (HPP+) of haloperidol in mouse brain tissue Motonari Yoshida1, Toyofumi Nakanishi2, Kana Sugimoto3, Shinji Tatsumi1, Kazuo Igarashi4 Department of Legal Medicine, Faculty of Medicine, Kinki University, 2Department of Clinical and Laboratory Medicine, Osaka Medical College, 3Department of Legal Medicine, Osaka University Graduate School of Medicine, 4Department of Research Development, Association of Medicinal Analysis 1 ࠙┠ⓗࠚ⤫ྜኻㄪ⒪⸆ࣁࣟ࣌ࣜࢻ࣮ࣝ㸦HP㸧ࡣࠊ➨୍ୡ௦ࡢᢠ⢭⚄⸆࡛࠶ࡿࡀࠊ⤫ྜ ኻㄪࡢ୰࡛ࡶᗁ⫈ࡸዶ࡞ࡢ≧ᨵၿࡢࡓࡵᗈࡃ⏝࠸ࡽࢀ࡚࠸ࡿࠋ୍᪉ࠊࡇࡢ⒪⸆ ࡢ㛗ᮇ⏝ࡼࡾࠊ స⏝ࡋ࡚⸆ᛶࣃ࣮࢟ࣥࢯࢽࢬ࣒ࡀㄏᑟࡉࢀࡿࡇࡶ▱ࡽࢀ࡚࠸ࡿࠋ ࡇࡢ HP ࡼࡿ⸆ᛶࣃ࣮࢟ࣥࢯࢽࢬ࣒Ⓨ⌧ࡢせᅉࡋ࡚ࠊIgarashi ➼ࡣ HP ࡼࡿ⚄⤒ẘ ᛶ௦ㅰ≀ࣆࣜࢪࢽ࣒࢘㸦HPP+㸧ࡢ㛵ࢆሗ࿌ࡋ࡚࠸ࡿࠋࡇࡢ௦ㅰ≀ HPP+ࡣ⚄⤒ẘᛶㄏⓎ≀㉁ MPTP ࡢࣆࣜࢪࢽ࣒࢘௦ㅰ≀ MPP+Ꮫᵓ㐀ⓗ㢮ఝࡋ࡚࠸ࡿࡇࡽࠊ㢮ఝࡋࡓ⬻⚄⤒ẘ ᛶࢆ᭷ࡍࡿ⪃࠼ࡽࢀࡿࠋࡲࡓࠊHP ᢞᚋࡢືែࡋ࡚ࠊLC/MS ศᯒࡼࡾ⬻ෆࣆࣜࢪࢽ࢘ ࣒௦ㅰ≀ HPP+ࡢᏑᅾࡀሗ࿌ࡉࢀ࡚࠸ࡿࠋᅇࡣࠊࡇࡢࣆࣜࢪࢽ࣒࢘௦ㅰ≀ HPP+ࡢ⬻ෆศᕸ ࡘ࠸࡚ࠊ㉁㔞࣓࣮ࢪࣥࢢᡭἲࡼࡿྍどࢆ᳨ウࡋࡓࠋ ࠙᪉ἲࠚᢞື≀ࡋ࡚ࠊICR ⣔࣐࢘ࢫ㸦8 㐌௧ࠊ㞝㸧ࢆ⏝ࡋࡓࠋHP ᢞ㔞ࡣ⬻ෆศᕸࢆ ᫂░ࡍࡿࡓࡵࠊ㏻ᖖ⏝㔞ࡼࡾ㧗⏝㔞ࢆ⏝ࡋࡓࠋHP ⁐ᾮࢆ 20 mg/kg ⭡⭍ෆὀᑕࡋࠊᢞ ᚋ 1 㛫⬻ࢆฟࡋࡓࠋฟ⬻ࡣ┤ࡕ 16ȣm.ཌࡢ⤖ษ∦ࢆసᡂࡋࡓࠋ࢜ࣥヨ ⸆ HCCA-Matrix ࢆ⏝ࡋࠊMALDI-TOF-MS ⨨㸦Bruker Daltonics Autofelex III-OM㸧 ࡼࡿ㉁㔞࣓࣮ࢪࣥࢢࢆ⾜ࡗࡓࠋ௦ㅰ≀ HPP+ ᐃࠊm/z 354.1 ࢆࣉ࣮ࣜ࢝ࢧ࣮࢜ࣥࡋ ࡚ࠊm/z 165.4 ࢆࢻ࣮ࢱ࣮࢜ࣥࡋ࡚⏝࠸ࡓࠋศᯒࢯࣇࢺࡣ Flex Imaging V3.0 ࢆ⏝ࡋ ࡓࠋ ࠙⤖ᯝ࠾ࡼࡧ⪃ᐹࠚHP ᢞ࣐࢘ࢫ࠾ࡅࡿ⚄⤒ẘᛶࣆࣜࢪࢽ࣒࢘௦ㅰ≀ HPP+ࡢ⬻ෆศᕸࢆࠊ ㉁㔞࣓࣮ࢪࣥࢢἲࢆ⏝࠸࡚ྍどࢆ᳨ウࡋࡓࠋ⬻ษ∦ୖࡢ≉ᐃ㒊ࠊ௦ㅰ≀ HPP+ᅛ᭷ ࡢ㉁㔞ࢆྍどࡍࡿࡇࡀฟ᮶ࡓࠋࡇࡢ㒊ࡘ࠸࡚ࠊ⬻⚄⤒⣽⬊ࠊ≉ࢻࣃ࣑ࣥ⚄⤒⣽ ⬊➼ࡢ☜ᐃࢆࠊච⤌⧊ᏛᰁⰍ➼ࡼࡾ᳨ウ୰࡛࠶ࡿࠋ ́́ P-61 ᪂㩭⤖ங⒴⤌⧊ษ∦ࢆ⏝࠸ࡓ MALDI-IMS ゎᯒࡼࡿங⒴≉␗ࢱࣥࣃࢡศᏊ ೃ⿵ࡢྠᐃ బ⸨ኤᏊ㸯,2, ୰す㇏ᩥ 2, ᒾᮏᙪ㸯, ෆᒣஂ㸯 㸯 㜰་⛉Ꮫ㝃ᒓ㝔ங⭢ෆศἪእ⛉, 㸰㜰་⛉Ꮫ⮫ᗋ᳨ᰝ་Ꮫᩍᐊ Identifications of candidate breast cancer-specific biomarkers in fresh frozen breast tissue sections by the MALDI-imaging coupled with on-tissue digestion Nayuko Sato1,2, Toyofumi Nakanishi2, Mitsuhiko Iwamoto1, Kazuhisa Uchiyama㸯 Department of Breast and Endocrine Surgery, Osaka Medical College Hospital, 2 Department of Clinical and Laboratory Medicine, Osaka Medical College 1 ࠙┠ⓗࠚ㏆ᖺࠊࢯࣇࢺ࢜ࣥ㉁㔞ศᯒἲࡢⓏሙࡼࡾࠊゎᯒᑐ㇟ࡀపศᏊࡽ⏕య㧗ศᏊ ᗈࡀࡾࠊ⏕⌧㇟ࢆྖࡿࢱࣥࣃࢡ㉁ࡢྠᐃࡀྍ⬟࡞ࡗࡓࠋ᭦ࠊ㉁㔞࣓࣮ࢪࣥࢢ ᡭἲࡼࡾࠊ㉁㔞ศᯒ࡛ᚓࡽࢀࡓศᏊෆᵓ㐀ሗྠࡑࡢ⤌⧊ෆᒁᅾࢆྍどࡍࡿࡇ ࡛ࠊᚑ᮶ࡢ⌮⤌⧊ീ㢮ఝࡍࡿ࣐ࢫ࣓࣮ࢪ㸦Heat map㸧ࡀᚓࡽࢀࡿࡼ࠺࡞ࡗࡓࠋ ᅇࠊங⒴ษ㝖᪂㩭⤌⧊ษ∦ࢆゎᯒᑐ㇟ࠊ࣐ࢺࣜࢵࢡࢫᨭ࣮ࣞࢨ࣮⬺㞳㣕⾜㛫ᆺ ㉁㔞ศᯒ࣓࣮ࢪࣥࢢ㸦௨ୗ MALDI-IMS㸧ἲࢆ⏝࠸ࠊ⤌⧊ษ∦ୖ࡛┤᥋ࢺࣜࣉࢩࣥᾘࢆ⾜ ࠺ࠊon-tissue digestion ࢆ⏝࠸࡚ங⒴⤌⧊≉ᚩⓗ࡞ࢱࣥࣃࢡ㉁ࢆ」ᩘྠᐃࡋࡓࡢ࡛ࠊᩥ ⊩ⓗ⪃ᐹࢆຍ࠼࡚ሗ࿌ࡍࡿࠋ ࠙᪉ἲࠚங⒴ᡭ⾡㝿ࡋ࡚ฟࡋࡓ᪂㩭⤖ங⒴⤌⧊㸰㸮ࢆࠊon-tissue digestion ᚋ MALDI-IMS㸦Autoflex speed㸸Bruker Daltonics ♫〇㸧ゎᯒࡋࠊྍどࡉࢀࡓ Heat map ࢆ HE ᰁⰍീẚ㍑ࡋࠊ⒴㒊ࠊṇᖖ⤌⧊㛵ᚰ㡿ᇦ㸦ROI :Region of interests㸧ࢆタᐃࡋࠊ ࢱࣥࣃࢡ㉁ࣉࣟࣇࣝࢆྍどࡋࡓࠋࡑࢀࡒࢀࡢ ROI ࡛ศ㢮ࡋࠊ୧⪅࡛␗࡞ࡿศᏊ࢜ ࣥࢆ㑅ฟࡋࠊࢥࣥࣆ࣮ࣗࢱ࣮ゎᯒࡼࡾ᭷ពᕪࡢ࠶ࡿศᏊ࢜ࣥࢆぢฟࡋࡓࠋࡑࢀࡽᑐ ࡋ࡚ࠊon-tissue 㓝⣲ᾘ㸭࣮ࣞࢨ࣮࢜ࣥᅄ㔜ᴟ࢜ࣥࢺࣛࢵࣉ㣕⾜㛫ᆺ㉁㔞ศᯒ 㸦MALDI- QIT-TOFMS㸸ᓥὠ〇సᡤ〇㸧ἲ࡚ࠊ୧⪅㛫࡛Ⓨ⌧ࡢ␗࡞ࡿࢱࣥࣃࢡ㉁ࢆྠᐃࡋ ࡓࠋ ࠙⤖ᯝࠚࢺࣜࣉࢩࣥᾘ≀ࡽ࠸ࡃࡘࡢங⒴≉␗࣌ࣉࢳࢻ㸦MH㸩㸧ࡀぢฟࡉࢀࠊMSMS ゎᯒ ࡢ⤖ᯝࠊࡑࢀࡽࡢ࣌ࣉࢳࢻࡣ Peptidylprolyl isomerase A. (PPIA)ࠊI ᆺ &ROODJHQȘ-2 (COL1A2)ࠊHistone4 (H4)ࠊHistone2A (H2A1A)ྠᐃฟ᮶ࡓࠋ ࠙⥲ᣓࠚங⒴ࡢᝏᛶᗘࡢ㛵ࢆ♧ࡍ⪃࠼ࡽࢀࡿࢱࣥࣃࢡ㉁ࢆᩘ✀㢮ྠᐃࡍࡿࡇࡀ࡛ࡁ ࡓࠋᚋࠊ≉␗ᢠయࢆ⏝࠸ࡓච⤌⧊ᏛᰁⰍ࡚㉁㔞ศᯒ࡛ᚓࡽࢀࡓ⤖ᯝࢆ᳨ドࡋࠊELISA ἲ ࡛ࢱࣥࣃࢡ㉁ࡢᐃ㔞ࢆ⾜࠸ࠊ᪂つᝏᛶᗘ㛵㐃ࢱࣥࣃࢡ࡞ࡿྰࢆぢᴟࡵࠊᐇ㝿ࡢᶆ ⓗࢱࣥࣃࢡศᏊೃ⿵ࡋࡓ࠸ࠋ ́́ P-62 LC/MS ゎᯒࡼࡿ⾑୰ CRP 」ྜయࡘ࠸࡚ࡢ᳨ウ ᑠᙬୡᏊ 1,3ࠊ㔛ᮧཌྖ 1ࠊᫍ㔝 ᛅ 1ࠊⲨᓥᗣ 1ࠊᚿ᪉࠼ࡾࡉ 1ࠊ⸨ᒸ⨾ 1ࠊୗ⃝㐩㞝 3ࠊ ୰ᒣᬛ⚈ 1 1 ᪥ᮏᏛ་Ꮫ㒊 ែ⌮Ꮫ⣔ ⮫ᗋ᳨ᰝ་Ꮫศ㔝ࠊ2 ᪥ᮏᏛ㝔 ⮫ᗋ᳨ᰝ་Ꮫ⛉ࠊ 3 ᮾிᏛ་Ꮫ㒊ᒓ㝔 ᳨ᰝ㒊 Proteome analysis of CPR binding protein Sayoko Ogura1,3, Atsushi Satomura1, Tadashi Hoshino1, Yasutomo Arashima1, Erisa Shikata1, Kazumi Fujioka1, Tatsuo Shimosawa3, Tomohiro Nakayama1 Division of Laboratory Medicine, Department of Pathology and Microbiology, Faculty of Medicine, Nihon University School of Medicine ࠙⫼ᬒ࣭┠ⓗࠚ C-reactive protein(CRP)ࡣ⫢⮚࡛⏘⏕ࡉࢀࠊ⅖࡞ࡢ่⃭ࡼࡗ࡚ᩘⓒಸࡶ⏘⏕ࡀ ቑຍࡋࠊ⾑Ύ୰ࡢ CRP ⃰ᗘࡣឤᰁࡢ㔜ᗘࡸ⤌⧊യᐖࡢ᭷↓ࡢุᐃᗈࡃ⏝࠸ࡽࢀ࡚࠸ ࡿࠋCRP ࡣከ⢾యࡸࣜࣥ㓟࡞⤖ྜࡋ࡚࠾ࡾࠊ」ྜయࢆᙧᡂࡋ࡚࠸ࡿࡇࡀሗ࿌ࡉࢀ࡚࠸ ࡿࠋࡇࢀࡽࡢ CRP ࡢ」ྜయࡘ࠸࡚ࡣ࠸ࡃࡘ ᐃࡢሗ࿌ࡀ࠶ࡿࡀࠊ⮫ᗋⓗព⩏࠾ࡼࡧ ែࡢ㛵㐃ࡘ࠸࡚ࡣ᫂࡞ࡇࡶከ࠸ࠋ ࠙᪉ἲ᳨࣭ウ㡯┠ࠚ CRP ⤖ྜࡋ࡚࠸ࡿ」ྜయ࠾ࡼࡧࠊCRP ࡢ⤖ྜࡋ࡚࠸ࡿ complex ࢆචỿ㝆ἲ᳨࡛ฟ ࡋ CRP ṇᖖࠊ࠾ࡼࡧ㧗್ࡢ⾑Ύ࡛ẚ㍑ࡋࡓࠋ⾑Ύࡣ 2012 ᖺࡽ 2014 ᖺ᪥ᮏᏛ㝔ࢆ ཷデࡋࡓእ᮶࣭ධ㝔ᝈ⪅ṧ⾑Ύ㸦⌮ጤဨᢎㄆ῭㸧ࢆ⤖ࡋࠊTranditional ࠾ࡼࡧ Magnet ࢆ⏝࠸ࡓචỿ㝆ἲ࡛ᢠ CRP ᢠయ㸦Thermo㸧 Negative control (mouse IgG) ࢆ࠾ࡼࡧ Cross link Magnet(Pearce)ࢆ⤖ྜࡉࡏࠊࡑࡢᚋ⾑Ύࡶ 1 㛫ᇵ㣴ࡋࡓࠋ⤖ྜࡋࡓ⺮ⓑࢆ 2 ḟ ඖ㟁ẼὋື(pH3㸫10)࡚ὋືࡋࠊGel spot ࢆ⏬ീゎᯒ࢙࢘㸦SameSpots㸧࡚ゎᯒࡋࠊⓎ ⌧㔞ࡢ㐪࠸ࡢㄆࡵࡽࢀࡿࢫ࣏ࢵࢺࢆษࡾฟࡋࠊLC/MS ゎᯒࢆ⾜ࡗࡓࠋ ࠙⤖ᯝࠚ ᢠ CRP ᢠయ࡛චỿ㝆ࡋࡓࡶࡢ Negative control (mouse IgG)࡛චỿ㝆ࡋࡓࡶࡢ࡛Ⓨ⌧ 㔞ࡢ␗࡞ࡿࢫ࣏ࢵࢺࡣࡁࡃ 3 ࡘ࠶ࡗࡓࠋࡑࡢ࠺ࡕ᭱ࡶᕪࡢ࠶ࡿࡶࡢࢆ LC/MS ࡢゎᯒ࡚ VitaminD binding protein ࡀྠᐃࡉࢀࡓࠋ ࠙⪃ᐹ࣭⤖ㄒࠚ ᅇࡢ⤖ᯝࡽ CRP 」ྜయࡋ࡚ Vitamin D binding protein ࡀ᪂ࡓྠᐃࡉࢀࡓࠋ Vitamin D binding protein ࡣࣅࢱ࣑ࣥ㹂⤖ྜࡋࠊ⾑୰࡛ࡢ VitaminD ࡢ⃰ᗘࡸ Vitamin D binding protein ࡢ⃰ᗘࡣෙື⬦ᝈ┦㛵ࡀࡿࡢሗ࿌ࡀ࠶ࡿࠋᚋࡣ CRP 」ྜయࡋ࡚ ࡢ VitaminD binding protein 㔞ࢆ ᐃࡋࠊ⮫ᗋⓗព⩏ࢆ᳨ウࡍࡿࠋ ́́ ㅮ₇せ᪨ 㸦LS㸸ࣛࣥࢳࣙࣥࢭ࣑ࢼ࣮࣭MS㸸࣮ࣔࢽࣥࢢࢭ࣑ࢼ࣮㸧 ́́ LS-1 ࣓࣮ࢪࣥࢢ㉁㔞ศᯒ࠾ࡅࡿ㧗ศゎ⬟࣭㧗⢭ᗘࣁࢫ࣮ࣝࣉࢵࢺࡢ࠸ศࡅ 㡞⃝ ᓫ 1 1 ࣈ࣮࣭ࣝ࢝ࢲࣝࢺࢽࢡࢫᰴᘧ♫ How to choose the high resolution or high throughput instrument for Imaging applications. Takashi Nirasawa1 1 Bruker Daltonics K.K. ࠊ ࣓࣮͆ࢪࣥࢢ㉁㔞ศᯒ͇㛵ࡍࡿሗ࿌ࢆ┠ࡍࡿᶵࡀቑ࠼࡚ࡁࡲࡋࡓࠋ་⒪࡛ ⏝࠸ࡽࢀ࡚࠸ࡿ CT㸦ࢥࣥࣆ࣮ࣗࢱ᩿ᒙᙳ㸧 ࠊMRI㸦᰾☢Ẽඹ㬆⏬ീἲ㸧ࡸ PET㸦࣏ࢪࢺࣟ ᩿ࣥᒙἲ㸧࡞ࡢ㠀◚ቯ࡛ࡢྍどἲࡣ␗࡞ࡾࠊ࣓࣮ࢪࣥࢢ㉁㔞ศᯒࡣ◚ቯศᯒࡢ୍ ࡘ࡛ࡍࡀࠊ≀㉁ᅛ᭷ࡢ㉁㔞ࢆ⏝࠸࡚ྍどࡍࡿࡓࡵࠊࡑࡢ≀㉁ࡢヲ⣽࡞ᒁᅾࢆᤊ࠼ࡿࡇ ࡀᮇᚅ࡛ࡁࡲࡍࠋ ⏕య⤌⧊ษ∦ࢆࡣࡌࡵࡍࡿ 2 ḟඖ࣭ᖹ㠃≧ࢧࣥࣉࣝࡘ࠸࡚ࠊࢫ࢟ࣕࣥࡍࡿࡼ࠺ᚤ ᑠ㡿ᇦࡢ㉁㔞ศᯒࢆᩘ༓㹼ᩘᅇ⾜࠸ࡲࡍࠋࡑࢀࡼࡗ࡚ࠊࢧࣥࣉࣝෆࡢ࠶ࡿ≉ᐃࡢ≀㉁ ࡢᒁᅾࢆ⢭ᐦྍどࡍࡿࡇࡀ࡛ࡁࡿࡼ࠺࡞ࡾࡲࡍࠋ ㏆ᖺࠊᵝࠎ࡞࢜ࣥἲ࠾ࡼࡧศ㞳ศᯒἲࢆ⤌ࡳྜࢃࡏࡓ㉁㔞ศᯒ⨨ࡼࡿྍどࡀ ヨࡳࡽࢀ࡚࠸ࡲࡍࡀࠊࡑࡢ୰࡛ࡶ MALDI-TOF ᆺ㉁㔞ศᯒ⨨ࡼࡿࢱࣥࣃࢡ㉁࣭⬡㉁ࡢྍ どࡸࠊFT-ICR ᆺ㉁㔞ศᯒ⨨ࢆ⏝࠸ࡓ⸆≀࣭௦ㅰ≀ࡢྍどࡀࠊ࣓࣮ࢪࣥࢢࡢ௦⾲ ࡋ࡚ᣲࡆࡽࢀࡲࡍࠋ ᮏㅮ₇࡛ࡣࠊᗈ࠸㡿ᇦࡢྍどࢆ⾜࠺᭱᪂࣭㧗㏿ MALDI-TOF ᆺ㉁㔞ศᯒ⨨㸸rapiflex ࠊ㉸㧗㉁㔞ศゎ࣭㧗㉁㔞⢭ᗘࢆഛ࠼ࡓ FT-ICR ᆺ㉁㔞ศᯒ⨨㸸solariX-XR ࢆ⏝࠸ࡓࠊ᭱ ᪂ࡢ࣓࣮ࢪࣥࢢ㉁㔞ศᯒࢆࡈ⤂⮴ࡋࡲࡍࠋ ࠙ᑠᆺࣂ࣮ࢳࣕࣝࢫࣛࢻࢫ࢟ࣕࢼ NanoZoomer-SQ ࡘ࠸࡚ࠚ MALDI-TOF ࢩࢫࢸ࣒ࡢࡳ࡛⾜࠺࣓࣮ࢪࣥࢢศᯒࡢ㞴Ⅼࡣࠊ⤌⧊ࢆ ᐃࡋࡓศᯒࢹ࣮ࢱ 㧗ゎീᗘ࡞⤌⧊⏬ീࢆ⤌ࡳྜࢃࡏ࡚ほᐹࡍࡿࡀᅔ㞴࡞≧ἣ࡛ࡋࡓࠋࡑࡢㄢ㢟ࢆゎỴࡍࡿࡢ ࡀࠊᯇ࣍ࢺࢽࢡࢫ♫〇 ᑠᆺࣂ࣮ࢳࣕࣝࢫࣛࢻࢫ࢟ࣕࢼ NanoZoomer-SQ ࣈ࣮࣭ࣝ࢝ ࢲࣝࢺࢽࢡࢫ♫ᵝࡢ MALDI-TOF ࢩࢫࢸ࣒ࢆ⤌ࡳྜࢃࡏࡓ㐠⏝࡛ࡍࠋࡇࡢࢩࢫࢸ࣒ࡢ⤌ࡳ ྜࢃࡏࡼࡾࠊࢱࣥࣃࢡ㉁ࡸ௦ㅰ≀➼ࡢᑐ㇟≀⤌⧊ᙧែࢆ↷ࡽࡋྜࢃࡏ࡞ࡀࡽࡢほᐹ ࡀྍ⬟࡞ࡾࡲࡍࠊNanoZoomer-SQ ࡣᑠᆺ࣭ప౯᱁ᑐ㇟⤌⧊ࡢࣂ࣮ࢳࣕࣝࢫࣛࢻࢆసᡂ ࡍࡿ⨨࡛࠶ࡾࠊ⡆༢࡞᧯స࡛ࣂ࣮ࢳࣕࣝࢫࣛࢻࡢྲྀᚓࡀྍ⬟࡛ࡍࠋ㸦࠙ࣂ࣮ࢳࣕࣝࢫࣛ ࢻࠚࡣࠊࣉࣞࣃ࣮ࣛࢺࡉࢀࡓ⤌⧊ࡸ⣽⬊࡞ࡢࢧࣥࣉࣝయࢆ㧗ゎീᗘࢹࢪࢱࣝ ࡋࡓ⏬ീࢹ࣮ࢱࢆᣦࡋࡲࡍ㸧 ́́ LS-2 ࣐ࣝࢳ࣑࢜ࢵࢡࢫ࡞ࢹ࣮ࢱゎᯒࠊಖ⟶ࠊඹ᭷ࢆྍ⬟ࡍࡿ BaseSpace ࢡࣛ࢘ࢻ 㛵 ᗈ 1 1 ࣑ࣝࢼᰴᘧ♫ ࣉࣟࢲࢡࢺ࣐࣮ࢣࢸࣥࢢ㒊 ࣉࣟࢲࢡࢺ࣐ࢿ࣮ࢪ࣮ࣕ The BaseSpace Cloud enabled multi-omics data analysis, storage and sharing Norihiro Seki1 1 Product Marketing Manager, Regional Marketing, Illumina K.K. Japan BaseSpace ࢡࣛ࢘ࢻࢹ࣮ࢱゎᯒࢧ࣮ࣅࢫࢆᥦ౪ࡍࡿ࣑ࣝࢼࡣࠊḟୡ௦ࢩ࣮ࢣࣥࢧ࣮ࢆጞ ࡵࡍࡿࢤࣀ࣒ゎᯒᚲせ࡞〇ရࢆࠕSample to Answerࠖ࠸࠺ࢥࣥࢭࣉࢺࡢඖ୍㈏ࡋ ࡓࢯ࣮ࣜࣗࢩࣙࣥࢆᥦ౪ࡋ࡚࠸ࡲࡍࠋຊࡢḟୡ௦ࢩ࣮ࢣࣥࢧ࣮ࡣࠊࡇࢀࡲ࡛ࠊᵝࠎ࡞ ᅜ㝿ࢤࣀ࣒ࣉࣟࢪ࢙ࢡࢺ࡛᥇⏝ࡉࢀࠊᩘከࡃࡢ᪂ࡓ࡞Ⓨぢ㈉⊩ࡋ࡚ࡁࡲࡋࡓࠋ⌧ᅾ࡛ࡣࠊ 1 ᗘ᭱ 16 ேศࡢࢤࣀ࣒ゎᯒᚲせ࡞ࢹ࣮ࢱࢆࢧࣥࣉࣝ࠶ࡓࡾ 1000 ࢻ࡛ࣝ⏘ฟࡍࡿ ࡇࡀྍ⬟࡞ࡾࡲࡋࡓࠋ୍᪉࡛ࠊḟୡ௦ࢩ࣮ࢣࣥࢧ࣮ࡣ᪂ࡓ࡞ၥ㢟ࢆ⏕ࡳฟࡋࡲࡋࡓࠋ ࡑࢀࡣࠊ᪥ࠎቑࡍࡿࢤࣀ࣒ࢹ࣮ࢱࢆຠ⋡ࡼࡃゎᯒ࠾ࡼࡧಖ⟶ࡍࡿ⎔ቃࢆᩚ࠼ࡿᚲせࡀ࠶ ࡿ࠸࠺ࡇ࡛ࡍࠋ ࡇࢀࡽࡢၥ㢟ࢆゎỴࡍࡿࡓࡵࠊ࣑ࣝࢼࡣ BaseSpace ࢡࣛ࢘ࢻࢹ࣮ࢱゎᯒࢧ࣮ࣅࢫࡢ ᥦ౪ࢆ㛤ጞࡋࡲࡋࡓࠋࡇࢀࡼࡾࠊࡇࢀࡲ࡛ከࡃࡢ࣮ࣘࢨ࣮ࡢ㢌ࢆᝎࡲࡋ࡚࠸ࡓࠊ↹㞧࡞ ᧯సࢆᚲせࡍࡿࢹ࣮ࢱゎᯒࠊ㔞ࢹ࣮ࢱࡢಖ⟶࠾ࡼࡧඹྠ◊✲⪅ࡢゎᯒ⤖ᯝࡢඹ᭷ ࠸࠺ၥ㢟ࢆ୍ᗘゎỴࡍࡿࡇࡀྍ⬟࡞ࡾࡲࡋࡓࠋࡇࡢ BaseSpace ࢡࣛ࢘ࢻࡣࢤࣀ࣒ゎ ᯒ≉ࡋࡓࡶࡢ࡛ࡣ࡞ࡃࠊ⮬⏤ᗘࡢ㧗࠸ࣉࣛࢵࢺࣇ࢛࣮࣒ࡋ࡚タィࡉࢀ࡚࠸ࡿࡢ࡛ࠊ ࢤࣀ࣒௨እࡢࢹ࣮ࢱࢆゎᯒࡍࡿࡇࡶྍ⬟࡛ࡍࠋ ≉ࠊ࣐ࢫࢫ࣌ࢡࢺࣝࡢࢹ࣮ࢱࡢゎᯒࡣࠊࡑࢀࡒࢀࡢ ᐃ⤖ᯝࢆ༢⊂࡛ゎᯒࡍࡿࡔࡅ࡛ ࡞ࡃࠊࢤࣀ࣒ࡸ㑇ఏᏊⓎ⌧ゎᯒࡢ⤖ᯝ⤌ྜࡏࡓ࣑࢜ࢵࢡࢫゎᯒࢆ⾜࠺ࡇ࡛᪂ࡓ࡞Ⓨぢ ࡘ࡞ࡀࡿࡇࡀᮇᚅࡉࢀࡲࡍࠋࡇࡇ࡛ࡣࠊBaseSpace ࢡࣛ࢘ࢻࢆ⏝ࡍࡿ࣓ࣜࢵࢺ࠾ࡼࡧ ᾏእ࡛ࡢ⏝ࡘ࠸࡚⤂ࡋࡲࡍࠋ ́́ LS-3 LC-QTOF ࢆ⏝࠸ࡓ༴㝤ࢻࣛࢵࢢࡢศᯒ ᇣᫀᙪ 1 1 ࢪࣞࣥࢺ㺃ࢸࢡࣀࣟࢪ࣮ᰴᘧ♫ Analysis of designer drugs by LC-QTOF Masahiko Takino1 1 Agilent Technologies Japan, Ltd. 㯞⸆ྠᵝࡢస⏝࠾ࡼࡧ༴㝤ᛶࢆᣢࡗࡓ༴㝤ࢻࣛࢵࢢࡀࠊࡁ࡞♫ၥ㢟࡞ࡗ࡚࠸ࡿࠋ ࡇࢀࡽ༴㝤ࢻࣛࢵࢢࡣつไ⸆≀ࡢศᏊᵓ㐀ࡢ୍㒊ࢆኚ࠼ࡓྜᡂ⸆≀࡛࠶ࡾࠊᶆ‽ရࡢ㎿㏿ ࡞ධᡭࡀᅔ㞴࡞ሙྜࡀከ࠸ࠋ࡞༴㝤ࢻࣛࢵࢢࡢᡂศࡣࠊྜᡂ࢝ࢳࣀࣥ㢮ࡸྜᡂ࢝ࣥࢼࣅ ࣀࢻ㢮࡛࠶ࡿࡀࠊ᭱㏆࡛ࡣࣇ࢙ࢿࢳ࣑ࣝࣥ㢮ࠊྜᡂ࢜ࣆ࢜ࢻࠊ࣋ࣥࢰࣇࣛࣥ㢮ࠊ ࣑ࣀࣥࢲࣥ㢮࡞ᵝࠎ࡞༴㝤ࢻࣛࢵࢢࡀሗ࿌ࡉࢀ࡚࠸ࡿࠋࡋࡓࡀࡗ࡚ࠊ༴㝤ࢻࣛࢵࢢࡢ ศᯒ࡛ࡣᐃᛶศᯒࡽጞࡲࡿࠋࡉࡽࠊྜᡂ࢝ࣥࢼࣅࣀࢻ㢮ࡣ⾑ᾮࡸᒀ࡞ࡢ⏕యヨᩱ ࡽࡣᮍኚయࡢ⃰ᗘࡀᴟࡵ࡚పࡃࠊ௦ㅰ≀ࡢ᥈⣴ࡣ⏝ࡋࡓ༴㝤ࢻࣛࢵࢢࡢ᥎ᐃ㔜せ ࡛࠶ࡿࠋࡋࡋࠊ༴㝤ࢻࣛࢵࢢࡣ᪂つྜ≀ࡀከ࠸ࡇࡽ⏕యෆ࡛ࡢ௦ㅰ㛵ࡍࡿሗ࿌ ࡣᴟࡵ࡚ᑡ࡞࠸ࠋࡇࢀࡲ࡛₇⪅ࡽࡣࠊᅄ㔜ᴟ-㣕⾜㛫ᆺ㉁㔞ศᯒィࢆ⏝࠸ࡓ LC-QTOF ࢆ⏝ ࠸࡚༴㝤ࢻࣛࢵࢢࢆྵࡵࡓᵝࠎ࡞⸆≀ࡢศᯒᡭἲࢆ㛤Ⓨࡋ࡚ࡁࡓࠋLC-QTOF ࡣ㧗ศゎ⬟࡛⢭ ᐦ㉁㔞 ᐃࡀྍ⬟࡞ࡇࡽࠊ༴㝤ࢻࣛࢵࢢศᯒࡣ㠀ᖖ᭷ຠ࡞⨨࡛࠶ࡿࠋࡋࡋࠊ LC-QTOF ࡣᵝࠎ࡞ ᐃᡭἲࠊࢹ࣮ࢱゎᯒᡭἲࡀሗ࿌ࡉࢀ࡚࠾ࡾࠊࡇࢀࡽ ᐃᡭἲࡸゎᯒᡭἲ ࡢ≉ᚩࢆ༑ศ⌮ゎࡍࡿᚲせࡀ࠶ࡿࠋࡑࡇ࡛ᮏࢭ࣑ࢼ࣮࡛ࡣ༴㝤ࢻࣛࢵࢢศᯒ⏝࠸ࡽࢀ ࡿ LC/QTOF ࡢ ᐃᡭἲࡸࢹ࣮ࢱゎᯒᡭἲࡘ࠸࡚ゎㄝࡍࡿࠋࡉࡽࠊMetaboliteID ࢯࣇࢺ ࢚࢘ࡼࡿ༴㝤ࢻࣛࢵࢢࡢ௦ㅰ≀ศᯒࡸ࢜ࣥࣔࣅࣜࢸ࣮ᢏ⾡ࢆഛ࠼ࡓ LC-QTOF ࡼࡿ༴㝤ࢻࣛࢵࢢศᯒࡘ࠸࡚ࡶ⤂ࡍࡿࠋ ́́ MS-1 LC/MS/MS ࡢ⮫ᗋ᳨ᰝᛂ⏝ࡢྲྀࡾ⤌ࡳ బ⸨ Ᏺ 1 ඛ⏕ 1 ༓ⴥᏛ་Ꮫ㒊㝃ᒓ㝔࣐ࢫࢫ࣌ࢡࢺ࣓ࣟࢺ᳨࣮ࣜᰝデ᩿Ꮫ Clinical application of LC/MS/MS - focusing on vitamin D metabolites testing - Mamoru Sato1 1 Divisions of Clinical Mass Spectrometry and Clinical Genetics, Chiba University Hospital ࢧ࣮ࣔࣇࢵࢩ࣮ࣕࢧ࢚ࣥࢸࣇࢵࢡᰴᘧ♫ࡣ 2015 ᖺ 5 ᭶㉁㔞ศᯒィࢆ᳨ฟჾ ࡍࡿ㧗㏿ᾮయࢡ࣐ࣟࢺࢢࣛࣇศᯒ⨨ࢆ་⒪ᶵჾ㸦Ⓩ㘓␒ྕ㸸14B3X00012000030㸧ࡋ ࡚᪥ᮏᅜෆ࡛Ⓩ㘓ࡋࡲࡋࡓࠋࣁࢫ࣮ࣝࣉࢵࢺ࡛ࠊࡘᏳᐃࡋࡓࢩࢫࢸ࣒ࡀせồࡉࢀࡿデ ᩿ᶵჾࡋ࡚ࠊ㸰ࢳࣕࣥࢿࣝࡢ 2 ḟඖ LC ᵓᡂ࡞ࡗ࡚࠸ࡲࡍࠋ1 ḟඖ┠࡛㉁㔞ศᯒィࡸศ ᯒ࣒࢝ࣛࡢởࢀࢆ㍍ῶࡍࡿࡓࡵࡢ㝖ࢱࣥࣃࢡ㉁ฎ⌮ࢆ⾜࠸ࠊ2 ḟඖ┠࡛㏻ᖖࡢ LC ศ㞳ࢆ⾜ ࠸ࡲࡍࠋࡲࡓࠊศᯒ㛫ࢆ▷⦰ࡍࡿࡓࡵ 2 ࢳࣕࣥࢿࣝᵓᡂࡋࠊ୍᪉ࡀ LC-MS ศᯒࢆ⾜ ࡗ࡚࠸ࡿ㛫ࡶ࠺୍᪉ࡀ 1 ḟඖ┠ࡢ๓ฎ⌮ࡸ 2 ḟඖ┠ࡢ࣒࢝ࣛࡢᖹ⾮ࢆ⾜࠼ࡿࡼ࠺࡞ ࡗ࡚࠸ࡲࡍࠋྛࢳࣕࣥࢿࣝࡢὶ㊰ࠊ⛣ື┦࣎ࢺࣝࡣ⊂❧ࡋ࡚࠾ࡾࠊ」ᩘࡢࢵࢭࢆ 1 ྎ ࡢࢩࢫࢸ࣒⤌ࡳ㎸ࢇ࡛࠾ࡃࡇࡶྍ⬟࡛ࠊࢵࢭࡈ⛣ື┦ࡸ࣒࢝ࣛࢆࡍࡿᚲ せࡣ࠶ࡾࡲࡏࢇࠋ ᮏࢭ࣑ࢼ࣮࡛ࡣࠊྠࢩࢫࢸ࣒ࢆ⏝ࡉࢀ࡚࠸ࡿ༓ⴥᏛᒓ㝔ࡢబ⸨ඛ⏕ LC-MS ࡢ ⮫ᗋ᳨ᰝᛂ⏝ࡘ࠸࡚ࡈㅮ₇࠸ࡓࡔࡁࡲࡍࠋ ࠙ࡈㅮ₇せ᪨ࠚ ⌧ᅾࡢ⮫ᗋ᳨ᰝᐊ࡛ࡣࠊྛ✀ࢫࢸࣟࢻ࣭࣍ࣝࣔࣥࣅࢱ࣑ࣥ D ௦ㅰ≀࡞ࡢపศᏊྜ ≀ࡢศᯒࡣᢠయࡼࡿචᏛⓗ ᐃἲࡀ⏝࠸ࡽࢀ࡚࠸ࡿࠋචᏛⓗ ᐃἲࡣ᳨యฎ ⌮⬟ຊࡀ㧗ࡃࠊ⮫ᗋ᳨ᰝ࠾࠸࡚ᚲ㡲࡛࠶ࡿ୍᪉ࠊᕪᛂࡢᏑᅾࡸ࢟ࢵࢺ㛫ᕪ࣭タ㛫 ᕪࡢၥ㢟ࡀᣦࡉࢀ࡚࠸ࡿࠋపศᏊྜ≀ࡣഃ㙐ᵓ㐀࡞ࡢᚤᑠ࡞㐪࠸ࡼࡾ⏕≀Ꮫⓗά ᛶࡀࡁࡃ␗࡞ࡿࡓࡵࠊ⢭ᐦ࡞௦ㅰືែࡢホ౯ࡣࠊᚤᑠᵓ㐀ᕪࢆᘚูࡍࡿࡇࡢ࡛ࡁࡿ LC/MS/MS ࡛ࡢ ᐃࡀ㠀ᖖ᭷⏝࡛࠶ࡿࠋᮏⓎ⾲࡛ࡣࠊLC/MS/MS ࡢ⮫ᗋ᳨ᰝᐊᑟධࡢ㸯 ࡋ࡚ࠊࣅࢱ࣑ࣥ D ௦ㅰ≀ࡢศᯒࢆ⤂ࡍࡿࠋᡃࠎࡣࠊάᛶᆺࣅࢱ࣑ࣥ D ᐦ᥋࡞㛵ಀ ࠶ࡿάᛶᆺࣅࢱ࣑ࣥ D㸦24,25(OH)2D3㸧ࡶྵࡵࡓ 4 ✀ࡢࣅࢱ࣑ࣥ D ௦ㅰ≀ࡘ࠸᳨࡚ᰝ ᛂ⏝ࢆ┠ⓗࡋ࡚ࠊ⮫ᗋ᳨ᰝࢆ⾜࠺㝿⤯ᑐồࡵࡽࢀࡿṇ☜ᗘ࣭⌧ᛶ࣭Ᏻᐃᛶ࣭᭱ప ᐃ㔞ឤᗘ࣭࣐ࢺࣜࢡࢫࡢᖸ΅࣭᥇⾑⟶✀ࡢᙳ㡪࣭ᚑ᮶ἲࡢ┦㛵ࡘ࠸࡚ヲ⣽᳨ウࢆ⾜ ࡗࡓࠋ ́́ ㅮ₇せ᪨ 㸦TF㸸ࢸࢡࣀࣟࢪ࣮ࣇ࢛࣮࣒ࣛ㸧 ́́ TF-1 ᭱᪂ࡢ㉁㔞ศᯒ࣓࣮ࢪࣥࢢ࢜ࣥࣔࣅࣜࢸ࣮QTof ᑎᓮ┿ᶞ 1, ࢱࢼ ࣃࢡࢫࢺࣥ 1 1 ᪥ᮏ࢛࣮࢘ࢱ࣮ࢬᰴᘧ♫ Waters Full Spectrum molecular imaging and Ion mobility Mass Spectromerty QTof – Vion IMS QTof Maki Terasaki1, Thanai Paxton1 LC/MS ศᯒᚲせ࡞ヨ⸆ࡽࠊ๓ฎ⌮〇ရࠊᾮయࢡ࣐ࣟࢺࢢࣛࣇࠊศ㞳࣒࢝ࣛࠊ㉁㔞ศᯒ ィࠊゎᯒࢯࣇࢺࠊࢧ࣏࣮ࢺࢧ࣮ࣅࢫࡲ࡛ࠊࢺ࣮ࢱࣝ〇ရࢆࡈᥦ౪ࡍࡿ࢛࣮࢘ࢱ࣮ࢬࡼࡾࠊ ᭱᪂ࡢ㉁㔞ศᯒ࣓࣮ࢪࣥࢢ࢜ࣥࣔࣅࣜࢸ࣮QTof ࢆࡈ⤂ࡋࡲࡍࠋ ࠙ࣇࣝࢫ࣌ࢡࢺࣝศᏊ࣓࣮ࢪࣥࢢࠚࣉࣟࢸ࣑࢜ࢡࢫࠊ࣓ࢱ࣑࣎ࣟࢡࢫࠊ⣽⬊⏕≀Ꮫࡸ⤌⧊ ⏕≀Ꮫࠊ⌮◊✲࠾ࡼࡧ⤌⧊Ꮫ࠸ࡗࡓศ㔝࠾࠸࡚࠶ࡽࡺࡿಶูࡢ࣓࣮ࢪࣥࢢᢏ⾡ࢆ ㉸࠼ࡿヲ⣽ศᏊሗࡢྲྀᚓࢆᐇ⌧ࡍࡿࡓࡵࠊMALDI㸦࣐ࢺࣜࢡࢫᨭ࣮ࣞࢨ࣮⬺㞳࢜ ࣥ㸧ࠊDESI㸦⬺㞳࢚ࣞࢡࢺࣟࢫࣉ࣮ࣞ࢜ࣥ㸧ࠊ࢜ࣥࣔࣅࣜࢸ࣮ศ㞳ࢆ⤫ྜࡋࡓ Waters ࣇࣝࢫ࣌ࢡࢺࣝศᏊ࣓࣮ࢪࣥࢢࣉࣛࢵࢺ࣮࣒࣍ࢆ Pittcon 2015 ࡛Ⓨ⾲ࡋࠊ Editor's Award 㖟㈹ࢆཷ㈹ࡋࡲࡋࡓࠋࣇࣝࢫ࣌ࢡࢺࣝศᏊ࣓࣮ࢪࣥࢢࢩࢫࢸ࣒ࡣࠊ≉ᐃ ࡢࢱࣉࡢศᏊ㸦࣌ࣉࢳࢻࠊ⬡㉁ࠊపศᏊ௦ㅰ≀ࠊ⢾㢮࡞㸧ࢆศᯒࡍࡿࡢ㠀ᖖ㐺ࡋ ࡓ㉁㔞ศᯒᢏ⾡ࡢ⤌ࡳྜࢃࡏ࡛ࡍࠋࡇࢀࡽࡢᢏ⾡ࡣࠊ㉁㔞ศᯒ࣓࣮ࢪࣥࢢ࡛ᚓࡽࢀࡿ ሗࢆ᭱㝈ໟᣓⓗ࡞ࡶࡢࡍࡿࡓࡵ࠾࠸⿵ࡋྜ࠺ࡶࡢ࡛ࡍࠋ ࠙Vion IMS QTof ㉁㔞ศᯒィࠚ࣋ࣥࢳࢺࢵࣉᆺ⨨ࡋ࡚ᅄ㔜ᴟ㣕⾜㛫ᆺ㉁㔞ศᯒ࢜ ࣥࣔࣅࣜࢸ࣮ศ㞳ࡢⅬࢆ⤌ࡳྜࢃࡏࡓ Vion IMS QTof ㉁㔞ศᯒィ ࡼࡾࠊ᫂░࡛ಙ 㢗ᛶࡢ࠶ࡿ࣮ࣝࢳࣥศᯒࢆ⾜࠺ࡇࡀ࡛ࡁࡿࡼ࠺࡞ࡾࡲࡍࠋ ࢜ࣥࣔࣅࣜࢸ࣮࡛ࡣࠊ࢜ࣥࢆࡑࢀࡒࢀࡢᙧࠊ㉁㔞ࠊ࠾ࡼࡧ㟁Ⲵࡼࡾ࠸ศ㞳 ࡍࡿࡇ࡛ࠊศ㞳࠾࠸࡚ࡶ࠺ 1 ࡘูࡢḟඖࡀᚓࡽࢀࡲࡍࠋ࢜ࣥࣔࣅࣜࢸ࣮ࡢ㑅ᢥᛶ ࡼࡾࢫ࣌ࢡࢺࣝᖸ΅ࡀ㝖ཤࡉࢀࠊࢧࣥࣉࣝ࢜ࣥࡣࢡ࣐ࣟࢺࢢࣛࣇ࣮࡛ඹ⁐ฟࡉࢀࡿ ྜ≀ࡸࣂࢵࢡࢢࣛ࢘ࣥࢻᖸ΅ࡽ༊ูࡉࢀࡿࡓࡵࠊࡍ࡚ࡢࢫ࣌ࢡࢺࣝࡀ᫂░࡞ࡾࠊ ☜ಙ࡛ࡁࡿྜ≀ࡢ≉ᛶゎᯒࢆ⾜࠺ࡇࡀ࡛ࡁࡲࡍࠋࡉࡽࡍ࡚ࡢ࢜ࣥࡘ࠸࡚⾪✺ ᩿㠃✚ (CCS) ್ࡀ⏕ᡂࡉࢀࡿࡓࡵࠊᚑ᮶ࡢ LC-MS ᐇ㦂ࡼࡾከࡃࡢሗࢆᚓࡿࡇࡀ࡛ࡁ ࡲࡍࠋ ́́ TF-2 Agilent 6560 Ion Mobility Q-TOF LC/MSC-QTOF ࡢ⤂ ᇣᫀᙪ 1 1 ࢪࣞࣥࢺ㺃ࢸࢡࣀࣟࢪ࣮ᰴᘧ♫ Agilent 6560 Ion Mobility Q-TOF LC/MSC-QTOF Masahiko Takino1 1 Agilent Technologies Japan, Ltd. Ion Mobility Spectrometry (IMS)ࡣࠊ1950 ᖺ௦㛤Ⓨࡉࢀࡓ࢜ࣥࡢ⛣ືᗘࡼࡾ࢜ ࣥࢆศ㞳ࡍࡿᢏ⾡࡛࠶ࡾࠊྍᦙᆺࡢ⌧ሙ࡛ࡢ⇿Ⓨ≀ศᯒ࡞⏝࠸ࡽࢀ࡚ࡁࡓࠋࡇࡢศ㞳 ᢏ⾡ࡣ LC-MS ࡞⤌ࡳྜࢃࡏࡿ➨ 3 ࡢศ㞳ᢏ⾡࡛࠶ࡾࠊࢡ࣐ࣟࢺࢢࣛࣇ࣮ࡸ㉁㔞ศ ᯒィ࡛ࡣྍ⬟࡞㉁㔞ࡀྠ୍ࡢጉᐖ࢜ࣥࡢศ㞳ࡸࠊ࢜ࣥࡢ❧యᵓ㐀ゎᯒࢆྍ⬟ࡋࠊ ࡼࡾ≉␗ⓗ࡛ヲ⣽࡞ሗࢆᚓࡿࡇࡀྍ⬟࡛࠶ࡿ Agilent 6560 Ion Mobility Q-TOF LC/MS ࢩࢫࢸ࣒ࡣࠊࡇࡢ᪂ࡓ࡞ศ㞳ᢏ⾡࡛࠶ࡿ IMS ࢆഛ࠼᪂ࡓ࡞ศᯒࢆᥦ౪ࡍࡿ㉁㔞ศᯒィ࡛࠶ ࡿࠋᮏ࣮࣡ࢡࢩࣙࢵࣉ࡛ࡣ IMS ࡼࡿᵓ㐀␗ᛶయࡢศ㞳ࠊࢻࣜࣇࢺࢫ࣌ࢡࢺࣝࢆ⏝ࡋࡓ 㑅ᢥᛶࡢᨵၿࠊAll Ions MSMS ἲ IMS ࡢ⤌ࡳྜࢃࡏࡼࡿࣇࣛࢢ࣓ࣥࢺ࢜ࣥࡢ㛵㐃ࡅ ࡞ࡢᡭἲࡘ࠸࡚⤂ࡍࡿࠋ ́́ TF-3 ࣓࣮ࢪࣥࢢ㉁㔞ศᯒࡢ࣎ࢺࣝࢿࢵࢡࢆゎᾘࡍࡿ rapifleXTM MALDI Tissuetyper TM ๓⏣ᩧ 1 1 ࣈ࣮࣭ࣝ࢝ࢲࣝࢺࢽࢡࢫᰴᘧ♫ High Speed Scan instrument, rapifleXTM MALDI TissuetyperTM break though MS imaging bottleneck Masahiro Maeda1 1 Bruker Daltonics K.K. ㉁㔞ศᯒࡼࡿ⤌⧊࣓࣮ࢪࣥࢢᢏ⾡ࡢ㐍Ṍࡣ᪂ࡋ࠸◊✲ศ㔝ࢆ㛤ᣅࡋࠊ≉⌮ศ㔝 ࡛ከࡃࡢᐇ⦼ࢆୖࡆ࡚࠸ࡿࠋ ึᮇࡢẁ㝵࡛ࡣ⤌⧊ୖࡽ┤᥋㉁㔞ศᯒࢆ⾜࠺ࡇࡀ◊✲ ࢸ࣮࣐࡛࠶ࡗࡓࡀࠊ⌧ᅾࡣከࡃࡢሗࢆ࡛ࡁࡿ㝈ࡾ⤌⧊ୖࡽᚓ࡚ࠊ᭷ព࡞ሗࡋ࡚ᚓ ࡿࡇࡀࢸ࣮࣐ࡢ୍ࡘ࡞ࡗ࡚࠸ࡿࠋ ከࡃࡢሗࢆ୍ᅇࡢ ᐃ࡛ᚓࡿⅭࡣ࠸ࡃࡘࡢ ࣏ࣥࢺ࡛ᢏ⾡ࡢᨵၿࡀồࡵࡽࢀ࡚࠸ࡿࠋࡑࡢ࠺ࡕࡢ࠸ࡃࡘࢆୖࡆ࡚ࡳࡿࠊ࣮ࣞࢨ࣮ ࢆᚤ⣽↷ᑕࡍࡿᢏ⾡ࠊ⤌⧊ୖᒁᅾࡍࡿࢱ࣮ࢤࢵࢺ≀㉁ࡢຠ⋡ࡢࡼ࠸࢜ࣥࠊ࢜ ࣥࡋࡓ≀㉁ࡢ⢭ᗘࡢࡼ࠸ศᯒࠊឤᗘࡢᨵၿࠊ ᐃࢫࣆ࣮ࢻࡢᨵၿ࡞࡛࠶ࡿࠋࡑࢀࡒࢀ ࡢᨵⰋࡣ㉁㔞ศᯒ⨨ࡢྛᶵ⬟ࡢᨵⰋࡼࡾ㐩ᡂࡉࢀࡿᮇᚅࡉࢀࡿࠋ ᅇ⤂ࡍࡿ rapifleXTM MALDI Tissuetyper TM ࡣ࣮ࣞࢨ࣮↷ᑕࡢ࣓࢝ࢽࢬ࣒ࢆᨵⰋࡋࠊ ᚑ᮶ࡢ⤌⧊ษ∦↷ᑕࡍࡿࢫࣆ࣮ࢻࢆ㸯㸮ಸ௨ୖᨵၿࡋ࡚࠸ࡿࠋ ࢜ࣥࡉࢀࡓ≀㉁ࡣ 㣕⾜㛫ࡼࡾศ㞳ࡉࢀࠊࢹ࣮ࢱࡋ࡚✚ࡉࢀࡿࠋ㞟ࡋࡓⳘ࡞ሗࡣ MALDI Tissuetyper ⏝ࡢᑓ⏝ࢯࣇࢺ㸦flexImaging,SCiLS Lab,SCiLS Lab 3D㸧࡚㉁㔞ศᯒࢹ࣮ࢱࢆྍ どࡉࢀࡿࠋ ᭱᪂ࡢ࣓࣮ࢪࣥࢢ㉁㔞ศᯒࢩࢫࢸ࣒ rapifleXTM MALDI Tissuetyper ࡿ⤖ᯝࡸࡑࡢᶵ⬟ࡘ࠸࡚ゎㄝࡍࡿࠋ ́́ TM ࡼࡗ࡚ᚓࡽࢀ TF-4 ㉁㔞ศᯒィࢆ᳨ฟჾࡍࡿయእデ᩿⏝་⒪ᶵჾ Prelude MD ࡢ⤂ ❑⏣㞞அ 1 1 ࢧ࣮ࣔࣇࢵࢩ࣮ࣕࢧ࢚ࣥࢸࣇࢵࢡᰴᘧ♫ Prelude MD liquid chromatograph equipped with mass spectrometer for clinical diagnostics Masayuki Kubota1 1 Thermo Fisher Scientific K.K. ㏆ᖺࠊḢ⡿࡛ࡣᾮయࢡ࣐ࣟࢺࢢࣛࣇ㉁㔞ศᯒィ㸦LC-MS㸧ࡢデ᩿་⒪ᛂ⏝ࡢ⠊ᅖࡀᗈࡀࡾ ࡘࡘ࠶ࡾࠊ᪥ᮏ࡛ࡶ᭱ඛ➃デ᩿ᢏ⾡ࡢࡦࡘࡋ࡚ὀ┠ࡉࢀ࡚࠸ࡲࡍࠋࢧ࣮ࣔࣇࢵࢩࣕ ࣮ࢧ࢚ࣥࢸࣇࢵࢡᰴᘧ♫ࡣ 2015 ᖺ 5 ᭶㉁㔞ศᯒィࢆ᳨ฟჾࡍࡿ㧗㏿ᾮయࢡࣟ ࣐ࢺࢢࣛࣇศᯒ⨨ࢆ་⒪ᶵჾ㸦Ⓩ㘓␒ྕ㸸14B3X00012000030㸧ࡋ࡚᪥ᮏᅜෆ࡛Ⓩ㘓ࡋ ࡲࡋࡓࠋLC-MS ࡣ」ᩘࡢศᯒᑐ㇟ࢆྠ᳨ฟ࡛ࡁࠊLC ࡢศᯒ᮲௳ࡀྠࡌ࡛࠶ࢀࡤ」ᩘࡢ ᳨ᰝ㡯┠ࢆ୍ᗘ᳨࡛ᰝ࡛ࡁࡿࡢࡀࡁ࡞࣓ࣜࢵࢺ࡛ࡍࠋࡋࡋࠊᐇ㝿ࡣ LC ࡢ᮲௳ࢆࡦ ࡘ⤫୍ࡍࡿࡇࡣᅔ㞴࡛ࠊ」ᩘࡢ᮲௳ࢆࢭࢵࢺࢵࣉ࡛ࡁࡿࡇࡀ᳨ᰝᐊࡢ⮬ືࠊ┬ ຊࠊࡑࡋ࡚ศᯒ㛫ࡢ▷⦰㔜せ࡞ࡾࡲࡍࠋࡲࡓࠊࢧࣥࣉࣝࡢ๓ฎ⌮ࡢ⮬ືࡶ㔜せ ࡛ࡍࠋ ࡇࡇ࡛ࡈ⤂ࡍࡿ Thermo Scientific™ Prelude MD™ࡣࠊࣁࢫ࣮ࣝࣉࢵࢺ࡛ࠊࡘᏳᐃᛶࡀ せồࡉࢀࡿデ᩿ᶵჾࡋ࡚ࠊ2 ࢳࣕࣥࢿࣝࡢ 2 ḟඖ LC ᵓᡂ࡞ࡗ࡚࠸ࡲࡍࠋ2 ḟඖ LC ࡢ 1 ḟඖ┠࡛㉁㔞ศᯒィࡸศᯒ࣒࢝ࣛࡢởࢀࢆ㍍ῶࡍࡿࡓࡵࡢ㝖ࢱࣥࣃࢡ㉁ฎ⌮ࢆ⾜࠸ࠊ2 ḟ ඖ┠࡛㏻ᖖࡢ LC ศ㞳ࢆ⾜࠸ࡲࡍࠋࡲࡓࠊศᯒ㛫ࢆ▷⦰ࡍࡿࡓࡵ๓㏙ࡢ 2 ḟඖ LC ࢆ 2 ࢳࣕࣥࢿࣝᵓᡂࡋࠊ୍᪉ࡀ LC-MS ศᯒࢆ⾜ࡗ࡚࠸ࡿ㛫ࡶ࠺୍᪉ࡀ 1 ḟඖ┠ࡢ๓ฎ⌮ࡸ 2 ḟඖ┠ࡢ࣒࢝ࣛࡢᖹ⾮ࢆ⾜࠼ࡿࡼ࠺࡞ࡗ࡚࠸ࡲࡍࠋྛࢳࣕࣥࢿࣝࡢὶ㊰ࠊ⛣ື┦࣎ࢺ ࣝࡣ⊂❧ࡋ࡚࠾ࡾࠊ」ᩘࡢࢵࢭࢆ 1 ྎࡢࢩࢫࢸ࣒⤌ࡳ㎸ࢇ࡛࠾ࡃࡇࡶྍ⬟࡛ࠊ ࢵࢭࡈ⛣ື┦ࡸ࣒࢝ࣛࢆࡍࡿᚲせࡣ࠶ࡾࡲࡏࢇࠋ ᮏㅮ₇࡛ࡣࠊPrelude MD ࡢࢩࢫࢸ࣒ᴫせࡘ࠸࡚ࡈ⤂ࡋࡲࡍࠋ ́́ TF-5 SWATH® Next-Generation Proteomics OneOmicsτࡼࡿ⥙⨶ⓗ࡞ࢱ࣮ࢤࢵࢺᐃ 㔞ࣉࣟࢸ࣮࣒࢜ゎᯒ ᰘ⏣ ⊛ 1 1 ࢧ࢚ࢵࢡࢫ ࣉࣜࢣ࣮ࢩࣙࣥࢧ࣏࣮ࢺ Comprehensive Targeted Quantitative Proteomics using SWATH® Next-Generation Proteomics and OneOmics Takeshi Sibata1 1 K.K. SCIEX Application Support ⏕యෆࡢࢱࣥࣃࢡ㉁ࡢኚືࢆᐃ㔞ⓗゎᯒࡍࡿࡣ⏕⌧㇟ࡢ⌮ゎࡢࡓࡵ㔜せ࡛ࡍࠋ ㉁㔞ศᯒᢏ⾡ࢆ୰ᚰࡋࡓࣉࣟࢸ࣮࣒࢜ゎᯒᢏ⾡ࡢⓎᒎక࠸ࠊᩘ༓ࡢࢱࣥࣃࢡ㉁ࡢྠᐃ ࡀྍ⬟࡞ࡾࠊࡲࡓᐃ㔞ᢏ⾡ࡶ㐍ᒎࡋࡘࡘ࠶ࡾࡲࡍࠋᚑ᮶ࡢࢱࣥࣃࢡ㉁ᐃ㔞ἲ࡛ࡣឤᗘࡸ ≉␗ᛶࠊࢲࢼ࣑ࢵࢡࣞࣥࢪࡸࢫ࣮ࣝࣉࢵࢺ࡞࠸ࡃࡘࡢၥ㢟Ⅼࡀᣦࡉࢀ࡚࠸ࡲࡋࡓ ࡀࠊつᶍ࡞ࢹࣇࣞࣥࢩࣕࣝゎᯒࡢᛂ⏝ࡋ࡚ࠊ୍ᗘࡢ ᐃ࡛ Data independent ࡚ࡢ࢜ࣥࢆྲྀᚓྍ⬟࡞ᡭἲ࡛࠶ࡿ SWATH® Next-Generation Proteomics ࡀ㛤Ⓨࡉࢀࡲ ࡋࡓࠋࡇࢀࡼࡾࠊ୍ᗘ㠀ᖖከࡃࡢࢱࣥࣃࢡ㉁ࡢᐃ㔞ሗࢆ⥙⨶ⓗྲྀᚓࡍࡿࡇࡀ ྍ⬟࡞ࡾࡲࡋࡓࠋ୍᪉࡛ࡣࠊ⭾࡞ࣉࣟࢸ࣑࢜ࢡࢫࡢຠ⋡ⓗ࡞ࢹ࣮ࢱゎᯒࠊ⟶⌮࡞ࡢ ᪂ࡓ࡞ㄢ㢟┤㠃ࡋ࡚࠸ࡲࡍࠋ ᭱㏆ࠊ࣑ࣝࢼ♫ࡼࡿ BaseSpace®ୖࡢࣉࣜࢣ࣮ࢩࣙࣥࡋ࡚㛤Ⓨࡉࢀࡓ OneOmics™ ࡣࠊࢡࣛ࢘ࢻࢥࣥࣆ࣮ࣗࢸࣥࢢࢆ⏝ࡋࡓ㉁㔞ศᯒࢹ࣮ࢱࡢᐃ㔞ゎᯒࡤࡾ࡛ࡣ࡞ࡃࠊ ࢹ࣮ࢱࡢ⤫ィฎ⌮ࣃࢫ࢙࢘ゎᯒ࠸ࡗࡓ⏕≀Ꮫⓗ࡞ពࡅࡢ࠶ࡿゎᯒࡸࠊ࣑ࣝࢼ ♫ࡢḟୡ௦ࢩ࣮ࢡ࢚ࣥࢧ࣮ࢆࡣࡌࡵࡍࡿࢤࣀ࣒ሗࡢ⤫ྜゎᯒࢆ Web ୖࡢ⡆౽࡞ࣥ ࢱ࣮ࣇ࢙ࢫࢆ⏝࠸࡚ྍ⬟࡞ࡾࡲࡋࡓࠋ ᅇࡣࠊSWATH®ࡼࡾᚓࡽࢀࡓࢩࢢࢼࣝఏ㐩ࢿࢵࢺ࣮࣡ࢡࡢ⥙⨶ⓗ࡞ࣜࣥ㓟ࣉࣟࢸ࢜ ࣑ࢡࢫࢹ࣮ࢱࢆ OneOmics™ ࡚ά⏝ࡋࡓࢆ⤂ࡉࡏ࡚࠸ࡓࡔࡁࡲࡍࠋࢩࢢࢼࣝఏ㐩⣔ ࠾ࡅࡿ࢟ࢼ࣮ࢮࢿࢵࢺ࣮࣡ࢡࡸ」ᩘࡢࢩࢢࢼࣝఏ㐩⣔ࡢẚ㍑ࢆ⾜࠺ࡇࡀ࡛ࡁࠊࢩࢢࢼ ࣝఏ㐩⣔యࡢࢩࢫࢸ࣒ࡋ࡚ࡢ⌮ゎ᭷ຠ࡛࠶ࡿࡇࡀ♧ࡉࢀࡲࡋࡓࠋBaseSpace®ୖࡢ ྛ✀ࢤࣀ࣒ࢶ࣮ࣝࡸ OneOmicsτࡢά⏝ࡼࡾࠊࢇ࡞㑇ఏᏊࡀⓎ⌧ࡋ࡚࠸ࡿ(ࢤࣀ࣑ࢡࢫ)ࠊ ࡲࡓࠊࡢࡼ࠺࡞ࢱࣥࣃࢡ㉁ࡀാ࠸࡚࠸ࡿ(ࣉࣟࢸ࣑࢜ࢡࢫ)࡞ࡢ࣑࢜ࢵࢡࢫ㸦Omics㸧 ሗࢆ㥑ࡋࠊࣂ࣐࣮࣮࢜࢝ࡢⓎぢࡸࠊࡀࢇ࡞ࡢྛ✀ᝈࡢ⸆◊✲ࡢά⏝ࡀᮇᚅ ࡉࢀࡲࡍࠋ ́́ TF-6 ࣜࣥ⬡㉁ࡢ㝖ཤࣜࣥ⬡㉁ࢆᢳฟࡍࡿ๓ฎ⌮〇ရࡘ࠸࡚ 㕥ᮌ୍, ኴ⏣ⱱᚨ, ⏤ኤ† ࢪ࣮࢚ࣝࢧ࢚ࣥࢫᰴᘧ♫ The introduction for products of phospholipids removal and phospholipids enrichment Kenichi Suzuki, Shigenori Ota, Yuko Yui GL Sciences Inc. ࠙せ᪨ᮏᩥࠚ㏆ᖺࠊLC/MS/MS ࡢឤᗘྥୖక࠸⏕యヨᩱࡢ๓ฎ⌮ࡶ⡆౽࡞㝖ࢱࣥࣃࢡฎ⌮ࡀ ᖜᗈࡃ⏝࠸ࡽࢀ࡚࠸ࡿࠋࡋࡋࠊ㝖ࢱࣥࣃࢡ㉁ฎ⌮࡛ࡣࠊࣜࣥ⬡㉁࡞ࡀヨᩱṧᏑࡋ࡚ ࠾ࡾࠊ࢜ࣥࢧࣉࣞࢵࢩࣙࣥࡢせᅉ࡞ࡗ࡚࠸ࡿࠋࡲࡓࠊṧᏑࡋ࡚࠸ࡿࣜࣥ⬡㉁ࡢ㔞ࡣࠊ ヨᩱࡈ㐪࠸ࠊ࢜ࣥࢧࣉࣞࢵࢩࣙࣥࡢ≧ἣࡶヨᩱࡼࡾ␗࡞ࡿࡓࡵࠊࡇࢀࡀ ᐃ⤖ᯝ ࡢࣂࣛࡘࡁࡘ࡞ࡀࡿࡇࡀゎࡗ࡚࠸ࡿࠋࡇࢀࢆᨵၿࡍࡿ᪉ἲࡋ࡚ࠊᖺࡢᮏᏛ ࠾࠸࡚ࠊ96WellPlate ࣇ࢛࣮࣐ࢵࢺࡢ㝖ࢱࣥࣃࢡࣉ࣮ࣞࢺࢳࢱࢽࢪࣝࢥࢽࢆሸࡋ ࡓࣜࣥ⬡㉁㝖ཤᶵ⬟ࢆᣢࡓࡏࡓࣇࣝࢱ࣮ࣉ࣮ࣞࢺࢆ⤂ࡋࡓࠋࢳࢱࢽࢪࣝࢥࢽࡣࠊ ྵࣜࣥ㓟ྜ≀ᑐࡋ࡚ࠊᏛⓗ࡞ࣇࢽࢸ࣮ࡶఝࡓ⤖ྜ≉ᛶࢆᣢࡗ࡚࠸ࡿࡓࡵࠊ ࡼࡾ㑅ᢥⓗ࡞ࣜࣥ⬡㉁ࡢ㝖ཤࡀྍ⬟࡞ࡿࠋᅇࡣࠊࣇࣝࢺ࣮ࣞࢩࣙࣥἲࢆ⏝࠸࡞࠸ሙ ྜࠊฎ⌮ࡋࡓヨᩱ୰ࡢࣜࣥ⬡㉁ࡢ㝖ཤࡍࡿࡓࡵࡢࢶ࣮ࣝࢆ㛤Ⓨࡋࡓࡢ࡛⤂ࡍࡿࠋ ࡲࡓࠊ㏆ᖺࡣࠊ࣓ࢱ࣑࣎ࣟࢡࢫ◊✲࡞࡛ࠊࣜࣥ⬡㉁⮬యࢆࢱ࣮ࢤࢵࢺࡍࡿ◊✲ࡀቑ࠼ ࡚ࡁ࡚࠾ࡾࠊヨᩱ୰ࡢࣜࣥ⬡㉁ࢆ㑅ᢥⓗᢳฟࡍࡿ᪉ἲࡀồࡵࡽࢀ࡚ࡁ࡚࠸ࡿࠋ๓㏙ࡢࣜ ࣥ⬡㉁ࢆ㝖ཤࡍࡿ〇ရ⏝ࡋ࡚࠸ࡿሸࡣࠊࣜࣥ⬡㉁ࡢᏛⓗ⤖ྜࡀᙉࡃ⬺╔ࡀᝏ ࠸ഴྥࡀ࠶ࡾࠊ๓ฎ⌮⏝ሸࡋ࡚ࡣࠊ᭱㐺࡛ࡣ࡞࠸ࠋ ᚤᑡヨᩱᑐᛂࡢࢫࣆ࣒ࣥ࢝ࣛᆺᅛ┦ᢳฟ࣒࡛࢝ࣛ࠶ࡿ MonoSpin ࢳࢱࢽࢪࣝࢥࢽ ࢆࢥ࣮ࢸࣥࢢࡉࡏࡓ࣒࢝ࣛࡀࣜࣥ⬡㉁ࡢ㑅ᢥⓗ྾╔⬟ࡣ⥔ᣢࡋࡓࡲࡲࠊ⬺╔ຠ⋡ඃࢀ ࡚࠾ࡾࠊࣜࣥ⬡㉁⏝ᅛ┦ᢳฟ࣒࢝ࣛࡋ࡚᭱㐺ࡍࡿࡇࡀ࡛ࡁࡓࠋࡲࡓࠊᚑ᮶ࡢࢫࣆࣥ ࣒࢝ࣛࡔࡅ࡛ࡣ࡞ࡃࠊࢹࢵࢻ࣮࣒࣎ࣜࣗࡀᑡ࡞ࡃ┦ᑐⓗᑡ㔞⁐ฟࡀྍ⬟࡞≉ᛶࢆ⥔ᣢࡋ ࡓࡲࡲࠊ10mL ࡲ࡛ࡢヨᩱ㐺ᛂࡍࡿࡓࡵࡢ MonoSpin L ࡶୖᕷࡋ࡚࠸ࡿࠋࡇࡢࣜࣥ⬡㉁ฎ ⌮⏝ࡢ࣒࢝ࣛࡶ L ᆺࢆ‽ഛࡋࡓࡢ࡛ࡇࡇ࡛ేࡏ࡚⤂ࡍࡿࠋ ́́ TF-7 Hybrid SPE®-Phospholipid ࢆ⏝࠸ࡓࣜࣥ⬡㉁㝖ཤࡼࡿ㧗ឤᗘศᯒ ᯇᓥỤ㔛㤶 1 1 ࢩࢢ࣐ࣝࢻࣜࢵࢳ ࢪࣕࣃࣥྜྠ♫ High sensitive analysis by the removal of phospholipids using “Hybrid SPE-Phospholipid” Erika Matsushima1 1 Sigma-Aldrich Japan ⾑₢ࡸ⾑Ύ࡞ࡢ⏕యヨᩱ୰ࡢྜ≀ࡸ௦ㅰ≀ࡢ LC-MS ࡢศᯒ࠾࠸࡚ࠊ」㞧࡞ࢧࣥࣉ ࣐ࣝࢺࣜࢵࢡࢫࡽࡢᖸ΅࠶࠺ࡇࡀከࡃ࠶ࡾࠊࡑࡢཎᅉࡢ୍ࡘࡋ࡚ࣜࣥ⬡㉁ጉᐖࡀ ▱ࡽࢀ࡚࠸ࡿࠋ ᮏⓎ⾲࡛ࡣࠊࣜࣥ⬡㉁㝖ཤཬࡧ⃰⦰ࡀྍ⬟࡞๓ฎ⌮⏝ᅛ┦ᢳฟ⟶ Hybrid SPE-Phospholipid ࢆ⏝࠸ࡓࣜࣥ⬡㉁ࡢ㝖ཤࢆ୰ᚰࠊ⏕యヨᩱ୰ࡢྜ≀ࡢྠᐃᐃ㔞㛵ࡋࠊ㎿㏿ࡘ㧗 ࠸ಙ㢗ᛶࢆᐇ⌧ࡍࡿࠊHPLC ⏝࣒࢝ࣛࡽㄆドᶆ‽≀㉁(CRM)ࡲ࡛ ᐃ⏝ࡍࡿ୍㐃ࡢࢶ࣮ ࣝࢆ⤂ࡍࡿࠋ ́́ TF-8 LC-MS/MS ࡼࡿ⾑୰་⸆ရศᯒࡢࡓࡵࡢ⮬ື๓ฎ⌮ࢩࢫࢸ࣒ ᑿᓥ⾜ 1, ✄ᇉ▱Ꮚ 1, ሯᮏከ▴ 1, ᰘ⏣ ග 1,2, ᕝୖ㍜ 1 1 (ᰴ)ᓥὠ〇సᡤ ศᯒィ ᴗ㒊ࠊ2Shimadzu Scientific Instruments Inc. Clinical laboratory automated modules for the extraction of medical drugs from blood prior to LC-MS/MS analysis Noriyuki Ojima1, Tomoko Inagaki1, Taku Tsukamoto1, Hikaru Shibata1,2, Daisuke Kawakami1 1 Shimadzu Corporation, Analytical & Measuring Instruments Division 2 Shimadzu Scientific Instruments Inc. ㉁㔞ศᯒᢏ⾡ࡢⓎ㐩ࡼࡿศᯒࡢ㧗ឤᗘࡣせồࡉࢀࡿヨᩱࡢ㔞ࢆῶࡽࡋࠊᚤ㔞ᡂศࡢ ᳨ฟࢆᐜ᫆ࡋ࡚ࡁࡲࡋࡓࠋࡉࡽࡇࡇᩘᖺࡢศᯒࡢ㧗㏿ࡣ⤖ᯝࡀ࡛ࡿࡲ࡛ࡢ㛫ࢆ ᖜ▷⦰ࡋࠊ㉁㔞ศᯒィࡢᮏ᱁ⓗ࡞⮫ᗋ⌧ሙ࡛ࡢᛂ⏝ࢆ⌧ᐇⓗࡋ࡚࠸ࡲࡍࠋࡋࡋ࡞ࡀ ࡽࠊ㉁㔞ศᯒィࡀ㧗㏿࡞ࢀࡤ࡞ࡿࠊࡑࡢ๓ẁࡢᡭసᴗ࡛ࡢ๓ฎ⌮᧯సࡀ࣎ࢺࣝࢿࢵ ࢡ࡞ࡗ࡚ࡁ࡚࠸ࡲࡍࠋ ࡑࡇ࡛ࠊᙜ♫ࡣ㛗ᖺᇵࡗ࡚ࡁࡓ⾑ᾮจᅛศᯒ⨨ࡢᢏ⾡ࢆ᥇⏝ࡋࠊ᥇⾑⟶࡞ࢆࢭࢵࢺ ࡍࡿࡔࡅ࡛⾑ᾮ࡞ᾮయ⏕యヨᩱࢆศᯒࡍࡿࡓࡵࡢ๓ฎ⌮ࡽ LCMS ศᯒࡲ࡛ࢆ⮬ື࡛⾜ ࠺ࢩࢫࢸ࣒ࢆ㛤Ⓨࡋࡲࡋࡓࠋࡇࡢࢩࢫࢸ࣒ࡼࡾேᡭࢆ┬ࡅࡿࡔࡅ࡛࡞ࡃࠊ๓ฎ⌮ࡢᡭᢏ ࡼࡿ࣑ࢫࡸࣂࣛࢶ࢟ࢆపῶࡋ⌧ᛶࡢ㧗࠸ศᯒࢆ⾜࠺ࡇࡀ࡛ࡁࡲࡍࠋ㸯᳨యࡈࡢ㏲ ḟ୪ิฎ⌮ࢆ⾜࠼ࡿࡓࡵࠊฎ⌮୰࡛ࡶ᪂ࡓ࡞᳨యヨᩱࢆ㏣ຍࡍࡿࡇࡶྍ⬟࡞ࡗ࡚࠸ ࡲࡍࠋ ᮏ࣮࣡ࢡࢩࣙࢵࣉ࡛ࡣࡇࡢ⮬ື LC-MS/MS ᳨యศᯒ⨨ࢆ⏝࠸ࡓ⮬ືศᯒࡢ୍ࡋ ࡚⾑ᾮ୰ࡢ་⸆ရࡢ⃰ᗘศᯒࡢᐇࢆ♧ࡋ࡞ࡀࡽࠊヨ⸆ࠊࢥࣥࢺ࣮ࣟࣝヨᩱࠊ⨨ಖᏲࡢ ⟶⌮ᶵ⬟࡞⮫ᗋศᯒᚲせ࡞⢭ᗘ⟶⌮ᶵ⬟ࢆྵࢇࡔࢯ࣮ࣜࣗࢩࣙࣥࢆࡈ⤂ࡋࡲࡍࠋ ⒪⸆≀ࣔࢽࢱࣜࣥࢢࡢᛂ⏝ࡔࡅ࡛࡞ࡃࠊ⌧ᅾ㛤Ⓨ୰ࡢศᯒἲࡢ⮬ືࡢࡓࡵࡢ㑅 ᢥ⫥ࡢ୍ࡘຍ࠼࡚࠸ࡓࡔࡅࢀࡤᖾ࠸࡛ࡍࠋ ́́ ́́ Ꮫ㈶ຓဨ୍ぴ㸦ᖹᡂ 27 ᖺᗘ㸧 ᰴᘧ♫ᓥὠ〇సᡤ ᪥ᮏ㟁Ꮚᰴᘧ♫ ᰴᘧ♫㈨⏕ᇽ ࢧ࣮ࣔࣇࢵࢩ࣮ࣕࢧ࢚ࣥࢸࣇࢵࢡᰴᘧ♫ ᰴᘧ♫࢚ࢫ࣮࢚ࣝࣝ ᰴᘧ♫࢚࣮ࣅ࣮࣭ࢧ࢚ࢵࢡࢫ ᪥ᮏ࢛࣮࢘ࢱ࣮ࢬᰴᘧ♫ ࣈ࣮࣭ࣝ࢝ࢲࣝࢺࢽࢡࢫᰴᘧ♫ ▼〇⸆ᰴᘧ♫ 㸦9 ♫㸧 ́́ ᖺ༠㈶ᴗ୍ぴ ࡇࡢᗘࡢᖺ㛤ദ࠶ࡓࡾࠊᴗ࣭ᅋయࡢⓙᵝࡽ༠㈶㔠ࠊᒎ♧ࠊᗈ࿌ᥖ㍕ࠊࡑࡢࡢ ࡈ༠ຊࢆ࠸ࡓࡔࡁࡲࡋࡓࠋࡇࡇᴗྡࢆᥖ㍕ࡋࠊ῝ࡃឤㅰ⏦ࡋୖࡆࡲࡍࠋ 㸦2015 ᖺ 8 ᭶ 14 ᪥㸧 ࢧࣄࢢ࣮ࣝࣉ࣮࣍ࣝࢹࣥࢢࢫᰴ ᘧ♫ ࢩࢢ࣐ࣝࢻࣜࢵࢳࢪࣕࣃࣥྜྠ♫ ࢩࢫ࣓ࢵࢡࢫ࣭ࣅ࣓࣮࢜ࣜࣗᰴᘧ♫ ࢪࣞࣥࢺ࣭ࢸࢡࣀࣟࢪ࣮ᰴᘧ♫ ࢩࣗࣉ࣮࣭ࣜࣥ࢞ࢪࣕࣃࣥᰴᘧ♫ 㹋㹑㹒 ୍⯡㈈ᅋἲே ᮦᩱ⛉Ꮫᢏ⾡ ⯆㈈ᅋ ✚Ỉ࣓ࢹ࢝ࣝᰴᘧ♫ ሯ〇⸆ᰴᘧ♫ ࢽࢵࢺ࣮࣮࣓࣎ࢹ࢝ࣝᰴᘧ♫ ᰴᘧ♫ఀ⸨ᅬ ᪥ᮏ࢛࣮࢘ࢱ࣮ࢬᰴᘧ♫ ᰴᘧ♫࢚࣮ࣅ࣮࣭ࢧ࢚ࢵࢡࢫ ᪥ᮏ㟁Ꮚᰴᘧ♫ ᰴᘧ♫࣮࢝ࢡ ࣂ࢜ࢱ࣮ࢪ࣭ࢪࣕࣃࣥᰴᘧ♫ ᰴᘧ♫㈨⏕ᇽ ᯇ࣍ࢺࢽࢡࢫᰴᘧ♫ ᰴᘧ♫ᓥὠ〇సᡤ ࣈ࣮࣭ࣝ࢝ࢲࣝࢺࢽࢡࢫᰴᘧ♫ ᰴᘧ♫ࢶ࣒ࣛ ࣐ࢺࣜࢵࢡࢫࢧ࢚ࣥࢫᰴᘧ♫ ᰴᘧ♫⨺ᅵ♫ ࣐ࣝࣁࢽࢳࣟᰴᘧ♫ ࢟ࣜࣥᰴᘧ♫ ୕ሗᰴᘧ♫ ࢧ࣮ࣔࣇࢵࢩ࣮ࣕࢧ࢚ࣥࢸࣇ ࢵࢡᰴᘧ♫ ࣛ࢜ࣥᰴᘧ♫ ⌮⛉◊ᰴᘧ♫ ࢧࢵ࣏ࣟࣅ࣮ࣝᰴᘧ♫ ࢪ࣮࢚ࣝࢧ࢚ࣥࢫᰴᘧ♫ 㸦30 ♫ࠊ༑㡢㡰ࠊᩗ⛠␎㸧 ́́ ᒎ♧ᴗ୍ぴ ࢪࣞࣥࢺ࣭ࢸࢡࣀࣟࢪ࣮ᰴᘧ♫ 㹋㹑㹒 ୍⯡㈈ᅋἲே ᮦᩱ⛉Ꮫᢏ⾡⯆㈈ᅋ ሯ〇⸆ᰴᘧ♫ ᰴᘧ♫࢚࣮ࣅ࣮࣭ࢧ࢚ࢵࢡࢫ ᰴᘧ♫ᓥὠ〇సᡤ ࢧ࣮ࣔࣇࢵࢩ࣮ࣕࢧ࢚ࣥࢸࣇࢵࢡᰴᘧ♫ ࢪ࣮࢚ࣝࢧ࢚ࣥࢫᰴᘧ♫ ࢩࢢ࣐ࣝࢻࣜࢵࢳࢪࣕࣃࣥྜྠ♫ ࢩࢫ࣓ࢵࢡࢫ࣭ࣅ࣓࣮࢜ࣜࣗᰴᘧ♫ ᪥ᮏ࢛࣮࢘ࢱ࣮ࢬᰴᘧ♫ ࣈ࣮࣭ࣝ࢝ࢲࣝࢺࢽࢡࢫᰴᘧ♫ 㸦11 ♫ࠊ༑㡢㡰ࠊᩗ⛠␎㸧 ́́ ᖺ㐠Ⴀጤဨ୍ぴ ᖺ㛗 ℩⸨ ග ᯇ་⛉Ꮫゎ๗Ꮫㅮᗙ 㐠Ⴀጤဨࢫࢱࢵࣇ㸦༑㡢㡰㸧 ᭷ಙ ဴဢ ឡ▱་⛉Ꮫ་Ꮫ㒊Ꮫᩍᐊ ⊦㣫 ឡ▱┴⾨⏕◊✲ᡤ ụୖ ᾈྖ ᯇ་⛉Ꮫゎ๗Ꮫㅮᗙ ▼ ྡྂᒇᏛᏛ㝔་Ꮫ⣔◊✲⛉ἲ་࣭⏕⌮Ꮫ ᑠᕝ அ ឡ▱་⛉Ꮫ་Ꮫ㒊ἲ་Ꮫㅮᗙ ᮌᮧ ⰾ ⚄ዉᕝ┴❧ಖ⚟♴Ꮫே㛫⥲ྜ࣭ᑓ㛛ᇶ♏ ㏆⸨ ᯇ་⛉Ꮫゎ๗Ꮫㅮᗙ ㏆⸨ ᩥ㞝 ឡ▱་⛉Ꮫ་Ꮫ㒊⸆⌮Ꮫㅮᗙ ⤃㔝 ᅾ ᯇ་⛉Ꮫ࣓ࢹ࢝ࣝࣇ࢛ࢺࢽࢡࢫ◊✲ࢭࣥࢱ࣮ ୕ᯞ ㍜ ᮾᏛᮾ࣓ࢹ࣭࣓࢝ࣝ࢞ࣂࣥࢡᶵᵓ బ⸨ 㥴ᖹ ᯇ་⛉Ꮫゎ๗Ꮫㅮᗙ బ⸨ ᬛோ ᯇ་⛉Ꮫゎ๗Ꮫㅮᗙ 㔜ᯇ 㝧 ⚟Ꮫ་Ꮫ㒊ᗣ⛉Ꮫ ᮡᒣ ᰤ ᯇ་⛉Ꮫゎ๗Ꮫㅮᗙ 㕥ᮌ ಟ ᯇ་⛉Ꮫ⌮ ጒᑿ ὒ ឡ▱་⛉Ꮫ་Ꮫ㒊ἲ་Ꮫㅮᗙ ᯇ་⛉Ꮫゎ๗Ꮫㅮᗙ Ṋ ྐ㑻 ሐෆ せ ୰㒊Ꮫᛂ⏝⏕≀Ꮫ㒊ᛂ⏝⏕≀Ꮫ⛉ ୰す ㇏ᩥ 㜰་⛉Ꮫ⥲ྜ་Ꮫㅮᗙ⮫ᗋ᳨ᰝ་Ꮫᩍᐊ ⩚ ಟᩥᏛᗣᰤ㣴Ꮫ㒊⟶⌮ᰤ㣴Ꮫ⛉ ẚ ⬟அ ⸨⏣ಖ⾨⏕Ꮫ⭈⮚ෆ⛉ ๓⏣ ᗣ༤ ྡྂᒇᕷ❧ᏛᏛ㝔⸆Ꮫ◊✲⛉㝔⸆Ꮫศ㔝 ๓ᕝ ┿ே ᯇ་⛉Ꮫ⮫ᗋ᳨ᰝ་Ꮫㅮᗙ ṇᮌ ⣖㝯 ᯇ་⛉Ꮫゎ๗Ꮫㅮᗙ ᯇୗ ⚈Ꮚ ᯇ་⛉Ꮫゎ๗Ꮫㅮᗙ ᐑᇛ ᦶ㔛Ꮚ ᯇ་⛉Ꮫゎ๗Ꮫㅮᗙ ᐑᔱ ⿱᫂ ᯇ་⛉Ꮫෆ⛉Ꮫ➨୍ㅮᗙ ▮ᑿ ⫱Ꮚ ᯇ་⛉Ꮫ࣓ࢹ࢝ࣝࣇ࢛ࢺࢽࢡࢫ◊✲ࢭࣥࢱ࣮ ᒣᓮ ᩥ⩏ ᯇ་⛉Ꮫゎ๗Ꮫㅮᗙ ́́ ἇὅἩἽЭϼྸỆỊ 第 41 回 年 会 長：妹尾 日本医用マススペクトル学会年会のお知らせ 洋（愛知医科大学法医学講座） 会 期：平成 28 年 9 月 15 日（木）、16 日（金） （9 月 17 日：医用質量分析認定士 第 4 回講習会開催予定） 場 所：ウインクあいち 一般社団法人 日本医用マススペクトル学会 JSBMS Letters Vol.40 Supplement, 2015 第 40 回 日本医用マススペクトル学会年会 プログラム・抄録集 発 行 日： 平成 27 年 8 月 20 日 編 集 者： 第 40 回日本医用マススペクトル学会年会 （年会長）瀬藤光利 発行責任者： 丹羽利充 編集委員会：（委員長）瀬藤光利／浅井清文／有田 誠／五十嵐一雄／伊藤哲哉／ 妹尾 発 行 洋／谷口寿章／中西豊文 所： 一般社団法人 日本医用マススペクトル学会事務局 〒491-0938 修文大学 愛知県一宮市日光町 6 健康栄養学部内 E-mail：[email protected] ホームページ：http://www.jsbms.jp/ 印 刷 所： オオゼキ写真印刷株式会社 〒433-8111 静岡県浜松市中区葵西 2‐5‐20 TEL／053-436-1956 FAX／053-437-6095